Pharmacokinetic	O
properties	O
of	O
abacavir	S-drug
were	O
not	O
altered	O
by	O
the	O
addition	O
of	O
either	O
lamivudine	S-drug
or	O
zidovudine	S-drug
or	O
the	O
combination	O
of	O
lamivudine	S-drug
and	O
zidovudine	S-drug
.	O

No	O
clinically	O
significant	O
changes	O
to	O
lamivudine	S-drug
or	O
zidovudine	S-drug
pharmacokinetics	O
were	O
observed	O
following	O
concomitant	O
administration	O
of	O
abacavir	S-drug
.	O

Abacavir	S-drug
has	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
properties	O
of	O
ethanol	S-drug
.	O

Ethanol	S-drug-ME-1
decreases	O
the	O
elimination	O
of	O
abacavir	S-drug-ME-2
causing	O
an	O
increase	O
in	O
overall	O
exposure	O
.	O
The	O
addition	O
of	O
methadone	S-drug
has	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
pharmacokinetic	O
properties	O
of	O
abacavir	S-drug
.	O

In	O
a	O
study	O
of	O
11	O
HIV	O
-	O
infected	O
patients	O
receiving	O
methadone	S-drug-ME-1
-	O
maintenance	O
therapy	O
(	O
40	O
mg	O
and	O
90	O
mg	O
daily	O
)	O
with	O
600	O
mg	O
of	O
ZIAGEN	S-brand-ME-2
twice	O
daily	O
(	O
twice	O
the	O
currently	O
recommended	O
dose	O
)	O
,	O
oral	O
methadone	S-drug
clearance	O
increased	O
22	O
%	O
(	O
90	O
%	O
CI	O
6	O
%	O
to	O
42	O
%	O
)	O
.	O

This	O
alteration	O
will	O
not	O
result	O
in	O
a	O
methadone	S-drug
dose	O
modification	O
in	O
the	O
majority	O
of	O
patients	O
;	O

however	O
,	O
an	O
increased	O
methadone	S-drug
dose	O
may	O
be	O
required	O
in	O
a	O
small	O
number	O
of	O
patients	O
.	O

Cholestyramine	S-drug
:	O
Concomitant	O
cholestyramine	S-drug-ME-1
administration	O
decreased	O
the	O
mean	O
AUC	O
of	O
total	O
ezetimibe	S-drug-ME-2
approximately	O
55	O
%	O
.	O

The	O
incremental	O
LDL	O
-	O
C	O
reduction	O
due	O
to	O
adding	O
ezetimibe	S-drug-EF-1
to	O
cholestyramine	S-drug-EF-2
may	O
be	O
reduced	O
by	O
this	O
interaction	O
.	O

Fibrates	S-group
:	O
The	O
safety	O
and	O
effectiveness	O
of	O
ezetimibe	S-drug
administered	O
with	O
fibrates	S-group
have	O
not	O
been	O
established	O
.	O

Fibrates	S-group
may	O
increase	O
cholesterol	O
excretion	O
into	O
the	O
bile	O
,	O
leading	O
to	O
cholelithiasis	O
.	O

In	O
a	O
preclinical	O
study	O
in	O
dogs	O
,	O
ezetimibe	S-drug
increased	O
cholesterol	O
in	O
the	O
gallbladder	O
bile	O
.	O

Co	O
-	O
administration	O
of	O
ZETIA	S-brand-AD-1
with	O
fibrates	S-group-AD-2
is	O
not	O
recommended	O
until	O
use	O
in	O
patients	O
is	O
studied	O
.	O

Fenofibrate	S-drug
:	O
In	O
a	O
pharmacokinetic	O
study	O
,	O
concomitant	O
fenofibrate	S-drug-ME-1
administration	O
increased	O
total	O
ezetimibe	S-drug-ME-2
concentrations	O
approximately	O
1.5	O
-	O
fold	O
.	O

Gemfibrozil	S-drug
:	O
In	O
a	O
pharmacokinetic	O
study	O
,	O
concomitant	O
gemfibrozil	S-drug
administration	O
increased	O
total	O
ezetimibe	S-drug
concentrations	O
approximately	O
1.7	O
-	O
fold	O
.	O

HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
:	O
No	O
clinically	O
significant	O
pharmacokinetic	O
interactions	O
were	O
seen	O
when	O
ezetimibe	S-drug
was	O
co	O
-	O
administered	O
with	O
atorvastatin	S-drug
,	O
simvastatin	S-drug
,	O
pravastatin	S-drug
,	O
lovastatin	S-drug
,	O
or	O
fluvastatin	S-drug
.	O

Cyclosporine	S-drug
:	O
The	O
total	O
ezetimibe	S-drug-ME-1
level	O
increased	O
12	O
-	O
fold	O
in	O
one	O
renal	O
transplant	O
patient	O
receiving	O
multiple	O
medications	O
,	O
including	O
cyclosporine	S-drug-ME-2
.	O

Patients	O
who	O
take	O
both	O
ezetimibe	S-drug-AD-1
and	O
cyclosporine	S-drug-AD-2
should	O
be	O
carefully	O
monitored	O
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
,	O
Impairment	O
of	O
Fertility	O
A	O
104	O
-	O
week	O
dietary	O
carcinogenicity	O
study	O
with	O
ezetimibe	S-drug
was	O
conducted	O
in	O
rats	O
at	O
doses	O
up	O
to	O
1500	O
mg	O
/	O
kg	O
/	O
day	O
(	O
males	O
)	O
and	O
500	O
mg	O
/	O
kg	O
/	O
day	O
(	O
females	O
)	O
(	O
~	O
20	O
times	O
the	O
human	O
exposure	O
at	O
10	O
mg	O
daily	O
based	O
on	O
AUC0	O
-	O
24hr	O
for	O
total	O
ezetimibe	S-drug
)	O
.	O

A	O
104	O
-	O
week	O
dietary	O
carcinogenicity	O
study	O
with	O
ezetimibe	S-drug
was	O
also	O
conducted	O
in	O
mice	O
at	O
doses	O
up	O
to	O
500	O
mg	O
/	O
kg	O
/	O
day	O
(	O
>	O
150	O
times	O
the	O
human	O
exposure	O
at	O
10	O
mg	O
daily	O
based	O
on	O
AUC0	O
-	O
24hr	O
for	O
total	O
ezetimibe	S-drug
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
increases	O
in	O
tumor	O
incidences	O
in	O
drug	O
-	O
treated	O
rats	O
or	O
mice	O
.	O

No	O
evidence	O
of	O
mutagenicity	O
was	O
observed	O
in	O
vitro	O
in	O
a	O
microbial	O
mutagenicity	O
(	O
Ames	O
)	O
test	O
with	O
Salmonella	O
typhimurium	O
and	O
Escherichia	O
coli	O
with	O
or	O
without	O
metabolic	O
activation	O
.	O

No	O
evidence	O
of	O
clastogenicity	O
was	O
observed	O
in	O
vitro	O
in	O
a	O
chromosomal	O
aberration	O
assay	O
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
or	O
without	O
metabolic	O
activation	O
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
evidence	O
of	O
genotoxicity	O
in	O
the	O
in	O
vivo	O
mouse	O
micronucleus	O
test	O
.	O

In	O
oral	O
(	O
gavage	O
)	O
fertility	O
studies	O
of	O
ezetimibe	S-drug
conducted	O
in	O
rats	O
,	O
there	O
was	O
no	O
evidence	O
of	O
reproductive	O
toxicity	O
at	O
doses	O
up	O
to	O
1000	O
mg	O
/	O
kg	O
/	O
day	O
in	O
male	O
or	O
female	O
rats	O
(	O
~	O
7	O
times	O
the	O
human	O
exposure	O
at	O
10	O
mg	O
daily	O
based	O
on	O
AUC0	O
-	O
24hr	O
for	O
total	O
ezetimibe	S-drug
)	O
.	O

Pregnancy	O
Pregnancy	O
Category	O
:	O
C	O
There	O
are	O
no	O
adequate	O
and	O
well	O
-	O
controlled	O
studies	O
of	O
ezetimibe	S-drug
in	O
pregnant	O
women	O
.	O

Ezetimibe	S-drug
should	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
the	O
potential	O
benefit	O
justifies	O
the	O
risk	O
to	O
the	O
fetus	O
.	O

In	O
oral	O
(	O
gavage	O
)	O
embryo	O
-	O
fetal	O
development	O
studies	O
of	O
ezetimibe	S-drug
conducted	O
in	O
rats	O
and	O
rabbits	O
during	O
organogenesis	O
,	O
there	O
was	O
no	O
evidence	O
of	O
embryolethal	O
effects	O
at	O
the	O
doses	O
tested	O
(	O
250	O
,	O
500	O
,	O
1000	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

In	O
rats	O
,	O
increased	O
incidences	O
of	O
common	O
fetal	O
skeletal	O
findings	O
(	O
extra	O
pair	O
of	O
thoracic	O
ribs	O
,	O
unossified	O
cervical	O
vertebral	O
centra	O
,	O
shortened	O
ribs	O
)	O
were	O
observed	O
at	O
1000	O
mg	O
/	O
kg	O
/	O
day	O
(	O
~	O
10	O
times	O
the	O
human	O
exposure	O
at	O
10	O
mg	O
daily	O
based	O
on	O
AUC0	O
-	O
24hr	O
for	O
total	O
ezetimibe	S-drug
)	O
.	O

In	O
rabbits	O
treated	O
with	O
ezetimibe	S-drug
,	O
an	O
increased	O
incidence	O
of	O
extra	O
thoracic	O
ribs	O
was	O
observed	O
at	O
1000	O
mg	O
/	O
kg	O
/	O
day	O
(	O
150	O
times	O
the	O
human	O
exposure	O
at	O
10	O
mg	O
daily	O
based	O
on	O
AUC0	O
-	O
24hr	O
for	O
total	O
ezetimibe	S-drug
)	O
.	O

Ezetimibe	S-drug
crossed	O
the	O
placenta	O
when	O
pregnant	O
rats	O
and	O
rabbits	O
were	O
given	O
multiple	O
oral	O
doses	O
.	O

Multiple	O
dose	O
studies	O
of	O
ezetimibe	S-drug
given	O
in	O
combination	O
with	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
(	O
statins	S-group
)	O
in	O
rats	O
and	O
rabbits	O
during	O
organogenesis	O
result	O
in	O
higher	O
ezetimibe	S-drug
and	O
statin	O
exposures	O
.	O

Reproductive	O
findings	O
occur	O
at	O
lower	O
doses	O
in	O
combination	O
therapy	O
compared	O
to	O
monotherapy	O
.	O

All	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitors	E-group
are	O
contraindicated	O
in	O
pregnant	O
and	O
nursing	O
women	O
.	O

When	O
ZETIA	S-brand
is	O
administered	O
with	O
an	O
HMG	B-group
-	I-group
CoA	I-group
reductase	I-group
inhibitor	E-group
in	O
a	O
woman	O
of	O
childbearing	O
potential	O
,	O
refer	O
to	O
the	O
pregnancy	O
category	O
and	O
package	O
labeling	O
for	O
the	O
HMG	B-drug
-	I-drug
CoA	I-drug
reductase	I-drug
inhibitor	E-drug
.	O

Labor	O
and	O
Delivery	O
The	O
effects	O
of	O
ZETIA	S-brand
on	O
labor	O
and	O
delivery	O
in	O
pregnant	O
women	O
are	O
unknown	O
.	O

Nursing	O
Mothers	O
In	O
rat	O
studies	O
,	O
exposure	O
to	O
total	O
ezetimibe	S-drug
in	O
nursing	O
pups	O
was	O
up	O
to	O
half	O
of	O
that	O
observed	O
in	O
maternal	O
plasma	O
.	O

It	O
is	O
not	O
known	O
whether	O
ezetimibe	S-drug
is	O
excreted	O
into	O
human	O
breast	O
milk	O
;	O

therefore	O
,	O
ZETIA	S-brand
should	O
not	O
be	O
used	O
in	O
nursing	O
mothers	O
unless	O
the	O
potential	O
benefit	O
justifies	O
the	O
potential	O
risk	O
to	O
the	O
infant	O
.	O

Pediatric	O
Use	O
The	O
pharmacokinetics	O
of	O
ZETIA	S-brand
in	O
adolescents	O
(	O
10	O
to	O
18	O
years	O
)	O
have	O
been	O
shown	O
to	O
be	O
similar	O
to	O
that	O
in	O
adults	O
.	O

Treatment	O
experience	O
with	O
ZETIA	S-brand
in	O
the	O
pediatric	O
population	O
is	O
limited	O
to	O
4	O
patients	O
(	O
9	O
to	O
17	O
years	O
)	O
in	O
the	O
sitosterolemia	O
study	O
and	O
5	O
patients	O
(	O
11	O
to	O
17	O
years	O
)	O
in	O
the	O
HoFH	O
study	O
.	O

Treatment	O
with	O
ZETIA	S-brand
in	O
children	O
(	O
<	O
10	O
years	O
)	O
is	O
not	O
recommended	O
.	O

Geriatric	O
Use	O
Of	O
the	O
patients	O
who	O
received	O
ZETIA	S-brand
in	O
clinical	O
studies	O
,	O
948	O
were	O
65	O
and	O
older	O
(	O
this	O
included	O
206	O
who	O
were	O
75	O
and	O
older	O
)	O
.	O

The	O
effectiveness	O
and	O
safety	O
of	O
ZETIA	S-brand
were	O
similar	O
between	O
these	O
patients	O
and	O
younger	O
subjects	O
.	O

Greater	O
sensitivity	O
of	O
some	O
older	O
individuals	O
can	O
not	O
be	O
ruled	O
out	O
.	O

Clinically	O
or	O
potentially	O
significant	O
drug	O
interactions	O
between	O
DIFLUCAN	S-brand
and	O
the	O
following	O
agents	O
/	O
classes	O
have	O
been	O
observed	O
.	O

These	O
are	O
described	O
in	O
greater	O
detail	O
below	O
:	O
DIFLUCAN	S-brand
and	O
the	O
following	O
agents	O
/	O
classes	O
have	O
been	O
observed	O
.	O

These	O
are	O
described	O
in	O
greater	O
detail	O
below	O
:	O
Oral	O
hypoglycemics	S-group
,	O
Coumarin	B-group
-	I-group
type	I-group
anticoagulants	E-group
,	O
Phenytoin	S-drug
,	O
Cyclosporine	S-drug
,	O
Rifampin	S-drug
,	O
Theophylline	S-drug
,	O
Terfenadine	S-drug
,	O
Cisapride	S-drug
,	O
Astemizole	S-drug
,	O
Rifabutin	S-drug
,	O
Tacrolimus	S-drug
,	O
Short	B-group
-	I-group
acting	I-group
benzodiazepines	E-group
,	O
Oral	O
hypoglycemics	S-group
:	O
Clinically	O
significant	O
hypoglycemia	O
may	O
be	O
precipitated	O
by	O
the	O
use	O
of	O
DIFLUCAN	S-brand-EF-1
with	O
oral	O
hypoglycemic	B-group-EF-2
agents	E-group-EF-2
;	O

one	O
fatality	O
has	O
been	O
reported	O
from	O
hypoglycemia	O
in	O
association	O
with	O
combined	O
DIFLUCAN	S-brand-EF-1
and	O
glyburide	S-drug-EF-2
use	O
.	O

DIFLUCAN	S-brand-ME-1
reduces	O
the	O
metabolism	O
of	O
tolbutamide	S-drug-ME-2
,	O
glyburide	S-drug-ME-2
,	O
and	O
glipizide	S-drug-ME-2
and	O
increases	O
the	O
plasma	O
concentration	O
of	O
these	O
agents	O
.	O

When	O
DIFLUCAN	S-brand-AD-1
is	O
used	O
concomitantly	O
with	O
these	O
or	O
other	O
sulfonylurea	B-group-AD-2
oral	I-group-AD-2
hypoglycemic	I-group-AD-2
agents	E-group-AD-2
,	O
blood	O
glucose	O
concentrations	O
should	O
be	O
carefully	O
monitored	O
and	O
the	O
dose	O
of	O
the	O
sulfonylurea	S-group
should	O
be	O
adjusted	O
as	O
necessary	O
.	O

Coumarin	B-group
-	I-group
type	I-group
anticoagulants	E-group
:	O
Prothrombin	O
time	O
may	O
be	O
increased	O
in	O
patients	O
receiving	O
concomitant	O
DIFLUCAN	S-brand-EF-1
and	O
coumarin	B-group-EF-2
-	I-group-EF-2
type	I-group-EF-2
anticoagulants	E-group-EF-2
.	O

In	O
post	O
-	O
marketing	O
experience	O
,	O
as	O
with	O
other	O
azole	B-group
antifungals	E-group
,	O
bleeding	O
events	O
(	O
bruising	O
,	O
epistaxis	O
,	O
gastrointestinal	O
bleeding	O
,	O
hematuria	O
,	O
and	O
melena	O
)	O
have	O
been	O
reported	O
in	O
association	O
with	O
increases	O
in	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
fluconazole	S-drug-EF-1
concurrently	O
with	O
warfarin	S-drug-EF-2
.	O

Careful	O
monitoring	O
of	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
DIFLUCAN	S-brand-AD-1
and	O
coumarin	B-group-AD-2
-	I-group-AD-2
type	I-group-AD-2
anticoagulants	E-group-AD-2
is	O
recommended	O
.	O

(	O
See	O
<	O
a	O
href	O
=	O
``	O
flucon_cp.htm	O
#	O
CP	O
``	O
>	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
Interaction	O
Studies	O
.	O
)	O

Phenytoin	S-drug
:	O
DIFLUCAN	S-brand-ME-1
increases	O
the	O
plasma	O
concentrations	O
of	O
phenytoin	S-drug-ME-2
.	O

Careful	O
monitoring	O
of	O
phenytoin	S-drug
concentrations	O
in	O
patients	O
receiving	O
DIFLUCAN	S-brand-AD-1
and	O
phenytoin	S-drug-AD-2
is	O
recommended	O
.	O

(	O
See	O
<	O
a	O
href	O
=	O
``	O
flucon_cp.htm	O
#	O
CP	O
``	O
>	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
Interaction	O
Studies	O
.	O
)	O

Cyclosporine	S-drug
:	O
DIFLUCAN	S-brand-ME-1
may	O
significantly	O
increase	O
cyclosporine	S-drug-ME-2
levels	O
in	O
renal	O
transplant	O
patients	O
with	O
or	O
without	O
renal	O
impairment	O
.	O

Careful	O
monitoring	O
of	O
cyclosporine	S-drug
concentrations	O
and	O
serum	O
creatinine	O
is	O
recommended	O
in	O
patients	O
receiving	O
DIFLUCAN	S-brand-AD-1
and	O
cyclosporine	S-drug-AD-2
.	O

(	O
See	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
Interaction	O
Studies	O
.	O
)	O

Rifampin	S-drug
:	O
Rifampin	S-drug-ME-1
enhances	O
the	O
metabolism	O
of	O
concurrently	O
administered	O
DIFLUCAN	S-brand-ME-2
.	O

Depending	O
on	O
clinical	O
circumstances	O
,	O
consideration	O
should	O
be	O
given	O
to	O
increasing	O
the	O
dose	O
of	O
DIFLUCAN	S-brand-AD-1
when	O
it	O
is	O
administered	O
with	O
rifampin	S-drug-AD-2
.	O

Theophylline	S-drug
:	O
DIFLUCAN	S-brand-ME-1
increases	O
the	O
serum	O
concentrations	O
of	O
theophylline	S-drug-ME-2
.	O

Careful	O
monitoring	O
of	O
serum	O
theophylline	S-drug
concentrations	O
in	O
patients	O
receiving	O
DIFLUCAN	S-brand-AD-1
and	O
theophylline	S-drug-AD-2
is	O
recommended	O
.	O

Terfenadine	S-drug
:	O
Because	O
of	O
the	O
occurrence	O
of	O
serious	O
cardiac	O
dysrhythmias	O
secondary	O
to	O
prolongation	O
of	O
the	O
QTc	O
interval	O
in	O
patients	O
receiving	O
azole	B-group-EF-1
antifungals	E-group-EF-1
in	O
conjunction	O
with	O
terfenadine	S-drug-EF-2
,	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

One	O
study	O
at	O
a	O
200	O
-	O
mg	O
daily	O
dose	O
of	O
fluconazole	S-drug
failed	O
to	O
demonstrate	O
a	O
prolongation	O
in	O
QTc	O
interval	O
.	O

Another	O
study	O
at	O
a	O
400	O
-	O
mg	O
and	O
800	O
-	O
mg	O
daily	O
dose	O
of	O
fluconazole	S-drug
demonstrated	O
that	O
DIFLUCAN	S-brand-ME-1
taken	O
in	O
doses	O
of	O
400	O
mg	O
per	O
day	O
or	O
greater	O
significantly	O
increases	O
plasma	O
levels	O
of	O
terfenadine	S-drug-ME-2
when	O
taken	O
concomitantly	O
.	O

The	O
combined	O
use	O
of	O
fluconazole	S-drug-AD-1
at	O
doses	O
of	O
400	O
mg	O
or	O
greater	O
with	O
terfenadine	S-drug-AD-2
is	O
contraindicated	O
.	O

The	O
coadministration	O
of	O
fluconazole	S-drug-AD-1
at	O
doses	O
lower	O
than	O
400	O
mg	O
/	O
day	O
with	O
terfenadine	S-drug-AD-2
should	O
be	O
carefully	O
monitored	O
.	O

Cisapride	S-drug
:	O
There	O
have	O
been	O
reports	O
of	O
cardiac	O
events	O
,	O
including	O
torsade	O
de	O
pointes	O
in	O
patients	O
to	O
whom	O
fluconazole	S-drug-EF-1
and	O
cisapride	S-drug-EF-2
were	O
coadministered	O
.	O

A	O
controlled	O
study	O
found	O
that	O
concomitant	O
fluconazole	S-drug-ME-1
200	O
mg	O
once	O
daily	O
and	O
cisapride	S-drug-ME-2
20	O
mg	O
four	O
times	O
a	O
day	O
yielded	O
a	O
significant	O
increase	O
in	O
cisapride	S-drug
plasma	O
levels	O
and	O
prolongation	O
of	O
QTc	O
interval	O
.	O

The	O
combined	O
use	O
of	O
fluconazole	S-drug-AD-1
with	O
cisapride	S-drug-AD-2
is	O
contraindicated	O
.	O

Astemizole	S-drug
:	O
The	O
use	O
of	O
fluconazole	S-drug-ME-1
in	O
patients	O
concurrently	O
taking	O
astemizole	S-drug-ME-2
or	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
may	O
be	O
associated	O
with	O
elevations	O
in	O
serum	O
levels	O
of	O
these	O
drugs	O
.	O

In	O
the	O
absence	O
of	O
definitive	O
information	O
,	O
caution	O
should	O
be	O
used	O
when	O
coadministering	O
fluconazole	S-drug
.	O

Patients	O
should	O
be	O
carefully	O
monitored	O
.	O

Rifabutin	S-drug
:	O
There	O
have	O
been	O
reports	O
of	O
uveitis	O
in	O
patients	O
to	O
whom	O
fluconazole	S-drug-EF-1
and	O
rifabutin	S-drug-EF-2
were	O
coadministered	O
.	O

Patients	O
receiving	O
rifabutin	S-drug-AD-1
and	O
fluconazole	S-drug-AD-2
concomitantly	O
should	O
be	O
carefully	O
monitored	O
.	O

Tacrolimus	S-drug
:	O
There	O
have	O
been	O
reports	O
of	O
nephrotoxicity	O
in	O
patients	O
to	O
whom	O
fluconazole	S-drug-EF-1
and	O
tacrolimus	S-drug-EF-2
were	O
coadministered	O
.	O

Patients	O
receiving	O
tacrolimus	S-drug-AD-1
and	O
fluconazole	S-drug-AD-2
concomitantly	O
should	O
be	O
carefully	O
monitored	O
.	O

Short	B-group
-	I-group
acting	I-group
Benzodiazepines	E-group
:	O
Following	O
oral	O
administration	O
of	O
midazolam	S-drug-ME-1
,	O
fluconazole	S-drug-ME-2
resulted	O
in	O
substantial	O
increases	O
in	O
midazolam	S-drug
concentrations	O
and	O
psychomotor	O
effects	O
.	O

This	O
effect	O
on	O
midazolam	S-drug-EF-1
appears	O
to	O
be	O
more	O
pronounced	O
following	O
oral	O
administration	O
of	O
fluconazole	S-drug-EF-2
than	O
with	O
fluconazole	S-drug
administered	O
intravenously	O
.	O

If	O
short	B-group-AD-1
-	I-group-AD-1
acting	I-group-AD-1
benzodiazepines	E-group-AD-1
,	O
which	O
are	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
,	O
are	O
concomitantly	O
administered	O
with	O
fluconazole	S-drug-AD-2
,	O
consideration	O
should	O
be	O
given	O
to	O
decreasing	O
the	O
benzodiazepine	S-group
dosage	O
,	O
and	O
the	O
patients	O
should	O
be	O
appropriately	O
monitored	O
.	O

Fluconazole	S-drug-ME-1
tablets	O
coadministered	O
with	O
ethinyl	B-drug-ME-2
estradiol	E-drug-ME-2
-	O
and	O
levonorgestrel	S-drug-ME-2
-	O
containing	O
oral	O
contraceptives	S-group
produced	O
an	O
overall	O
mean	O
increase	O
in	O
ethinyl	B-drug
estradiol	E-drug
and	O
levonorgestrel	S-drug
levels	O
;	O

however	O
,	O
in	O
some	O
patients	O
there	O
were	O
decreases	O
up	O
to	O
47	O
%	O
and	O
33	O
%	O
of	O
ethinyl	B-drug
estradiol	E-drug
and	O
levonorgestrel	S-drug
levels	O
.	O

The	O
data	O
presently	O
available	O
indicate	O
that	O
the	O
decreases	O
in	O
some	O
individual	O
ethinyl	B-drug
estradiol	E-drug
and	O
levonorgestrel	S-drug
AUC	O
values	O
with	O
fluconazole	S-drug
treatment	O
are	O
likely	O
the	O
result	O
of	O
random	O
variation	O
.	O

While	O
there	O
is	O
evidence	O
that	O
fluconazole	S-drug-ME-1
can	O
inhibit	O
the	O
metabolism	O
of	O
ethinyl	B-drug-ME-2
estradiol	E-drug-ME-2
and	O
levonorgestrel	S-drug-ME-2
,	O
there	O
is	O
no	O
evidence	O
that	O
fluconazole	S-drug
is	O
a	O
net	O
inducer	O
of	O
ethinyl	B-drug
estradiol	E-drug
or	O
levonorgestrel	S-drug
metabolism	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
effects	O
is	O
presently	O
unknown	O
.	O

Physicians	O
should	O
be	O
aware	O
that	O
interaction	O
studies	O
with	O
medications	O
other	O
than	O
those	O
listed	O
in	O
the	O
<	O
a	O
href	O
=	O
``	O
flucon_cp.htm	O
#	O
CP	O
``	O
>	O
CLINICAL	O
PHARMACOLOGY	O
section	O
have	O
not	O
been	O
conducted	O
,	O
but	O
such	O
interactions	O
may	O
occur	O
.	O

You	O
can	O
not	O
take	O
mazindol	S-drug-AD-1
if	O
you	O
have	O
taken	O
a	O
monoamine	B-group-AD-2
oxidase	I-group-AD-2
inhibitor	E-group-AD-2
(	O
MAOI	S-group-AD-2
)	O
such	O
as	O
isocarboxazid	S-drug-AD-2
(	O
Marplan	S-brand-AD-2
)	O
,	O
tranylcypromine	S-drug-AD-2
(	O
Parnate	S-brand-AD-2
)	O
,	O
or	O
phenelzine	S-drug-AD-2
(	O
Nardil	S-brand-AD-2
)	O
in	O
the	O
last	O
14	O
days	O
.	O

Changes	O
in	O
insulin	S-drug-AD-1
and	O
other	O
diabetes	O
drug	O
therapies	O
may	O
be	O
necessary	O
during	O
treatment	O
with	O
mazindol	S-drug-AD-2
.	O

Mazindol	S-drug-EF-1
may	O
reduce	O
the	O
effects	O
of	O
guanethidine	S-drug-EF-2
(	O
Ismelin	S-brand-EF-2
)	O
.	O

This	O
could	O
lead	O
to	O
an	O
increase	O
in	O
blood	O
pressure	O
.	O

Tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
guanethidine	S-drug
.	O

Before	O
taking	O
this	O
medication	O
,	O
tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
a	O
tricyclic	B-group
antidepressant	E-group
such	O
as	O
amitriptyline	S-drug
(	O
Elavil	S-brand
)	O
,	O
amoxapine	S-drug
(	O
Asendin	S-brand
)	O
,	O
doxepin	S-drug
(	O
Sinequan	S-brand
)	O
,	O
nortriptyline	S-drug
(	O
Pamelor	S-brand
)	O
,	O
imipramine	S-drug
(	O
Tofranil	S-brand
)	O
,	O
clomipramine	S-drug
(	O
Anafranil	S-brand
)	O
,	O
protriptyline	S-drug
(	O
Vivactil	S-brand
)	O
,	O
or	O
desipramine	S-drug
(	O
Norpramin	S-brand
)	O
.	O

These	O
drugs	O
may	O
decrease	O
the	O
effects	O
of	O
mazindol	S-drug
.	O

Preliminary	O
evidence	O
suggests	O
that	O
cimetidine	S-drug-ME-1
inhibits	O
mebendazole	S-drug-ME-2
metabolism	O
and	O
may	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
mebendazole	S-drug
.	O

Patients	O
receiving	O
antibiotics	S-group-AD-1
and	O
sulfonamides	S-group-AD-1
generally	O
should	O
not	O
be	O
treated	O
with	O
ganglion	B-group-AD-2
blockers	E-group-AD-2
.	O

The	O
action	O
of	O
Mecamylamine	S-drug-EF-1
may	O
be	O
potentiated	O
by	O
anesthesia	O
,	O
other	O
antihypertensive	B-group-EF-2
drugs	E-group-EF-2
and	O
alcohol	S-drug-EF-2
.	O

No	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
depo	B-brand
-	I-brand
subQ	I-brand
provera	I-brand
104	E-brand
.	O

Aminoglutethimide	S-drug-ME-1
administered	O
concomitantly	O
with	O
depo	B-brand-ME-2
-	I-brand-ME-2
subQ	I-brand-ME-2
provera	I-brand-ME-2
104	E-brand-ME-2
may	O
significantly	O
decrease	O
the	O
serum	O
concentrations	O
of	O
MPA	S-drug
.	O

Laboratory	O
Tests	O
The	O
pathologist	O
should	O
be	O
advised	O
of	O
progestin	O
therapy	O
when	O
relevant	O
specimens	O
are	O
submitted	O
.	O

The	O
physician	O
should	O
be	O
informed	O
that	O
certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
,	O
and	O
blood	O
components	O
may	O
be	O
affected	O
by	O
progestin	O
therapy	O
:	O
(	O
a	O
)	O
Plasma	O
and	O
urinary	O
steroid	O
levels	O
are	O
decreased	O
(	O
e.g	O
.	O
,	O
progesterone	O
,	O
estradiol	O
,	O
pregnanediol	O
,	O
testosterone	O
,	O
cortisol	O
)	O
.	O

(	O
b	O
)	O
Plasma	O
and	O
urinary	O
gonadotropin	O
levels	O
are	O
decreased	O
(	O
e.g	O
.	O
,	O
LH	O
,	O
FSH	O
)	O
.	O

(	O
c	O
)	O
SHBG	O
concentrations	O
are	O
decreased	O
.	O

(	O
d	O
)	O
T3	O
-	O
uptake	O
values	O
may	O
decrease	O
.	O

(	O
e	O
)	O
There	O
may	O
be	O
small	O
changes	O
in	O
coagulation	O
factors	O
.	O

(	O
f	O
)	O
Sulfobromophthalein	O
and	O
other	O
liver	O
function	O
test	O
values	O
may	O
be	O
increased	O
slightly	O
.	O

(	O
g	O
)	O
There	O
may	O
be	O
small	O
changes	O
in	O
lipid	O
profiles	O
.	O

Pharmacokinetic	O
studies	O
show	O
that	O
there	O
are	O
no	O
significant	O
alterations	O
in	O
pharmacokinetic	O
parameters	O
of	O
zidovudine	S-drug
or	O
rifabutin	S-drug
to	O
warrant	O
dosage	O
adjustment	O
when	O
megestrol	B-drug
acetate	E-drug
is	O
administered	O
with	O
these	O
drugs	O
.	O

A	O
pharmacokinetic	O
study	O
demonstrated	O
that	O
coadministration	O
of	O
megestrol	B-drug-ME-1
acetate	E-drug-ME-1
and	O
indinavir	S-drug-ME-2
results	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
pharmacokinetic	O
parameters	O
(	O
~	O
36	O
%	O
for	O
Cmax	O
and	O
~	O
28	O
%	O
for	O
AUC	O
)	O
of	O
indinavir	S-drug
.	O

Administration	O
of	O
a	O
higher	O
dose	O
of	O
indinavir	S-drug-AD-1
should	O
be	O
considered	O
when	O
coadministering	O
with	O
megestrol	B-drug-AD-2
acetate	E-drug-AD-2
.	O

The	O
effects	O
of	O
indinavir	S-drug
,	O
zidovudine	S-drug
or	O
rifabutin	S-drug
on	O
the	O
pharmacokinetics	O
of	O
megestrol	B-drug
acetate	E-drug
were	O
not	O
studied	O
.	O

Melatonin	S-drug-IN-1
may	O
interact	O
with	O
the	O
following	O
drugs	O
:	O
aspirin	S-brand-IN-2
and	O
other	O
NSAIDs	S-group-IN-2
(	O
may	O
lower	O
melatonin	S-drug
levels	O
)	O
,	O
fluvoxamine	S-drug-IN-2
(	O
bioavailability	O
of	O
oral	O
melatonin	S-drug
is	O
increased	O
with	O
coadministration	O
)	O
,	O
beta	B-group-IN-2
blockers	E-group-IN-2
(	O
may	O
decrease	O
melatonin	S-drug
levels	O
)	O
,	O
fluoxetine	S-drug-IN-2
(	O
reports	O
of	O
psychotic	O
episodes	O
when	O
coadministered	O
)	O
,	O
progestin	S-group-IN-2
(	O
coadministration	O
of	O
melatonin	S-drug-EF-1
with	O
progestin	S-group-EF-2
can	O
inhibit	O
ovarian	O
function	O
in	O
women	O
)	O
,	O
benzodiazepenes	S-group-IN-2
and	O
other	O
sedating	O
drugs	O
(	O
may	O
result	O
in	O
additive	O
sedation	O
and	O
an	O
increased	O
incidence	O
of	O
adverse	O
effects	O
)	O
,	O
and	O
corticosteroids	S-group-IN-2
(	O
coadministration	O
of	O
melatonin	S-drug-EF-1
and	O
corticosteroids	S-group-EF-2
may	O
interfere	O
with	O
the	O
efficacy	O
of	O
the	O
corticosteroids	S-group
)	O
.	O

ACE	B-group
inhibitors	E-group
Reports	O
suggest	O
that	O
NSAIDs	S-group-EF-1
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
angiotensin	B-group-EF-2
-	I-group-EF-2
converting	I-group-EF-2
enzyme	I-group-EF-2
(	I-group-EF-2
ACE	I-group-EF-2
)	I-group-EF-2
inhibitors	E-group-EF-2
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	S-group-AD-1
concomitantly	O
with	O
ACE	B-group-AD-2
inhibitors	E-group-AD-2
.	O

Aspirin	S-brand
:	O
Concomitant	O
administration	O
of	O
aspirin	S-brand-ME-1
(	O
1000	O
mg	O
TID	O
)	O
to	O
healthy	O
volunteers	O
tended	O
to	O
increase	O
the	O
AUC	O
(	O
10	O
%	O
)	O
and	O
Cmax	O
(	O
24	O
%	O
)	O
of	O
meloxicam	S-drug-ME-2
.	O

The	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
known	O
;	O

however	O
,	O
as	O
with	O
other	O
NSAIDs	S-group-AD-1
,	O
concomitant	O
administration	O
of	O
meloxicam	S-drug-AD-1
and	O
aspirin	S-brand-AD-2
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
for	O
increased	O
adverse	O
effects	O
.	O

Concomitant	O
administration	O
of	O
low	O
-	O
dose	O
aspirin	S-brand-EF-1
with	O
MOBIC	S-brand-EF-2
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
,	O
compared	O
to	O
use	O
of	O
MOBIC	S-brand
alone	O
.	O

MOBIC	S-brand
is	O
not	O
a	O
substitute	O
for	O
aspirin	S-brand
for	O
cardiovascular	O
prophylaxis	O
.	O

Cholestyramine	S-drug
:	O
Pretreatment	O
for	O
four	O
days	O
with	O
cholestyramine	S-drug-ME-1
significantly	O
increased	O
the	O
clearance	O
of	O
meloxicam	S-drug-ME-2
by	O
50	O
%	O
.	O

This	O
resulted	O
in	O
a	O
decrease	O
in	O
t1	O
/	O
2	O
,	O
from	O
19.2	O
hours	O
to	O
12.5	O
hours	O
,	O
and	O
a	O
35	O
%	O
reduction	O
in	O
AUC	O
.	O

This	O
suggests	O
the	O
existence	O
of	O
a	O
recirculation	O
pathway	O
for	O
meloxicam	S-drug
in	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
clinical	O
relevance	O
of	O
this	O
interaction	O
has	O
not	O
been	O
established	O
.	O

Cimetidine	S-drug
:	O
Concomitant	O
administration	O
of	O
200	O
mg	O
cimetidine	S-drug
QID	O
did	O
not	O
alter	O
the	O
single	O
-	O
dose	O
pharmacokinetics	O
of	O
30	O
mg	O
meloxicam	S-drug
.	O

Digoxin	S-drug
:	O
Meloxicam	S-drug
15	O
mg	O
once	O
daily	O
for	O
7	O
days	O
did	O
not	O
alter	O
the	O
plasma	O
concentration	O
profile	O
of	O
digoxin	S-drug
after	O
b	O
-	O
acetyldigoxin	O
administration	O
for	O
7	O
days	O
at	O
clinical	O
doses	O
.	O

In	O
vitro	O
testing	O
found	O
no	O
protein	O
binding	O
drug	O
interaction	O
between	O
digoxin	S-drug
and	O
meloxicam	S-drug
.	O

Furosemide	S-drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	S-group-EF-1
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	S-drug-EF-2
and	O
thiazide	B-group-EF-2
diuretics	E-group-EF-2
in	O
some	O
patients	O
.	O

This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

Studies	O
with	O
furosemide	S-drug
agents	O
and	O
meloxicam	S-drug
have	O
not	O
demonstrated	O
a	O
reduction	O
in	O
natriuretic	O
effect	O
.	O

Furosemide	S-drug
:	O
single	O
and	O
multiple	O
dose	O
pharmacodynamics	O
and	O
pharmacokinetics	O
are	O
not	O
affected	O
by	O
multiple	O
doses	O
of	O
meloxicam	S-drug
.	O

Nevertheless	O
,	O
during	O
concomitant	O
therapy	O
with	O
furosemide	S-drug-AD-1
and	O
MOBIC	S-brand-AD-2
,	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
declining	O
renal	O
function	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	O
efficacy	O
.	O

Lithium	S-drug
:	O
In	O
clinical	O
trials	O
,	O
NSAIDs	S-group-ME-1
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	S-drug-ME-2
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	S-drug
clearance	O
.	O

In	O
a	O
study	O
conducted	O
in	O
healthy	O
subjects	O
,	O
mean	O
pre	O
-	O
dose	O
lithium	S-drug
concentration	O
and	O
AUC	O
were	O
increased	O
by	O
21	O
%	O
in	O
subjects	O
receiving	O
lithium	S-drug-ME-1
doses	O
ranging	O
from	O
804	O
to	O
1072	O
mg	O
BID	O
with	O
meloxicam	S-drug-ME-2
15	O
mg	O
QD	O
as	O
compared	O
to	O
subjects	O
receiving	O
lithium	S-drug
alone	O
.	O

These	O
effects	O
have	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
MOBIC	S-brand
.	O

Patients	O
on	O
lithium	S-drug-AD-1
treatment	O
should	O
be	O
closely	O
monitored	O
when	O
MOBIC	S-brand-AD-2
is	O
introduced	O
or	O
withdrawn	O
.	O

Methotrexate	S-drug
:	O
A	O
study	O
in	O
13	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
evaluated	O
the	O
effects	O
of	O
multiple	O
doses	O
of	O
meloxicam	S-drug
on	O
the	O
pharmacokinetics	O
of	O
methotrexate	S-drug
taken	O
once	O
weekly	O
.	O

Meloxicam	S-drug
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
single	O
doses	O
of	O
methotrexate	S-drug
.	O

In	O
vitro	O
,	O
methotrexate	S-drug
did	O
not	O
displace	O
meloxicam	S-drug
from	O
its	O
human	O
serum	O
binding	O
sites	O
.	O

Warfarin	S-drug
:	O
Anticoagulant	O
activity	O
should	O
be	O
monitored	O
,	O
particularly	O
in	O
the	O
first	O
few	O
days	O
after	O
initiating	O
or	O
changing	O
MOBIC	S-brand-AD-1
therapy	O
in	O
patients	O
receiving	O
warfarin	S-drug-AD-2
or	O
similar	O
agents	O
,	O
since	O
these	O
patients	O
are	O
at	O
an	O
increased	O
risk	O
of	O
bleeding	O
.	O

The	O
effect	O
of	O
meloxicam	S-drug
on	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	S-drug
was	O
studied	O
in	O
a	O
group	O
of	O
healthy	O
subjects	O
receiving	O
daily	O
doses	O
of	O
warfarin	S-drug
that	O
produced	O
an	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
between	O
1.2	O
and	O
1.8	O
.	O

In	O
these	O
subjects	O
,	O
meloxicam	S-drug
did	O
not	O
alter	O
warfarin	S-drug
pharmacokinetics	O
and	O
the	O
average	O
anticoagulant	O
effect	O
of	O
warfarin	S-drug
as	O
determined	O
by	O
prothrombin	O
time	O
.	O

However	O
,	O
one	O
subject	O
showed	O
an	O
increase	O
in	O
INR	O
from	O
1.5	O
to	O
2.1	O
.	O

Caution	O
should	O
be	O
used	O
when	O
administering	O
MOBIC	S-brand-AD-1
with	O
warfarin	S-drug-AD-2
since	O
patients	O
on	O
warfarin	S-drug
may	O
experience	O
changes	O
in	O
INR	O
and	O
an	O
increased	O
risk	O
of	O
bleeding	O
complications	O
when	O
a	O
new	O
medication	O
is	O
introduced	O
.	O

DRUG	O
INTERACTIONS	O
There	O
are	O
no	O
known	O
drug	O
/	O
drug	O
interactions	O
with	O
oral	O
ALKERAN	S-brand
Vaccinations	O
with	O
live	B-group
organism	I-group
vaccines	E-group
are	O
not	O
recommended	O
in	O
immunocompromised	O
individuals	O
Nalidixic	B-drug-EF-1
acid	E-drug-EF-1
together	O
with	O
high	O
-	O
dose	O
intravenous	O
melphalan	S-drug-EF-2
has	O
caused	O
deaths	O
in	O
children	O
due	O
to	O
haemorrhagic	O
enterocolitis	O
.	O

Impaired	O
renal	O
function	O
has	O
been	O
described	O
in	O
bone	O
marrow	O
transplant	O
patients	O
who	O
were	O
conditioned	O
with	O
high	O
-	O
dose	O
intravenous	O
melphalan	S-drug-EF-1
and	O
who	O
subsequently	O
received	O
cyclosporin	S-drug-EF-2
to	O
prevent	O
graft	O
-	O
versus	O
-	O
host	O
disease	O

The	O
following	O
agents	O
may	O
increase	O
certain	O
actions	O
or	O
side	O
effects	O
of	O
anticholinergic	B-group-EF-1
drugs	E-group-EF-1
:	O
amantadine	S-drug-EF-2
,	O
antiarrhythmic	B-group-EF-2
agents	I-group-EF-2
of	I-group-EF-2
class	I-group-EF-2
I	E-group-EF-2
(	O
e.g	O
.	O
,	O
quinidine	S-drug-EF-2
)	O
,	O
antihistamines	S-group-EF-2
,	O
antipsychotic	B-group-EF-2
agents	E-group-EF-2
(	O
e.g	O
.	O
,	O
phenothiazines	S-group-EF-2
)	O
,	O
benzodiazepines	S-group-EF-2
,	O
MAO	B-group-EF-2
inhibitors	E-group-EF-2
,	O
narcotic	B-group-EF-2
analgesics	E-group-EF-2
(	O
e.g	O
.	O
,	O
meperidine	S-drug-EF-2
)	O
,	O
nitrates	S-group-EF-2
and	O
nitrites	S-group-EF-2
,	O
sympathomimetic	B-group-EF-2
agents	E-group-EF-2
,	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
,	O
and	O
other	O
drugs	O
having	O
anticholinergic	O
activity	O
.	O

Anticholinergics	S-group-EF-1
antagonize	O
the	O
effects	O
of	O
antiglaucoma	B-group-EF-2
agents	E-group-EF-2
.	O

Anticholinergic	B-group-EF-1
drugs	E-group-EF-1
in	O
the	O
presence	O
of	O
increased	O
intraocular	O
pressure	O
may	O
be	O
hazardous	O
when	O
taken	O
concurrently	O
with	O
agents	O
such	O
as	O
corticosteroids	S-group-EF-2
.	O

Anticholinergic	B-group-ME-1
agents	E-group-ME-1
may	O
affect	O
gastrointestinal	O
absorption	O
of	O
various	O
drugs	O
,	O
such	O
as	O
slowly	O
dissolving	O
dosage	O
forms	O
of	O
digoxin	S-drug-ME-2
;	O

increased	O
serum	O
digoxin	S-drug
concentrations	O
may	O
result	O
.	O

Anticholinergic	B-group-EF-1
drugs	E-group-EF-1
may	O
antagonize	O
the	O
effects	O
of	O
drugs	O
that	O
alter	O
gastrointestinal	O
motility	O
,	O
such	O
as	O
metoclopramide	S-drug-EF-2
.	O

Because	O
antacids	S-group-ME-1
may	O
interfere	O
with	O
the	O
absorption	O
of	O
anticholinergic	B-group-ME-2
agents	E-group-ME-2
,	O
simultaneous	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

The	O
inhibiting	O
effects	O
of	O
anticholinergic	B-group
drugs	E-group
on	O
gastric	O
hydrochloric	O
acid	O
secretion	O
are	O
antagonized	O
by	O
agents	O
used	O
to	O
treat	O
achlorhydria	O
and	O
those	O
used	O
to	O
test	O
gastric	O
secretion	O
.	O

Interaction	O
with	O
Other	O
Central	B-group
Nervous	I-group
System	I-group
Depressants	E-group
:	O
MEPERIDINE	S-drug-AD-1
SHOULD	O
BE	O
USED	O
WITH	O
GREAT	O
CAUTION	O
AND	O
IN	O
REDUCED	O
DOSAGE	O
IN	O
PATIENTS	O
WHO	O
ARE	O
CONCURRENTLY	O
RECEIVING	O
OTHER	O
NARCOTIC	B-group-AD-2
ANALGESICS	E-group-AD-2
,	O
GENERAL	O
ANESTHETICS	S-group-AD-2
,	O
PHENOTHIAZINES	S-group-AD-2
,	O
OTHER	O
TRANQUILIZERS	S-group-AD-2
,	O
SEDATIVE	B-group-AD-2
-	I-group-AD-2
HYPNOTICS	E-group-AD-2
(	O
INCLUDING	O
BARBITURATES	S-group-AD-2
)	O
,	O
TRICYCLIC	B-group-AD-2
ANTIDEPRESSANTS	E-group-AD-2
AND	O
OTHER	O
CNS	B-group-AD-2
DEPRESSANTS	E-group-AD-2
(	O
INCLUDING	O
ALCOHOL	S-drug-AD-2
)	O
.	O

RESPIRATORY	O
DEPRESSION	O
,	O
HYPOTENSION	O
,	O
AND	O
PROFOUND	O
SEDATION	O
OR	O
COMA	O
MAY	O
RESULT	O
.	O

Some	O
anticonvulsants	S-group-IN-1
may	O
interact	O
with	O
Mephenytoin	S-drug-IN-2
.	O

They	O
can	O
either	O
increase	O
or	O
decrease	O
the	O
effect	O
of	O
Mephenytoin	S-drug
.	O

Those	O
anticonvulsants	S-group
include	O
divalproex	B-drug
sodium	E-drug
,	O
valproic	B-drug
acid	E-drug
,	O
and	O
phenobarbital	S-drug
.	O

Mephenytoin	S-drug-EF-1
may	O
also	O
affect	O
the	O
effects	O
of	O
other	O
drugs	O
,	O
which	O
include	O
some	O
steroid	B-group-EF-2
medications	E-group-EF-2
,	O
warfarin	S-drug-EF-2
,	O
certain	O
heart	O
medicines	O
,	O
birth	O
control	O
pills	O
,	O
anti	B-group-EF-2
-	I-group-EF-2
infective	I-group-EF-2
medicines	E-group-EF-2
,	O
furosemide	S-drug-EF-2
and	O
theophylline	S-drug-EF-2
Please	O
note	O
that	O
Mephenytoin	S-drug
may	O
interact	O
with	O
other	O
drugs	O
that	O
are	O
not	O
listed	O
here	O
.	O

Mequitazine	S-drug-IN-1
can	O
interact	O
with	O
CNS	B-group-IN-2
depressant	E-group-IN-2
,	O
antichlolinergic	S-group-IN-2
,	O
TCA	S-group-IN-2
,	O
MAOIs	S-group-IN-2
,	O
and	O
alcohol	S-drug-IN-2
.	O

Probenecid	S-drug-ME-1
competes	O
with	O
meropenem	S-drug-ME-2
for	O
active	O
tubular	O
secretion	O
and	O
thus	O
inhibits	O
the	O
renal	O
excretion	O
of	O
meropenem	S-drug
.	O

This	O
led	O
to	O
statistically	O
significant	O
increases	O
in	O
the	O
elimination	O
half	O
-	O
life	O
(	O
38	O
%	O
)	O
and	O
in	O
the	O
extent	O
of	O
systemic	O
exposure	O
(	O
56	O
%	O
)	O
.	O

Therefore	O
,	O
the	O
coadministration	O
of	O
probenecid	S-drug-AD-1
with	O
meropenem	S-drug-AD-2
is	O
not	O
recommended	O
.	O

There	O
is	O
evidence	O
that	O
meropenem	S-drug-ME-1
may	O
reduce	O
serum	O
levels	O
of	O
valproic	B-drug-ME-2
acid	E-drug-ME-2
to	O
subtherapeutic	O
levels	O
(	O
therapeutic	O
range	O
considered	O
to	O
be	O
50	O
to	O
100	O
g	O
/	O
mL	O
total	O
valproate	S-drug
)	O
.	O

ARAMINE	S-brand
should	O
be	O
used	O
with	O
caution	O
in	O
digitalized	O
patients	O
,	O
since	O
the	O
combination	O
of	O
digitalis	S-group-EF-1
and	O
sympathomimetic	B-group-EF-2
amines	E-group-EF-2
may	O
cause	O
ectopic	O
arrhythmias	O
.	O

Monoamine	B-group-EF-1
oxidase	I-group-EF-1
inhibitors	E-group-EF-1
or	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
may	O
potentiate	O
the	O
action	O
of	O
sympathomimetic	B-group-EF-2
amines	E-group-EF-2
.	O

Therefore	O
,	O
when	O
initiating	O
pressor	O
therapy	O
in	O
patients	O
receiving	O
these	O
drugs	O
,	O
the	O
initial	O
dose	O
should	O
be	O
small	O
and	O
given	O
with	O
caution	O
.	O

SKELAXIN	S-brand-EF-1
may	O
enhance	O
the	O
effects	O
of	O
alcohol	S-drug-EF-2
,	O
barbiturates	S-group-EF-2
and	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
.	O

Methazolamide	S-drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
on	O
steroid	O
therapy	O
because	O
of	O
the	O
potential	O
for	O
developing	O
hypokalemia	O
.	O

Caution	O
is	O
advised	O
for	O
patients	O
receiving	O
high	O
-	O
dose	O
aspirin	S-brand-AD-1
and	O
methazolamide	S-drug-AD-2
concomitantly	O
,	O
as	O
anorexia	O
,	O
tachypnea	O
,	O
lethargy	O
,	O
coma	O
and	O
death	O
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
high	O
-	O
dose	O
aspirin	S-brand-EF-1
and	O
carbonic	B-group-EF-2
anhydrase	I-group-EF-2
inhibitors	E-group-EF-2
.	O

Anticoagulants	S-group
(	O
oral	O
)	O
:	O
The	O
activity	O
of	O
oral	O
anticoagulants	S-group-EF-1
may	O
be	O
potentiated	O
by	O
anti	O
-	O
vitamin	O
-	O
K	O
activity	O
attributed	O
to	O
methimazole	S-drug-EF-2
.	O

-	O
adrenergic	B-group
blocking	I-group
agents	E-group
:	O
Hyperthyroidism	O
may	O
cause	O
an	O
increased	O
clearance	O
of	O
beta	O
ratio	O
.	O

A	O
dose	O
reduction	O
of	O
beta	B-group
-	I-group
adrenergic	I-group
blockers	E-group
may	O
be	O
needed	O
when	O
a	O
hyperthyroid	O
patient	O
becomes	O
euthyroid	O
.	O

Digitalis	B-group
glycosides	E-group
:	O
Serum	O
digitalis	O
levels	O
may	O
be	O
increased	O
when	O
hyperthyroid	O
patients	O
on	O
a	O
stable	O
digitalis	B-group
glycoside	E-group
regimen	O
become	O
euthyroid	O
;	O

reduced	O
dosage	O
of	O
digitalis	B-group
glycosides	E-group
may	O
be	O
required	O
.	O

Theophylline	S-drug
:	O
Theophylline	S-drug
clearance	O
may	O
decrease	O
when	O
hyperthyroid	O
patients	O
on	O
a	O
stable	O
theophylline	S-drug
regimen	O
become	O
euthyroid	O
;	O

a	O
reduced	O
dose	O
of	O
theophylline	S-drug
may	O
be	O
needed	O
.	O

Dosages	O
of	O
concomitantly	O
administered	O
opioids	S-group-EF-1
should	O
be	O
reduced	O
by	O
approximately	O
half	O
,	O
because	O
levomepromazine	S-drug-EF-M
amplifies	O
the	O
therapeutic	O
actions	O
and	O
side	O
-	O
effects	O
of	O
opioids	S-group-EF-2
.	O

Combination	O
with	O
tramadol	S-drug
(	O
Ultram	S-brand
)	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
seizures	O
.	O

Additive	O
sedative	O
effects	O
and	O
confusional	O
states	O
may	O
emerge	O
if	O
levomepromazine	S-drug-EF-1
is	O
given	O
with	O
benzodiazepines	S-group-EF-2
or	O
barbiturates	S-group-EF-2
.	O

This	O
may	O
be	O
avoided	O
by	O
using	O
the	O
lowest	O
dose	O
possible	O
with	O
the	O
substances	O
in	O
question	O
.	O

Exert	O
particular	O
caution	O
in	O
combining	O
levomepromazine	S-drug-AD-1
with	O
other	O
anticholinergic	B-group-AD-2
drugs	E-group-AD-2
(	O
tricyclic	B-group-AD-2
antidepressants	E-group-AD-2
and	O
antiparkinsonian	B-group-AD-2
-	I-group-AD-2
agents	E-group-AD-2
)	O
:	O
Particularly	O
the	O
elderly	O
may	O
develop	O
delirium	O
,	O
high	O
fever	O
,	O
severe	O
obstipation	O
,	O
even	O
ileus	O
and	O
glaucoma	O
.	O

Reduce	O
both	O
the	O
dose	O
of	O
levomepromazine	S-drug
and	O
the	O
dose	O
of	O
the	O
other	O
drug	O
.	O

If	O
possible	O
,	O
avoid	O
such	O
combinations	O
.	O

Caffeine	S-drug-EF-1
and	O
/	O
or	O
stimulantes	O
of	O
the	O
ephedrine	S-drug-EF-1
/	O
amphetamine	S-drug-EF-1
type	O
may	O
counteract	O
the	O
specific	O
actions	O
of	O
levomepromazine	S-drug-EF-2
.	O

Concomitant	O
use	O
of	O
these	O
substances	O
should	O
be	O
avoided	O
.	O

Coffee	O
and	O
black	O
tea	O
should	O
be	O
avoided	O
because	O
they	O
decrease	O
the	O
absorption	O
of	O
levomepromazine	S-drug
considerably	O
.	O

The	O
same	O
is	O
true	O
for	O
antacids	S-group
;	O

these	O
should	O
be	O
given	O
1	O
to	O
2	O
hours	O
before	O
or	O
after	O
oral	O
administration	O
of	O
leveomepromazine	S-drug
.	O

Since	O
Celontin	S-brand-AD-1
(	O
methsuximide	S-drug-AD-1
)	O
may	O
interact	O
with	O
concurrently	O
administered	O
antiepileptic	B-group-AD-2
drugs	E-group-AD-2
,	O
periodic	O
serum	O
level	O
determinations	O
of	O
these	O
drugs	O
may	O
be	O
necessary	O
(	O
eg	O
methsuximide	S-drug-ME-1
may	O
increase	O
the	O
plasma	O
concentrations	O
of	O
phenytoin	S-drug-ME-2
and	O
phenobarbital	S-drug-ME-2
)	O
.	O

Hypokalemia	O
can	O
sensitize	O
or	O
exaggerate	O
the	O
response	O
of	O
the	O
heart	O
to	O
the	O
toxic	O
effects	O
of	O
digitalis	S-group
(	O
e.g	O
.	O
,	O
increased	O
ventricular	O
irritability	O
)	O
.	O

Hypokalemia	O
may	O
develop	O
during	O
concomitant	O
use	O
of	O
steroids	S-group
or	O
ACTH	S-drug
.	O

Insulin	S-drug
requirements	O
in	O
diabetic	O
patients	O
may	O
be	O
increased	O
,	O
decreased	O
,	O
or	O
unchanged	O
.	O

Thiazides	S-group-EF-1
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	S-drug-EF-2
.	O

This	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O

Thiazide	B-group-EF-1
drugs	E-group-EF-1
may	O
increase	O
the	O
responsiveness	O
of	O
tubocurarine	S-drug-EF-2
.	O

Lithium	S-drug-ME-1
renal	O
clearance	O
is	O
reduced	O
by	O
thiazides	S-group-ME-2
,	O
increasing	O
the	O
risk	O
of	O
lithium	S-drug
toxicity	O
.	O

Thiazides	S-group-EF-1
may	O
add	O
to	O
or	O
potentiate	O
the	O
action	O
of	O
other	O
antihypertensive	B-group-EF-2
drugs	E-group-EF-2
.	O

Potentiation	O
occurs	O
with	O
ganglionic	S-group
or	O
peripheral	B-group
adrenergic	I-group
blocking	I-group
drugs	E-group
.	O

When	O
methyldopa	S-drug-EF-1
is	O
used	O
with	O
other	O
antihypertensive	B-group-EF-2
drugs	E-group-EF-2
,	O
potentiation	O
of	O
antihypertensive	O
effect	O
may	O
occur	O
.	O

Patients	O
should	O
be	O
followed	O
carefully	O
to	O
detect	O
side	O
reactions	O
or	O
unusual	O
manifestations	O
of	O
drug	O
idiosyncrasy	O
.	O

Patients	O
may	O
require	O
reduced	O
doses	O
of	O
anesthetics	S-group-AD-1
when	O
on	O
methyldopa	S-drug-AD-2
.	O

If	O
hypotension	O
does	O
occur	O
during	O
anesthesia	O
,	O
it	O
usually	O
can	O
be	O
controlled	O
by	O
vasopressors	S-group
.	O

The	O
adrenergic	O
receptors	O
remain	O
sensitive	O
during	O
treatment	O
with	O
methyldopa	S-drug
.	O

When	O
methyldopa	S-drug-AD-1
and	O
lithium	S-drug-AD-2
are	O
given	O
concomitantly	O
the	O
patient	O
should	O
be	O
carefully	O
monitored	O
for	O
symptoms	O
of	O
lithium	S-drug
toxicity	O
.	O

Read	O
the	O
circular	O
for	O
lithium	S-drug
preparations	O
.	O

Several	O
studies	O
demonstrate	O
a	O
decrease	O
in	O
the	O
bioavailability	O
of	O
methyldopa	S-drug-ME-1
when	O
it	O
is	O
ingested	O
with	O
ferrous	B-drug-ME-2
sulfate	E-drug-ME-2
or	O
ferrous	B-drug-ME-2
gluconate	E-drug-ME-2
.	O

This	O
may	O
adversely	O
affect	O
blood	O
pressure	O
control	O
in	O
patients	O
treated	O
with	O
methyldopa	S-drug
.	O

Coadministration	O
of	O
methyldopa	S-drug-AD-1
with	O
ferrous	B-drug-AD-2
sulfate	E-drug-AD-2
or	O
ferrous	B-drug-AD-2
gluconate	E-drug-AD-2
is	O
not	O
recommended	O
.	O

Monoamine	B-group
oxidase	I-group
(	I-group
MAO	I-group
)	I-group
inhibitors	E-group
:	O
See	O
CONTRAINDICATIONS	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Methyldopa	S-drug
may	O
interfere	O
with	O
measurement	O
of	O
:	O
urinary	O
uric	O
acid	O
by	O
the	O
phosphotungstate	O
method	O
,	O
serum	O
creatinine	O
by	O
the	O
alkaline	O
picrate	O
method	O
,	O
and	O
SGOT	O
by	O
colorimetric	O
methods	O
.	O

Interference	O
with	O
spectrophotometric	O
methods	O
for	O
SGOT	O
analysis	O
has	O
not	O
been	O
reported	O
.	O

Since	O
methyldopa	S-drug
causes	O
fluorescence	O
in	O
urine	O
samples	O
at	O
the	O
same	O
wave	O
lengths	O
as	O
catecholamines	O
,	O
falsely	O
high	O
levels	O
of	O
urinary	O
catecholamines	O
may	O
be	O
reported	O
.	O

This	O
will	O
interfere	O
with	O
the	O
diagnosis	O
of	O
pheochromocytoma	O
.	O

It	O
is	O
important	O
to	O
recognize	O
this	O
phenomenon	O
before	O
a	O
patient	O
with	O
a	O
possible	O
pheochromocytoma	O
is	O
subjected	O
to	O
surgery	O
.	O

Methyldopa	S-drug
does	O
not	O
interfere	O
with	O
measurement	O
of	O
VMA	S-drug_n
(	O
vanillylmandelic	B-drug_n
acid	E-drug_n
)	O
,	O
a	O
test	O
for	O
pheochromocytoma	O
,	O
by	O
those	O
methods	O
which	O
convert	O
VMA	S-drug_n
to	O
vanillin	S-drug_n
.	O

Methyldopa	S-drug
is	O
not	O
recommended	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
pheochromocytoma	O
.	O

Rarely	O
,	O
when	O
urine	O
is	O
exposed	O
to	O
air	O
after	O
voiding	O
,	O
it	O
may	O
darken	O
because	O
of	O
breakdown	O
of	O
methyldopa	S-drug
or	O
its	O
metabolites	O
.	O

CYP	O
3A4	O
Inhibitors	O
(	O
e.g	O
.	O
Macrolide	B-group
Antibiotics	E-group
and	O
Protease	B-group
Inhibitors	E-group
)	O
There	O
have	O
been	O
rare	O
reports	O
of	O
serious	O
adverse	O
events	O
in	O
connection	O
with	O
the	O
coadministration	O
of	O
certain	O
ergot	B-group
alkaloid	I-group
drugs	E-group
(	O
e.g	O
.	O
dihydroergotamine	S-drug
and	O
ergotamine	S-drug
)	O
and	O
potent	O
CYP	O
3A4	O
inhibitors	O
,	O
resulting	O
in	O
vasospasm	O
leading	O
to	O
cerebral	O
ischemia	O
and	O
/	O
or	O
ischemia	O
of	O
the	O
extremities	O
.	O

Although	O
there	O
have	O
been	O
no	O
reports	O
of	O
such	O
interactions	O
with	O
methylergonovine	S-drug
alone	O
,	O
potent	O
CYP	O
3A4	O
inhibitors	O
should	O
not	O
be	O
coadministered	O
with	O
methylergonovine	O
.	O

Examples	O
of	O
some	O
of	O
the	O
more	O
potent	O
CYP	O
3A4	O
inhibitors	O
include	O
macrolide	B-group
antibiotics	E-group
(	O
e.g	O
.	O
,	O
erythromycin	S-drug
,	O
troleandomycin	S-drug
,	O
clarithromycin	S-drug
)	O
,	O
HIV	B-group
protease	E-group
or	O
reverse	B-group
transcriptase	I-group
inhibitors	E-group
(	O
e.g	O
.	O
,	O
ritonavir	S-drug
,	O
indinavir	S-drug
,	O
nelfinavir	S-drug
,	O
delavirdine	S-drug
)	O
or	O
azole	B-group
antifungals	E-group
(	O
e.g	O
.	O
,	O
ketoconazole	S-drug
,	O
itraconazole	S-drug
,	O
voriconazole	S-drug
)	O
.	O

Less	O
potent	O
CYP	O
3A4	O
inhibitors	O
should	O
be	O
administered	O
with	O
caution	O
.	O

Less	O
potent	O
inhibitors	O
include	O
saquinavir	S-drug
,	O
nefazodone	S-drug
,	O
fluconazole	S-drug
,	O
grapefruit	O
juice	O
,	O
fluoxetine	S-drug
,	O
fluvoxamine	S-drug
,	O
zileuton	S-drug
,	O
and	O
clotrimazole	S-drug
.	O

These	O
lists	O
are	O
not	O
exhaustive	O
,	O
and	O
the	O
prescriber	O
should	O
consider	O
the	O
effects	O
on	O
CYP	O
3A4	O
of	O
other	O
agents	O
being	O
considered	O
for	O
concomitant	O
use	O
with	O
methylergonovine	S-drug
.	O

No	O
pharmacokinetic	O
interactions	O
involving	O
other	O
cytochrome	O
P450	O
isoenzymes	O
are	O
known	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
Methergine	S-brand-AD-1
(	O
methylergonovine	B-drug-AD-1
maleate	E-drug-AD-1
)	O
is	O
used	O
concurrently	O
with	O
other	O
vasoconstrictors	S-group-AD-2
or	O
ergot	B-group-AD-2
alkaloids	E-group-AD-2
.	O

Ritalin	S-brand-EF-1
may	O
decrease	O
the	O
hypotensive	O
effect	O
of	O
guanethidine	S-drug-EF-2
.	O

Use	O
cautiously	O
with	O
pressor	O
agents	O
.	O

Human	O
pharmacologic	O
studies	O
have	O
shown	O
that	O
Ritalin	S-brand-ME-1
may	O
inhibit	O
the	O
metabolism	O
of	O
coumarin	B-group-ME-2
anticoagulants	E-group-ME-2
,	O
anticonvulsants	S-group-ME-2
(	O
phenobarbital	S-drug-ME-2
,	O
diphenylhydantoin	S-drug-ME-2
,	O
primidone	S-drug-ME-2
)	O
,	O
phenylbutazone	S-drug-ME-2
,	O
and	O
tricyclic	B-group-ME-2
drugs	E-group-ME-2
(	O
imipramine	S-drug-ME-2
,	O
clomipramine	S-drug-ME-2
,	O
desipramine	S-drug-ME-2
)	O
.	O

Downward	O
dosage	O
adjustments	O
of	O
these	O
drugs	O
may	O
be	O
required	O
when	O
given	O
concomitantly	O
with	O
Ritalin	S-brand
.	O

Serious	O
adverse	O
events	O
have	O
been	O
reported	O
in	O
concomitant	O
use	O
with	O
clonidine	S-drug
,	O
although	O
no	O
causality	O
for	O
the	O
combination	O
has	O
been	O
established	O
.	O

The	O
safety	O
of	O
using	O
methylphenidate	S-drug
in	O
combination	O
with	O
clonidine	S-drug
or	O
other	O
centrally	O
acting	O
alpha	B-group
-	I-group
2	I-group
agonists	E-group
has	O
not	O
been	O
systemically	O
evaluated	O
.	O

The	O
pharmacokinetic	O
interactions	O
listed	O
below	O
are	O
potentially	O
clinically	O
important	O
.	O

Mutual	O
inhibition	O
of	O
metabolism	O
occurs	O
with	O
concurrent	O
use	O
of	O
cyclosporin	S-drug-ME-1
and	O
methylprednisolone	S-drug-ME-2
;	O

therefore	O
,	O
it	O
is	O
possible	O
that	O
adverse	O
events	O
associated	O
with	O
the	O
individual	O
use	O
of	O
either	O
drug	O
may	O
be	O
more	O
apt	O
to	O
occur	O
.	O

convulsions	O
have	O
been	O
reported	O
with	O
concurrent	O
use	O
of	O
methylprednisolone	S-drug-EF-1
and	O
cyclosporin	S-drug-EF-2
.	O

Drugs	O
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	S-drug-MU-1
,	O
phenytoin	S-drug-MU-1
,	O
and	O
rifampin	S-drug-MU-1
may	O
increase	O
the	O
clearance	O
of	O
methylprednisolone	S-drug-ME-2
and	O
may	O
require	O
increased	O
in	O
methylprednisolone	S-drug-AD-2
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Drugs	O
such	O
as	O
troleandomycin	S-drug-ME-1
and	O
ketoconazole	S-drug-ME-1
may	O
inhibit	O
the	O
metabolism	O
of	O
methylprednisolone	S-drug-ME-2
and	O
thus	O
decrease	O
its	O
clearance	O
.	O

Therefore	O
,	O
the	O
dose	O
of	O
methylprednisolone	S-drug
should	O
be	O
titrated	O
to	O
avoid	O
steroid	O
toxicity	O
.	O

Methylprednisolone	S-drug-ME-1
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	S-brand-ME-2
.	O

This	O
could	O
lead	O
to	O
decreased	O
salicylate	S-group
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	S-group-EF-1
toxicity	O
when	O
methylprednisolone	S-drug-EF-2
is	O
withdrawn	O
.	O

Aspirin	S-brand-AD-1
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
corticosteroids	S-group-AD-2
in	O
patients	O
suffering	O
from	O
hypoprothrombinemia	O
.	O

The	O
effect	O
of	O
methylprednisolone	S-drug
on	O
oral	O
anticoagulants	S-group
is	O
variable	O
.	O

There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulant	S-group-EF-1
when	O
given	O
concurrently	O
with	O
corticosteroids	S-group-EF-2
.	O

Therefore	O
,	O
coagulation	O
indices	O
should	O
be	O
monitored	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O

Methscopolamine	S-drug-IN-1
may	O
interact	O
with	O
antidepressants	S-group
(	O
tricyclic	S-group-IN-2
type	O
)	O
,	O
MAO	B-group-IN-2
inhibitors	E-group-IN-2
(	O
e.g	O
.	O
,	O
phenelzine	S-drug-IN-2
,	O
linezolid	S-drug-IN-2
,	O
tranylcypromine	S-drug-IN-2
,	O
isocarboxazid	S-drug-IN-2
,	O
selegiline	S-drug-IN-2
,	O
furazolidone	S-drug-IN-2
)	O
,	O
quinidine	S-drug-IN-2
,	O
amantadine	S-drug-IN-2
,	O
antihistamines	S-group-IN-2
(	O
e.g	O
.	O
,	O
diphenhydramine	S-drug-IN-2
)	O
,	O
other	O
anticholinergics	S-group-IN-2
,	O
potassium	B-drug-IN-2
chloride	E-drug-IN-2
supplements	O
,	O
antacids	S-group-IN-2
,	O
absorbent	B-group-IN-2
-	I-group-IN-2
type	I-group-IN-2
anti	I-group-IN-2
-	I-group-IN-2
diarrhea	I-group-IN-2
medicines	E-group-IN-2
(	O
e.g	O
.	O
,	O
kaolin	S-drug-IN-2
-	O
pectin	S-drug-IN-2
)	O
,	O
phenothiazines	S-group-IN-2
(	O
e.g	O
.	O
,	O
chlorpromazine	S-drug-IN-2
,	O
promethazine	S-drug-IN-2
)	O
.	O

Methyprylon	S-drug
may	O
interact	O
with	O
other	O
addictive	O
medications	O
,	O
in	O
that	O
it	O
may	O
increase	O
the	O
likelyhood	O
of	O
addiction	O
and	O
abuse	O
.	O

Concurrent	O
use	O
of	O
alcohol	S-drug-EF-1
and	O
other	O
CNS	B-group-EF-1
depression	I-group-EF-1
-	I-group-EF-1
producing	I-group-EF-1
drugs	E-group-EF-1
may	O
increase	O
the	O
CNS	O
depressant	O
effects	O
of	O
methyprylon	S-drug-EF-2
or	O
these	O
other	O
medications	O
.	O

Methysergide	S-drug-EF-1
may	O
reverse	O
the	O
analgesic	O
activity	O
of	O
narcotic	B-group-EF-2
analgesics	E-group-EF-2
.	O

Concurrent	O
use	O
with	O
vasoconstrictor	B-group
agents	E-group
including	O
ergot	B-group
alkaloids	E-group
,	O
sumatriptan	S-drug
,	O
and	O
nicotine	S-drug
(	O
e.g	O
.	O
smoking	O
)	O
may	O
result	O
in	O
enhanced	O
vasoconstriction	O
.	O

The	O
effects	O
of	O
metoclopramide	S-drug-EF-1
on	O
gastrointestinal	O
motility	O
are	O
antagonized	O
by	O
anticholinergic	B-group-EF-2
drugs	E-group-EF-2
and	O
narcotic	B-group-EF-2
analgesics	E-group-EF-2
.	O

Additive	O
sedative	O
effects	O
can	O
occur	O
when	O
metoclopramide	S-drug-EF-1
is	O
given	O
with	O
alcohol	S-drug-EF-2
,	O
sedatives	S-group-EF-2
,	O
hypnotics	S-group-EF-2
,	O
narcotics	S-group-EF-2
,	O
or	O
tranquilizers	S-group-EF-2
.	O

The	O
finding	O
that	O
metoclopramide	S-drug-AD-1
releases	O
catecholamines	O
in	O
patients	O
with	O
essential	O
hypertension	O
suggests	O
that	O
it	O
should	O
be	O
used	O
cautiously	O
,	O
if	O
at	O
all	O
,	O
in	O
patients	O
receiving	O
monoamine	B-group-AD-2
oxi	I-group-AD-2
-	I-group-AD-2
dase	I-group-AD-2
inhibitors	E-group-AD-2
.	O

Absorption	O
of	O
drugs	O
from	O
the	O
stomach	O
may	O
be	O
diminished	O
(	O
e.g	O
.	O
,	O
digoxin	S-drug-ME-1
)	O
by	O
metoclopramide	S-drug-ME-M
,	O
whereas	O
the	O
rate	O
and	O
/	O
or	O
extent	O
of	O
absorption	O
of	O
drugs	O
from	O
the	O
small	O
bowel	O
may	O
be	O
increased	O
(	O
e.g	O
.	O
,	O
acetaminophen	S-drug-ME-2
,	O
tetracycline	S-drug
,	O
levodopa	S-drug
,	O
ethanol	S-drug
,	O
cyclosporine	S-drug
)	O
.	O

Gastroparesis	O
(	O
gastric	O
stasis	O
)	O
may	O
be	O
responsible	O
for	O
poor	O
diabetic	O
control	O
in	O
some	O
patients	O
.	O

Exogenously	O
administered	O
insulin	S-drug
may	O
begin	O
to	O
act	O
before	O
food	O
has	O
left	O
the	O
stomach	O
and	O
lead	O
to	O
hypoglycemia	O
.	O

Because	O
the	O
action	O
of	O
metoclopramide	S-drug-AD-1
will	O
influence	O
the	O
delivery	O
of	O
food	O
to	O
the	O
intestines	O
and	O
thus	O
the	O
rate	O
of	O
absorption	O
,	O
insulin	S-drug-AD-2
dosage	O
or	O
timing	O
of	O
dosage	O
may	O
require	O
adjustment	O
.	O

Diuretics	S-group
:	O
Furosemide	S-drug-EF-1
and	O
probably	O
other	O
loop	B-group-EF-1
diuretics	E-group-EF-1
given	O
concomitantly	O
with	O
metolazone	S-drug-EF-2
can	O
cause	O
unusually	O
large	O
or	O
prolonged	O
losses	O
of	O
fluid	O
and	O
electrolytes	O
.	O

Other	O
Antihypertensives	S-group
:	O
When	O
MYKROX	S-brand-AD-1
Tablets	O
are	O
used	O
with	O
other	O
antihypertensive	B-group-AD-2
drugs	E-group-AD-2
,	O
care	O
must	O
be	O
taken	O
,	O
especially	O
during	O
initial	O
therapy	O
.	O

Dosage	O
adjustments	O
of	O
other	O
antihypertensives	S-group
may	O
be	O
necessary	O
.	O

Alcohol	S-drug
,	O
Barbiturates	S-group
,	O
and	O
Narcotics	S-group
:	O
The	O
hypotensive	O
effects	O
of	O
these	O
drugs	O
may	O
be	O
potentiated	O
by	O
the	O
volume	O
contraction	O
that	O
may	O
be	O
associated	O
with	O
metolazone	S-drug
therapy	O
.	O

Digitalis	B-group
Glycosides	E-group
:	O
Diuretic	S-group-EF-1
-	O
induced	O
hypokalemia	O
can	O
increase	O
the	O
sensitivity	O
of	O
the	O
myocardium	O
to	O
digitalis	S-group-EF-2
.	O

Serious	O
arrhythmias	O
can	O
result	O
.	O

Corticosteroids	S-group
or	O
ACTH	S-drug
:	O
May	O
increase	O
the	O
risk	O
of	O
hypokalemia	O
and	O
increase	O
salt	O
and	O
water	O
retention	O
.	O

Lithium	S-drug
:	O
Serum	O
lithium	S-drug
levels	O
may	O
increase	O
.	O

Curariform	B-group
Drugs	E-group
:	O
Diuretic	S-group-EF-1
-	O
induced	O
hypokalemia	O
may	O
enhance	O
neuromuscular	O
blocking	O
effects	O
of	O
curariform	B-group-EF-2
drugs	E-group-EF-2
(	O
such	O
as	O
tubocurarine	S-drug-EF-2
)	O
the	O
most	O
serious	O
effect	O
would	O
be	O
respiratory	O
depression	O
which	O
could	O
proceed	O
to	O
apnea	O
.	O

Accordingly	O
,	O
it	O
may	O
be	O
advisable	O
to	O
discontinue	O
MYKROX	S-brand
Tablets	O
three	O
days	O
before	O
elective	O
surgery	O
.	O

Salicylates	S-group-EF-1
and	O
Other	O
Non	B-group-EF-1
-	I-group-EF-1
Steroidal	I-group-EF-1
Anti	I-group-EF-1
-	I-group-EF-1
Inflammatory	I-group-EF-1
Drugs	E-group-EF-1
:	O
May	O
decrease	O
the	O
antihypertensive	O
effects	O
of	O
MYKROX	S-brand-EF-2
Tablets	O
.	O

Sympathomimetics	S-group
:	O
Metolazone	S-drug-EF-1
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	S-drug-EF-2
,	O
but	O
this	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O

Methenamine	S-drug-EF-1
:	O
Efficacy	O
may	O
be	O
decreased	O
due	O
to	O
urinary	O
alkalizing	O
effect	O
of	O
metolazone	S-drug-EF-2
.	O

Anticoagulants	S-group
:	O
Metolazone	S-drug-EF-1
,	O
as	O
well	O
as	O
other	O
thiazide	B-group
-	I-group
like	I-group
diuretics	E-group
,	O
may	O
affect	O
the	O
hypoprothrombinemic	O
response	O
to	O
anticoagulants	S-group-EF-2
;	O

dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e.g	O
.	O
,	O
reserpine	S-drug-EF-1
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

Patients	O
treated	O
with	O
extended	O
release	O
metoprolol	B-drug
succinate	E-drug
plus	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

Oral	O
metronidazole	S-drug-EF-1
has	O
been	O
reported	O
to	O
potentiate	O
the	O
anticoagulant	O
effect	O
of	O
coumarin	S-group-EF-2
and	O
warfarin	S-drug-EF-2
,	O
resulting	O
in	O
a	O
prolongation	O
of	O
prothrombin	O
time	O
.	O

Drug	O
interactions	O
should	O
be	O
kept	O
in	O
mind	O
when	O
METROGEL	S-brand
(	O
metronidazole	S-drug
gel	O
)	O
,	O
1	O
%	O
is	O
prescribed	O
for	O
patients	O
who	O
are	O
receiving	O
anticoagulant	O
treatment	O
,	O
although	O
they	O
are	O
less	O
likely	O
to	O
occur	O
with	O
topical	O
metronidazole	S-drug
administration	O
because	O
of	O
low	O
absorption	O
.	O

Drugs	O
affecting	O
pituitary	O
or	O
adrenocortical	O
function	O
,	O
including	O
all	O
corticosteroid	O
therapy	O
,	O
must	O
be	O
discontinued	O
prior	O
to	O
and	O
during	O
testing	O
with	O
Metopirone	S-brand
.	O

The	O
metabolism	O
of	O
Metopirone	S-brand-ME-1
is	O
accelerated	O
by	O
phenytoin	S-drug-ME-2
;	O

therefore	O
,	O
results	O
of	O
the	O
test	O
may	O
be	O
inaccurate	O
in	O
patients	O
taking	O
phenytoin	S-drug
within	O
two	O
weeks	O
before	O
.	O

Asubnormal	O
response	O
may	O
occur	O
in	O
patients	O
on	O
estrogen	O
therapy	O
.	O

Metopirone	S-brand-MU-1
inhibits	O
the	O
glucuronidation	O
of	O
acetaminophen	S-drug-ME-2
and	O
could	O
possibly	O
potentiate	O
acetaminophen	S-drug-EF-2
toxicity	O
.	O

Caution	O
should	O
be	O
observed	O
in	O
administering	O
DEMSER	S-brand-AD-1
to	O
patients	O
receiving	O
phenothiazines	S-group-AD-2
or	O
haloperidol	S-drug-AD-2
because	O
the	O
extrapyramidal	O
effects	O
of	O
these	O
drugs	O
can	O
be	O
expected	O
to	O
be	O
potentiated	O
by	O
inhibition	O
of	O
catecholamine	O
synthesis	O
.	O

Concurrent	O
use	O
of	O
DEMSER	S-brand-EF-1
with	O
alcohol	S-drug-EF-2
or	O
other	O
CNS	B-drug-EF-2
depressants	E-drug-EF-2
can	O
increase	O
their	O
sedative	O
effects	O
.	O

Since	O
MEXITIL	S-brand
is	O
a	O
substrate	O
for	O
the	O
metabolic	O
pathways	O
involving	O
CYP2D6	O
and	O
CYP1A2	O
enzymes	O
,	O
inhibition	O
or	O
induction	O
of	O
either	O
of	O
these	O
enzymes	O
would	O
be	O
expected	O
to	O
alter	O
mexiletine	S-drug
plasma	O
concentrations	O
.	O

In	O
a	O
formal	O
,	O
single	O
-	O
dose	O
interaction	O
study	O
(	O
n	O
=	O
6	O
males	O
)	O
the	O
clearance	O
of	O
mexiletine	S-drug-ME-1
was	O
decreased	O
by	O
38	O
%	O
following	O
the	O
coadministration	O
of	O
fluvoxamine	S-drug-ME-2
,	O
an	O
inhibitor	O
of	O
CYP1A2	O
.	O

In	O
another	O
formal	O
study	O
(	O
n	O
=	O
8	O
extensive	O
and	O
n	O
=	O
7	O
poor	O
metabolizers	O
of	O
CYP2D6	O
)	O
,	O
coadministration	O
of	O
propafenone	S-drug
did	O
not	O
alter	O
the	O
kinetics	O
of	O
mexiletine	S-drug
in	O
the	O
poor	O
CYP2D6	O
metabolizer	O
group	O
.	O

However	O
,	O
the	O
metabolic	O
clearance	O
of	O
mexiletine	S-drug
in	O
the	O
extensive	O
metabolizer	O
phenotype	O
decreased	O
by	O
about	O
70	O
%	O
making	O
the	O
poor	O
and	O
extensive	O
metabolizer	O
groups	O
indistinguishable	O
.	O

In	O
this	O
crossover	O
steady	O
state	O
study	O
,	O
the	O
pharmacokinetics	O
of	O
propafenone	S-drug
were	O
unaffected	O
in	O
either	O
phenotype	O
by	O
the	O
coadministration	O
of	O
mexiletine	S-drug
.	O

Addition	O
of	O
mexiletine	S-drug
to	O
propafenone	S-drug
did	O
not	O
lead	O
to	O
further	O
electrocardiographic	O
parameters	O
changes	O
of	O
QRS	O
,	O
QTc	O
,	O
RR	O
,	O
and	O
PR	O
intervals	O
than	O
propafenone	S-drug
alone	O
.	O

When	O
concomitant	O
administration	O
of	O
either	O
of	O
these	O
two	O
drugs	O
with	O
mexiletine	S-drug
is	O
initiated	O
,	O
the	O
dose	O
of	O
mexiletine	S-drug
should	O
be	O
slowly	O
titrated	O
to	O
desired	O
effect	O
.	O

In	O
a	O
large	O
compassionate	O
use	O
program	O
Mexitil	S-brand
has	O
been	O
used	O
concurrently	O
with	O
commonly	O
employed	O
antianginal	O
,	O
antihypertensive	S-group
,	O
and	O
anticoagulant	B-group
drugs	E-group
without	O
observed	O
interactions	O
.	O

A	O
variety	O
of	O
antiarrhythmics	S-group
such	O
as	O
quinidine	S-drug
or	O
propranolol	S-drug
were	O
also	O
added	O
,	O
sometimes	O
with	O
improved	O
control	O
of	O
ventricular	O
ectopy	O
.	O

When	O
phenytoin	S-drug-ME-1
or	O
other	O
hepatic	O
enzyme	O
inducers	O
such	O
as	O
rifampin	S-drug-ME-1
and	O
phenobarbital	S-drug-ME-1
have	O
been	O
taken	O
concurrently	O
with	O
Mexitil	S-brand-ME-2
,	O
lowered	O
Mexitil	S-brand
plasma	O
levels	O
have	O
been	O
reported	O
.	O

Monitoring	O
of	O
Mexitil	S-brand
plasma	O
levels	O
is	O
recommended	O
during	O
such	O
concurrent	O
use	O
to	O
avoid	O
ineffective	O
therapy	O
.	O

In	O
a	O
formal	O
study	O
,	O
benzodiazepines	S-group
were	O
shown	O
not	O
to	O
affect	O
Mexitil	S-brand
plasma	O
concentrations	O
.	O

ECG	O
intervals	O
(	O
PR	O
,	O
QRS	O
,	O
and	O
QT	O
)	O
were	O
not	O
affected	O
by	O
concurrent	O
Mexitil	S-brand
and	O
digoxin	S-drug
,	O
diuretics	S-group
,	O
or	O
propranolol	S-drug
.	O

Concurrent	O
administration	O
of	O
cimetidine	S-drug-ME-1
and	O
Mexitil	S-brand-ME-2
has	O
been	O
reported	O
to	O
increase	O
,	O
decrease	O
,	O
or	O
leave	O
unchanged	O
Mexitil	S-brand
plasma	O
levels	O
;	O

therefore	O
patients	O
should	O
be	O
followed	O
carefully	O
during	O
concurrent	O
therapy	O
.	O

Mexitil	S-brand
does	O
not	O
alter	O
serum	O
digoxin	S-drug
levels	O
but	O
magnesium	B-drug-ME-1
-	I-drug-ME-1
aluminum	I-drug-ME-1
hydroxide	E-drug-ME-1
,	O
when	O
used	O
to	O
treat	O
gastrointestinal	O
symptoms	O
due	O
to	O
Mexitil	S-brand
,	O
has	O
been	O
reported	O
to	O
lower	O
serum	O
digoxin	S-drug-ME-2
levels	O
.	O

Concurrent	O
use	O
of	O
Mexitil	S-brand-ME-1
and	O
theophylline	S-drug-ME-2
may	O
lead	O
to	O
increased	O
plasma	O
theophylline	S-drug
levels	O
.	O

One	O
controlled	O
study	O
in	O
eight	O
normal	O
subjects	O
showed	O
a	O
72	O
%	O
mean	O
increase	O
(	O
range	O
35	O
-	O
136	O
%	O
)	O
in	O
plasma	O
theophylline	S-drug
levels	O
.	O

This	O
increase	O
was	O
observed	O
at	O
the	O
first	O
test	O
point	O
which	O
was	O
the	O
second	O
day	O
after	O
starting	O
Mexitil	S-brand
.	O
Theophylline	S-drug-ME-1
plasma	O
levels	O
returned	O
to	O
pre	O
-	O
Mexitil	S-brand
values	O
within	O
48	O
hours	O
after	O
discontinuing	O
Mexitil	S-brand-ME-2
.	O
If	O
Mexitil	S-brand-AD-1
and	O
theophylline	S-drug-AD-2
are	O
to	O
be	O
used	O
concurrently	O
,	O
theophylline	S-drug
blood	O
levels	O
should	O
be	O
monitored	O
,	O
particularly	O
when	O
the	O
Mexitil	S-brand
dose	O
is	O
changed	O
.	O

An	O
appropriate	O
adjustment	O
in	O
theophylline	S-drug
dose	O
should	O
be	O
considered	O
.	O

Additionally	O
,	O
in	O
one	O
controlled	O
study	O
in	O
five	O
normal	O
subjects	O
and	O
seven	O
patients	O
,	O
the	O
clearance	O
of	O
caffeine	S-drug-ME-1
was	O
decreased	O
50	O
%	O
following	O
the	O
administration	O
of	O
Mexitil	S-brand-ME-2
.	O

Posicor	S-brand-ME-1
inhibits	O
some	O
of	O
the	O
liver	O
's	O
ability	O
to	O
metabolize	O
some	O
other	O
drugs	O
-	O
terfenadine	S-drug-ME-2
,	O
astemizole	S-drug-ME-2
,	O
cisapride	S-drug-ME-2
,	O
cyclosporine	S-drug-ME-2
,	O
and	O
tricyclic	B-group-ME-2
antidepressants	E-group-ME-2
.	O

Thus	O
the	O
concentrations	O
of	O
these	O
drugs	O
would	O
increase	O
meaning	O
side	O
effects	O
may	O
be	O
seen	O
.	O

A	O
dose	O
adjustment	O
may	O
be	O
required	O
.	O

A	O
total	O
of	O
11	O
clinical	O
drug	O
-	O
drug	O
interaction	O
studies	O
were	O
conducted	O
in	O
healthy	O
volunteers	O
to	O
evaluate	O
the	O
potential	O
for	O
interaction	O
between	O
MYCAMINE	S-brand
and	O
mycophenolate	B-drug
mofetil	E-drug
,	O
cyclosporine	S-drug
,	O
tacrolimus	S-drug
,	O
prednisolone	S-drug
,	O
sirolimus	S-drug
,	O
nifedipine	S-drug
,	O
fluconazole	S-drug
,	O
ritonavir	S-drug
,	O
and	O
rifampin	S-drug
.	O

In	O
these	O
studies	O
,	O
no	O
interaction	O
that	O
altered	O
the	O
pharmacokinetics	O
of	O
micafungin	S-drug
was	O
observed	O
.	O

There	O
was	O
no	O
effect	O
of	O
a	O
single	O
dose	O
or	O
multiple	O
doses	O
of	O
MYCAMINE	S-brand
on	O
mycophenolate	B-drug
mofetil	E-drug
,	O
cyclosporine	S-drug
,	O
tacrolimus	S-drug
,	O
prednisolone	S-drug
,	O
and	O
fluconazole	S-drug
pharmacokinetics	O
.	O

Sirolimus	S-drug-ME-1
AUC	O
was	O
increased	O
by	O
21	O
%	O
with	O
no	O
effect	O
on	O
Cmax	O
in	O
the	O
presence	O
of	O
steady	O
-	O
state	O
MYCAMINE	S-brand-ME-2
compared	O
with	O
sirolimus	S-drug
alone	O
.	O

Nifedipine	S-drug-ME-1
AUC	O
and	O
Cmax	O
were	O
increased	O
by	O
18	O
%	O
and	O
42	O
%	O
,	O
respectively	O
,	O
in	O
the	O
presence	O
of	O
steady	O
-	O
state	O
MYCAMINE	S-brand-ME-2
compared	O
with	O
nifedipine	S-drug
alone	O
.	O

Patients	O
receiving	O
sirolimus	S-drug-AD-1
or	O
nifedipine	S-drug-AD-1
in	O
combination	O
with	O
MYCAMINE	S-brand-AD-2
should	O
be	O
monitored	O
for	O
sirolimus	S-drug
or	O
nifedipine	S-drug
toxicity	O
and	O
sirolimus	S-drug
or	O
nifedipine	S-drug
dosage	O
should	O
be	O
reduced	O
if	O
necessary	O
.	O

Micafungin	S-drug
is	O
not	O
an	O
inhibitor	O
of	O
P	O
-	O
glycoprotein	O
and	O
,	O
therefore	O
,	O
would	O
not	O
be	O
expected	O
to	O
alter	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
drug	O
transport	O
activity	O
.	O

Drug	O
Interactions	O
:	O
Inhibitors	O
of	O
CYP3A4	O
Isozymes	O
:	O
Caution	O
is	O
advised	O
when	O
midazolam	S-drug-AD-1
is	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
are	O
known	O
to	O
inhibit	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
(	O
ie	O
,	O
some	O
drugs	O
in	O
the	O
drug	O
classes	O
of	O
azole	B-group-AD-2
antimycotics	E-group-AD-2
,	O
protease	B-group-AD-2
inhibitors	E-group-AD-2
,	O
calcium	B-group-AD-2
channel	I-group-AD-2
antagonists	E-group-AD-2
,	O
and	O
macrolide	B-group-AD-2
antibiotics	E-group-AD-2
)	O
.	O

Drugs	O
such	O
as	O
erythromycin	S-drug-ME-1
,	O
diltiazem	S-drug-ME-1
,	O
verapamil	S-drug-ME-1
,	O
ketoconazole	S-drug-ME-1
,	O
fluconazole	S-drug-ME-1
and	O
itraconazole	S-drug-ME-1
were	O
shown	O
to	O
significantly	O
increase	O
the	O
C	O
max	O
and	O
AUC	O
of	O
orally	O
administered	O
midazolam	S-drug-ME-2
.	O

These	O
drug	O
interactions	O
may	O
result	O
in	O
increased	O
and	O
prolonged	O
sedation	O
due	O
to	O
a	O
decrease	O
in	O
plasma	O
clearance	O
of	O
midazolam	S-drug
.	O

Although	O
not	O
studied	O
,	O
the	O
potent	O
cytochrome	O
P450	O
3A4	O
inhibitors	O
ritonavir	S-drug-ME-1
and	O
nelfinavir	S-drug-ME-1
may	O
cause	O
intense	O
and	O
prolonged	O
sedation	O
and	O
respiratory	O
depression	O
due	O
to	O
a	O
decrease	O
in	O
plasma	O
clearance	O
of	O
midazolam	S-drug-ME-2
.	O

Caution	O
is	O
advised	O
when	O
VERSED	B-brand
Syrup	E-brand
is	O
used	O
concomitantly	O
with	O
these	O
drugs	O
.	O

Dose	O
adjustments	O
should	O
be	O
considered	O
and	O
possible	O
prolongation	O
and	O
intensity	O
of	O
effect	O
should	O
be	O
anticipated	O
.	O

Inducers	O
of	O
CYP3A4	O
Isozymes	O
:	O
Cytochrome	O
P450	O
inducers	O
,	O
such	O
as	O
rifampin	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
,	O
and	O
phenytoin	S-drug-ME-1
,	O
induce	O
metabolism	O
and	O
caused	O
a	O
markedly	O
decreased	O
C	O
max	O
and	O
AUC	O
of	O
oral	O
midazolam	S-drug-ME-2
in	O
adult	O
studies	O
.	O

Although	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
,	O
phenobarbital	S-drug
is	O
expected	O
to	O
have	O
the	O
same	O
effect	O
.	O

Caution	O
is	O
advised	O
when	O
administering	O
VERSED	B-brand
Syrup	E-brand
to	O
patients	O
receiving	O
these	O
medications	O
and	O
if	O
necessary	O
dose	O
adjustments	O
should	O
be	O
considered	O
.	O

The	O
difficulty	O
in	O
achieving	O
adequate	O
sedation	O
may	O
have	O
been	O
the	O
result	O
of	O
decreased	O
absorption	O
of	O
the	O
sedatives	S-group
due	O
to	O
both	O
the	O
gastrointestinal	O
effects	O
and	O
stimulant	O
effects	O
of	O
methylphenidate	S-drug
.	O

The	O
sedative	O
effect	O
of	O
VERSED	B-brand-EF-1
Syrup	E-brand-EF-1
is	O
accentuated	O
by	O
any	O
concomitantly	O
administered	O
medication	O
which	O
depresses	O
the	O
central	O
nervous	O
system	O
,	O
particularly	O
narcotics	S-group-EF-2
(	O
eg	O
,	O
morphine	S-drug-EF-2
,	O
meperidine	S-drug-EF-2
and	O
fentanyl	S-drug-EF-2
)	O
,	O
propofol	S-drug-EF-2
,	O
ketamine	S-drug-EF-2
,	O
nitrous	B-drug-EF-2
oxide	E-drug-EF-2
,	O
secobarbital	S-drug-EF-2
and	O
droperidol	S-drug-EF-2
.	O

Consequently	O
,	O
the	O
dose	O
of	O
VERSED	B-brand
Syrup	E-brand
should	O
be	O
adjusted	O
according	O
to	O
the	O
type	O
and	O
amount	O
of	O
concomitant	O
medications	O
administered	O
and	O
the	O
desired	O
clinical	O
response	O
.	O

No	O
significant	O
adverse	O
interactions	O
with	O
common	O
premedications	O
(	O
such	O
as	O
atropine	S-drug
,	O
scopolamine	S-drug
,	O
glycopyrrolate	S-drug
,	O
diazepam	S-drug
,	O
hydroxyzine	S-drug
,	O
and	O
other	O
muscle	B-group
relaxants	E-group
)	O
or	O
local	O
anesthetics	S-group
have	O
been	O
observed	O
.	O

When	O
administered	O
concomitantly	O
with	O
ProAmatine	S-brand-EF-1
,	O
cardiac	B-group-EF-2
glycosides	E-group-EF-2
may	O
enhance	O
or	O
precipitate	O
bradycardia	O
,	O
A.V	O
.	O

block	O
or	O
arrhythmia	O
.	O

The	O
use	O
of	O
drugs	O
that	O
stimulate	O
alpha	O
-	O
adrenergic	O
receptors	O
(	O
e.g	O
.	O
,	O
phenylephrine	S-drug-EF-1
,	O
pseudoephedrine	S-drug-EF-1
,	O
ephedrine	S-drug-EF-1
,	O
phenylpropanolamine	S-drug-EF-1
or	O
dihydroergotamine	S-drug-EF-1
)	O
may	O
enhance	O
or	O
potentiate	O
the	O
pressor	O
effects	O
of	O
ProAmatine	S-brand-EF-2
.	O
Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
ProAmatine	S-brand
is	O
administered	O
concomitantly	O
with	O
agents	O
that	O
cause	O
vasoconstriction	O
.	O

ProAmatine	S-brand
has	O
been	O
used	O
in	O
patients	O
concomitantly	O
treated	O
with	O
salt	O
-	O
retaining	O
steroid	O
therapy	O
(	O
i.e	O
.	O
,	O
fludrocortisone	B-drug
acetate	E-drug
)	O
,	O
with	O
or	O
without	O
salt	O
supplementation	O
.	O

The	O
potential	O
for	O
supine	O
hypertension	O
should	O
be	O
carefully	O
monitored	O
in	O
these	O
patients	O
and	O
may	O
be	O
minimized	O
by	O
either	O
reducing	O
the	O
dose	O
of	O
fludrocortisone	B-drug
acetate	E-drug
or	O
decreasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
.	O

ProAmatine	S-brand
.	O
Alpha	B-group-EF-1
-	I-group-EF-1
adrenergic	I-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
,	O
such	O
as	O
prazosin	S-drug-EF-1
,	O
terazosin	S-drug-EF-1
,	O
and	O
doxazosin	S-drug-EF-1
,	O
can	O
antagonize	O
the	O
effects	O
of	O
ProAmatine	S-brand-EF-2
.	O
Potential	O
for	O
Drug	O
Interactions	O
:	O
It	O
appears	O
possible	O
,	O
although	O
there	O
is	O
no	O
supporting	O
experimental	O
evidence	O
,	O
that	O
the	O
high	O
renal	O
clearance	O
of	O
desglymidodrine	S-drug_n-ME-1
(	O
a	O
base	O
)	O
is	O
due	O
to	O
active	O
tubular	O
secretion	O
by	O
the	O
base	O
-	O
secreting	O
system	O
also	O
responsible	O
for	O
the	O
secretion	O
of	O
such	O
drugs	O
as	O
metformin	S-drug-ME-2
,	O
cimetidine	S-drug-ME-2
,	O
ranitidine	S-drug-ME-2
,	O
procainamide	S-drug-ME-2
,	O
triamterene	S-drug-ME-2
,	O
flecainide	S-drug-ME-2
,	O
and	O
quinidine	S-drug-ME-2
.	O

Thus	O
there	O
may	O
be	O
a	O
potential	O
for	O
drug	O
-	O
drug	O
interactions	O
with	O
these	O
drugs	O
.	O

Although	O
specific	O
drug	O
or	O
food	O
interactions	O
with	O
mifepristone	S-drug
have	O
not	O
been	O
studied	O
,	O
on	O
the	O
basis	O
of	O
this	O
drug	O
s	O
metabolism	O
by	O
CYP	O
3A4	O
,	O
it	O
is	O
possible	O
that	O
ketoconazole	S-drug-ME-1
,	O
itraconazole	S-drug-ME-1
,	O
erythromycin	S-drug-ME-1
,	O
and	O
grapefruit	O
juice	O
may	O
inhibit	O
its	O
metabolism	O
(	O
increasing	O
serum	O
levels	O
of	O
mifepristone	S-drug-ME-2
)	O
.	O

Furthermore	O
,	O
rifampin	S-drug
,	O
dexamethasone	S-drug
,	O
St	O
.	O

John	O
s	O
Wort	O
,	O
and	O
certain	O
anticonvulsants	S-group-ME-1
(	O
phenytoin	S-drug-ME-1
,	O
phenobarbital	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
)	O
may	O
induce	O
mifepristone	S-drug-ME-2
metabolism	O
(	O
lowering	O
serum	O
levels	O
of	O
mifepristone	S-drug
)	O
.	O

Based	O
on	O
in	O
vitro	O
inhibition	O
information	O
,	O
coadministration	O
of	O
mifepristone	S-drug
may	O
lead	O
to	O
an	O
increase	O
in	O
serum	O
levels	O
of	O
drugs	O
that	O
are	O
CYP	O
3A4	O
substrates	O
.	O

Due	O
to	O
the	O
slow	O
elimination	O
of	O
mifepristone	S-drug
from	O
the	O
body	O
,	O
such	O
interaction	O
may	O
be	O
observed	O
for	O
a	O
prolonged	O
period	O
after	O
its	O
administration	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
mifepristone	S-drug
is	O
administered	O
with	O
drugs	O
that	O
are	O
CYP	O
3A4	O
substrates	O
and	O
have	O
narrow	O
therapeutic	O
range	O
,	O
including	O
some	O
agents	O
used	O
during	O
general	O
anesthesia	O
.	O

While	O
co	O
-	O
administration	O
of	O
ZAVESCA	S-brand-ME-1
appeared	O
to	O
increase	O
the	O
clearance	O
of	O
Cerezyme	S-brand-ME-2
by	O
70	O
%	O
,	O
these	O
results	O
are	O
not	O
conclusive	O
because	O
of	O
the	O
small	O
number	O
of	O
subjects	O
studied	O
and	O
because	O
patients	O
took	O
variable	O
doses	O
of	O
Cerezyme	S-brand
.	O

Combination	O
therapy	O
with	O
Cerezyme	S-brand-AD-1
(	O
imiglucerase	S-drug-AD-1
)	O
and	O
ZAVESCA	S-brand-AD-2
is	O
not	O
indicated	O
.	O

Because	O
tetracyclines	S-group-AD-1
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
,	O
patients	O
who	O
are	O
on	O
anticoagulant	S-group-AD-2
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	S-group
dosage	O
.	O

Since	O
bacteriostatic	O
drugs	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillin	S-drug
,	O
it	O
is	O
advisable	O
to	O
avoid	O
giving	O
tetracycline	B-group-AD-1
class	I-group-AD-1
drugs	E-group-AD-1
in	O
conjunction	O
with	O
penicillin	S-drug-AD-2
.	O

Absorption	O
of	O
tetracyclines	S-group-ME-1
is	O
impaired	O
by	O
antacids	S-group
containing	O
aluminum	S-drug-ME-2
,	O
calcium	S-drug-ME-2
or	O
magnesium	S-drug-ME-2
,	O
and	O
iron	S-drug-ME-2
-	O
containing	O
preparations	O
.	O

The	O
concurrent	O
use	O
of	O
tetracycline	S-group-EF-1
and	O
methoxyflurane	S-drug-EF-2
has	O
been	O
reported	O
to	O
result	O
in	O
fatal	O
renal	O
toxicity	O
.	O

Concurrent	O
use	O
of	O
tetracyclines	S-group-EF-1
with	O
oral	O
contraceptives	S-group-EF-2
may	O
render	O
oral	O
contraceptives	S-group
less	O
effective	O
.	O

Interaction	O
with	O
Guanethidine	S-drug
:	O
Although	O
minoxidil	S-drug-EF-1
does	O
not	O
itself	O
cause	O
orthostatic	O
hypotension	O
,	O
its	O
administration	O
to	O
patients	O
already	O
receiving	O
guanethidine	S-drug-EF-2
can	O
result	O
in	O
profound	O
orthostatic	O
effects	O
.	O

If	O
at	O
all	O
possible	O
guanethidine	S-drug-AD-1
should	O
be	O
discontinued	O
well	O
before	O
minoxidil	S-drug-AD-2
is	O
begun	O
.	O

Where	O
this	O
is	O
not	O
possible	O
,	O
minoxidil	S-drug
therapy	O
should	O
be	O
started	O
in	O
the	O
hospital	O
and	O
the	O
patient	O
should	O
remain	O
institutionalized	O
until	O
severe	O
orthostatic	O
effects	O
are	O
no	O
longer	O
present	O
or	O
the	O
patient	O
has	O
learned	O
to	O
avoid	O
activities	O
that	O
provoke	O
them	O
.	O

As	O
with	O
other	O
drugs	O
,	O
the	O
potential	O
for	O
interaction	O
by	O
a	O
variety	O
of	O
mechanisms	O
(	O
e.g	O
.	O
,	O
pharmacodynamic	O
,	O
pharmacokinetic	O
inhibition	O
or	O
enhancement	O
,	O
etc	O
.	O
)	O

is	O
a	O
possibility	O
.	O

Drugs	O
Affecting	O
Hepatic	O
Metabolism	O
The	O
metabolism	O
and	O
pharmacokinetics	O
of	O
REMERON	B-brand
SolTab	E-brand
(	O
mirtazapine	S-drug
)	O
Orally	O
Disintegrating	O
Tablets	O
may	O
be	O
affected	O
by	O
the	O
induction	O
or	O
inhibition	O
of	O
drug	O
-	O
metab	O
-	O
olizing	O
enzymes	O
.	O

Drugs	O
that	O
are	O
Metabolized	O
by	O
and	O
/	O
or	O
Inhibit	O
Cytochrome	O
P450	O
Enzymes	O
Many	O
drugs	O
are	O
metabolized	O
by	O
and	O
/	O
or	O
inhibit	O
various	O
cytochrome	O
P450	O
enzymes	O
,	O
e.g	O
.	O
,	O
2D6	O
,	O
1A2	O
,	O
3A4	O
,	O
etc	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
mirtazapine	S-drug
is	O
a	O
substrate	O
for	O
several	O
of	O
these	O
enzymes	O
,	O
including	O
2D6	O
,	O
1A2	O
,	O
and	O
3A4	O
.	O

While	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
mirtazapine	S-drug
is	O
not	O
a	O
potent	O
inhibitor	O
of	O
any	O
of	O
these	O
enzymes	O
,	O
an	O
indication	O
that	O
mirtazapine	S-drug
is	O
not	O
likely	O
to	O
have	O
a	O
clinically	O
significant	O
inhibitory	O
effect	O
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
that	O
are	O
substrates	O
for	O
these	O
cytochrome	O
P450	O
enzymes	O
,	O
the	O
concomitant	O
use	O
of	O
REMERON	B-brand
SolTab	E-brand
with	O
most	O
other	O
drugs	O
metabolized	O
by	O
these	O
enzymes	O
has	O
not	O
been	O
formally	O
studied	O
.	O

Consequently	O
,	O
it	O
is	O
not	O
possible	O
to	O
make	O
any	O
definitive	O
statements	O
about	O
the	O
risks	O
of	O
coadministration	O
of	O
REMERON	B-brand
SolTab	E-brand
with	O
such	O
drugs	O
.	O

Alcohol	S-drug
:	O
Concomitant	O
administration	O
of	O
alcohol	S-drug-ME-1
(	O
equivalent	O
to	O
60	O
g	O
)	O
had	O
a	O
minimal	O
effect	O
on	O
plasma	O
levels	O
of	O
mirtazapine	S-drug-ME-2
(	O
15	O
mg	O
)	O
in	O
6	O
healthy	O
male	O
subjects	O
.	O

However	O
,	O
the	O
impairment	O
of	O
cognitive	O
and	O
motor	O
skills	O
produced	O
by	O
REMERON	S-brand-EF-1
were	O
shown	O
to	O
be	O
additive	O
with	O
those	O
produced	O
by	O
alcohol	S-drug-EF-2
.	O

Accordingly	O
,	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
alcohol	S-drug-AD-1
while	O
taking	O
REMERON	B-brand-AD-2
SolTab	E-brand-AD-2
.	O
Diazepam	S-drug
:	O
Concomitant	O
administration	O
of	O
diazepam	S-drug-ME-1
(	O
15	O
mg	O
)	O
had	O
a	O
minimal	O
effect	O
on	O
plasma	O
levels	O
of	O
mirtazapine	S-drug-ME-2
(	O
15	O
mg	O
)	O
in	O
12	O
healthy	O
subjects	O
.	O

However	O
,	O
the	O
impairment	O
of	O
motor	O
skills	O
produced	O
by	O
REMERON	S-brand-EF-1
has	O
been	O
shown	O
to	O
be	O
additive	O
with	O
those	O
caused	O
by	O
diazepam	S-drug-EF-2
.	O

Accordingly	O
,	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
diazepam	S-drug-AD-1
and	O
other	O
similar	O
drugs	O
while	O
taking	O
REMERON	B-brand-AD-2
SolTab	E-brand-AD-2
.	O

Mitotane	S-drug-ME-1
has	O
been	O
reported	O
to	O
accelerate	O
the	O
metabolism	O
of	O
warfarin	S-drug-ME-2
by	O
the	O
mechanism	O
of	O
hepatic	O
microsomal	O
enzyme	O
induction	O
,	O
leading	O
to	O
an	O
increase	O
in	O
dosage	O
requirements	O
for	O
warfarin	S-drug
.	O

Therefore	O
,	O
physicians	O
should	O
closely	O
monitor	O
patients	O
for	O
a	O
change	O
in	O
anticoagulant	S-group
dosage	O
requirements	O
when	O
administering	O
Mitotane	S-drug-AD-1
to	O
patients	O
on	O
coumarin	B-group-AD-2
-	I-group-AD-2
type	I-group-AD-2
anticoagulants	E-group-AD-2
.	O

In	O
addition	O
,	O
Mitotane	S-drug
should	O
be	O
given	O
with	O
caution	O
to	O
patients	O
receiving	O
other	O
drugs	O
susceptible	O
to	O
the	O
influence	O
of	O
hepatic	O
enzyme	O
induction	O
.	O

Although	O
MIVACRON	S-brand
(	O
a	O
mixture	O
of	O
three	O
stereoisomers	O
)	O
has	O
been	O
administered	O
safely	O
following	O
succinylcholine	O
-	O
facilitated	O
tracheal	O
intubation	O
,	O
the	O
interaction	O
between	O
MIVACRON	S-brand
and	O
succinylcholine	S-drug
has	O
not	O
been	O
systematically	O
studied	O
.	O

Prior	O
administration	O
of	O
succinylcholine	S-drug-EF-1
can	O
potentiate	O
the	O
neuromuscular	O
blocking	O
effects	O
of	O
nondepolarizing	B-group-EF-2
agents	E-group-EF-2
.	O

Evidence	O
of	O
spontaneous	O
recovery	O
from	O
succinylcholine	S-drug-AD-1
should	O
be	O
observed	O
before	O
the	O
administration	O
of	O
MIVACRON	S-brand-AD-2
.	O

The	O
use	O
of	O
MIVACRON	S-brand
before	O
succinylcholine	S-drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	S-drug
has	O
not	O
been	O
studied	O
.	O

There	O
are	O
no	O
clinical	O
data	O
on	O
the	O
use	O
of	O
MIVACRON	S-brand
with	O
other	O
nondepolarizing	B-group
neuromuscular	I-group
blocking	I-group
agents	E-group
.	O

Isoflurane	S-drug
and	O
enflurane	S-drug
(	O
administered	O
with	O
nitrous	B-drug
oxide	E-drug
/	O
oxygen	S-drug
to	O
achieve	O
1.25	O
M.C	O
.	O

decrease	O
the	O
ED50	O
of	O
MIVACRON	S-brand
by	O
as	O
much	O
as	O
25	O
%	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Pharmacodynamics	O
and	O
Individualization	O
of	O
Dosages	O
)	O
.	O

These	O
agents	O
may	O
also	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
and	O
decrease	O
the	O
average	O
infusion	O
requirement	O
of	O
MIVACRON	S-brand
by	O
as	O
much	O
as	O
35	O
%	O
to	O
40	O
%	O
.	O

A	O
greater	O
potentiation	O
of	O
the	O
neuromuscular	O
blocking	O
effects	O
of	O
MIVACRON	S-brand
may	O
be	O
expected	O
with	O
higher	O
concentrations	O
of	O
enflurane	S-drug
or	O
isoflurane	S-drug
.	O

Halothane	S-drug
has	O
little	O
or	O
no	O
effect	O
on	O
the	O
ED50	O
,	O
but	O
may	O
prolong	O
the	O
duration	O
of	O
action	O
and	O
decrease	O
the	O
average	O
infusion	O
requirement	O
by	O
as	O
much	O
as	O
20	O
%	O
.	O

Other	O
drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	B-drug-IN-1
agents	E-drug-IN-1
such	O
as	O
MIVACRON	S-brand-IN-1
include	O
certain	O
antibiotics	S-group-IN-2
(	O
e.g	O
.	O
,	O
aminoglycosides	S-group-IN-2
,	O
tetracyclines	S-group-IN-2
,	O
bacitracin	S-drug-IN-2
,	O
polymyxins	S-group-IN-2
,	O
lincomycin	S-drug-IN-2
,	O
clindamycin	S-drug-IN-2
,	O
colistin	S-drug-IN-2
,	O
and	O
sodium	B-drug-IN-2
colistimethate	E-drug-IN-2
)	O
,	O
magnesium	S-group-IN-2
salts	O
,	O
lithium	S-drug-IN-2
,	O
local	O
anesthetics	S-group-IN-2
,	O
procainamide	S-drug-IN-2
,	O
and	O
quinidine	S-drug-IN-2
.	O

The	O
neuromuscular	O
blocking	O
effect	O
of	O
MIVACRON	S-brand-EF-1
may	O
be	O
enhanced	O
by	O
drugs	O
that	O
reduce	O
plasma	O
cholinesterase	O
activity	O
(	O
e.g	O
.	O
,	O
chronically	O
administered	O
oral	O
contraceptives	S-group-EF-2
,	O
glucocorticoids	S-group-EF-2
,	O
or	O
certain	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
)	O
or	O
by	O
drugs	O
that	O
irreversibly	O
inhibit	O
plasma	O
cholinesterase	O
.	O
Resistance	O
to	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	O
neuromuscular	B-group-EF-1
blocking	I-group-EF-1
agents	E-group-EF-1
has	O
been	O
demonstrated	O
in	O
patients	O
chronically	O
administered	O
phenytoin	S-drug-EF-2
or	O
carbamazepine	S-drug-EF-2
.	O

While	O
the	O
effects	O
of	O
chronic	O
phenytoin	S-drug-EF-1
or	O
carbamazepine	S-drug-EF-1
therapy	O
on	O
the	O
action	O
of	O
MIVACRON	S-brand-EF-2
are	O
unknown	O
,	O
slightly	O
shorter	O
durations	O
of	O
neuromuscular	O
block	O
may	O
be	O
anticipated	O
and	O
infusion	O
rate	O
requirements	O
may	O
be	O
higher	O
.	O

Some	O
drug	O
interactions	O
are	O
:	O
-	O
birth	O
control	O
pills	O
-	O
corticosteroids	S-group
-	O
medicines	O
for	O
angina	O
or	O
high	O
blood	O
pressure	O
-	O
medicines	O
for	O
pain	O
-	O
medicines	O
to	O
control	O
seizures	O
such	O
as	O
phenytoin	S-drug
or	O
carbamazepine	S-drug
-	O
certain	O
antibiotics	S-group
given	O
by	O
injection	O
-	O
cisplatin	S-drug
-	O
edrophonium	S-drug
-	O
neostigmine	S-drug
-	O
polymyxin	B-drug
B	E-drug
or	O
bacitracin	S-drug
-	O
local	O
anesthetics	S-group
such	O
as	O
procaine	S-drug
-	O
general	O
anesthetics	S-group
-	O
succinylcholine	S-drug
or	O
other	O
muscle	B-group
relaxants	E-group

Diuretics	S-group
:	O
Excessive	O
reductions	O
in	O
blood	O
pressure	O
may	O
occur	O
in	O
patients	O
on	O
diuretic	O
therapy	O
when	O
ACE	B-group
inhibitors	E-group
are	O
started	O
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
UNIVASC	S-brand
can	O
be	O
minimized	O
by	O
discontinuing	O
diuretic	O
therapy	O
for	O
several	O
days	O
or	O
cautiously	O
increasing	O
salt	O
intake	O
before	O
initiation	O
of	O
treatment	O
with	O
UNIVASC	S-brand
.	O
If	O
this	O
is	O
not	O
possible	O
,	O
the	O
starting	O
dose	O
of	O
moexpril	S-drug
should	O
be	O
reduced..	O

Potassium	S-drug
Supplements	O
and	O
Potassium	B-group
-	I-group
Sparing	I-group
Diuretics	E-group
:	O
UNIVASC	S-brand
can	O
increase	O
serum	O
potassium	O
because	O
it	O
decreases	O
aldosterone	O
secretion	O
.	O

Use	O
of	O
potassium	B-group-EF-1
-	I-group-EF-1
sparing	I-group-EF-1
diuretics	E-group-EF-1
(	O
spironolactone	S-drug-EF-1
,	O
triamterene	S-drug-EF-1
,	O
amiloride	S-drug-EF-1
)	O
or	O
potassium	S-drug-EF-1
supplements	O
concomitantly	O
with	O
ACE	B-group-EF-2
inhibitors	E-group-EF-2
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
,	O
they	O
should	O
be	O
given	O
with	O
caution	O
and	O
the	O
patient	O
's	O
serum	O
potassium	O
should	O
be	O
monitored	O
.	O

Oral	O
Anticoagulants	S-group
:	O
Interaction	O
studies	O
with	O
warfarin	S-drug
failed	O
to	O
identify	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
serum	O
concentrations	O
of	O
the	O
anticoagulant	S-group
or	O
on	O
its	O
anticoagulant	O
effect	O
.	O

Lithium	S-drug
:	O
Increased	O
serum	O
lithium	S-drug
levels	O
and	O
symptoms	O
of	O
lithium	S-drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B-group-EF-1
inhibitors	E-group-EF-1
during	O
therapy	O
with	O
lithium	S-drug-EF-2
.	O

These	O
drugs	O
should	O
be	O
coadministered	O
with	O
caution	O
,	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	S-drug
levels	O
is	O
recommended	O
.	O

If	O
a	O
diuretic	S-group-EF-1
is	O
also	O
used	O
,	O
the	O
risk	O
of	O
lithium	S-drug-EF-2
toxicity	O
may	O
be	O
increased	O
.	O

Other	O
Agents	O
:	O
No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
UNIVASC	S-brand
was	O
administered	O
concomitantly	O
with	O
hydrochlorothiazide	S-drug
,	O
digoxin	S-drug
,	O
or	O
cimetidine	S-drug
.	O

UNIVASC	S-brand
has	O
been	O
used	O
in	O
clinical	O
trials	O
concomitantly	O
with	O
calcium	B-group
-	I-group
channel	I-group
-	I-group
blocking	I-group
agents	E-group
,	O
diuretics	S-group
,	O
H2	B-group
blockers	E-group
,	O
digoxin	S-drug
,	O
oral	O
hypoglycemic	B-group
agents	E-group
,	O
and	O
cholesterol	O
-	O
lowering	O
agents	O
.	O

There	O
was	O
no	O
evidence	O
of	O
clinically	O
important	O
adverse	O
interactions	O
.	O

In	O
clinical	O
studies	O
,	O
the	O
concurrent	O
administration	O
of	O
the	O
ASMANEX	B-brand
TWISTHALER	E-brand
inhaler	O
and	O
other	O
drugs	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
asthma	O
was	O
not	O
associated	O
with	O
any	O
unusual	O
adverse	O
events	O
.	O

However	O
,	O
ketoconazole	S-drug-ME-1
,	O
a	O
potent	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
,	O
may	O
increase	O
plasma	O
levels	O
of	O
mometasone	B-drug-ME-2
furoate	E-drug-ME-2
during	O
concomitant	O
dosing	O
.	O

Montelukast	S-drug
at	O
a	O
Dose	O
of	O
10	O
mg	O
Once	O
Daily	O
Dosed	O
to	O
Pharmacokinetic	O
Steady	O
State	O
-	O
did	O
not	O
cause	O
clinically	O
significant	O
changes	O
in	O
the	O
kinetics	O
of	O
a	O
single	O
intravenous	O
dose	O
of	O
theophylline	S-drug
(	O
predominantly	O
a	O
cytochrome	O
P450	O
1A2	O
substrate	O
)	O
.	O

-	O
did	O
not	O
change	O
the	O
pharmacokinetic	O
profile	O
of	O
warfarin	S-drug
(	O
a	O
substrate	O
of	O
cytochromes	O
P450	O
2A6	O
and	O
2C9	O
)	O
or	O
influence	O
the	O
effect	O
of	O
a	O
single	O
30	O
-	O
mg	O
oral	O
dose	O
of	O
warfarin	S-drug
on	O
prothrombin	O
time	O
or	O
the	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
.	O

-	O
did	O
not	O
change	O
the	O
pharmacokinetic	O
profile	O
or	O
urinary	O
excretion	O
of	O
immunoreactive	O
digoxin	S-drug
.	O

-	O
did	O
not	O
change	O
the	O
plasma	O
concentration	O
profile	O
of	O
terfenadine	S-drug
(	O
a	O
substrate	O
of	O
cytochrome	O
P450	O
3A4	O
)	O
or	O
fexofenadine	S-drug
,	O
its	O
carboxylated	O
metabolite	O
,	O
and	O
did	O
not	O
prolong	O
the	O
QTc	O
interval	O
following	O
co	O
-	O
administration	O
with	O
terfenadine	S-drug
60	O
mg	O
twice	O
daily	O
.	O

Montelukast	S-drug
at	O
Doses	O
of	O
100	O
mg	O
Daily	O
Dosed	O
to	O
Pharmacokinetic	O
Steady	O
State	O
:	O
-	O
did	O
not	O
significantly	O
alter	O
the	O
plasma	O
concentrations	O
of	O
either	O
component	O
of	O
an	O
oral	O
contraceptive	S-group
containing	O
norethindrone	S-drug
1	O
mg	O
/	O
ethinyl	O
estradiol	S-drug
35	O
mcg	O
.	O

-	O
did	O
not	O
cause	O
any	O
clinically	O
significant	O
change	O
in	O
plasma	O
profiles	O
of	O
prednisone	S-drug
or	O
prednisolone	S-drug
following	O
administration	O
of	O
either	O
oral	O
prednisone	S-drug
or	O
intravenous	O
prednisolone	S-drug
.	O

Phenobarbital	S-drug
,	O
which	O
induces	O
hepatic	O
metabolism	O
,	O
decreased	O
the	O
AUC	O
of	O
montelukast	S-drug
approximately	O
40	O
%	O
following	O
a	O
single	O
10	O
-	O
mg	O
dose	O
of	O
montelukast	S-drug
.	O

No	O
dosage	O
adjustment	O
for	O
montelukast	S-drug
is	O
recommended	O
.	O

It	O
is	O
reasonable	O
to	O
employ	O
appropriate	O
clinical	O
monitoring	O
when	O
potent	O
cytochrome	O
P450	O
enzyme	O
inducers	O
,	O
such	O
as	O
phenobarbital	S-drug-AD-1
or	O
rifampin	S-drug-AD-1
,	O
are	O
co	O
-	O
administered	O
with	O
montelukast	S-drug-AD-2
.	O

Montelukast	S-drug
has	O
been	O
administered	O
with	O
other	O
therapies	O
routinely	O
used	O
in	O
the	O
prophylaxis	O
and	O
chronic	O
treatment	O
of	O
asthma	O
with	O
no	O
apparent	O
increase	O
in	O
adverse	O
reactions	O
.	O

In	O
drug	O
-	O
interaction	O
studies	O
,	O
the	O
recommended	O
clinical	O
dose	O
of	O
montelukast	S-drug
did	O
not	O
have	O
clinically	O
important	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
the	O
following	O
drugs	O
:	O
theophylline	S-drug
,	O
prednisone	S-drug
,	O
prednisolone	S-drug
,	O
oral	O
contraceptives	S-group
(	O
norethindrone	S-drug
1	O
mg	O
/	O
ethinyl	B-drug
estradiol	E-drug
35	O
mcg	O
)	O
,	O
terfenadine	S-drug
,	O
digoxin	S-drug
,	O
and	O
warfarin	S-drug
.	O

Although	O
additional	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
,	O
montelukast	S-drug
was	O
used	O
concomitantly	O
with	O
a	O
wide	O
range	O
of	O
commonly	O
prescribed	O
drugs	O
in	O
clinical	O
studies	O
without	O
evidence	O
of	O
clinical	O
adverse	O
interactions	O
.	O

These	O
medications	O
included	O
thyroid	B-group
hormones	E-group
,	O
sedative	B-group
hypnotics	E-group
,	O
non	B-group
-	I-group
steroidal	I-group
anti	I-group
-	I-group
inflammatory	I-group
agents	E-group
,	O
benzodiazepines	S-group
,	O
and	O
decongestants	S-group
.	O

Phenobarbital	S-drug
,	O
which	O
induces	O
hepatic	O
metabolism	O
,	O
decreased	O
the	O
AUC	O
of	O
montelukast	S-drug
approximately	O
40	O
%	O
following	O
a	O
single	O
10	O
-	O
mg	O
dose	O
of	O
montelukast	S-drug
.	O

No	O
dosage	O
adjustment	O
for	O
montelukast	S-drug
is	O
recommended	O
.	O

It	O
is	O
reasonable	O
to	O
employ	O
appropriate	O
clinical	O
monitoring	O
when	O
potent	O
cytochrome	O
P450	O
enzyme	O
inducers	O
,	O
such	O
as	O
phenobarbital	S-drug-AD-1
or	O
rifampin	S-drug-AD-1
,	O
are	O
co	O
-	O
administered	O
with	O
montelukast	S-drug-AD-2
.	O

Use	O
with	O
Other	O
Central	B-group
Nervous	I-group
System	I-group
Depressants	E-group
:	O
The	O
depressant	O
effects	O
of	O
morphine	S-drug-EF-1
are	O
potentiated	O
by	O
the	O
presence	O
of	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
such	O
as	O
alcohol	S-drug-EF-2
,	O
sedatives	S-group-EF-2
,	O
antihistaminics	S-group-EF-2
,	O
or	O
psychotropic	B-group-EF-2
drugs	E-group-EF-2
.	O

Use	O
of	O
neuroleptics	S-group-EF-1
in	O
conjunction	O
with	O
oral	O
morphine	S-drug-EF-2
may	O
increase	O
the	O
risk	O
of	O
respiratory	O
depression	O
,	O
hypotension	O
and	O
profound	O
sedation	O
or	O
coma	O
.	O

Interaction	O
with	O
Mixed	B-group
Agonist	I-group
/	I-group
Antagonist	I-group
Opioid	I-group
Analgesics	E-group
:	O
Agonist	B-group-AD-1
/	I-group-AD-1
antagonist	I-group-AD-1
analgesics	E-group-AD-1
(	O
i.e	O
.	O
,	O
pentazocine	S-drug-AD-1
,	O
nalbuphine	S-drug-AD-1
,	O
butorphanol	S-drug-AD-1
,	O
or	O
buprenorphine	S-drug-AD-1
)	O
should	O
NOT	O
be	O
administered	O
to	O
patients	O
who	O
have	O
received	O
or	O
are	O
receiving	O
a	O
course	O
of	O
therapy	O
with	O
a	O
proof	O
opioid	B-group-AD-2
agonist	I-group-AD-2
analgesic	E-group-AD-2
.	O

In	O
these	O
patients	O
,	O
the	O
mixed	O
agonist	O
/	O
antagonist	O
may	O
alter	O
the	O
analgesic	O
effect	O
or	O
may	O
precipitate	O
withdrawal	O
symptoms	O
.	O

Antacids	S-group
:	O
Absorption	O
of	O
a	O
single	O
dose	O
of	O
Myfortic	S-brand-ME-1
was	O
decreased	O
when	O
administered	O
to	O
12	O
stable	O
renal	O
transplant	O
patients	O
also	O
taking	O
magnesium	S-drug-ME-2
-	O
aluminum	S-drug-ME-2
containing	O
antacids	S-group
(	O
30	O
mL	O
)	O
:	O
the	O
mean	O
Cmax	O
and	O
AUC	O
(	O
0	O
-	O
t	O
)	O
values	O
for	O
MPA	O
were	O
25	O
%	O
and	O
37	O
%	O
lower	O
,	O
respectively	O
,	O
than	O
when	O
Myfortic	S-brand
was	O
administered	O
alone	O
under	O
fasting	O
conditions	O
.	O

It	O
is	O
recommended	O
that	O
Myfortic	S-drug-AD-1
and	O
antacids	S-group-AD-2
not	O
be	O
administered	O
simultaneously	O
.	O

Cyclosporine	S-drug
:	O
When	O
studied	O
in	O
stable	O
renal	O
transplant	O
patients	O
,	O
cyclosporine	S-drug
,	O
USP	O
(	O
MODIFIED	O
)	O
pharmacokinetics	O
were	O
unaffected	O
by	O
steady	O
state	O
dosing	O
of	O
Myfortic	S-brand
.	O

Acyclovir	S-drug
/	O
Ganciclovir	S-drug
:	O
may	O
be	O
taken	O
with	O
Myfortic	S-brand
;	O

however	O
,	O
during	O
the	O
period	O
of	O
treatment	O
,	O
physicians	O
should	O
monitor	O
blood	O
cell	O
counts	O
.	O

Both	O
acyclovir	S-drug
/	O
ganciclovir	S-drug
and	O
MPAG	S-drug_n
concentrations	O
are	O
increased	O
in	O
the	O
presence	O
of	O
renal	O
impairment	O
,	O
their	O
coexistence	O
may	O
compete	O
for	O
tubular	O
secretion	O
and	O
further	O
increase	O
in	O
the	O
concentrations	O
of	O
the	O
two	O
.	O

Azathioprine	S-drug
/	O
Mycophenolate	B-drug
Mofetil	E-drug
:	O
Given	O
that	O
azathioprine	S-drug
and	O
mycophenolate	B-drug
mofetil	E-drug
inhibit	O
purine	O
metabolism	O
,	O
it	O
is	O
recommended	O
that	O
Myfortic	S-brand-AD-1
not	O
be	O
administered	O
concomitantly	O
with	O
azathioprine	S-drug-AD-2
or	O
mycophenolate	B-drug-AD-2
mofetil	E-drug-AD-2
.	O

Cholestyramine	S-drug
and	O
Drugs	O
that	O
Bind	O
Bile	O
Acids	O
:	O
These	O
drugs	O
interrupt	O
enterohepatic	O
recirculation	O
and	O
reduce	O
MPA	S-drug_n
exposure	O
when	O
coadministered	O
with	O
mycophenolate	B-drug
mofetil	E-drug
.	O

Therefore	O
,	O
do	O
not	O
administer	O
Myfortic	S-drug-AD-1
with	O
cholestyramine	S-drug-AD-2
or	O
other	O
agents	O
that	O
may	O
interfere	O
with	O
enterohepatic	O
recirculation	O
or	O
drugs	O
that	O
may	O
bind	O
bile	O
acids	O
,	O
for	O
example	O
bile	O
acid	O
sequestrates	O
or	O
oral	O
activated	B-drug-AD-2
charcoal	E-drug-AD-2
,	O
because	O
of	O
the	O
potential	O
to	O
reduce	O
the	O
efficacy	O
of	O
Myfortic	S-brand
.	O

Oral	O
Contraceptives	S-group
:	O
Given	O
the	O
different	O
metabolism	O
of	O
Myfortic	S-brand
and	O
oral	O
contraceptives	S-group
,	O
no	O
drug	O
interaction	O
between	O
these	O
two	O
classes	O
of	O
drug	O
is	O
expected	O
.	O

However	O
,	O
in	O
a	O
drug	O
-	O
drug	O
interaction	O
study	O
,	O
mean	O
levonorgesterol	S-drug-ME-1
AUC	O
was	O
decreased	O
by	O
15	O
%	O
when	O
coadministered	O
with	O
mycophenolate	B-drug-ME-2
mofetil	E-drug-ME-2
.	O

Therefore	O
,	O
it	O
is	O
recommended	O
that	O
oral	O
contraceptives	S-group-AD-1
are	O
co	O
-	O
administered	O
with	O
Myfortic	S-brand-AD-2
with	O
caution	O
and	O
additional	O
birth	O
control	O
methods	O
be	O
considered	O
.	O

Live	B-group
Vaccines	E-group
:	O
During	O
treatment	O
with	O
Myfortic	S-drug-AD-1
,	O
the	O
use	O
of	O
live	B-group-AD-2
attenuated	I-group-AD-2
vaccines	E-group-AD-2
should	O
be	O
avoided	O
and	O
patients	O
should	O
be	O
advised	O
that	O
vaccinations	O
may	O
be	O
less	O
effective	O
.	O

Influenza	O
vaccination	O
may	O
be	O
of	O
value	O
.	O

Prescribers	O
should	O
refer	O
to	O
national	O
guidelines	O
for	O
influenza	O
vaccination	O
.	O

Drugs	O
that	O
alter	O
the	O
gastrointestinal	O
flora	O
may	O
interact	O
with	O
Myfortic	S-brand
by	O
disrupting	O
enterohepatic	O
recirculation	O
.	O

Interference	O
of	O
MPAG	S-drug_n
hydrolysis	O
may	O
lead	O
to	O
less	O
MPA	S-drug_n
available	O
for	O
absorption	O
.	O

Ondansetron	S-drug
does	O
not	O
itself	O
appear	O
to	O
induce	O
or	O
inhibit	O
the	O
cytochrome	O
P	O
-	O
450	O
drug	O
-	O
metabolizing	O
enzyme	O
system	O
of	O
the	O
liver	O
.	O

Because	O
ondansetron	S-drug
is	O
metabolized	O
by	O
hepatic	O
cytochrome	O
P	O
-	O
450	O
drug	O
-	O
metabolizing	O
enzymes	O
(	O
CYP3A4	O
,	O
CYP2D6	O
,	O
CYP1A2	O
)	O
,	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
may	O
change	O
the	O
clearance	O
and	O
,	O
hence	O
,	O
the	O
half	O
-	O
life	O
of	O
ondansetron	S-drug
.	O

On	O
the	O
basis	O
of	O
limited	O
available	O
data	O
,	O
no	O
dosage	O
adjustment	O
is	O
recommended	O
for	O
patients	O
on	O
these	O
drugs	O
.	O

Phenytoin	S-drug
,	O
Carbamazepine	S-drug
,	O
and	O
Rifampicin	S-drug
:	O
In	O
patients	O
treated	O
with	O
potent	O
inducers	O
of	O
CYP3A4	O
(	O
i.e	O
.	O
,	O
phenytoin	S-drug-ME-1
,	O
carbamazepine	S-drug-ME-1
,	O
and	O
rifampicin	S-drug-ME-1
)	O
,	O
the	O
clearance	O
of	O
ondansetron	S-drug-ME-2
was	O
significantly	O
increased	O
and	O
ondansetron	S-drug-ME-2
blood	O
concentrations	O
were	O
decreased	O
.	O

However	O
,	O
on	O
the	O
basis	O
of	O
available	O
data	O
,	O
no	O
dosage	O
adjustment	O
for	O
ondansetron	S-drug
is	O
recommended	O
for	O
patients	O
on	O
these	O
drugs.1,3	O
Tramadol	S-drug
:	O
Although	O
no	O
pharmacokinetic	O
drug	O
interaction	O
between	O
ondansetron	S-drug
and	O
tramadol	S-drug
has	O
been	O
observed	O
,	O
data	O
from	O
2	O
small	O
studies	O
indicate	O
that	O
ondansetron	S-drug-EF-1
may	O
be	O
associated	O
with	O
an	O
increase	O
in	O
patient	O
controlled	O
administration	O
of	O
tramadol.4,5	O
Chemotherapy	O
:	O
Tumor	O
response	O
to	O
chemotherapy	O
in	O
the	O
P	O
388	O
mouse	O
leukemia	O
model	O
is	O
not	O
affected	O
by	O
ondansetron	S-drug
.	O

In	O
humans	O
,	O
carmustine	S-drug
,	O
etoposide	S-drug
,	O
and	O
cisplatin	S-drug
do	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
ondansetron	S-drug
.	O

In	O
a	O
crossover	O
study	O
in	O
76	O
pediatric	O
patients	O
,	O
I.V	O
.	O

ondansetron	S-drug
did	O
not	O
increase	O
blood	O
levels	O
of	O
high	O
-	O
dose	O
methotrexate	S-drug
.	O

Other	O
beta	B-group-AD-1
adrenergic	I-group-AD-1
aerosol	I-group-AD-1
bronchodilators	E-group-AD-1
should	O
not	O
be	O
used	O
concomitantly	O
with	O
Alupent	S-brand-AD-2
(	O
metaproterenol	B-drug-AD-2
sulfate	E-drug-AD-2
USP	O
)	O
because	O
they	O
may	O
have	O
additive	O
effects	O
.	O

Beta	B-group-AD-1
adrenergic	I-group-AD-1
agonists	E-group-AD-1
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
monoamine	B-group-AD-2
oxidase	I-group-AD-2
inhibitors	E-group-AD-2
or	O
tricyclic	B-group-AD-2
antidepressants	E-group-AD-2
,	O
since	O
the	O
action	O
of	O
beta	B-group
adrenergic	I-group
agonists	E-group
on	O
the	O
vascular	O
system	O
may	O
be	O
potentiated	O
.	O

Alcohol	S-drug
:	O
In	O
a	O
multiple	O
-	O
dose	O
study	O
in	O
30	O
normal	O
weight	O
subjects	O
,	O
coadministration	O
of	O
XENICAL	S-brand
and	O
40	O
grams	O
of	O
alcohol	S-drug
(	O
e.g	O
.	O
,	O
approximately	O
3	O
glasses	O
of	O
wine	O
)	O
did	O
not	O
result	O
in	O
alteration	O
of	O
alcohol	S-drug
pharmacokinetics	O
,	O
orlistat	S-drug
pharmacodynamics	O
(	O
fecal	O
fat	O
excretion	O
)	O
,	O
or	O
systemic	O
exposure	O
to	O
orlistat	S-drug
.	O

Cyclosporine	S-drug
:	O
Preliminary	O
data	O
from	O
a	O
XENICAL	S-brand
and	O
cyclosporine	S-drug
drug	O
interaction	O
study	O
indicate	O
a	O
reduction	O
in	O
cyclosporine	S-drug
plasma	O
levels	O
when	O
XENICAL	S-brand-ME-1
was	O
coadministered	O
with	O
cyclosporine	S-drug-ME-2
.	O

Digoxin	S-drug
:	O
In	O
12	O
normal	O
-	O
weight	O
subjects	O
receiving	O
XENICAL	S-brand
120	O
mg	O
three	O
times	O
a	O
day	O
for	O
6	O
days	O
,	O
XENICAL	S-brand
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
dose	O
of	O
digoxin	S-drug
.	O

Fat	B-group
-	I-group
soluble	I-group
Vitamin	I-group
Supplements	E-group
and	O
Analogues	O
:	O
A	O
pharmacokinetic	O
interaction	O
study	O
showed	O
a	O
30	O
%	O
reduction	O
in	O
beta	B-drug-ME-1
-	I-drug-ME-1
carotene	E-drug-ME-1
supplement	O
absorption	O
when	O
concomitantly	O
administered	O
with	O
XENICAL	S-brand-ME-2
.	O

XENICAL	S-brand-ME-1
inhibited	O
absorption	O
of	O
a	O
vitamin	B-drug-ME-2
E	I-drug-ME-2
acetate	E-drug-ME-2
supplement	O
by	O
approximately	O
60	O
%	O
.	O

The	O
effect	O
of	O
orlistat	S-drug
on	O
the	O
absorption	O
of	O
supplemental	O
vitamin	B-group
D	E-group
,	O
vitamin	B-group
A	E-group
,	O
and	O
nutritionally	O
-	O
derived	O
vitamin	B-group
K	E-group
is	O
not	O
known	O
at	O
this	O
time	O
.	O

Glyburide	S-drug
:	O
In	O
12	O
normal	O
-	O
weight	O
subjects	O
receiving	O
orlistat	S-drug
80	O
mg	O
three	O
times	O
a	O
day	O
for	O
5	O
days	O
,	O
orlistat	S-drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
(	O
blood	O
glucose	O
-	O
lowering	O
)	O
of	O
glyburide	S-drug
.	O

Nifedipine	S-drug
(	O
extended	O
-	O
release	O
tablets	O
)	O
:	O
In	O
17	O
normal	O
-	O
weight	O
subjects	O
receiving	O
XENICAL	S-brand
120	O
mg	O
three	O
times	O
a	O
day	O
for	O
6	O
days	O
,	O
XENICAL	S-brand
did	O
not	O
alter	O
the	O
bioavailability	O
of	O
nifedipine	S-drug
(	O
extended	O
-	O
release	O
tablets	O
)	O
.	O

Oral	O
Contraceptives	S-group
:	O
In	O
20	O
normal	O
-	O
weight	O
female	O
subjects	O
,	O
the	O
treatment	O
of	O
XENICAL	S-brand
120	O
mg	O
three	O
times	O
a	O
day	O
for	O
23	O
days	O
resulted	O
in	O
no	O
changes	O
in	O
the	O
ovulation	O
-	O
suppressing	O
action	O
of	O
oral	O
contraceptives	S-group
.	O

Phenytoin	S-drug
:	O
In	O
12	O
normal	O
-	O
weight	O
subjects	O
receiving	O
XENICAL	S-brand
120	O
mg	O
three	O
times	O
a	O
day	O
for	O
7	O
days	O
,	O
XENICAL	S-brand
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
300	O
-	O
mg	O
dose	O
of	O
phenytoin	S-drug
.	O

Pravastatin	S-drug
:	O
In	O
a	O
2	O
-	O
way	O
crossover	O
study	O
of	O
24	O
normal	O
-	O
weight	O
,	O
mildly	O
hypercholesterolemic	O
patients	O
receiving	O
XENICAL	S-brand
120	O
mg	O
three	O
times	O
a	O
day	O
for	O
6	O
days	O
,	O
XENICAL	S-brand
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
pravastatin	S-drug
.	O

Warfarin	S-drug
:	O
In	O
12	O
normal	O
-	O
weight	O
subjects	O
,	O
administration	O
of	O
XENICAL	S-brand
120	O
mg	O
three	O
times	O
a	O
day	O
for	O
16	O
days	O
did	O
not	O
result	O
in	O
any	O
change	O
in	O
either	O
warfarin	S-drug
pharmacokinetics	O
(	O
both	O
R	O
-	O
and	O
S	O
-	O
enantiomers	O
)	O
or	O
pharmacodynamics	O
(	O
prothrombin	O
time	O
and	O
serum	O
Factor	O
VII	O
)	O
.	O

Although	O
undercarboxylated	O
osteocalcin	O
,	O
a	O
marker	O
of	O
vitamin	O
K	O
nutritional	O
status	O
,	O
was	O
unaltered	O
with	O
XENICAL	S-brand
administration	O
,	O
vitamin	O
K	O
levels	O
tended	O
to	O
decline	O
in	O
subjects	O
taking	O
XENICAL	S-brand
.	O

Therefore	O
,	O
as	O
vitamin	B-group-ME-1
K	E-group-ME-1
absorption	O
may	O
be	O
decreased	O
with	O
XENICAL	S-brand-ME-2
,	O
patients	O
on	O
chronic	O
stable	O
doses	O
of	O
warfarin	S-drug-AD-1
who	O
are	O
prescribed	O
XENICAL	S-brand-AD-2
should	O
be	O
monitored	O
closely	O
for	O
changes	O
in	O
coagulation	O
parameters	O
.	O

Tetracycline	S-group-EF-1
,	O
a	O
bacteriostatic	O
antibiotic	S-group
,	O
may	O
antagonize	O
the	O
bactericidal	O
effect	O
of	O
penicillin	S-drug-EF-2
and	O
concurrent	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

No	O
specific	O
cytochrome	O
P450	O
-	O
based	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

No	O
pharmacokinetic	O
interaction	O
between	O
85	O
mg	O
/	O
m2	O
ELOXATIN	S-brand
and	O
infusional	O
5	B-drug
-	I-drug
FU	E-drug
has	O
been	O
observed	O
in	O
patients	O
treated	O
every	O
2	O
weeks	O
.	O

Increases	O
of	O
5	B-drug-ME-1
-	I-drug-ME-1
FU	E-drug-ME-1
plasma	O
concentrations	O
by	O
approximately	O
20	O
%	O
have	O
been	O
observed	O
with	O
doses	O
of	O
130	O
mg	O
/	O
m2	O
ELOXATIN	S-brand-ME-2
dosed	O
every	O
3	O
weeks	O
.	O

Since	O
platinum	O
containing	O
species	O
are	O
eliminated	O
primarily	O
through	O
the	O
kidney	O
,	O
clearance	O
of	O
these	O
products	O
may	O
be	O
decreased	O
by	O
coadministration	O
of	O
potentially	O
nephrotoxic	O
compounds	O
;	O

although	O
,	O
this	O
has	O
not	O
been	O
specifically	O
studied	O
.	O

Anticoagulants	S-group
Anabolic	B-group-EF-1
steroids	E-group-EF-1
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulants	S-group-EF-2
.	O

Dosage	O
of	O
the	O
anticoagulant	S-group
may	O
have	O
to	O
be	O
decreased	O
in	O
order	O
to	O
maintain	O
desired	O
prothrombin	O
time	O
.	O

Patients	O
receiving	O
oral	O
anticoagulant	O
therapy	O
require	O
close	O
monitoring	O
,	O
especially	O
when	O
anabolic	B-group
steroids	E-group
are	O
started	O
or	O
stopped	O
.	O

Warfarin	S-drug
:	O
A	O
multidose	O
study	O
of	O
oxandrolone	S-drug-ME-1
,	O
given	O
as	O
5	O
or	O
10	O
mg	O
BID	O
in	O
15	O
healthy	O
subjects	O
concurrently	O
treated	O
with	O
warfarin	S-drug-ME-2
,	O
resulted	O
in	O
a	O
mean	O
increase	O
in	O
S	B-drug
-	I-drug
warfarin	E-drug
half	O
-	O
life	O
from	O
26	O
to	O
48	O
hours	O
and	O
AUC	O
from	O
4.55	O
to	O
12.08	O
ng	O
*	O
hr	O
/	O
mL	O
:	O
similar	O
increases	O
in	O
R	B-drug
-	I-drug
warfarin	E-drug
half	O
-	O
life	O
and	O
AUC	O
were	O
also	O
detected	O
.	O

Microscopic	O
hematuria	O
(	O
9	O
/	O
15	O
)	O
and	O
gingival	O
bleeding	O
(	O
1	O
/	O
15	O
)	O
were	O
also	O
observed	O
.	O

A	O
5.5	O
-	O
fold	O
decrease	O
in	O
the	O
mean	O
warfarin	S-drug
dose	O
from	O
6.13	O
mg	O
/	O
day	O
to	O
1.13	O
mg	O
/	O
day	O
(	O
approximately	O
80	O
-	O
85	O
%	O
reduction	O
of	O
warfarin	S-drug
dose	O
)	O
,	O
was	O
necessary	O
to	O
maintain	O
a	O
target	O
INR	O
of	O
1.5	O
.	O

When	O
oxandrolone	S-drug-AD-1
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
already	O
receiving	O
treatment	O
with	O
warfarin	S-drug-AD-2
,	O
the	O
INR	O
or	O
prothrombin	O
time	O
(	O
PT	O
)	O
should	O
be	O
monitored	O
closely	O
and	O
the	O
dose	O
of	O
warfarin	S-drug
adjusted	O
as	O
necessary	O
until	O
a	O
stable	O
target	O
INR	O
or	O
PT	O
has	O
been	O
achieved	O
.	O

Furthermore	O
,	O
in	O
patients	O
receiving	O
both	O
drugs	O
,	O
careful	O
monitoring	O
of	O
the	O
INR	O
or	O
PT	O
,	O
and	O
adjustment	O
of	O
the	O
warfarin	S-drug-AD-1
dosage	O
if	O
indicated	O
are	O
recommended	O
when	O
the	O
oxandrolone	S-drug-AD-2
dose	O
is	O
changed	O
or	O
discontinued	O
.	O

Patients	O
should	O
be	O
closely	O
monitored	O
for	O
signs	O
and	O
symptoms	O
of	O
occult	O
bleeding	O
.	O

Oral	O
hypoglycemic	B-group
agents	E-group
Oxandrolone	S-drug-ME-1
may	O
inhibit	O
the	O
metabolism	O
of	O
oral	O
hypoglycemic	B-group-ME-2
agents	E-group-ME-2
.	O

Adrenal	B-group
steroids	E-group
or	O
ACTH	S-drug
In	O
patients	O
with	O
edema	O
,	O
concomitant	O
administration	O
with	O
adrenal	B-group
cortical	I-group
steroids	E-group
or	O
ACTH	S-drug
may	O
increase	O
the	O
edema	O
.	O

Drug	O
/	O
Laboratory	O
test	O
interactions	O
Anabolic	B-drug
steroids	E-drug
may	O
decrease	O
levels	O
of	O
thyroxine	O
-	O
binding	O
globulin	O
,	O
resulting	O
in	O
decreased	O
total	O
T4	O
serum	O
levels	O
and	O
increased	O
resin	O
uptake	O
of	O
T3	O
and	O
T4	O
.	O

Free	O
thyroid	O
hormone	O
levels	O
remain	O
unchanged	O
.	O

In	O
addition	O
,	O
a	O
decrease	O
in	O
PBI	O
and	O
radioactive	O
iodine	O
uptake	O
may	O
occur	O
.	O

The	O
concomitant	O
use	O
of	O
oxybutynin	S-drug-EF-1
with	O
other	O
anticholinergic	B-group-EF-2
drugs	E-group-EF-2
or	O
with	O
other	O
agents	O
which	O
produce	O
dry	O
mouth	O
,	O
constipation	O
,	O
somnolence	O
(	O
drowsiness	O
)	O
,	O
and	O
/	O
or	O
other	O
anticholinergic	O
-	O
like	O
effects	O
may	O
increase	O
the	O
frequency	O
and	O
/	O
or	O
severity	O
of	O
such	O
effects	O
.	O

Anticholinergic	B-group
agents	E-group
may	O
potentially	O
alter	O
the	O
absorption	O
of	O
some	O
concomitantly	O
administered	O
drugs	O
due	O
to	O
anticholinergic	O
effects	O
on	O
gastrointestinal	O
motility	O
.	O

This	O
may	O
be	O
of	O
concern	O
for	O
drugs	O
with	O
a	O
narrow	O
therapeutic	O
index	O
.	O

Mean	O
oxybutynin	B-drug
chloride	E-drug
plasma	O
concentrations	O
were	O
approximately	O
2	O
fold	O
higher	O
when	O
DITROPAN	B-brand-ME-1
XL	E-brand-ME-1
was	O
administered	O
with	O
ketoconazole	S-drug-ME-2
,	O
a	O
potent	O
CYP3A4	O
inhibitor	O
.	O

Other	O
inhibitors	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
,	O
such	O
as	O
antimycotic	B-group-ME-1
agents	E-group-ME-1
(	O
e.g	O
.	O
,	O
itraconazole	S-drug-ME-1
and	O
miconazole	S-drug-ME-1
)	O
or	O
macrolide	B-group-ME-1
antibiotics	E-group-ME-1
(	O
e.g	O
.	O
,	O
erythromycin	S-drug-ME-1
and	O
clarithromycin	S-drug-ME-1
)	O
,	O
may	O
alter	O
oxybutynin	S-drug-ME-2
mean	O
pharmacokinetic	O
parameters	O
(	O
i.e	O
.	O
,	O
Cmax	O
and	O
AUC	O
)	O
.	O

The	O
clinical	O
relevance	O
of	O
such	O
potential	O
interactions	O
is	O
not	O
known	O
.	O

Caution	O
should	O
be	O
used	O
when	O
such	O
drugs	O
are	O
co	O
-	O
administered	O
.	O

Concurrent	O
ingestion	O
of	O
antacid	S-group
(	O
20	O
mL	O
of	O
antacid	S-group
containing	O
aluminum	B-drug
hydroxide	E-drug
,	O
magnesium	B-drug
hydroxide	E-drug
,	O
and	O
simethicone	S-drug
)	O
did	O
not	O
significantly	O
affect	O
the	O
exposure	O
of	O
oxybutynin	S-drug
or	O
desethyloxybutynin	S-drug_n
.	O

The	O
CNS	O
depressant	O
effects	O
of	O
oxycodone	B-drug-EF-1
hydrochloride	E-drug-EF-1
may	O
be	O
additive	O
with	O
that	O
of	O
other	O
CNS	B-group-EF-2
depressants..	O

The	O
concomitant	O
use	O
of	O
other	O
CNS	B-group
depressants	E-group
including	O
sedatives	S-group
,	O
hypnotics	S-group
,	O
tranquilizers	S-group
,	O
general	O
anesthetics	S-group
,	O
phenothiazines	S-group
,	O
other	O
opioids	S-group
,	O
tricyclic	B-group
antidepressants	E-group
,	O
monoamine	B-group
oxidase	I-group
(	I-group
MAO	I-group
)	I-group
inhibitors	E-group
,	O
and	O
alcohol	S-drug
may	O
produce	O
additive	O
CNS	O
depressant	O
effects	O
.	O

When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

Anticholinergics	S-group-EF-1
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
when	O
used	O
concurrently	O
with	O
opioid	B-group-EF-2
analgesics	E-group-EF-2
may	O
result	O
in	O
increased	O
risk	O
of	O
urinary	O
retention	O
and	O
/	O
or	O
severe	O
constipation	O
,	O
which	O
may	O
lead	O
to	O
paralytic	O
ileus	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
incidence	O
of	O
bradycardia	O
was	O
increased	O
when	O
oxymorphone	S-drug-EF-1
was	O
combined	O
with	O
propofol	S-drug-EF-2
for	O
induction	O
of	O
anesthesia	O
.	O

In	O
addition	O
,	O
CNS	O
toxicity	O
has	O
been	O
reported	O
(	O
confusion	O
,	O
disorientation	O
,	O
respiratory	O
depression	O
,	O
apnea	O
,	O
seizures	O
)	O
following	O
coadministration	O
of	O
cimetidine	S-drug-EF-1
with	O
opioid	B-group-EF-2
analgesics	E-group-EF-2
;	O

no	O
clear	O
-	O
cut	O
cause	O
and	O
effect	O
relationship	O
was	O
established	O
.	O

Potential	O
for	O
INVEGA	S-brand
to	O
Affect	O
Other	O
Drugs	O
Paliperidone	S-drug
is	O
not	O
expected	O
to	O
cause	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
cytochrome	O
P450	O
isozymes	O
.	O

In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
showed	O
that	O
paliperidone	S-drug
does	O
not	O
substantially	O
inhibit	O
the	O
metabolism	O
of	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
isozymes	O
,	O
including	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C8	O
/	O
9	O
/	O
10	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
CYP3A4	O
,	O
and	O
CYP3A5	O
.	O

Therefore	O
,	O
paliperidone	S-drug
is	O
not	O
expected	O
to	O
inhibit	O
clearance	O
of	O
drugs	O
that	O
are	O
metabolized	O
by	O
these	O
metabolic	O
pathways	O
in	O
a	O
clinically	O
relevant	O
manner	O
.	O

Paliperidone	S-drug
is	O
also	O
not	O
expected	O
to	O
have	O
enzyme	O
inducing	O
properties	O
.	O

At	O
therapeutic	O
concentrations	O
,	O
paliperidone	S-drug
did	O
not	O
inhibit	O
P	O
-	O
glycoprotein	O
.	O

Paliperidone	S-drug
is	O
therefore	O
not	O
expected	O
to	O
inhibit	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
transport	O
of	O
other	O
drugs	O
in	O
a	O
clinically	O
relevant	O
manner	O
.	O

Given	O
the	O
primary	O
CNS	O
effects	O
of	O
paliperidone	S-drug-AD-1
,	O
INVEGA	S-brand-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
combination	O
with	O
other	O
centrally	B-group-AD-2
acting	I-group-AD-2
drugs	E-group-AD-2
and	O
alcohol	S-drug-AD-2
.	O

Paliperidone	S-drug-EF-1
may	O
antagonize	O
the	O
effect	O
of	O
levodopa	S-drug-EF-2
and	O
other	O
dopamine	B-group-EF-2
agonists	E-group-EF-2
.	O

Because	O
of	O
its	O
potential	O
for	O
inducing	O
orthostatic	O
hypotension	O
,	O
an	O
additive	O
effect	O
may	O
be	O
observed	O
when	O
INVEGA	S-brand
is	O
administered	O
with	O
other	O
therapeutic	O
agents	O
that	O
have	O
this	O
potential	O
.	O

Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
INVEGA	S-brand
Paliperidone	S-drug
is	O
not	O
a	O
substrate	O
of	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C9	O
,	O
and	O
CYP2C19	O
,	O
so	O
that	O
an	O
interaction	O
with	O
inhibitors	O
or	O
inducers	O
of	O
these	O
isozymes	O
is	O
unlikely	O
.	O

While	O
in	O
vitro	O
studies	O
indicate	O
that	O
CYP2D6	O
and	O
CYP3A4	O
may	O
be	O
minimally	O
involved	O
in	O
paliperidone	S-drug
metabolism	O
,	O
in	O
vivo	O
studies	O
do	O
not	O
show	O
decreased	O
elimination	O
by	O
these	O
isozymes	O
and	O
they	O
contribute	O
to	O
only	O
a	O
small	O
fraction	O
of	O
total	O
body	O
clearance	O
.	O

Pantoprazole	S-drug
is	O
metabolized	O
through	O
the	O
cytochrome	O
P450	O
system	O
,	O
primarily	O
the	O
CYP2C19	O
and	O
CYP3A4	O
isozymes	O
,	O
and	O
subsequently	O
undergoes	O
Phase	O
II	O
conjugation	O
.	O

Based	O
on	O
studies	O
evaluating	O
possible	O
interactions	O
of	O
pantoprazole	S-drug
with	O
other	O
drugs	O
,	O
no	O
dosage	O
adjustment	O
is	O
needed	O
with	O
concomitant	O
use	O
of	O
the	O
following	O
:	O
theophylline	S-drug
,	O
cisapride	S-drug
,	O
antipyrine	S-drug
,	O
caffeine	S-drug
,	O
carbamazepine	S-drug
,	O
diazepam	S-drug
(	O
and	O
its	O
active	O
metabolite	O
,	O
desmethyldiazepam	S-drug_n
)	O
,	O
diclofenac	S-drug
,	O
naproxen	S-drug
,	O
piroxicam	S-drug
,	O
digoxin	S-drug
,	O
ethanol	S-drug
,	O
glyburide	S-drug
,	O
an	O
oral	O
contraceptive	S-group
(	O
levonorgestrel	S-drug
/	O
ethinyl	B-drug
estradiol	E-drug
)	O
,	O
metoprolol	S-drug
,	O
nifedipine	S-drug
,	O
phenytoin	S-drug
,	O
warfarin	S-drug
,	O
midazolam	S-drug
,	O
clarithromycin	S-drug
,	O
metronidazole	S-drug
,	O
or	O
amoxicillin	S-drug
.	O

Clinically	O
relevant	O
interactions	O
of	O
pantoprazole	S-drug
with	O
other	O
drugs	O
with	O
the	O
same	O
metabolic	O
pathways	O
are	O
not	O
expected	O
.	O

Therefore	O
,	O
when	O
coadministered	O
with	O
pantoprazole	S-drug
,	O
adjustment	O
of	O
the	O
dosage	O
of	O
pantoprazole	S-drug
or	O
of	O
such	O
drugs	O
may	O
not	O
be	O
necessary	O
.	O

There	O
was	O
also	O
no	O
interaction	O
with	O
concomitantly	O
administered	O
antacids	S-group
.	O

There	O
have	O
been	O
postmarketing	O
reports	O
of	O
increased	O
INR	O
and	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
proton	B-group-EF-1
pump	I-group-EF-1
inhibitors	E-group-EF-1
,	O
including	O
pantoprazole	S-drug-EF-1
,	O
and	O
warfarin	S-drug-EF-2
concomitantly	O
.	O

Increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
may	O
lead	O
to	O
abnormal	O
bleeding	O
and	O
even	O
death	O
.	O

Patients	O
treated	O
with	O
proton	B-group-AD-1
pump	I-group-AD-1
inhibitors	E-group-AD-1
and	O
warfarin	S-drug-AD-2
concomitantly	O
should	O
be	O
monitored	O
for	O
increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
.	O

Because	O
of	O
profound	O
and	O
long	O
lasting	O
inhibition	O
of	O
gastric	O
acid	O
secretion	O
,	O
pantoprazole	S-drug-ME-1
may	O
interfere	O
with	O
absorption	O
of	O
drugs	O
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
their	O
bioavailability	O
(	O
eg	O
,	O
ketoconazole	S-drug-ME-2
,	O
ampicillin	S-drug-ME-2
esters	O
,	O
and	O
iron	S-drug-ME-2
salts	O
)	O
.	O

Laboratory	O
Tests	O
There	O
have	O
been	O
reports	O
of	O
false	O
-	O
positive	O
urine	O
screening	O
tests	O
for	O
tetrahydrocannabinol	S-drug
(	O
THC	S-drug
)	O
in	O
patients	O
receiving	O
most	O
proton	B-group
pump	I-group
inhibitors	E-group
,	O
including	O
pantoprazole	S-drug
.	O

An	O
alternative	O
confirmatory	O
method	O
should	O
be	O
considered	O
to	O
verify	O
positive	O
results	O
.	O

Paricalcitol	S-drug_n
is	O
not	O
expected	O
to	O
inhibit	O
the	O
clearance	O
of	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
enzymes	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2B6	O
,	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
CYP2E1	O
or	O
CYP3A	O
nor	O
induce	O
the	O
clearance	O
of	O
drugs	O
metabolized	O
by	O
CYP2B6	O
,	O
CYP2C9	O
or	O
CYP3A	O
.	O

A	O
multiple	O
dose	O
drug	O
-	O
drug	O
interaction	O
study	O
demonstrated	O
that	O
ketoconazole	S-drug-ME-1
approximately	O
doubled	O
paricalcitol	S-drug-ME-2
AUC0	O
-	O
.	O
Since	O
paricalcitol	S-drug
is	O
partially	O
metabolized	O
by	O
CYP3A	O
and	O
ketoconazole	S-drug
le	O
is	O
known	O
to	O
be	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A	O
enzyme	O
,	O
care	O
should	O
be	O
taken	O
while	O
dosing	O
paricalcitol	S-drug-AD-1
with	O
ketoconazole	S-drug-AD-2
and	O
other	O
strong	O
P450	O
3A	O
inhibitors	O
including	O
atazanavir	S-drug-AD-2
,	O
clarithromycin	S-drug-AD-2
,	O
indinavir	S-drug-AD-2
,	O
itraconazole	S-drug-AD-2
,	O
nefazodone	S-drug-AD-2
,	O
nelfinavir	S-drug-AD-2
,	O
ritonavir	S-drug-AD-2
,	O
saquinavir	S-drug-AD-2
,	O
telithromycin	S-drug-AD-2
or	O
voriconazole	S-drug-AD-2
.	O

Dose	O
adjustment	O
of	O
Zemplar	S-brand-AD-1
Capsules	O
may	O
be	O
required	O
,	O
and	O
iPTH	O
and	O
serum	O
calcium	O
concentrations	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
patient	O
initiates	O
or	O
discontinues	O
therapy	O
with	O
a	O
strong	O
CYP3A4	O
inhibitor	O
such	O
as	O
ketoconazole	S-drug-AD-2
.	O

Drugs	O
that	O
impair	O
intestinal	O
absorption	O
of	O
fat	B-group-ME-1
-	I-group-ME-1
soluble	I-group-ME-1
vitamins	E-group-ME-1
,	O
such	O
as	O
cholestyramine	S-drug-ME-M
,	O
may	O
interfere	O
with	O
the	O
absorption	O
of	O
Zemplar	S-brand-ME-2
Capsules	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
between	O
Neulasta	S-brand
and	O
other	O
drugs	O
have	O
been	O
performed	O
.	O

Drugs	O
such	O
as	O
lithium	S-drug
may	O
potentiate	O
the	O
release	O
of	O
neutrophils	O
;	O

patients	O
receiving	O
lithium	S-drug-AD-1
and	O
Neulasta	S-brand-AD-2
should	O
have	O
more	O
frequent	O
monitoring	O
of	O
neutrophil	O
counts	O
.	O

In	O
a	O
pharmacokinetic	O
study	O
of	O
18	O
chronic	O
hepatitis	O
C	O
patients	O
concomitantly	O
receiving	O
methadone	S-drug-ME-1
,	O
treatment	O
with	O
PEG	B-brand-ME-2
-	I-brand-ME-2
Intron	E-brand-ME-2
once	O
weekly	O
for	O
4	O
weeks	O
was	O
associated	O
with	O
a	O
mean	O
increase	O
of	O
16	O
%	O
in	O
methadone	S-drug
AUC	O
;	O

in	O
2	O
out	O
of	O
18	O
patients	O
,	O
methadone	S-drug
AUC	O
doubled	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
;	O

however	O
,	O
patients	O
should	O
be	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
increased	O
narcotic	O
effect	O
.	O

Acromegalic	O
patients	O
with	O
diabetes	O
mellitus	O
being	O
treated	O
with	O
insulin	S-drug-AD-1
and	O
/	O
or	O
oral	O
hypoglycemic	S-group-AD-1
agents	O
may	O
require	O
dose	O
reductions	O
of	O
these	O
therapeutic	O
agents	O
after	O
the	O
initiation	O
of	O
therapy	O
with	O
SOMAVERT	S-brand-AD-2
.	O

In	O
clinical	O
studies	O
,	O
patients	O
on	O
opioids	S-group-ME-1
often	O
needed	O
higher	O
serum	O
pegvisomant	S-drug-ME-2
concentrations	O
to	O
achieve	O
appropriate	O
IGF	O
-	O
I	O
suppression	O
compared	O
with	O
patients	O
not	O
receiving	O
opioids	S-group
.	O

The	O
mechanism	O
of	O
this	O
interaction	O
is	O
not	O
known	O
.	O

ALIMTA	S-brand
is	O
primarily	O
eliminated	O
unchanged	O
renally	O
as	O
a	O
result	O
of	O
glomerular	O
filtration	O
and	O
tubular	O
secretion	O
.	O

Concomitant	O
administration	O
of	O
nephrotoxic	O
drugs	O
could	O
result	O
in	O
delayed	O
clearance	O
of	O
ALIMTA	S-brand
.	O

Concomitant	O
administration	O
of	O
substances	O
that	O
are	O
also	O
tubularly	O
secreted	O
(	O
e.g	O
.	O
,	O
probenecid	S-drug-ME-1
)	O
could	O
potentially	O
result	O
in	O
delayed	O
clearance	O
of	O
ALIMTA	S-brand-ME-2
.	O

Although	O
ibuprofen	S-drug
(	O
400	O
mg	O
qid	O
)	O
can	O
be	O
administered	O
with	O
ALIMTA	S-brand
in	O
patients	O
with	O
normal	O
renal	O
function	O
(	O
creatinine	O
clearance	O
80	O
mL	O
/	O
min	O
)	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
ibuprofen	S-drug-AD-1
concurrently	O
with	O
ALIMTA	S-brand-AD-2
to	O
patients	O
with	O
mild	O
to	O
moderate	O
renal	O
insufficiency	O
(	O
creatinine	O
clearance	O
from	O
45	O
to	O
79	O
mL	O
/	O
min	O
)	O
.	O

Patients	O
with	O
mild	O
to	O
moderate	O
renal	O
insufficiency	O
should	O
avoid	O
taking	O
NSAIDs	S-group-AD-1
with	O
short	O
elimination	O
half	O
-	O
lives	O
for	O
a	O
period	O
of	O
2	O
days	O
before	O
,	O
the	O
day	O
of	O
,	O
and	O
2	O
days	O
following	O
administration	O
of	O
ALIMTA	S-brand-AD-2
.	O

In	O
the	O
absence	O
of	O
data	O
regarding	O
potential	O
interaction	O
between	O
ALIMTA	S-brand
and	O
NSAIDs	S-group
with	O
longer	O
half	O
-	O
lives	O
,	O
all	O
patients	O
taking	O
these	O
NSAIDs	S-group-AD-1
should	O
interrupt	O
dosing	O
for	O
at	O
least	O
5	O
days	O
before	O
,	O
the	O
day	O
of	O
,	O
and	O
2	O
days	O
following	O
ALIMTA	S-brand-AD-2
administration	O
.	O

If	O
concomitant	O
administration	O
of	O
an	O
NSAID	S-group
is	O
necessary	O
,	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
toxicity	O
,	O
especially	O
myelosuppression	O
,	O
renal	O
,	O
and	O
gastrointestinal	O
toxicity	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O

The	O
interaction	O
of	O
CYLERT	S-brand
(	O
pemoline	S-drug
)	O
with	O
other	O
drugs	O
has	O
not	O
been	O
studied	O
in	O
humans	O
.	O

Patients	O
who	O
are	O
receiving	O
CYLERT	S-brand
concurrently	O
with	O
other	O
drugs	O
,	O
especially	O
drugs	O
with	O
CNS	O
activity	O
,	O
should	O
be	O
monitored	O
carefully	O
.	O

Decreased	O
seizure	O
threshold	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
CYLERT	S-brand-EF-1
concomitantly	O
with	O
antiepileptic	B-group-EF-2
medications	E-group-EF-2
.	O

Concurrent	O
administration	O
of	O
bacteriostatic	B-group-EF-1
antibiotics	E-group-EF-1
(	O
e.g	O
.	O
,	O
erythromycin	S-drug-EF-1
,	O
tetracycline	S-drug-EF-1
)	O
may	O
diminish	O
the	O
bactericidal	O
effects	O
of	O
penicillins	S-group-EF-2
by	O
slowing	O
the	O
rate	O
of	O
bacterial	O
growth	O
.	O

Bactericidal	O
agents	O
work	O
most	O
effectively	O
against	O
the	O
immature	O
cell	O
wall	O
of	O
rapidly	O
proliferating	O
microorganisms	O
.	O

This	O
has	O
been	O
demonstrated	O
in	O
vitro	O
;	O

however	O
,	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
well	O
documented	O
.	O

There	O
are	O
few	O
clinical	O
situations	O
in	O
which	O
the	O
concurrent	O
use	O
of	O
'	O
'	O
static	O
'	O
'	O
and	O
'	O
'	O
cidal	O
'	O
'	O
antibiotics	S-group
are	O
indicated	O
.	O

However	O
,	O
in	O
selected	O
circumstances	O
in	O
which	O
such	O
therapy	O
is	O
appropriate	O
,	O
using	O
adequate	O
doses	O
of	O
antibacterial	S-group
agents	O
and	O
beginning	O
penicillin	O
therapy	O
first	O
,	O
should	O
minimize	O
the	O
potential	O
for	O
interaction	O
.	O

Penicillin	S-group-ME-1
blood	O
levels	O
may	O
be	O
prolonged	O
by	O
concurrent	O
administration	O
of	O
probenecid	S-drug-ME-2
which	O
blocks	O
the	O
renal	O
tubular	O
secretion	O
of	O
penicillins	S-group
.	O

Displacement	O
of	O
penicillin	S-group
from	O
plasma	O
protein	O
binding	O
sites	O
will	O
elevate	O
the	O
level	O
of	O
free	O
penicillin	S-group
in	O
the	O
serum	O
.	O

Usage	O
with	O
Alcohol	S-drug
:	O
Due	O
to	O
the	O
potential	O
for	O
increased	O
CNS	O
depressants	O
effects	O
,	O
alcohol	S-drug-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
who	O
are	O
currently	O
receiving	O
pentazocine	S-drug-AD-2
.	O

Although	O
a	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
,	O
there	O
have	O
been	O
reports	O
of	O
bleeding	O
and	O
/	O
or	O
prolonged	O
prothrombin	O
time	O
in	O
patients	O
treated	O
with	O
TRENTAL	S-brand-EF-1
with	O
and	O
without	O
anticoagulants	S-group-EF-2
or	O
platelet	B-group-EF-2
aggregation	I-group-EF-2
inhibitors	E-group-EF-2
.	O

Patients	O
on	O
Warfarin	S-drug
should	O
have	O
more	O
frequent	O
monitoring	O
of	O
prothrombin	O
times	O
,	O
while	O
patients	O
with	O
other	O
risk	O
factors	O
complicated	O
by	O
hemorrhage	O
(	O
e.g	O
.	O
,	O
recent	O
surgery	O
,	O
peptic	O
ulceration	O
)	O
should	O
have	O
periodic	O
examinations	O
for	O
bleeding	O
including	O
hematocrit	O
and	O
/	O
or	O
hemoglobin	O
.	O

Concomitant	O
administration	O
of	O
TRENTAL	S-brand-ME-1
and	O
theophylline	S-drug-ME-2
-	O
containing	O
drugs	O
leads	O
to	O
increased	O
theophylline	S-drug
levels	O
and	O
theophylline	S-drug
toxicity	O
in	O
some	O
individuals	O
.	O

Such	O
patients	O
should	O
be	O
closely	O
monitored	O
for	O
signs	O
of	O
toxicity	O
and	O
have	O
their	O
theophylline	S-drug
dosage	O
adjusted	O
as	O
necessary	O
.	O

TRENTAL	S-brand
has	O
been	O
used	O
concurrently	O
with	O
antihypertensive	B-group
drugs	E-group
,	O
beta	B-group
blockers	E-group
,	O
digitalis	S-group
,	O
diuretics	S-group
,	O
antidiabetic	B-group
agents	E-group
,	O
and	O
antiarrhythmics	S-group
,	O
without	O
observed	O
problems	O
.	O

Small	O
decreases	O
in	O
blood	O
pressure	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
TRENTAL	S-brand
;	O

periodic	O
systemic	O
blood	O
pressure	O
monitoring	O
is	O
recommended	O
for	O
patients	O
receiving	O
concomitant	O
antihypertensive	O
therapy	O
.	O

If	O
indicated	O
,	O
dosage	O
of	O
the	O
antihypertensive	B-group
agents	E-group
should	O
be	O
reduced	O
.	O

Dopamine	B-group-AD-1
antagonists	E-group-AD-1
,	O
such	O
as	O
the	O
neuroleptics	S-group-AD-1
(	O
phenothiazines	S-group-AD-1
,	O
butyrophenones	S-group-AD-1
,	O
thioxanthines	S-group-AD-1
)	O
or	O
metoclopramide	S-drug-AD-1
,	O
ordinarily	O
should	O
not	O
be	O
administered	O
concurrently	O
with	O
Permax	S-brand-AD-2
(	O
a	O
dopamine	B-group
agonist	E-group
)	O
;	O

these	O
agents	O
may	O
diminish	O
the	O
effectiveness	O
of	O
Permax	S-brand
.	O

Because	O
pergolide	B-drug
mesylate	E-drug
is	O
approximately	O
90	O
%	O
bound	O
to	O
plasma	O
proteins	O
,	O
caution	O
should	O
be	O
exercised	O
if	O
pergolide	B-drug
mesylate	E-drug
is	O
coadministered	O
with	O
other	O
drugs	O
known	O
to	O
affect	O
protein	O
binding	O
.	O

Diuretics	S-group
:	O
Patients	O
on	O
diuretics	S-group-EF-1
,	O
and	O
especially	O
those	O
started	O
recently	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
ACEON	S-brand-EF-2
Tablets	O
therapy	O
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	S-group-EF-1
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
perindopril	S-drug-EF-2
.	O

If	O
diuretics	S-group-AD-1
can	O
not	O
be	O
interrupted	O
,	O
close	O
medical	O
supervision	O
should	O
be	O
provided	O
with	O
the	O
first	O
dose	O
of	O
ACEON	S-brand-AD-2
Tablets	O
,	O
for	O
at	O
least	O
two	O
hours	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
for	O
another	O
hour	O
.	O

The	O
rate	O
and	O
extent	O
of	O
perindopril	S-drug
absorption	O
and	O
elimination	O
are	O
not	O
affected	O
by	O
concomitant	O
diuretics	S-group
.	O

The	O
bioavailability	O
of	O
perindoprilat	S-drug_n
was	O
reduced	O
by	O
diuretics	S-group
,	O
however	O
,	O
and	O
this	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
plasma	O
ACE	O
inhibition	O
.	O

Potassium	S-drug
Supplements	O
and	O
Potassium	B-group
-	I-group
Sparing	I-group
Diuretics	E-group
:	O
ACEON	S-brand
Tablets	O
may	O
increase	O
serum	O
potassium	O
because	O
of	O
its	O
potential	O
to	O
decrease	O
aldosterone	O
production	O
.	O

Use	O
of	O
potassium	B-group
-	I-group
sparing	I-group
diuretics	E-group
(	O
spironolactone	S-drug
,	O
amiloride	S-drug
,	O
triamterene	S-drug
and	O
others	O
)	O
,	O
potassium	S-drug
supplements	O
or	O
other	O
drugs	O
capable	O
of	O
increasing	O
serum	O
potassium	O
(	O
indomethacin	S-drug
,	O
heparin	S-drug
,	O
cyclosporine	S-drug
and	O
others	O
)	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
,	O
they	O
should	O
be	O
given	O
with	O
caution	O
and	O
the	O
patient	O
's	O
serum	O
potassium	O
should	O
be	O
monitored	O
frequently	O
.	O

Lithium	S-drug
:	O
Increased	O
serum	O
lithium	S-drug
and	O
symptoms	O
of	O
lithium	S-drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	S-drug
and	O
ACE	O
inhibitor	O
therapy	O
.	O

These	O
drugs	O
should	O
be	O
coadministered	O
with	O
caution	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	S-drug
concentration	O
is	O
recommended	O
.	O

Use	O
of	O
a	O
diuretic	S-group
may	O
further	O
increase	O
the	O
risk	O
of	O
lithium	S-drug
toxicity	O
.	O

Digoxin	S-drug
:	O
A	O
controlled	O
pharmacokinetic	O
study	O
has	O
shown	O
no	O
effect	O
on	O
plasma	O
digoxin	S-drug
concentrations	O
when	O
coadministered	O
with	O
ACEON	S-brand
Tablets	O
,	O
but	O
an	O
effect	O
of	O
digoxin	S-drug-ME-1
on	O
the	O
plasma	O
concentration	O
of	O
perindopril	S-drug-ME-2
/	O
perindoprilat	S-drug_n-ME-2
has	O
not	O
been	O
excluded	O
.	O

Gentamicin	S-drug
:	O
Animal	O
data	O
have	O
suggested	O
the	O
possibility	O
of	O
interaction	O
between	O
perindopril	S-drug-IN-1
and	O
gentamicin	S-drug-IN-2
.	O

However	O
,	O
this	O
has	O
not	O
been	O
investigated	O
in	O
human	O
studies	O
.	O

Coadministration	O
of	O
both	O
drugs	O
should	O
proceed	O
with	O
caution	O
.	O

Food	O
Interaction	O
:	O
Oral	O
administration	O
of	O
ACEON	S-brand
Tablets	O
with	O
food	O
does	O
not	O
significantly	O
lower	O
the	O
rate	O
or	O
extent	O
of	O
perindopril	S-drug
absorption	O
relative	O
to	O
the	O
fasted	O
state	O
.	O

However	O
,	O
the	O
extent	O
of	O
biotransformation	O
of	O
perindopril	S-drug
to	O
the	O
active	O
metabolite	O
,	O
perindoprilat	S-drug_n
,	O
is	O
reduced	O
approximately	O
43	O
%	O
,	O
resulting	O
in	O
a	O
reduction	O
in	O
the	O
plasma	O
ACE	O
inhibition	O
curve	O
of	O
approximately	O
20	O
%	O
,	O
probably	O
clinically	O
insignificant	O
.	O

In	O
clinical	O
trials	O
,	O
perindopril	S-drug
was	O
generally	O
administered	O
in	O
a	O
non	O
-	O
fasting	O
state	O
.	O

Concomitant	O
use	O
of	O
alcohol	S-drug-IN-1
with	O
phentermine	B-drug-IN-2
hydrochloride	E-drug-IN-2
may	O
result	O
in	O
an	O
adverse	O
drug	O
interaction	O
.	O

Vasopressors	S-group-EF-1
,	O
particularly	O
metaraminol	S-drug-EF-1
,	O
may	O
cause	O
serious	O
cardiac	O
arrhythmias	O
during	O
halothane	S-drug-EF-2
anesthesia	O
and	O
therefore	O
should	O
be	O
used	O
only	O
with	O
great	O
caution	O
or	O
not	O
at	O
all	O
.	O

MAO	B-group
Inhibitors	E-group
:	O
The	O
pressor	O
effect	O
of	O
sympathomimetic	B-group-EF-1
pressor	I-group-EF-1
amines	E-group-EF-1
is	O
markedly	O
potentiated	O
in	O
patients	O
receiving	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
(	O
MAOI	S-group-EF-2
)	O
.	O

Therefore	O
,	O
when	O
initiating	O
pressor	O
therapy	O
in	O
these	O
patients	O
,	O
the	O
initial	O
dose	O
should	O
be	O
small	O
and	O
used	O
with	O
due	O
caution	O
.	O

The	O
pressor	O
response	O
of	O
adrenergic	B-group-EF-1
agents	E-group-EF-1
may	O
also	O
be	O
potentiated	O
by	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
.	O

Vasopressors	S-group-EF-1
,	O
particularly	O
metaraminol	S-drug-EF-1
,	O
may	O
cause	O
serious	O
cardiac	O
arrhythmias	O
during	O
halothane	S-drug-EF-2
anesthesia	O
and	O
therefore	O
should	O
be	O
used	O
only	O
with	O
great	O
caution	O
or	O
not	O
at	O
all	O
.	O

MAO	B-group
Inhibitors	E-group
-	O
The	O
pressor	O
effect	O
of	O
sympathomimetic	B-group-EF-1
pressor	I-group-EF-1
amines	E-group-EF-1
is	O
markedly	O
potentiated	O
in	O
patients	O
receiving	O
monoamine	B-group-EF-2
oxidase	I-group-EF-2
inhibitors	E-group-EF-2
(	O
MAOI	S-group-EF-2
)	O
.	O

Therefore	O
,	O
when	O
initiating	O
pressor	O
therapy	O
in	O
these	O
patients	O
,	O
the	O
initial	O
dose	O
should	O
be	O
small	O
and	O
used	O
with	O
due	O
caution	O
.	O

The	O
pressor	O
response	O
of	O
adrenergic	B-group-EF-1
agents	E-group-EF-1
may	O
also	O
be	O
potentiated	O
by	O
tricyclic	B-group-EF-2
antidepressants	E-group-EF-2
.	O

Pilocarpine	S-drug-AD-1
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
taking	O
beta	B-group-AD-2
adrenergic	I-group-AD-2
antagonists	E-group-AD-2
because	O
of	O
the	O
possibility	O
of	O
conduction	O
disturbances	O
.	O

Drugs	O
with	O
parasympathomimetic	O
effects	O
administered	O
concurrently	O
with	O
pilocarpine	S-drug
would	O
be	O
expected	O
to	O
result	O
in	O
additive	O
pharmacologic	O
effects	O
.	O

Pilocarpine	S-drug
might	O
antagonize	O
the	O
anticholinergic	O
effects	O
of	O
drugs	O
used	O
concomitantly	O
.	O

These	O
effects	O
should	O
be	O
considered	O
when	O
anticholinergic	O
properties	O
may	O
be	O
contributing	O
to	O
the	O
therapeutic	O
effect	O
of	O
concomitant	O
medication	O
(	O
e.g	O
.	O
,	O
atropine	S-drug
,	O
inhaled	O
ipratropium	S-drug
)	O
.	O

While	O
no	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
,	O
the	O
following	O
concomitant	O
drugs	O
were	O
used	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
in	O
either	O
or	O
both	O
Sj	O
grens	O
efficacy	O
studies	O
:	O
acetylsalicylic	B-drug
acid	E-drug
,	O
artificial	O
tears	O
,	O
calcium	S-drug
,	O
conjugated	B-drug
estrogens	E-drug
,	O
hydroxychloroquine	B-drug
sulfate	E-drug
,	O
ibuprofen	S-drug
,	O
levothyroxine	B-drug
sodium	E-drug
,	O
medroxyprogesterone	B-drug
acetate	E-drug
,	O
methotrexate	S-drug
,	O
multivitamins	S-group
,	O
naproxen	S-drug
,	O
omeprazole	S-drug
,	O
paracetamol	S-drug
,	O
and	O
prednisone	S-drug
.	O

Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e.g	O
.	O
,	O
reserpine	S-drug-EF-1
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-group-EF-2
-	I-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
.	O

Patients	O
receiving	O
pindolol	S-drug
plus	O
a	O
catecholamine	O
-	O
depleting	O
agent	O
should	O
,	O
therefore	O
,	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

Pindolol	S-drug
has	O
been	O
used	O
with	O
a	O
variety	O
of	O
antihypertensive	B-group
agents	E-group
,	O
including	O
hydrochlorothiazide	S-drug
,	O
hydralazine	S-drug
,	O
and	O
guanethidine	S-drug
without	O
unexpected	O
adverse	O
interactions	O
.	O

Pindolol	S-drug-ME-1
has	O
been	O
shown	O
to	O
increase	O
serum	O
thioridazine	S-drug-ME-2
levels	O
when	O
both	O
drugs	O
are	O
co	O
-	O
administered	O
.	O

Pindolol	S-drug
levels	O
may	O
also	O
be	O
increased	O
with	O
this	O
combination	O
.	O

Risk	O
of	O
anaphylactic	O
reaction	O
:	O
While	O
taking	O
beta	B-group
blockers	E-group
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	S-drug
used	O
to	O
treat	O
allergic	O
reactions	O
.	O

Other	O
short	B-group-AD-1
-	I-group-AD-1
acting	I-group-AD-1
beta	I-group-AD-1
adrenergic	I-group-AD-1
aerosol	I-group-AD-1
bronchodilators	E-group-AD-1
should	O
not	O
be	O
used	O
concomitantly	O
with	O
MAXAIR	B-brand-AD-2
AUTOHALER	E-brand-AD-2
because	O
they	O
may	O
have	O
additive	O
effects	O
.	O

FELDENE	S-brand
is	O
highly	O
protein	O
bound	O
,	O
and	O
therefore	O
,	O
might	O
be	O
expected	O
to	O
displace	O
other	O
protein	O
-	O
bound	O
drugs	O
.	O

Although	O
this	O
has	O
not	O
occurred	O
in	O
in	O
vitro	O
studies	O
with	O
coumarin	B-group
-	I-group
type	I-group
anticoagulants	E-group
,	O
interactions	O
with	O
coumarin	B-group-IN-1
-	I-group-IN-1
type	I-group-IN-1
anticoagulants	E-group-IN-1
have	O
been	O
reported	O
with	O
FELDENE	S-brand-IN-2
since	O
marketing	O
,	O
therefore	O
,	O
physicians	O
should	O
closely	O
monitor	O
patients	O
for	O
a	O
change	O
in	O
dosage	O
requirements	O
when	O
administering	O
FELDENE	S-brand-AD-1
to	O
patients	O
on	O
coumarin	B-group-AD-2
-	I-group-AD-2
type	I-group-AD-2
anticoagulants	E-group-AD-2
and	O
other	O
highly	O
protein	O
-	O
bound	O
drugs	O
.	O

Plasma	O
levels	O
of	O
piroxicam	S-drug
are	O
depressed	O
to	O
approximately	O
80	O
%	O
of	O
their	O
normal	O
values	O
when	O
FELDENE	S-brand-ME-1
is	O
administered	O
in	O
conjunction	O
with	O
aspirin	S-brand-ME-2
(	O
3900	O
mg	O
/	O
day	O
)	O
,	O
but	O
concomitant	O
administration	O
of	O
antacids	S-group
has	O
no	O
effect	O
on	O
piroxicam	S-drug
plasma	O
levels	O
.	O
Nonsteroidal	B-group-ME-1
anti	I-group-ME-1
-	I-group-ME-1
inflammatory	I-group-ME-1
agents	E-group-ME-1
,	O
including	O
FELDENE	S-brand-ME-1
,	O
have	O
been	O
reported	O
to	O
increase	O
steady	O
state	O
plasma	O
lithium	S-drug-ME-2
levels	O
.	O

It	O
is	O
recommended	O
that	O
plasma	O
lithium	S-drug-AD-1
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
and	O
discontinuing	O
FELDENE	S-brand-AD-2
.	O

When	O
atropine	S-drug-EF-1
and	O
pralidoxime	S-drug-EF-2
are	O
used	O
together	O
,	O
the	O
signs	O
of	O
atropinization	O
(	O
flushing	O
,	O
mydriasis	O
,	O
tachycardia	O
,	O
dryness	O
of	O
the	O
mouth	O
and	O
nose	O
)	O
may	O
occur	O
earlier	O
than	O
might	O
be	O
expected	O
when	O
atropine	S-drug
is	O
used	O
alone	O
.	O

This	O
is	O
especially	O
true	O
if	O
the	O
total	O
dose	O
of	O
atropine	S-drug
has	O
been	O
large	O
and	O
the	O
administration	O
of	O
pralidoxime	S-drug
has	O
been	O
delayed	O
.	O

2	O
-	O
4	O
The	O
following	O
precautions	O
should	O
be	O
kept	O
in	O
mind	O
in	O
the	O
treatment	O
of	O
anticholinesterase	O
poisoning	O
,	O
although	O
they	O
do	O
not	O
bear	O
directly	O
on	O
the	O
use	O
of	O
pralidoxime	S-drug
:	O
since	O
barbiturates	S-group-EF-1
are	O
potentiated	O
by	O
the	O
anticholinesterases	S-group-EF-2
,	O
they	O
should	O
be	O
used	O
cautiously	O
in	O
the	O
treatment	O
of	O
convulsions	O
;	O

morphine	S-drug
,	O
theophylline	S-drug
,	O
aminophylline	S-drug
,	O
succinylcholine	S-drug
,	O
reserpine	S-drug
,	O
and	O
phenothiazine	B-group
-	I-group
type	I-group
tranquilizers	E-group
should	O
be	O
avoided	O
in	O
patients	O
with	O
organophosphate	O
poisoning	O
.	O

Carbidopa	S-drug
/	O
Levodopa	S-drug
:	O
Carbidopa	S-drug
/	O
Levodopa	S-drug
does	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
pramipexole	S-drug
in	O
healthy	O
volunteers	O
(	O
N	O
=	O
10	O
)	O
.	O

5	O
hours	O
.	O

Selegiline	S-drug
:	O
In	O
healthy	O
volunteers	O
(	O
N	O
=	O
11	O
)	O
,	O
selegiline	S-drug
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
pramipexole	S-drug
.	O

Amantadine	S-drug
:	O
Population	O
pharmacokinetic	O
analysis	O
suggests	O
that	O
amantadine	S-drug
is	O
unlikely	O
to	O
alter	O
the	O
oral	O
clearance	O
of	O
pramipexole	S-drug
(	O
N	O
=	O
54	O
)	O
.	O

Cimetidine	S-drug
:	O
Cimetidine	S-drug-ME-1
,	O
a	O
known	O
inhibitor	O
of	O
renal	O
tubular	O
secretion	O
of	O
organic	O
bases	O
via	O
the	O
cationic	O
transport	O
system	O
,	O
caused	O
a	O
50	O
%	O
increase	O
in	O
pramipexole	S-drug-ME-2
AUC	O
and	O
a	O
40	O
%	O
increase	O
in	O
half	O
-	O
life	O
(	O
N	O
=	O
12	O
)	O
.	O

Probenecid	S-drug
:	O
Probenecid	S-drug
,	O
a	O
known	O
inhibitor	O
of	O
renal	O
tubular	O
secretion	O
of	O
organic	O
acids	O
via	O
the	O
aruonic	O
transporter	O
,	O
did	O
not	O
noticeably	O
influence	O
pramipexole	S-drug
pharmacokinetics	O
(	O
N	O
=	O
12	O
)	O
.	O

Other	O
drugs	O
eliminated	O
via	O
renal	O
secretion	O
:	O
Population	O
pharmacokinetic	O
analysis	O
suggests	O
that	O
coadministration	O
of	O
drugs	O
that	O
are	O
secreted	O
by	O
the	O
cationic	O
transport	O
system	O
(	O
e.g	O
.	O
,	O
cimetidine	S-drug-ME-1
,	O
ranitidine	S-drug-ME-1
,	O
diltiazem	S-drug-ME-1
,	O
triamterene	S-drug-ME-1
,	O
verapamil	S-drug-ME-1
,	O
quinidine	S-drug-ME-1
,	O
and	O
quinine	S-drug-ME-1
)	O
decreases	O
the	O
oral	O
clearance	O
of	O
pramipexole	S-drug-ME-2
by	O
about	O
20	O
%	O
,	O
while	O
those	O
secreted	O
by	O
the	O
anionic	O
transport	O
system	O
(	O
e.g	O
.	O
,	O
cephalosporins	S-group-ME-1
,	O
penicillins	S-group-ME-1
,	O
indomethacin	S-drug-ME-1
,	O
hydrochlorothiazide	S-drug-ME-1
,	O
and	O
chlorpropamide	S-drug-ME-1
)	O
are	O
likely	O
to	O
have	O
little	O
effect	O
on	O
the	O
oral	O
clearance	O
of	O
pramipexole	S-drug-ME-2
.	O

CYP	O
interactions	O
:	O
Inhibitors	O
of	O
cytochrome	O
P450	O
enzymes	O
would	O
not	O
be	O
expected	O
to	O
affect	O
pramipexole	S-drug
elimination	O
because	O
pramipexole	S-drug
is	O
not	O
appreciably	O
metabolized	O
by	O
these	O
enzymes	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O

Pramipexole	S-drug
does	O
not	O
inhibit	O
CYP	O
enzymes	O
CYPIA2	O
,	O
CYP2C9	O
,	O
CYP2CI9	O
,	O
CYP2EI	O
,	O
and	O
CYP3A4	O
.	O

Inhibition	O
of	O
CYP2D6	O
was	O
observed	O
with	O
an	O
apparent	O
Ki	O
of	O
30	O
uM	O
,	O
indicating	O
that	O
pramipexole	S-drug
will	O
not	O
inhibit	O
CYP	O
enzymes	O
at	O
plasma	O
concentrations	O
observed	O
following	O
the	O
highest	O
recommended	O
clinical	O
dose	O
(	O
1.5	O
mg	O
tid	O
)	O
.	O

Dopamine	B-group
antagonists	E-group
:	O
Since	O
pramipexole	S-drug
is	O
a	O
dopamine	B-group
agonist	E-group
,	O
it	O
is	O
possible	O
that	O
dopamine	B-group-EF-1
antagonists	E-group-EF-1
,	O
such	O
as	O
the	O
neuroleptics	S-group-EF-1
(	O
phenothiazines	S-group-EF-1
,	O
butyrophenones	S-group-EF-1
,	O
thioxanthenes	S-group-EF-1
)	O
or	O
metoclopramide	S-group-EF-1
,	O
may	O
diminish	O
the	O
effectiveness	O
of	O
MIRAPEX	S-brand-EF-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
MIRAPEX	S-brand
and	O
laboratory	O
tests	O
.	O

Due	O
to	O
its	O
effects	O
on	O
gastric	O
emptying	O
,	O
SYMLIN	S-brand-AD-1
therapy	O
should	O
not	O
be	O
considered	O
for	O
patients	O
taking	O
drugs	O
that	O
alter	O
gastrointestinal	O
motility	O
(	O
e.g	O
.	O
,	O
anticholinergic	B-group-AD-2
agents	E-group-AD-2
such	O
as	O
atropine	S-drug-AD-2
)	O
and	O
agents	O
that	O
slow	O
the	O
intestinal	O
absorption	O
of	O
nutrients	O
(	O
e.g	O
.	O
,	O
alpha	B-group-AD-2
glucosidase	I-group-AD-2
inhibitors	E-group-AD-2
)	O
.	O

Patients	O
using	O
these	O
drugs	O
have	O
not	O
been	O
studied	O
in	O
clinical	O
trials	O
.	O

SYMLIN	S-brand
has	O
the	O
potential	O
to	O
delay	O
the	O
absorption	O
of	O
concomitantly	O
administered	O
oral	O
medications	O
.	O

When	O
the	O
rapid	O
onset	O
of	O
a	O
concomitant	O
orally	O
administered	O
agent	O
is	O
a	O
critical	O
determinant	O
of	O
effectiveness	O
(	O
such	O
as	O
analgesics	S-group-AD-1
)	O
,	O
the	O
agent	O
should	O
be	O
administered	O
at	O
least	O
1	O
hour	O
prior	O
to	O
or	O
2	O
hours	O
after	O
SYMLIN	S-brand-AD-2
injection	O
.	O

In	O
clinical	O
trials	O
,	O
the	O
concomitant	O
use	O
of	O
sulfonylureas	S-group
or	O
biguanides	S-group
did	O
not	O
alter	O
the	O
adverse	O
event	O
profile	O
of	O
SYMLIN	S-brand
.	O

No	O
formal	O
interaction	O
studies	O
have	O
been	O
performed	O
to	O
assess	O
the	O
effect	O
of	O
SYMLIN	S-brand
on	O
the	O
kinetics	O
of	O
oral	O
antidiabetic	B-group
agents	E-group
.	O

Mixing	O
SYMLIN	S-brand
and	O
Insulin	S-drug
The	O
pharmacokinetic	O
parameters	O
of	O
SYMLIN	S-brand-ME-1
were	O
altered	O
when	O
mixed	O
with	O
regular	O
,	O
NPH	O
,	O
and	O
70	O
/	O
30	O
premixed	O
formulations	O
of	O
recombinant	O
human	B-drug-ME-2
insulin	E-drug-ME-2
immediately	O
prior	O
to	O
injection	O
.	O

Thus	O
,	O
SYMLIN	S-brand
and	O
insulin	S-drug
should	O
not	O
be	O
mixed	O
and	O
must	O
be	O
administered	O
separately	O
.	O

The	O
pharmacokinetic	O
interactions	O
listed	O
below	O
are	O
potentially	O
clinically	O
important	O
.	O

Drugs	O
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	S-drug-ME-1
,	O
phenytoin	S-drug-ME-1
and	O
rifampin	S-drug-ME-1
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	S-group-ME-2
and	O
may	O
require	O
increases	O
in	O
corticosteroid	S-group-ME-2
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Drugs	O
such	O
as	O
troleandomycin	S-drug-ME-1
and	O
ketoconazole	S-drug-ME-1
may	O
inhibit	O
the	O
metabolism	O
of	O
corticosteroids	S-group-ME-2
and	O
thus	O
decrease	O
their	O
clearance	O
.	O

Therefore	O
,	O
the	O
dose	O
of	O
corticosteroid	S-group
should	O
be	O
titrated	O
to	O
avoid	O
steroid	O
toxicity	O
.	O

Corticosteroids	S-group-ME-1
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	S-brand-ME-2
.	O

This	O
could	O
lead	O
to	O
decreased	O
salicylate	S-group
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	S-group-EF-1
toxicity	O
when	O
corticosteroid	S-group-EF-2
is	O
withdrawn	O
.	O

Aspirin	S-brand-AD-1
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
corticosteroids	S-group-AD-2
in	O
patients	O
suffering	O
from	O
hypoprothrombinemia	O
.	O

The	O
effect	O
of	O
corticosteroids	S-group-EF-1
on	O
oral	O
anticoagulants	S-group-EF-2
is	O
variable	O
.	O

There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulants	S-group-EF-1
when	O
given	O
concurrently	O
with	O
corticosteroids	S-group-EF-2
.	O

Therefore	O
,	O
coagulation	O
indices	O
should	O
be	O
monitored	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O

Anticholinesterases	S-group
:	O
Concurrent	O
use	O
of	O
procaine	B-drug-EF-1
hydrochloride	E-drug-EF-1
and	O
anticholinesterase	B-group-EF-2
agents	E-group-EF-2
may	O
result	O
in	O
increased	O
systemic	O
toxicity	O
since	O
anticholinesterases	S-group-ME-1
inhibit	O
the	O
breakdown	O
of	O
procaine	B-drug-ME-2
hydrochloride	E-drug-ME-2
.	O

Antimyasthenics	O
Concurrent	O
use	O
of	O
procaine	B-drug
hydrochloride	E-drug
and	O
antimyasthenics	O
may	O
result	O
in	O
loss	O
of	O
control	O
of	O
symptoms	O
of	O
myasthenia	O
gravis	O
due	O
to	O
antagonism	O
of	O
the	O
effects	O
of	O
antimyasthenics	O
on	O
skeletal	O
muscle	O
.	O

Temporary	O
dosage	O
adjustment	O
of	O
antimyasthenics	O
may	O
be	O
required	O
.	O

Also	O
antimyasthenics	O
may	O
have	O
anticholinesterase	O
activity	O
.	O

CNS	B-group
depressant	E-group
medications	O
:	O
Concurrent	O
use	O
of	O
procaine	B-drug-EF-1
hydrochloride	E-drug-EF-1
and	O
CNS	B-group-EF-2
depressant	I-group-EF-2
medications	E-group-EF-2
may	O
result	O
in	O
additive	O
depressant	O
effects	O
.	O

Hyaluronidase	S-drug
:	O
Hyaluronidase	S-drug-ME-1
may	O
increase	O
the	O
diffusion	O
rate	O
of	O
procaine	B-drug-ME-2
hydrochloride	E-drug-ME-2
,	O
resulting	O
in	O
a	O
decreased	O
time	O
of	O
onset	O
,	O
but	O
an	O
increase	O
in	O
systemic	O
toxicity	O
.	O

Neuromuscular	B-group
blocking	I-group
agents	E-group
(	O
such	O
as	O
suxamethonium	B-drug
chloride	E-drug
)	O
:	O
Concurrent	O
use	O
of	O
procaine	B-drug-EF-1
hydrochloride	E-drug-EF-1
and	O
neuromuscular	B-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
may	O
result	O
in	O
prolongation	O
or	O
enhancement	O
of	O
the	O
neuromuscular	O
blockade	O
.	O

Sulfonamides	S-group
:	O
Concurrent	O
use	O
of	O
procaine	B-drug-EF-1
hydrochloride	E-drug-EF-1
and	O
sulfonamides	S-group-EF-2
may	O
result	O
in	O
a	O
reduction	O
of	O
the	O
antibacterial	O
action	O
of	O
the	O
sulfonamide	S-group
.	O

Acetazolamide	S-drug
:	O
Concurrent	O
use	O
of	O
acetazolamide	S-drug-ME-1
and	O
procaine	B-drug-ME-2
hydrochloride	E-drug-ME-2
may	O
extend	O
the	O
plasma	O
half	O
-	O
life	O
of	O
procaine	S-drug
.	O

To	O
minimize	O
CNS	O
depression	O
and	O
possible	O
potentiation	O
,	O
barbiturates	S-group
,	O
antihistamines	S-group
,	O
narcotics	S-group
,	O
hypotensive	B-group
agents	E-group
or	O
phenothiazines	S-group
should	O
be	O
used	O
with	O
caution	O
.	O

Ethyl	B-drug
alcohol	E-drug
should	O
not	O
be	O
used	O
since	O
there	O
may	O
be	O
an	O
Antabuse	O
(	O
disulfiram	O
)	O
-	O
like	O
reaction	O
.	O

Because	O
Matulane	S-brand-AD-1
exhibits	O
some	O
monoamine	O
oxidase	O
inhibitory	O
activity	O
,	O
sympathomimetic	B-group-AD-2
drugs	E-group-AD-2
,	O
tricyclic	B-group-AD-2
antidepressant	E-group-AD-2
drugs	O
(	O
e.g	O
.	O
,	O
amitriptyline	B-drug-AD-2
HCl	E-drug-AD-2
,	O
imipramine	B-drug-AD-2
HCl	E-drug-AD-2
)	O
and	O
other	O
drugs	O
and	O
foods	O
with	O
known	O
high	O
tyramine	S-drug_n-AD-2
content	O
,	O
such	O
as	O
wine	O
,	O
yogurt	O
,	O
ripe	O
cheese	O
and	O
bananas	O
,	O
should	O
be	O
avoided	O
.	O

A	O
further	O
phenomenon	O
of	O
toxicity	O
common	O
to	O
many	O
hydrazine	B-group
derivatives	E-group
is	O
hemolysis	O
and	O
the	O
appearance	O
of	O
Heinz	O
-	O
Ehrlich	O
inclusion	O
bodies	O
in	O
erythrocytes	O
.	O

No	O
cross	O
-	O
resistance	O
with	O
other	O
chemotherapeutic	B-group
agents	E-group
,	O
radiotherapy	O
or	O
steroids	S-group
has	O
been	O
demonstrated	O
.	O

Thiazide	B-group-EF-1
diuretics	E-group-EF-1
may	O
accentuate	O
the	O
orthostatic	O
hypotension	O
that	O
may	O
occur	O
with	O
phenothiazines	S-group-EF-2
.	O

Antihypertensive	O
effects	O
of	O
guanethidine	S-drug-EF-1
and	O
related	O
compounds	O
may	O
be	O
counteracted	O
when	O
phenothiazines	S-group-EF-2
are	O
used	O
concomitantly	O
.	O

Concomitant	O
administration	O
of	O
propranolol	S-drug-ME-1
with	O
phenothiazines	S-group-ME-2
results	O
in	O
increased	O
plasma	O
levels	O
of	O
both	O
drugs	O
.	O

The	O
induction	O
dose	O
requirements	O
of	O
DIPRIVAN	S-brand-EF-1
Injectable	O
Emulsion	O
may	O
be	O
reduced	O
in	O
patients	O
with	O
intramuscular	O
or	O
intravenous	O
premedication	O
,	O
particularly	O
with	O
narcotics	S-group-EF-2
(	O
eg	O
,	O
morphine	S-drug-EF-2
,	O
meperidine	S-drug-EF-2
,	O
and	O
fentanyl	S-drug-EF-2
,	O
etc	O
.	O
)	O

and	O
combinations	O
of	O
opioids	S-group
and	O
sedatives	S-group
(	O
eg	O
,	O
benzodiazepines	S-group
,	O
barbiturates	S-group
,	O
chloral	B-drug
hydrate	E-drug
,	O
droperidol	S-drug
,	O
etc	O
.	O
)	O
.	O

These	O
agents	O
may	O
increase	O
the	O
anesthetic	O
or	O
sedative	O
effects	O
of	O
DIPRIVAN	S-brand
Injectable	O
Emulsion	O
and	O
may	O
also	O
result	O
in	O
more	O
pronounced	O
decreases	O
in	O
systolic	O
,	O
diastolic	O
,	O
and	O
mean	O
arterial	O
pressures	O
and	O
cardiac	O
output	O
.	O

During	O
maintenance	O
of	O
anesthesia	O
or	O
sedation	O
,	O
the	O
rate	O
of	O
DIPRIVAN	S-brand-AD-1
Injectable	O
Emulsion	O
administration	O
should	O
be	O
adjusted	O
according	O
to	O
the	O
desired	O
level	O
of	O
anesthesia	O
or	O
sedation	O
and	O
may	O
be	O
reduced	O
in	O
the	O
presence	O
of	O
supplemental	O
analgesic	B-group-AD-2
agents	E-group-AD-2
(	O
eg	O
,	O
nitrous	B-drug-AD-2
oxide	E-drug-AD-2
or	O
opioids	S-group-AD-2
)	O
.	O

The	O
concurrent	O
administration	O
of	O
potent	O
inhalational	O
agents	O
(	O
eg	O
,	O
isoflurane	S-drug
,	O
enflurane	S-drug
,	O
and	O
halothane	S-drug
)	O
during	O
maintenance	O
with	O
DIPRIVAN	S-brand
Injectable	O
Emulsion	O
has	O
not	O
been	O
extensively	O
evaluated	O
.	O

These	O
inhalational	O
agents	O
can	O
also	O
be	O
expected	O
to	O
increase	O
the	O
anesthetic	O
or	O
sedative	O
and	O
cardiorespiratory	O
effects	O
of	O
DIPRIVAN	S-brand
Injectable	O
Emulsion	O
.	O

DIPRIVAN	S-brand
Injectable	O
Emulsion	O
does	O
not	O
cause	O
a	O
clinically	O
significant	O
change	O
in	O
onset	O
,	O
intensity	O
,	O
or	O
duration	O
of	O
action	O
of	O
the	O
commonly	O
used	O
neuromuscular	B-group
blocking	I-group
agents	E-group
(	O
eg	O
,	O
succinylcholine	S-drug
and	O
nondepolarizing	B-group
muscle	I-group
relaxants	E-group
)	O
.	O

No	O
significant	O
adverse	O
interactions	O
with	O
commonly	O
used	O
premedications	O
or	O
drugs	O
used	O
during	O
anesthesia	O
or	O
sedation	O
(	O
including	O
a	O
range	O
of	O
muscle	B-group
relaxants	E-group
,	O
inhalational	O
agents	O
,	O
analgesic	B-group
agents	E-group
,	O
and	O
local	O
anesthetic	B-group
agents	E-group
)	O
have	O
been	O
observed	O
.	O

The	O
CNS	O
-	O
depressant	O
effect	O
of	O
propoxyphene	S-drug-EF-1
is	O
additive	O
with	O
that	O
of	O
other	O
CNS	B-group-EF-2
depressants	E-group-EF-2
,	O
including	O
alcohol	S-drug-EF-2
.	O

As	O
is	O
the	O
case	O
with	O
many	O
medicinal	O
agents	O
,	O
propoxyphene	S-drug
may	O
slow	O
the	O
metabolism	O
of	O
a	O
concomitantly	O
administered	O
drug	O
.	O

Should	O
this	O
occur	O
,	O
the	O
higher	O
serum	O
concentrations	O
of	O
that	O
drug	O
may	O
result	O
in	O
increased	O
pharmacologic	O
or	O
adverse	O
effects	O
of	O
that	O
drug	O
.	O

Such	O
occurrences	O
have	O
been	O
reported	O
when	O
propoxyphene	S-drug
was	O
administered	O
to	O
patients	O
on	O
antidepressants	S-group
,	O
anticonvulsants	S-group
,	O
or	O
warfarin	S-drug
-	O
like	O
drugs	O
.	O

Sever	O
neurologic	O
signs	O
,	O
including	O
coma	O
,	O
have	O
occurred	O
with	O
concurrent	O
use	O
of	O
carbamazepine	S-drug
.	O

MAO	B-group-EF-1
inhibitors	E-group-EF-1
and	O
beta	B-group-EF-1
adrenergic	I-group-EF-1
blockers	E-group-EF-1
increase	O
the	O
effects	O
of	O
pseudoephedrine	S-drug-EF-2
.	O

Sympathomimetics	S-group-EF-1
may	O
reduce	O
the	O
antihypertensive	O
effects	O
of	O
methyldopa	S-drug-EF-2
,	O
mecamylamine	S-drug-EF-2
,	O
reserpine	S-drug-EF-2
and	O
veratrum	B-group-EF-2
alkaloids	E-group-EF-2
.	O

Pyrimethamine	S-drug
may	O
be	O
used	O
with	O
sulfonamides	S-group
,	O
quinine	S-drug
and	O
other	O
antimalarials	S-group
,	O
and	O
with	O
other	O
antibiotics	S-group
.	O

If	O
signs	O
of	O
folate	O
deficiency	O
develop	O
,	O
pyrimethamine	S-drug
should	O
be	O
discontinued	O
.	O

Folinic	B-drug
acid	E-drug
(	O
leucovorin	S-drug
)	O
should	O
be	O
administered	O
until	O
normal	O
hematopoiesis	O
is	O
restored	O
.	O

Mild	O
hepatotoxicity	O
has	O
been	O
reported	O
in	O
some	O
patients	O
when	O
lorazepam	S-drug-EF-1
and	O
pyrimethamine	S-drug-EF-2
were	O
administered	O
concomitantly	O
.	O

Cholestyramine	S-drug
:	O
Cholestyramine	S-drug-MU-1
causes	O
a	O
60	O
%	O
reduction	O
in	O
the	O
absorption	O
and	O
enterohepatic	O
cycling	O
of	O
raloxifene	S-drug-ME-2
and	O
should	O
not	O
be	O
coadministered	O
with	O
EVISTA	S-brand-AD-2
.	O

Warfarin	S-drug
:	O
The	O
coadministration	O
of	O
EVISTA	S-brand
and	O
warfarin	S-drug
has	O
not	O
been	O
assessed	O
under	O
chronic	O
conditions	O
.	O

However	O
,	O
10	O
%	O
decreases	O
in	O
prothrombin	O
time	O
have	O
been	O
observed	O
in	O
single	O
-	O
dose	O
studies	O
.	O

If	O
EVISTA	S-brand-AD-1
is	O
given	O
concurrently	O
with	O
warfarin	S-drug-AD-2
,	O
prothrombin	O
time	O
should	O
be	O
monitored	O
.	O

Other	O
Highly	O
Protein	O
-	O
Bound	O
Drugs	O
:	O
Raloxifene	S-drug
is	O
more	O
than	O
95	O
%	O
bound	O
to	O
plasma	O
proteins	O
.	O

In	O
vitro	O
,	O
raloxifene	S-drug
did	O
not	O
affect	O
the	O
binding	O
of	O
warfarin	S-drug
,	O
phenytoin	S-drug
,	O
or	O
tamoxifen	S-drug
.	O

Caution	O
should	O
be	O
used	O
when	O
EVISTA	S-brand-AD-1
is	O
coadministered	O
with	O
other	O
highly	O
protein	O
-	O
bound	O
drugs	O
,	O
such	O
as	O
clofibrate	S-drug-AD-2
,	O
indomethacin	S-drug-AD-2
,	O
naproxen	S-drug-AD-2
,	O
ibuprofen	S-drug-AD-2
,	O
diazepam	S-drug-AD-2
,	O
and	O
diazoxide	S-drug-AD-2
.	O

See	O
also	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Drug	O
-	O
Drug	O
Interactions	O

Coadministration	O
of	O
TRITEC	S-brand-ME-1
with	O
clarithromycin	S-drug-ME-2
resulted	O
in	O
increased	O
plasma	O
ranitidine	S-drug
concentrations	O
(	O
57	O
%	O
)	O
,	O
increased	O
plasma	O
bismuth	O
trough	O
concentrations	O
(	O
48	O
%	O
)	O
,	O
and	O
increased	O
14	B-drug_n
-	I-drug_n
hydroxy	I-drug_n
-	I-drug_n
clarithromycin	E-drug_n
plasma	O
concentrations	O
(	O
31	O
%	O
)	O
.	O

Coadministration	O
with	O
aspirin	S-brand
results	O
in	O
a	O
slight	O
decrease	O
in	O
the	O
rate	O
of	O
salicylate	S-group
absorption	O
that	O
is	O
clinically	O
unimportant	O
.	O

Coadministration	O
with	O
a	O
high	O
dose	O
of	O
antacid	S-group-ME-1
(	O
170	O
mEq	O
)	O
results	O
in	O
a	O
28	O
%	O
decrease	O
in	O
plasma	O
concentrations	O
of	O
ranitidine	S-drug-ME-2
and	O
may	O
decrease	O
plasma	O
concentrations	O
of	O
bismuth	O
from	O
TRITEC	S-brand-ME-2
.	O

These	O
effects	O
are	O
clinically	O
insignificant	O
.	O

For	O
information	O
on	O
drug	O
interactions	O
associated	O
with	O
ranitidine	S-drug
,	O
refer	O
to	O
the	O
ZANTAC	S-brand
package	O
insert	O
.	O

Co	O
-	O
administration	O
of	O
oral	O
ketoconazole	S-drug-ME-1
200	O
mg	O
twice	O
daily	O
increased	O
retapamulin	S-drug
geometric	O
mean	O
AUC	O
(	O
0	O
-	O
24	O
)	O
and	O
Cmax	O
by	O
81	O
%	O
after	O
topical	O
application	O
of	O
retapamulin	S-drug-ME-2
ointment	O
,	O
1	O
%	O
on	O
the	O
abraded	O
skin	O
of	O
healthy	O
adult	O
males	O
.	O

Due	O
to	O
low	O
systemic	O
exposure	O
to	O
retapamulin	S-drug
following	O
topical	O
application	O
in	O
patients	O
,	O
dosage	O
adjustments	O
for	O
retapamulin	S-drug
are	O
unnecessary	O
when	O
co	O
-	O
administered	O
with	O
CYP3A4	O
inhibitors	O
,	O
such	O
as	O
ketoconazole	S-drug
.	O

Based	O
on	O
in	O
vitro	O
P450	O
inhibition	O
studies	O
and	O
the	O
low	O
systemic	O
exposure	O
observed	O
following	O
topical	O
application	O
of	O
ALTABAX	S-brand
,	O
retapamulin	S-drug
is	O
unlikely	O
to	O
affect	O
the	O
metabolism	O
of	O
other	O
P450	O
substrates	O
.	O

The	O
effect	O
of	O
concurrent	O
application	O
of	O
ALTABAX	S-brand
and	O
other	O
topical	O
products	O
to	O
the	O
same	O
area	O
of	O
skin	O
has	O
not	O
been	O
studied	O
.	O

The	O
interaction	O
of	O
Retavase	S-brand
with	O
other	O
cardioactive	O
drugs	O
has	O
not	O
been	O
studied	O
.	O

In	O
addition	O
to	O
bleeding	O
associated	O
with	O
heparin	S-drug-EF-1
and	O
vitamin	B-group-EF-1
K	I-group-EF-1
antagonists	E-group-EF-1
,	O
drugs	O
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
aspirin	S-brand-EF-1
,	O
dipyridamole	S-drug-EF-1
,	O
and	O
abciximab	S-drug-EF-1
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
or	O
after	O
Retavase	S-brand-EF-2
therapy	O
.	O

Interactions	O
for	O
Vitamin	B-drug
B2	E-drug
(	O
Riboflavin	S-drug
)	O
:	O
Alcohol	S-drug-ME-1
-	O
impairs	O
the	O
intestinal	O
absorption	O
of	O
riboflavin	S-drug-ME-2

Probenecid	S-drug-ME-1
-	O
concurrent	O
use	O
decreases	O
gastrointestinal	O
absorption	O
of	O
riboflavin	S-drug-ME-2
;	O

requirements	O
for	O
riboflavin	S-drug-EF-1
may	O
be	O
increased	O
in	O
patients	O
receiving	O
probenecid	S-drug-EF-2
.	O

Cimetidine	S-drug
:	O
The	O
effects	O
of	O
chronic	O
cimetidine	S-drug
use	O
on	O
the	O
metabolism	O
of	O
rimantadine	S-drug
are	O
not	O
known	O
.	O

When	O
a	O
single	O
100	O
mg	O
dose	O
of	O
rimantadine	B-drug-ME-1
HCl	E-drug-ME-1
was	O
administered	O
one	O
hour	O
after	O
the	O
initiation	O
of	O
Cimetidine	S-drug-ME-2
(	O
300	O
mg	O
four	O
times	O
a	O
day	O
)	O
,	O
the	O
apparent	O
total	O
rimantadine	S-drug
clearance	O
of	O
this	O
single	O
dose	O
in	O
normal	O
healthy	O
adults	O
was	O
reduced	O
by	O
18	O
%	O
(	O
compared	O
to	O
the	O
apparent	O
total	O
rimantadine	S-drug
clearance	O
in	O
the	O
same	O
subjects	O
in	O
the	O
absence	O
of	O
cimetidine	S-drug
)	O
.	O

Acetaminophen	S-drug
:	O
Rimantadine	B-drug
HCl	E-drug
,	O
100	O
mg	O
,	O
was	O
given	O
twice	O
daily	O
for	O
13	O
days	O
to	O
12	O
healthy	O
volunteers	O
.	O

On	O
day	O
11	O
,	O
acetaminophen	S-drug
(	O
650	O
mg	O
four	O
times	O
daily	O
)	O
was	O
started	O
and	O
continued	O
for	O
8	O
days	O
.	O

The	O
pharmacokinetics	O
of	O
rimantadine	S-drug
were	O
assessed	O
on	O
days	O
11	O
and	O
13	O
.	O

Coadministration	O
with	O
acetaminophen	S-drug-ME-1
reduced	O
the	O
peak	O
concentration	O
and	O
AUC	O
values	O
for	O
rimantadine	S-drug-ME-2
by	O
approximately	O
11	O
%	O
.	O

Aspirin	S-brand
:	O
Rimantadine	B-drug
HCl	E-drug
,	O
100	O
mg	O
,	O
was	O
given	O
twice	O
daily	O
fro	O
13	O
days	O
to	O
12	O
healthy	O
volunteers	O
.	O

On	O
day	O
11	O
,	O
aspirin	S-brand
(	O
650	O
mg	O
,	O
four	O
times	O
daily	O
)	O
was	O
started	O
and	O
continued	O
for	O
8	O
days	O
.	O

The	O
pharmacokinetics	O
of	O
rimantadine	S-drug
were	O
assessed	O
on	O
days	O
11	O
and	O
13	O
.	O

Peak	O
plasma	O
concentrations	O
and	O
AUC	O
of	O
rimantadine	S-drug-ME-1
were	O
reduced	O
approximately	O
10	O
%	O
in	O
the	O
presence	O
of	O
aspirin	S-brand-ME-2
.	O

Drug	O
-	O
Drug	O
Interactions	O
Effect	O
of	O
Exelon	S-brand
(	O
rivastigmine	B-drug
tartrate	E-drug
)	O
on	O
the	O
Metabolism	O
of	O
Other	O
Drugs	O
:	O
Rivastigmine	S-drug
is	O
primarily	O
metabolized	O
through	O
hydrolysis	O
by	O
esterases	O
.	O

Minimal	O
metabolism	O
occurs	O
via	O
the	O
major	O
cytochrome	O
P450	O
isoenzymes	O
.	O

Based	O
on	O
in	O
vitro	O
studies	O
,	O
no	O
pharmacokinetic	O
drug	O
interactions	O
with	O
drugs	O
metabolized	O
by	O
the	O
following	O
isoenzyme	O
systems	O
are	O
expected	O
:	O
CYP1A2	O
,	O
CYP2D6	O
,	O
CYP3A4	O
/	O
5	O
,	O
CYP2E1	O
,	O
CYP2C9	O
,	O
CYP2C8	O
,	O
or	O
CYP2C19	O
.	O

No	O
pharmacokinetic	O
interaction	O
was	O
observed	O
between	O
rivastigmine	S-drug
and	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
diazepam	S-drug
,	O
or	O
fluoxetine	S-drug
in	O
studies	O
in	O
healthy	O
volunteers	O
.	O

The	O
elevation	O
of	O
prothrombin	O
time	O
induced	O
by	O
warfarin	S-drug
is	O
not	O
affected	O
by	O
administration	O
of	O
Exelon	S-brand
.	O

Effect	O
of	O
Other	O
Drugs	O
on	O
the	O
Metabolism	O
of	O
Exelon	S-brand
:	O
Drugs	O
that	O
induce	O
or	O
inhibit	O
CYP450	O
metabolism	O
are	O
not	O
expected	O
to	O
alter	O
the	O
metabolism	O
of	O
rivastigmine	S-drug
.	O

Single	O
dose	O
pharmacokinetic	O
studies	O
demonstrated	O
that	O
the	O
metabolism	O
of	O
rivastigmine	S-drug
is	O
not	O
significantly	O
affected	O
by	O
concurrent	O
administration	O
of	O
digoxin	S-drug
,	O
warfarin	S-drug
,	O
diazepam	S-drug
,	O
or	O
fluoxetine	S-drug
.	O

Population	O
PK	O
analysis	O
with	O
a	O
database	O
of	O
625	O
patients	O
showed	O
that	O
the	O
pharmacokinetics	O
of	O
rivastigmine	S-drug
were	O
not	O
influenced	O
by	O
commonly	O
prescribed	O
medications	O
such	O
as	O
antacids	S-group
(	O
n	O
=	O
77	O
)	O
,	O
antihypertensives	S-group
(	O
n	O
=	O
72	O
)	O
,	O
calcium	B-group
channel	I-group
blockers	E-group
(	O
n	O
=	O
75	O
)	O
,	O
antidiabetics	S-group
(	O
n	O
=	O
21	O
)	O
,	O
nonsteroidal	B-group
anti	I-group
-	I-group
inflammatory	I-group
drugs	E-group
(	O
n	O
=	O
79	O
)	O
,	O
estrogens	S-group
(	O
n	O
=	O
70	O
)	O
,	O
salicylate	B-group
analgesics	E-group
(	O
n	O
=	O
177	O
)	O
,	O
antianginals	S-group
(	O
n	O
=	O
35	O
)	O
,	O
and	O
antihistamines	S-group
(	O
n	O
=	O
15	O
)	O
.	O

Use	O
with	O
Anticholinergics	S-group
:	O
Because	O
of	O
their	O
mechanism	O
of	O
action	O
,	O
cholinesterase	B-group-IN-1
inhibitors	E-group-IN-1
have	O
the	O
potential	O
to	O
interfere	O
with	O
the	O
activity	O
of	O
anticholinergic	B-group-IN-2
medications	E-group-IN-2
.	O

Use	O
with	O
Cholinomimetics	S-group
and	O
Other	O
Cholinesterase	B-group
Inhibitors	E-group
:	O
A	O
synergistic	O
effect	O
may	O
be	O
expected	O
when	O
cholinesterase	B-group-EF-1
inhibitors	E-group-EF-1
are	O
given	O
concurrently	O
with	O
succinylcholine	S-drug-EF-2
,	O
similar	O
neuromuscular	B-group-EF-2
blocking	I-group-EF-2
agents	E-group-EF-2
or	O
cholinergic	B-group-EF-2
agonists	E-group-EF-2
such	O
as	O
bethanechol	S-drug-EF-2
.	O

Drug	O
Interactions	O
:	O
The	O
use	O
of	O
ZEMURON	S-brand
(	O
rocuronium	B-drug
bromide	E-drug
)	O
Injection	O
before	O
succinylcholine	S-drug
,	O
for	O
the	O
purpose	O
of	O
attenuating	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	S-drug
,	O
has	O
not	O
been	O
studied	O
.	O

If	O
ZEMURON	S-brand-AD-1
is	O
administered	O
following	O
administration	O
of	O
succinylcholine	S-drug-AD-2
,	O
it	O
should	O
not	O
be	O
given	O
until	O
recovery	O
from	O
succinylcholine	S-drug
has	O
been	O
observed	O
.	O

The	O
median	O
duration	O
of	O
action	O
of	O
ZEMURON	S-brand
0.6	O
mg	O
/	O
kg	O
administered	O
after	O
a	O
1	O
mg	O
/	O
kg	O
dose	O
of	O
succinylcholine	S-drug
when	O
T	O
1	O
returned	O
to	O
75	O
%	O
of	O
control	O
was	O
36	O
minutes	O
(	O
range	O
14	O
-	O
57	O
,	O
n	O
=	O
12	O
)	O
vs	O
.	O

28	O
minutes	O
(	O
17	O
-	O
51	O
,	O
n	O
=	O
12	O
)	O
without	O
succinylcholine	S-drug
.	O

There	O
are	O
no	O
controlled	O
studies	O
documenting	O
the	O
use	O
of	O
ZEMURON	S-brand
before	O
or	O
after	O
other	O
nondepolarizing	B-group
muscle	I-group
relaxants	E-group
.	O

Interactions	O
have	O
been	O
observed	O
when	O
other	O
nondepolarizing	B-group
muscle	I-group
relaxants	E-group
have	O
been	O
administered	O
in	O
succession	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
None	O
known	O
.	O

Ropivacaine	S-drug-AD-1
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
other	O
local	O
anesthetics	S-group-AD-2
or	O
agents	O
structurally	O
related	O
to	O
amide	B-group
-	I-group
type	I-group
local	I-group
anesthetics	E-group
,	O
since	O
the	O
toxic	O
effects	O
of	O
these	O
drugs	O
are	O
additive	O
.	O

Cytochrome	O
P4501A2	O
is	O
involved	O
in	O
the	O
formation	O
of	O
3	B-drug_n
-	I-drug_n
hydroxy	I-drug_n
ropivacaine	E-drug_n
,	O
the	O
major	O
metabolite	O
.	O

In	O
vivo	O
,	O
the	O
plasma	O
clearance	O
of	O
ropivacaine	S-drug-ME-1
was	O
reduced	O
by	O
70	O
%	O
during	O
coadministration	O
of	O
fluvoxamine	S-drug-ME-2
(	O
25	O
mg	O
bid	O
for	O
2	O
days	O
)	O
,	O
a	O
selective	O
and	O
potent	O
CYP1A2	O
inhibitor	O
.	O

Thus	O
strong	O
inhibitors	O
of	O
cytochrome	O
P4501A2	O
,	O
such	O
as	O
fluvoxamine	S-drug-IN-1
,	O
given	O
concomitantly	O
during	O
administration	O
of	O
Ropivacaine	S-drug-IN-2
,	O
can	O
interact	O
with	O
Ropivacaine	S-drug
leading	O
to	O
increased	O
ropivacaine	S-drug
plasma	O
levels	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
CYP1A2	O
inhibitors	O
are	O
coadministered	O
.	O

Possible	O
interactions	O
with	O
drugs	O
known	O
to	O
be	O
metabolized	O
by	O
CYP1A2	O
via	O
competitive	O
inhibition	O
such	O
as	O
theophylline	S-drug
and	O
imipramine	S-drug
may	O
also	O
occur	O
.	O

Coadministration	O
of	O
a	O
selective	O
and	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
ketoconazole	S-drug-ME-1
(	O
100	O
mg	O
bid	O
for	O
2	O
days	O
with	O
ropivacaine	S-drug
infusion	O
administered	O
1	O
hour	O
after	O
ketoconazole	S-drug
)	O
caused	O
a	O
15	O
%	O
reduction	O
in	O
in	O
-	O
vivo	O
plasma	O
clearance	O
of	O
ropivacaine	S-drug-ME-2
.	O

An	O
inhibitor	O
of	O
CYP2C8	O
(	O
such	O
as	O
gemfibrozil	S-drug-ME-1
)	O
may	O
increase	O
the	O
AUC	O
of	O
rosiglitazone	S-drug-ME-2
and	O
an	O
inducer	O
of	O
CYP2C8	O
(	O
such	O
as	O
rifampin	S-drug-ME-1
)	O
may	O
decrease	O
the	O
AUC	O
of	O
rosiglitazone	S-drug-ME-2
.	O

Therefore	O
,	O
if	O
an	O
inhibitor	O
or	O
an	O
inducer	O
of	O
CYP2C8	O
is	O
started	O
or	O
stopped	O
during	O
treatment	O
with	O
rosiglitazone	S-drug
,	O
changes	O
in	O
diabetes	O
treatment	O
may	O
be	O
needed	O
based	O
upon	O
clinical	O
response	O
.	O

Concomitant	O
administration	O
contra	O
-	O
indicated	O
:	O
-	O
Vasoconstrictive	O
ergot	B-group
alkaloids	E-group
.	O

Concomitant	O
administrations	O
not	O
recommended	O
:	O
-	O
Terfenadine	S-drug
and	O
astemizole	S-drug
:	O
Certain	O
macrolides	S-group-IN-1
interact	O
with	O
terfenadine	S-drug-IN-2
and	O
astemizole	S-drug-IN-2
leading	O
to	O
increased	O
serum	O
concentrations	O
of	O
the	O
latter	O
.	O

This	O
may	O
result	O
in	O
severe	O
ventricular	O
arrhythmia	O
,	O
typically	O
torsades	O
de	O
pointe	O
.	O

Although	O
such	O
a	O
reaction	O
has	O
not	O
been	O
demonstrated	O
with	O
roxithromycin	S-drug
,	O
concomitant	O
administration	O
of	O
roxithromycin	S-drug-AD-1
with	O
terfenadine	S-drug-AD-2
or	O
astemizole	S-drug-AD-2
is	O
not	O
recommended	O
.	O

-	O
Cisapride	S-drug
,	O
pimozide	S-drug-ME-1
:	O
Other	O
drugs	O
such	O
as	O
cisapride	S-drug-ME-1
or	O
pimozide	S-drug
,	O
which	O
are	O
metabolised	O
by	O
hepatic	O
CYP3A	O
isozymes	O
have	O
been	O
associated	O
with	O
QT	O
interval	O
prolongation	O
and	O
/	O
or	O
cardiac	O
arrythmias	O
(	O
typically	O
torsades	O
de	O
pointe	O
)	O
as	O
a	O
result	O
of	O
increase	O
in	O
their	O
serum	O
level	O
subsequent	O
to	O
interaction	O
with	O
significant	O
inhibitors	O
of	O
the	O
isozyme	O
,	O
including	O
some	O
macrolide	B-group-ME-2
antibacterials	E-group-ME-2
.	O

Although	O
such	O
a	O
risk	O
is	O
not	O
verified	O
for	O
roxithromycin	S-drug
,	O
combination	O
of	O
roxithromycin	S-drug
with	O
such	O
drugs	O
is	O
not	O
recommended	O
.	O

Nasal	O
Spray	O
:	O
Formal	O
studies	O
designed	O
to	O
evaluate	O
drug	O
interactions	O
with	O
Calcitonin	B-drug
(	I-drug
salmon	I-drug
)	E-drug
have	O
not	O
been	O
done	O
.	O

No	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Calcitonin	B-drug
(	I-drug
salmon	I-drug
)	E-drug
nasal	O
spray	O
ingredients	O
.	O

Currently	O
,	O
no	O
drug	O
interactions	O
with	O
Calcitonin	B-drug
(	I-drug
salmon	I-drug
)	E-drug
have	O
been	O
observed	O
.	O

The	O
effects	O
of	O
prior	O
use	O
of	O
diphosphonates	S-group
in	O
postmenopausal	O
osteoporosis	O
patients	O
have	O
not	O
been	O
assessed	O
;	O

however	O
,	O
in	O
patients	O
with	O
Paget	O
's	O
Disease	O
prior	O
diphosphonate	S-group-EF-1
use	O
appears	O
to	O
reduce	O
the	O
anti	O
-	O
resorptive	O
response	O
to	O
Calcitonin	B-drug-EF-2
(	I-drug-EF-2
salmon	I-drug-EF-2
)	E-drug-EF-2
nasal	O
spray	O
.	O

Salicylates	S-group
antagonize	O
the	O
uricosuric	O
action	O
of	O
.	O
drugs	O
used	O
to	O
treat	O
gout	O
.	O

ASPIRIN	S-brand-EF-1
AND	O
OTHER	O
SALICYLATE	B-group-EF-1
DRUGS	E-group-EF-1
WILL	O
BE	O
ADDITIVE	O
TO	O
DISALCID	S-brand-EF-2
AND	O
MAY	O
INCREASE	O
PLASMA	O
CONCENTRATIONS	O
OF	O
SALICYLIC	B-drug
ACID	E-drug
TO	O
TOXIC	O
LEVELS	O
.	O

Drugs	O
and	O
foods	O
that	O
raise	O
urine	O
pH	O
will	O
increase	O
renal	O
clearance	O
and	O
urinary	O
excretion	O
of	O
salicylic	B-drug
acid	E-drug
,	O
thus	O
lowering	O
plasma	O
levels	O
;	O

acidifying	O
drugs	O
or	O
foods	O
will	O
decrease	O
urinary	O
excretion	O
and	O
increase	O
plasma	O
levels	O
.	O

Salicylates	S-group-EF-1
given	O
concomitantly	O
with	O
anticoagulant	B-group-EF-2
drugs	E-group-EF-2
may	O
predispose	O
to	O
systemic	O
bleeding	O
.	O

Salicylates	S-group-EF-1
may	O
enhance	O
the	O
hypoglycemic	O
effect	O
of	O
oral	O
antidiabetic	B-group-EF-2
drugs	E-group-EF-2
of	O
the	O
sulfonylurea	O
class	O
.	O

Salicylate	S-group-ME-1
competes	O
with	O
a	O
number	O
of	O
drugs	O
for	O
protein	O
binding	O
sites	O
,	O
notably	O
penicillin	S-drug-ME-2
,	O
thiopental	S-drug-ME-2
,	O
thyroxine	S-drug-ME-2
,	O
triiodothyronine	S-drug-ME-2
,	O
phenytoin	S-drug-ME-2
,	O
sulfinpyrazone	S-drug-ME-2
,	O
naproxen	S-drug-ME-2
,	O
warfarin	S-drug-ME-2
,	O
methotrexate	S-drug-ME-2
,	O
and	O
possibly	O
corticosteroids	S-group-ME-2
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Salicylate	S-group
competes	O
with	O
thyroid	O
hormone	O
for	O
binding	O
to	O
plasma	O
proteins	O
,	O
which	O
may	O
be	O
reflected	O
in	O
a	O
depressed	O
plasma	O
T4	O
value	O
in	O
some	O
patients	O
;	O

thyroid	O
function	O
and	O
basal	O
metabolism	O
are	O
unaffected	O
.	O

Interactions	O
between	O
Leukine	S-brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O

Drugs	O
which	O
may	O
potentiate	O
the	O
myeloproliferative	O
effects	O
of	O
Leukine	S-brand-EF-1
,	O
such	O
as	O
lithium	S-drug-EF-2
and	O
corticosteroids	S-group-EF-2
,	O
should	O
be	O
used	O
with	O
caution	O
.	O

The	O
absorption	O
of	O
oral	O
medications	O
may	O
be	O
decreased	O
during	O
the	O
concurrent	O
use	O
of	O
scopolamine	S-drug
because	O
of	O
decreased	O
gastric	O
motility	O
and	O
delayed	O
gastric	O
emptying	O
.	O

Scopolamine	S-drug-AD-1
should	O
be	O
used	O
with	O
care	O
in	O
patients	O
taking	O
other	O
drugs	O
that	O
are	O
capable	O
of	O
causing	O
CNS	O
effects	O
such	O
as	O
sedatives	S-group-AD-2
,	O
tranquilizers	S-group-AD-2
,	O
or	O
alcohol	S-drug-AD-2
.	O

Special	O
attention	O
should	O
be	O
paid	O
to	O
potential	O
interactions	O
with	O
drugs	O
having	O
anticholinergic	O
properties	O
;	O

e.g	O
.	O
,	O
other	O
belladonna	B-group
alkaloids	E-group
,	O
antihistamines	S-group
(	O
including	O
meclizine	S-drug
)	O
,	O
tricyclic	B-group
antidepressants	E-group
,	O
and	O
muscle	B-group
relaxants	E-group
.	O

Laboratory	O
Test	O
Interactions	O
Scopolamine	S-drug
will	O
interfere	O
with	O
the	O
gastric	O
secretion	O
test	O
.	O

Barbiturates	S-group-IN-1
may	O
decrease	O
the	O
effectiveness	O
of	O
oral	O
contraceptives	S-group-IN-2
,	O
certain	O
antibiotics	S-group-IN-2
,	O
quinidine	S-group-IN-2
,	O
theophylline	S-drug-IN-2
,	O
corticosteroids	S-group-IN-2
,	O
anticoagulants	S-group-IN-2
,	O
and	O
beta	B-group-IN-2
blockers	E-group-IN-2
.	O

The	O
occurrence	O
of	O
stupor	O
,	O
muscular	O
rigidity	O
,	O
severe	O
agitation	O
,	O
and	O
elevated	O
temperature	O
has	O
been	O
reported	O
in	O
some	O
patients	O
receiving	O
the	O
combination	O
of	O
selegiline	S-drug-EF-1
and	O
meperidine	S-drug-EF-2
.	O

Symptoms	O
usually	O
resolve	O
over	O
days	O
when	O
the	O
combination	O
is	O
discontinued	O
.	O

This	O
is	O
typical	O
of	O
the	O
interaction	O
of	O
meperidine	S-drug-IN-1
and	O
MAOIs	S-group-IN-2
.	O

Other	O
serious	O
reactions	O
(	O
including	O
severe	O
agitation	O
,	O
hallucinations	O
,	O
and	O
death	O
)	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
this	O
combination	O
.	O

Severe	O
toxicity	O
has	O
also	O
been	O
reported	O
in	O
patients	O
receiving	O
the	O
combination	O
of	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
and	O
ELDEPRYL	S-brand-EF-2
and	O
selective	B-group-EF-1
serotonin	I-group-EF-1
reuptake	I-group-EF-1
inhibitors	E-group-EF-1
and	O
ELDEPRYL	S-brand-EF-2
.	O

One	O
case	O
of	O
hypertensive	O
crisis	O
has	O
been	O
reported	O
in	O
a	O
patient	O
taking	O
the	O
recommended	O
doses	O
of	O
selegiline	S-drug-EF-1
and	O
a	O
sympathomimetic	B-group-EF-2
medication	E-group-EF-2
(	O
ephedrine	S-drug-EF-2
)	O
.	O

Digoxin	S-drug
:	O
There	O
was	O
a	O
slight	O
increase	O
in	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
,	O
11	O
%	O
)	O
and	O
mean	O
peak	O
drug	O
concentration	O
(	O
Cmax	O
,	O
18	O
%	O
)	O
of	O
digoxin	S-drug-ME-1
with	O
the	O
co	O
-	O
administration	O
of	O
100	O
mg	O
sitagliptin	S-drug-ME-2
for	O
10	O
days	O
.	O

Patients	O
receiving	O
digoxin	S-drug
should	O
be	O
monitored	O
appropriately	O
.	O

No	O
dosage	O
adjustment	O
of	O
digoxin	S-drug
or	O
JANUVIA	S-brand
is	O
recommended	O
.	O

Additives	O
may	O
be	O
incompatible	O
;	O

norepinephrine	S-drug-IN-1
and	O
dobutamine	S-drug-IN-1
are	O
incompatible	O
with	O
sodium	B-drug-IN-2
bicarbonate	E-drug-IN-2
solution	O
.	O

The	O
addition	O
of	O
sodium	B-drug
bicarbonate	E-drug
to	O
parenteral	O
solutions	O
containing	O
calcium	S-drug
should	O
be	O
avoided	O
,	O
except	O
where	O
compatibility	O
has	O
been	O
previously	O
established	O
.	O

Precipitation	O
or	O
haze	O
may	O
result	O
from	O
sodium	O
bicarbonate	O
-	O
calcium	O
admixtures	O
.	O

NOTE	O
:	O
Do	O
not	O
use	O
the	O
injection	O
if	O
it	O
contains	O
precipitate	O
.	O

Additives	O
may	O
be	O
incompatible	O
.	O

Consult	O
with	O
pharmacist	O
,	O
if	O
available	O
.	O

When	O
introducing	O
additives	O
,	O
use	O
aseptic	O
technique	O
,	O
mix	O
thoroughly	O
and	O
do	O
not	O
store	O
.	O

Do	O
not	O
exceed	O
a	O
5	O
mg	O
daily	O
dose	O
of	O
VESIcare	S-brand-AD-1
when	O
administered	O
with	O
therapeutic	O
doses	O
of	O
ketoconazole	S-drug-AD-2
or	O
other	O
potent	O
CYP3A4	O
inhibitors	O
.	O

Patients	O
with	O
Congenital	O
or	O
Acquired	O
QT	O
Prolongation	O
In	O
a	O
study	O
of	O
the	O
effect	O
of	O
solifenacin	S-drug
on	O
the	O
QT	O
interval	O
in	O
76	O
healthy	O
women	O
,	O
the	O
QT	O
prolonging	O
effect	O
appeared	O
less	O
with	O
solifenacin	S-drug
10	O
mg	O
than	O
with	O
30	O
mg	O
(	O
three	O
times	O
the	O
maximum	O
recommended	O
dose	O
)	O
,	O
and	O
the	O
effect	O
of	O
solifenacin	S-drug
30	O
mg	O
did	O
not	O
appear	O
as	O
large	O
as	O
that	O
of	O
the	O
positive	O
control	O
moxifloxacin	S-drug
at	O
its	O
therapeutic	O
dose	O
.	O

This	O
observation	O
should	O
be	O
considered	O
in	O
clinical	O
decisions	O
to	O
prescribe	O
VESIcare	S-brand
for	O
patients	O
with	O
a	O
known	O
history	O
of	O
QT	O
prolongation	O
or	O
patients	O
who	O
are	O
taking	O
medications	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
.	O

Excessive	O
glucocorticoid	O
therapy	O
will	O
inhibit	O
the	O
growth	O
-	O
promoting	O
effect	O
of	O
human	B-drug
GH	E-drug
.	O

Patients	O
with	O
ACTH	O
deficiency	O
should	O
have	O
their	O
glucocorticoid	S-group
-	O
replacement	O
dose	O
carefully	O
adjusted	O
to	O
avoid	O
an	O
inhibitory	O
effect	O
on	O
growth	O
.	O

The	O
use	O
of	O
Nutropin	S-brand
in	O
patients	O
with	O
chronic	O
renal	O
insufficiency	O
receiving	O
glucocorticoid	O
therapy	O
has	O
not	O
been	O
evaluated	O
.	O

Concomitant	O
glucocorticoid	O
therapy	O
may	O
inhibit	O
the	O
growth	O
-	O
promoting	O
effect	O
of	O
Nutropin	S-brand
.	O

If	O
glucocorticoid	S-group
replacement	O
is	O
required	O
,	O
the	O
glucocorticoid	S-group
dose	O
should	O
be	O
carefully	O
adjusted	O
.	O

There	O
was	O
no	O
evidence	O
in	O
the	O
controlled	O
studies	O
of	O
Nutropin	S-brand
s	O
interaction	O
with	O
drugs	O
commonly	O
used	O
in	O
chronic	O
renal	O
insufficiency	O
patients	O
.	O

Limited	O
published	O
data	O
indicate	O
that	O
GH	S-drug-ME-1
treatment	O
increases	O
cytochrome	O
P450	O
(	O
CP450	O
)	O
mediated	O
antipyrine	S-drug-ME-2
clearance	O
in	O
man	O
.	O

These	O
data	O
suggest	O
that	O
GH	S-drug-ME-1
administration	O
may	O
alter	O
the	O
clearance	O
of	O
compounds	O
known	O
to	O
be	O
metabolized	O
by	O
CP450	O
liver	O
enzymes	O
(	O
e.g	O
.	O
,	O
corticosteroids	S-group-ME-2
,	O
sex	B-group-ME-2
steroids	E-group-ME-2
,	O
anticonvulsants	S-group-ME-2
,	O
cyclosporin	S-drug-ME-2
)	O
.	O

Careful	O
monitoring	O
is	O
advisable	O
when	O
GH	S-drug
is	O
administered	O
in	O
combination	O
with	O
other	O
drugs	O
known	O
to	O
be	O
metabolized	O
by	O
CP450	O
liver	O
enzymes	O
.	O

Caution	O
is	O
recommended	O
when	O
administering	O
NEXAVAR	S-brand-AD-1
with	O
compounds	O
that	O
are	O
metabolized	O
/	O
eliminated	O
predominantly	O
by	O
the	O
UGT1A1	O
pathway	O
(	O
e.g	O
.	O
irinotecan	S-drug-AD-2
)	O
.	O

Concomitant	O
treatment	O
with	O
NEXAVAR	S-brand-ME-1
resulted	O
in	O
a	O
21	O
%	O
increase	O
in	O
the	O
AUC	O
of	O
doxorubicin	S-drug-ME-2
.	O

Caution	O
is	O
recommended	O
when	O
administering	O
doxorubicin	S-drug-AD-1
with	O
NEXAVAR	S-brand-AD-2
.	O

Sorafenib	S-drug
inhibits	O
CYP2B6	O
and	O
CYP2C8	O
in	O
vitro	O
with	O
Ki	O
values	O
of	O
6	O
and	O
1	O
-	O
2	O
?	O
M	O
,	O
respectively	O
.	O

Systemic	O
exposure	O
to	O
substrates	O
of	O
CYP2B6	O
and	O
CYP2C8	O
is	O
expected	O
to	O
increase	O
when	O
co	O
-	O
administered	O
with	O
NEXAVAR	S-brand
.	O

Caution	O
is	O
recommended	O
when	O
administering	O
substrates	O
of	O
CYP2B6	O
and	O
CYP2C8	O
with	O
NEXAVAR	S-brand
.	O

Zidovudine	S-drug-EF-1
competitively	O
inhibits	O
the	O
intracellular	O
phosphorylation	O
of	O
stavudine	S-drug-EF-2
.	O

Therefore	O
,	O
use	O
of	O
zidovudine	S-drug-AD-1
in	O
combination	O
with	O
ZERIT	S-brand-AD-2
should	O
be	O
avoided	O
.	O

In	O
vitro	O
data	O
indicate	O
that	O
the	O
phosphorylation	O
of	O
stavudine	S-drug-EF-1
is	O
also	O
inhibited	O
at	O
relevant	O
concentrations	O
by	O
doxorubicin	S-drug-EF-2
and	O
ribavirin	S-drug-EF-2
.	O

The	O
clinical	O
significance	O
of	O
these	O
in	O
vitro	O
interactions	O
is	O
unknown	O
;	O

therefore	O
,	O
concomitant	O
use	O
of	O
stavudine	S-drug
with	O
either	O
of	O
these	O
drugs	O
should	O
be	O
undertaken	O
with	O
caution	O
.	O

The	O
interaction	O
of	O
Streptase	S-brand
,	O
Streptokinase	S-drug
,	O
with	O
other	O
drugs	O
has	O
not	O
been	O
well	O
studied	O
.	O

Use	O
of	O
Anticoagulants	S-group
and	O
Antiplatelet	B-group
Agents	E-group
-	O
-	O
Streptase	S-brand-EF-1
,	O
Streptokinase	S-drug-EF-1
,	O
alone	O
or	O
in	O
combination	O
with	O
antiplatelet	B-group-EF-2
agents	E-group-EF-2
and	O
anticoagulants	S-group-EF-2
,	O
may	O
cause	O
bleeding	O
complications	O
.	O

Therefore	O
,	O
careful	O
monitoring	O
is	O
advised	O
.	O

In	O
the	O
treatment	O
of	O
acute	O
MI	O
,	O
aspirin	S-brand
,	O
when	O
not	O
otherwise	O
contraindicated	O
,	O
should	O
be	O
administered	O
with	O
Streptokinase	S-drug
(	O
see	O
below	O
)	O
.	O

Anticoagulation	O
and	O
Antiplatelets	S-group
After	O
Treatment	O
for	O
Myocardial	O
Infarction	O
-	O
-	O
In	O
the	O
treatment	O
of	O
acute	O
myocardial	O
infarction	O
,	O
the	O
use	O
of	O
aspirin	S-brand
has	O
been	O
shown	O
to	O
reduce	O
the	O
incidence	O
of	O
reinfarction	O
and	O
stroke	O
.	O

The	O
addition	O
of	O
aspirin	S-brand-EF-1
to	O
Streptokinase	S-drug-EF-2
causes	O
a	O
minimal	O
increase	O
in	O
the	O
risk	O
of	O
minor	O
bleeding	O
(	O
3.9	O
%	O
vs.	O
3.1	O
%	O
)	O
,	O
but	O
does	O
not	O
appear	O
to	O
increase	O
the	O
incidence	O
of	O
major	O
bleeding	O
(	O
see	O

ZANOSAR	S-brand
may	O
demonstrate	O
additive	O
toxicity	O
when	O
used	O
in	O
combination	O
with	O
other	O
cytotoxic	O
drugs	O
.	O

Streptozocin	S-drug-ME-1
has	O
been	O
reported	O
to	O
prolong	O
the	O
elimination	O
half	O
-	O
life	O
of	O
doxorubicin	S-drug-ME-2
and	O
may	O
lead	O
to	O
severe	O
bone	O
marrow	O
suppression	O
;	O

a	O
reduction	O
of	O
the	O
doxorubicin	S-drug-AD-1
dosage	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
ZANOSAR	S-brand-AD-2
concurrently	O
.	O

The	O
concurrent	O
use	O
of	O
streptozocin	S-drug-EF-1
and	O
phenytoin	S-drug-EF-2
has	O
been	O
reported	O
in	O
one	O
case	O
to	O
result	O
in	O
reduced	O
streptozocin	S-drug
cytotoxicity	O
.	O

CHEMET	S-brand
is	O
not	O
known	O
to	O
interact	O
with	O
other	O
drugs	O
including	O
iron	S-drug
supplements	O
;	O

interactions	O
have	O
not	O
been	O
systematically	O
studied	O
.	O

Concomitant	O
administration	O
of	O
CHEMET	S-brand-AD-1
with	O
other	O
chelation	O
therapy	O
,	O
such	O
as	O
CaNa	B-drug-AD-2
2	I-drug-AD-2
EDTA	E-drug-AD-2
is	O
not	O
recommended	O
.	O

Drug	O
/	O
Laboratory	O
Tests	O
Interaction	O
:	O
Succimer	S-drug
may	O
interfere	O
with	O
serum	O
and	O
urinary	O
laboratory	O
tests	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
succimer	S-drug
to	O
cause	O
false	O
positive	O
results	O
for	O
ketones	O
in	O
urine	O
using	O
nitroprusside	O
reagents	O
such	O
as	O
Ketostix	O
and	O
falsely	O
decreased	O
measurements	O
of	O
serum	O
uric	O
acid	O
and	O
CPK	O
.	O

Sulfamethizole	S-drug-EF-1
may	O
increase	O
the	O
effects	O
of	O
barbiturates	S-group-EF-2
,	O
tolbutamide	S-drug-EF-2
,	O
and	O
uricosurics	S-group-EF-2
.	O

It	O
may	O
also	O
interact	O
with	O
thiazides	S-group
(	O
increased	O
thrombocytopenia	O
)	O
,	O
cyclosporine	S-drug
(	O
increased	O
nephrotoxicity	O
)	O
,	O
sulfonylurea	B-group
agents	E-group
(	O
increased	O
hypoglycemic	O
response	O
)	O
,	O
warfarin	S-drug
(	O
increased	O
anticoagulant	O
effect	O
)	O
,	O
methotrexate	S-drug
(	O
decreased	O
renal	O
excretion	O
of	O
methotrexate	S-drug
)	O
,	O
phenytoin	S-drug
(	O
decreased	O
hepatic	O
clearance	O
of	O
phenytoin	S-drug
)	O
.	O

In	O
elderly	O
patients	O
concurrently	O
receiving	O
certain	O
diuretics	S-group
,	O
primarily	O
thiazides	S-group
,	O
an	O
increased	O
incidence	O
of	O
thrombopenia	O
with	O
purpura	O
has	O
been	O
reported	O
.	O

It	O
has	O
been	O
reported	O
that	O
sulfamethoxazole	S-drug-EF-1
may	O
prolong	O
the	O
prothrombin	O
time	O
in	O
patients	O
who	O
are	O
receiving	O
the	O
anticoagulant	S-group
warfarin	S-drug-EF-2
.	O

This	O
interaction	O
should	O
be	O
kept	O
in	O
mind	O
when	O
Gantanol	S-brand
is	O
given	O
to	O
patients	O
already	O
on	O
anticoagulant	O
therapy	O
,	O
and	O
the	O
coagulation	O
time	O
should	O
be	O
reassessed	O
.	O

Sulfamethoxazole	S-drug-ME-1
may	O
inhibit	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	S-drug-ME-2
.	O

At	O
a	O
1.6	O
-	O
g	O
dose	O
,	O
sulfamethoxazole	S-drug-ME-1
produced	O
a	O
slight	O
but	O
significant	O
increase	O
in	O
the	O
half	O
-	O
life	O
of	O
phenytoin	S-drug-ME-2
but	O
did	O
not	O
produce	O
a	O
corresponding	O
decrease	O
in	O
the	O
metabolic	O
clearance	O
rate	O
.	O

When	O
administering	O
these	O
drugs	O
concurrently	O
,	O
one	O
should	O
be	O
alert	O
for	O
possible	O
excessive	O
phenytoin	S-drug
effect	O
.	O

Sulfonamides	S-group-ME-1
can	O
also	O
displace	O
methotrexate	S-drug-ME-2
from	O
plasma	O
protein	O
-	O
binding	O
sites	O
,	O
thus	O
increasing	O
free	O
methotrexate	S-drug
concentrations	O
.	O

The	O
presence	O
of	O
sulfamethoxazole	S-drug
may	O
interfere	O
with	O
the	O
Jaff	O
alkaline	O
picrate	O
reaction	O
assay	O
for	O
creatinine	O
,	O
resulting	O
in	O
overestimations	O
of	O
about	O
10	O
%	O
in	O
the	O
range	O
of	O
normal	O
values	O
.	O

Reduced	O
absorption	O
of	O
folic	B-drug-ME-1
acid	E-drug-ME-1
and	O
digoxin	S-drug-ME-1
have	O
been	O
reported	O
when	O
those	O
agents	O
were	O
administered	O
concomitantly	O
with	O
sulfasalazine	S-drug-ME-2
.	O

When	O
daily	O
doses	O
of	O
sulfasalazine	S-drug
2	O
g	O
and	O
weekly	O
doses	O
of	O
methotrexate	S-drug
7.5	O
mg	O
were	O
coadministered	O
to	O
15	O
rheumatoid	O
arthritis	O
patients	O
in	O
a	O
drug	O
-	O
drug	O
interaction	O
study	O
,	O
the	O
pharmacokinetic	O
disposition	O
of	O
the	O
drugs	O
was	O
not	O
altered	O
.	O

Daily	O
doses	O
of	O
sulfasalazine	S-drug
2	O
g	O
(	O
maximum	O
3	O
g	O
)	O
and	O
weekly	O
doses	O
of	O
methotrexate	S-drug
7.5	O
mg	O
(	O
maximum	O
15	O
mg	O
)	O
were	O
administered	O
alone	O
or	O
in	O
combination	O
to	O
310	O
rheumatoid	O
arthritis	O
patients	O
in	O
two	O
controlled	O
52	O
-	O
week	O
clinical	O
studies	O
.	O

The	O
overall	O
toxicity	O
profile	O
of	O
the	O
combination	O
revealed	O
an	O
increased	O
incidence	O
of	O
gastrointestinal	O
adverse	O
events	O
,	O
especially	O
nausea	O
,	O
when	O
compared	O
to	O
the	O
incidence	O
associated	O
with	O
either	O
drug	O
administered	O
alone	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
The	O
presence	O
of	O
sulfasalazine	S-drug
or	O
its	O
metabolites	O
in	O
body	O
fluids	O
has	O
not	O
been	O
reported	O
to	O
interfere	O
with	O
laboratory	O
test	O
procedures	O
.	O

REFERENCES	O
7.Farr	O
M	O
,	O
et	O
al	O
.	O

Immunodeficiencies	O
associated	O
with	O
sulphasalazine	S-drug
therapy	O
in	O
inflammatory	O
arthritis	O
.	O

British	O
Jnl	O
Rheum	O
1991	O
;	O
30	O
:	O
413	O
-	O
417	O
.	O

Sulfoxone	S-drug-EF-1
may	O
increase	O
the	O
effects	O
of	O
barbiturates	S-group-EF-2
,	O
tolbutamide	S-drug-EF-2
,	O
and	O
uricosurics	S-group-EF-2
.	O

It	O
may	O
also	O
interact	O
with	O
thiazides	S-group
(	O
increased	O
thrombocytopenia	O
)	O
,	O
cyclosporine	S-drug
(	O
increased	O
nephrotoxicity	O
)	O
,	O
sulfonylurea	B-group
agents	E-group
(	O
increased	O
hypoglycemic	O
response	O
)	O
,	O
warfarin	S-drug
(	O
increased	O
anticoagulant	O
effect	O
)	O
,	O
methotrexate	S-drug
(	O
decreased	O
renal	O
excretion	O
of	O
methotrexate	S-drug
)	O
,	O
phenytoin	S-drug
(	O
decreased	O
hepatic	O
clearance	O
of	O
phenytoin	S-drug
)	O
.	O

Ergot	S-group
-	O
containing	O
drugs	O
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O

Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
,	O
use	O
of	O
ergotamine	S-drug-AD-1
-	O
containing	O
or	O
ergot	B-group-AD-1
-	I-group-AD-1
type	I-group-AD-1
medications	E-group-AD-1
(	O
like	O
dihydroergotamine	S-drug-AD-1
or	O
methysergide	S-drug-AD-1
)	O
and	O
sumatriptan	S-drug-AD-2
within	O
24	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
.	O

MAO	B-group-ME-1
-	I-group-ME-1
A	I-group-ME-1
inhibitors	E-group-ME-1
reduce	O
sumatriptan	S-drug-ME-2
clearance	O
,	O
significantly	O
increasing	O
systemic	O
exposure	O
.	O

Therefore	O
,	O
the	O
use	O
of	O
sumatriptan	B-drug-AD-1
succinate	E-drug-AD-1
tablets	O
in	O
patients	O
receiving	O
MAO	B-group-AD-2
-	I-group-AD-2
A	I-group-AD-2
inhibitors	E-group-AD-2
is	O
contraindicated	O
.	O
Selective	B-group-EF-1
serotonin	I-group-EF-1
reuptake	I-group-EF-1
inhibitors	E-group-EF-1
(	O
SSRIs	S-group-EF-1
)	O
(	O
e.g	O
.	O
,	O
fluoxetine	S-drug-EF-1
,	O
fluvoxamine	S-drug-EF-1
,	O
paroxetine	S-drug-EF-1
,	O
sertraline	S-drug-EF-1
)	O
have	O
been	O
reported	O
,	O
rarely	O
,	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
sumatriptan	S-drug-EF-2
.	O

If	O
concomitant	O
treatment	O
with	O
sumatriptan	S-drug-AD-1
and	O
an	O
SSRI	S-group-AD-2
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Co	O
-	O
administration	O
of	O
SUTENT	S-brand-ME-1
with	O
strong	O
inhibitors	O
of	O
the	O
CYP3A4	O
family	O
(	O
e.g	O
.	O
,	O
ketoconazole	S-drug-ME-2
,	O
itraconazole	S-drug-ME-2
,	O
clarithromycin	S-drug-ME-2
,	O
atazanavir	S-drug-ME-2
,	O
indinavir	S-drug-ME-2
,	O
nefazodone	S-drug-ME-2
,	O
nelfinavir	S-drug-ME-2
,	O
ritonavir	S-drug-ME-2
,	O
saquinavir	S-drug-ME-2
,	O
telithromycin	S-drug-ME-2
,	O
voriconizole	S-drug-ME-2
)	O
may	O
increases	O
sunitinib	S-drug
concentrations	O
.	O

Grapefruit	O
may	O
also	O
increase	O
plasma	O
concentrations	O
of	O
SUTENT	S-brand
.	O

Co	O
-	O
administration	O
of	O
SUTENT	S-brand-ME-1
with	O
inducers	O
of	O
the	O
CYP3A4	O
family	O
(	O
e.g	O
.	O
,	O
dexamethasone	S-drug-ME-2
,	O
phenytoin	S-drug-ME-2
,	O
carbamazepine	S-drug-ME-2
,	O
rifampin	S-drug-ME-2
,	O
rifabutin	S-drug-ME-2
,	O
rifapentin	S-drug-ME-2
,	O
phenobarbital	S-drug-ME-2
,	O
St.	O
Johns	O
Wort	O
)	O
may	O
decrease	O
sunitinib	S-drug
concentrations	O
.	O

St	O
.	O

Johns	O
Wort	O
may	O
decrease	O
SUTENT	S-brand
plasma	O
concentrations	O
unpredictably	O
.	O

Patients	O
receiving	O
SUTENT	S-brand
should	O
not	O
take	O
St	O
.	O

Johns	O
Wort	O
concomitantly	O
.	O

SUTENT	S-brand
dose	O
modification	O
is	O
recommended	O
in	O
patients	O
using	O
concomitant	O
CYP3A4	O
inhibitors	O
or	O
inducers	O
.	O

Other	O
eye	O
drops	O
or	O
medications	O
such	O
as	O
acetylcholine	B-drug-EF-1
chloride	E-drug-EF-1
(	O
Miochol	S-brand-EF-1
)	O
and	O
carbachol	S-drug-EF-1
(	O
Carboptic	S-brand-EF-1
,	O
Isopto	B-brand-EF-1
Carbachol	E-brand-EF-1
)	O
may	O
decrease	O
the	O
effects	O
of	O
suprofen	S-drug-EF-2
ophthalmic	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
:	O
The	O
pharmacokinetic	O
and	O
pharmacodynamic	O
interactions	O
between	O
FLOMAX	S-brand
capsules	O
and	O
other	O
alpha	B-group
-	I-group
adrenergic	I-group
blocking	I-group
agents	E-group
have	O
not	O
been	O
determined	O
.	O

However	O
,	O
interactions	O
may	O
be	O
expected	O
and	O
FLOMAX	S-brand-AD-1
capsules	O
should	O
NOT	O
be	O
used	O
in	O
combination	O
with	O
other	O
alpha	B-group-AD-2
-	I-group-AD-2
adrenergic	I-group-AD-2
blocking	I-group-AD-2
agents	E-group-AD-2
.	O

The	O
pharmacokinetic	O
interaction	O
between	O
cimetidine	S-drug
and	O
FLOMAX	S-brand
capsules	O
was	O
investigated	O
.	O

The	O
results	O
indicate	O
significant	O
changes	O
in	O
tamsulosin	B-drug
HCI	E-drug
clearance	O
(	O
26	O
%	O
decrease	O
)	O
and	O
AUC	O
(	O
44	O
%	O
increase	O
)	O
.	O

Therefore	O
,	O
FLOMAX	S-brand-AD-1
capsules	O
should	O
be	O
used	O
with	O
caution	O
in	O
combination	O
with	O
cimetidine	S-drug-AD-2
,	O
particularly	O
at	O
doses	O
higher	O
than	O
0.4	O
mg	O
.	O

Results	O
from	O
limited	O
in	O
vitro	O
and	O
in	O
vivo	O
drug	O
-	O
drug	O
interaction	O
studies	O
between	O
tamsulosin	B-drug
HCI	E-drug
and	O
warfarin	S-drug
are	O
inconclusive	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
with	O
concomitant	O
administration	O
of	O
warfarin	S-drug-AD-1
and	O
FLOMAX	S-brand-AD-2
capsules	O
.	O

Administration	O
of	O
valproic	B-drug-ME-1
acid	E-drug-ME-1
decreases	O
oral	O
clearance	O
of	O
temozolomide	S-drug-ME-2
by	O
about	O
5	O
%	O
.	O

The	O
clinical	O
implication	O
of	O
this	O
effect	O
is	O
not	O
known	O
.	O

Patients	O
with	O
Severe	O
Hepatic	O
or	O
Renal	O
Impairment	O
Caution	O
should	O
be	O
exercised	O
when	O
TEMODAR	S-brand
Capsules	O
are	O
administered	O
to	O
patients	O
with	O
severe	O
hepatic	O
or	O
renal	O
impairment	O
.	O

Formal	O
interaction	O
studies	O
of	O
TNKase	S-brand
with	O
other	O
drugs	O
have	O
not	O
been	O
performed	O
.	O

Patients	O
studied	O
in	O
clinical	O
trials	O
of	O
TNKase	S-brand
were	O
routinely	O
treated	O
with	O
heparin	S-drug
and	O
aspirin	S-brand
.	O

Anticoagulants	S-group-EF-1
(	O
such	O
as	O
heparin	S-drug-EF-1
and	O
vitamin	B-group-EF-1
K	I-group-EF-1
antagonists	E-group-EF-1
)	O
and	O
drugs	O
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
acetylsalicylic	B-drug-EF-1
acid	E-drug-EF-1
,	O
dipyridamole	S-drug-EF-1
,	O
and	O
GP	O
IIb	O
/	O
IIIa	O
inhibitors	O
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
,	O
during	O
,	O
or	O
after	O
TNKase	S-brand-EF-2
therapy	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
During	O
TNKase	S-brand
therapy	O
,	O
results	O
of	O
coagulation	O
tests	O
and	O
/	O
or	O
measures	O
of	O
fibrinolytic	O
activity	O
may	O
be	O
unreliable	O
unless	O
specific	O
precautions	O
are	O
taken	O
to	O
prevent	O
in	O
vitro	O
artifacts	O
.	O

Tenecteplase	S-drug
is	O
an	O
enzyme	O
that	O
,	O
when	O
present	O
in	O
blood	O
in	O
pharmacologic	O
concentrations	O
,	O
remains	O
active	O
under	O
in	O
vitro	O
conditions	O
.	O

This	O
can	O
lead	O
to	O
degradation	O
of	O
fibrinogen	O
in	O
blood	O
samples	O
removed	O
for	O
analysis	O
.	O

In	O
a	O
study	O
in	O
which	O
34	O
different	O
drugs	O
were	O
tested	O
,	O
therapeutically	O
relevant	O
concentrations	O
of	O
tolbutamide	S-drug-ME-1
,	O
sodium	B-drug-ME-1
salicylate	E-drug-ME-1
and	O
sulfamethizole	S-drug-ME-1
displaced	O
protein	O
-	O
bound	O
teniposide	S-drug-ME-2
in	O
fresh	O
human	O
serum	O
to	O
a	O
small	O
but	O
significant	O
extent	O
.	O

Because	O
of	O
the	O
extremely	O
high	O
binding	O
of	O
teniposide	S-drug
to	O
plasma	O
proteins	O
,	O
these	O
small	O
decreases	O
in	O
binding	O
could	O
cause	O
substantial	O
increases	O
in	O
free	O
drug	O
levels	O
in	O
plasma	O
which	O
could	O
result	O
in	O
potentiation	O
of	O
drug	O
toxicity	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
in	O
administering	O
VUMON	S-brand
(	O
teniposide	S-drug
injection	O
)	O
to	O
patients	O
receiving	O
these	O
other	O
agents	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
plasma	O
kinetics	O
of	O
teniposide	S-drug
when	O
coadministered	O
with	O
methotrexate	S-drug
.	O

However	O
,	O
the	O
plasma	O
clearance	O
of	O
methotrexate	S-drug
was	O
slightly	O
increased	O
.	O

An	O
increase	O
in	O
intracellular	O
levels	O
of	O
methotrexate	S-drug-ME-1
was	O
observed	O
in	O
vitro	O
in	O
the	O
presence	O
of	O
teniposide	S-drug-ME-2
.	O

In	O
vitro	O
studies	O
with	O
human	O
liver	O
microsomes	O
showed	O
that	O
terbinafine	S-drug
does	O
not	O
inhibit	O
the	O
metabolism	O
of	O
tolbutamide	S-drug
,	O
ethinylestradiol	S-drug
,	O
ethoxycoumarin	S-drug_n
,	O
and	O
cyclosporine	S-drug
.	O

In	O
vitro	O
studies	O
have	O
also	O
shown	O
that	O
terbinafine	S-drug
inhibits	O
CYP2D6	O
-	O
mediated	O
metabolism	O
.	O

This	O
may	O
be	O
of	O
clinical	O
relevance	O
for	O
compounds	O
predominantly	O
metabolized	O
by	O
this	O
enzyme	O
,	O
such	O
as	O
tricyclic	B-group
antidepressants	E-group
,	O
-	O
blockers	O
,	O
selective	B-group
serotonin	I-group
reuptake	I-group
inhibitors	E-group
(	O
SSRIs	S-group
)	O
,	O
and	O
monoamine	B-group
oxidase	I-group
inhibitors	I-group
(	I-group
MAO	I-group
-	I-group
Is	I-group
)	I-group
Type	I-group
B	E-group
,	O
if	O
they	O
have	O
a	O
narrow	O
therapeutic	O
window	O
.	O

In	O
vivo	O
drug	O
-	O
drug	O
interaction	O
studies	O
conducted	O
in	O
normal	O
volunteer	O
subjects	O
showed	O
that	O
terbinafine	S-drug
does	O
not	O
affect	O
the	O
clearance	O
of	O
antipyrine	S-drug
or	O
digoxin	S-drug
.	O

Terbinafine	S-drug-ME-1
decreases	O
the	O
clearance	O
of	O
caffeine	S-drug-ME-2
by	O
19	O
%	O
.	O

Terbinafine	S-drug-ME-1
increases	O
the	O
clearance	O
of	O
cyclosporine	S-drug-ME-2
by	O
15	O
%	O
.	O

There	O
have	O
been	O
spontaneous	O
reports	O
of	O
increase	O
or	O
decrease	O
in	O
prothrombin	O
times	O
in	O
patients	O
concomitantly	O
taking	O
oral	O
terbinafine	S-drug-EF-1
and	O
warfarin	S-drug-EF-2
,	O
however	O
,	O
a	O
causal	O
relationship	O
between	O
LAMISIL	S-brand
Tablets	O
and	O
these	O
changes	O
has	O
not	O
been	O
established	O
.	O

Terbinafine	S-drug-ME-1
clearance	O
is	O
increased	O
100	O
%	O
by	O
rifampin	S-drug-ME-2
,	O
a	O
CyP450	O
enzyme	O
inducer	O
,	O
and	O
decreased	O
33	O
%	O
by	O
cimetidine	S-drug-ME-2
,	O
a	O
CyP450	O
enzyme	O
inhibitor	O
.	O

Terbinafine	S-drug
clearance	O
is	O
unaffected	O
by	O
cyclosporine	S-drug
.	O

There	O
is	O
no	O
information	O
available	O
from	O
adequate	O
drug	O
-	O
drug	O
interaction	O
studies	O
with	O
the	O
following	O
classes	O
of	O
drugs	O
:	O
oral	O
contraceptives	S-group
,	O
hormone	O
replacement	O
therapies	O
,	O
hypoglycemics	S-group
,	O
theophyllines	S-drug
,	O
phenytoins	S-drug
,	O
thiazide	B-group
diuretics	E-group
,	O
beta	B-group
blockers	E-group
,	O
and	O
calcium	B-group
channel	I-group
blockers	E-group
.	O

Ketoconazole	S-drug
:	O
Spontaneous	O
adverse	O
reaction	O
reports	O
of	O
patients	O
taking	O
concomitant	O
ketoconazole	S-drug-EF-1
with	O
recommended	O
doses	O
of	O
terfenadine	S-drug-EF-2
demonstrate	O
QT	O
interval	O
prolongation	O
and	O
rare	O
serious	O
cardiac	O
events	O
,	O
e.g	O
.	O

death	O
,	O
cardiac	O
arrest	O
,	O
and	O
ventricular	O
arrhythmia	O
including	O
torsades	O
de	O
pointes	O
.	O

Pharmacokinetic	O
data	O
indicate	O
that	O
ketoconazole	S-drug-ME-1
markedly	O
inhibits	O
the	O
metabolism	O
of	O
terfenadine	S-drug-ME-2
,	O
resulting	O
in	O
elevated	O
plasma	O
terfenadine	S-drug
levels	O
.	O

Presence	O
of	O
unchanged	O
terfenadine	S-drug
is	O
associated	O
with	O
statistically	O
significant	O
prolongation	O
of	O
the	O
QT	O
and	O
QTc	O
intervals	O
.	O

Concomitant	O
administration	O
of	O
ketoconazole	S-drug-AD-1
and	O
terfenadine	S-drug-AD-2
is	O
contraindicated	O
.	O

Itraconazole	S-drug
:	O
Torsades	O
de	O
pointes	O
and	O
elevated	O
parent	O
terfenadine	S-drug
levels	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
terfenadine	S-drug-ME-1
and	O
itraconazole	S-drug-ME-2
in	O
clinical	O
trials	O
of	O
itraconazole	S-drug
and	O
from	O
foreign	O
post	O
-	O
marketing	O
sources	O
.	O

One	O
death	O
has	O
also	O
been	O
reported	O
from	O
foreign	O
post	O
-	O
marketing	O
sources	O
.	O

Concomitant	O
administration	O
of	O
itraconazole	S-drug-AD-1
and	O
terfenadine	S-drug-AD-2
is	O
contraindicated	O
.	O

Due	O
to	O
the	O
chemical	O
similarity	O
of	O
other	O
azole	B-group-AD-1
-	I-group-AD-1
type	I-group-AD-1
antifungal	I-group-AD-1
agents	E-group-AD-1
(	O
including	O
fluconazole	S-drug-AD-1
,	O
metronidazole	S-drug-AD-1
,	O
and	O
miconazole	S-drug-AD-1
)	O
to	O
ketoconazole	S-drug
,	O
and	O
itraconazole	S-drug
,	O
concomitant	O
use	O
of	O
these	O
products	O
with	O
terfenadine	S-drug-AD-2
is	O
not	O
recommended	O
pending	O
full	O
examination	O
of	O
potential	O
interactions	O
.	O

Macrolides	S-group
:	O
Clinical	O
drug	O
interaction	O
studies	O
indicate	O
that	O
erythromycin	S-drug-ME-1
and	O
clarithromycin	S-drug-ME-1
can	O
exert	O
an	O
effect	O
on	O
terfenadine	S-drug-ME-2
metabolism	O
by	O
a	O
mechanism	O
which	O
may	O
be	O
similar	O
to	O
that	O
of	O
ketoconazole	S-drug
,	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

Although	O
erythromycin	O
measurably	O
decreases	O
the	O
clearance	O
of	O
the	O
terfenadine	S-drug
acid	O
metabolite	O
,	O
its	O
influence	O
on	O
terfenadine	O
plasma	O
levels	O
is	O
still	O
under	O
investigation	O
.	O

A	O
few	O
spontaneous	O
accounts	O
of	O
QT	O
interval	O
prolongation	O
with	O
ventricular	O
arrhythmia	O
including	O
torsades	O
de	O
pointes	O
,	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
erythromycin	S-drug
or	O
troleandomycin	S-drug
.	O

Concomitant	O
administration	O
of	O
terfenadine	S-drug-AD-1
with	O
clarithromycin	S-drug-AD-2
,	O
erythromycin	S-drug-AD-2
,	O
or	O
troleandomycin	S-drug-AD-2
is	O
contraindicated	O
:	O
Pending	O
full	O
characterization	O
of	O
potential	O
interactions	O
,	O
concomitant	O
administration	O
of	O
terfenadine	S-drug-AD-1
with	O
other	O
macrolide	B-group-AD-2
antibiotics	E-group-AD-2
,	O
including	O
azithromycin	S-drug-AD-2
,	O
is	O
not	O
recommended	O
.	O

Studies	O
to	O
evaluate	O
potential	O
interactions	O
of	O
terfenadine	S-drug
with	O
azithromycin	S-drug
are	O
in	O
progress	O
.	O

When	O
administered	O
concurrently	O
,	O
testolactone	S-drug-EF-1
may	O
increase	O
the	O
effects	O
of	O
oral	O
anticoagulants	S-group-EF-2
;	O

monitor	O
and	O
adjust	O
anticoagulant	S-group
dosage	O
accordingly	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Physiologic	O
effects	O
of	O
testolactone	S-drug
may	O
result	O
in	O
decreased	O
estradiol	O
concentrations	O
with	O
radioimmunoassays	O
for	O
estradiol	O
,	O
increased	O
plasma	O
calcium	O
concentrations	O
,	O
and	O
increased	O
24	O
-	O
hour	O
urinary	O
excretion	O
of	O
creatine	O
and	O
17	O
-	O
ketosteroids	O
.	O

Thalidomide	S-drug-EF-1
has	O
been	O
reported	O
to	O
enhance	O
the	O
sedative	O
activity	O
of	O
barbiturates	S-group-EF-2
,	O
alcohol	S-drug
,	O
chlorpromazine	S-drug
,	O
and	O
reserpine	S-drug
.	O

Peripheral	O
Neuropathy	O
:	O
Medications	O
known	O
to	O
be	O
associated	O
with	O
peripheral	O
neuropathy	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
thalidomide	S-drug
.	O

Oral	O
Contraceptives	S-group
:	O
In	O
10	O
healthy	O
women	O
,	O
the	O
pharmacokinetic	O
profiles	O
of	O
norethindrone	S-drug
and	O
ethinyl	B-drug
estradiol	E-drug
following	O
administration	O
of	O
a	O
single	O
dose	O
containing	O
1.0	O
mg	O
of	O
norethindrone	B-drug
acetate	E-drug
and	O
75	O
g	O
of	O
ethinyl	B-drug
estradiol	E-drug
were	O
studied	O
.	O

The	O
results	O
were	O
similar	O
with	O
and	O
without	O
coadministration	O
of	O
thalidomide	S-drug
200	O
mg	O
/	O
day	O
to	O
steady	O
-	O
state	O
levels	O
.	O

Important	O
Non	O
-	O
Thalidomide	S-drug
Drug	O
Interactions	O
Drugs	O
That	O
Interfere	O
with	O
Hormonal	B-group
Contraceptives	E-group
:	O
Concomitant	O
use	O
of	O
HIV	B-group
-	I-group
protease	I-group
inhibitors	E-group
,	O
griseofulvin	S-drug
,	O
modafinil	S-drug
,	O
penicillins	S-group
,	O
rifampin	S-drug
,	O
rifabutin	S-drug
,	O
phenytoin	S-drug
,	O
carbamazepine	S-drug
,	O
or	O
certain	O
herbal	O
supplements	O
such	O
as	O
St	O
.	O

John	B-drug_n-EF-1
's	I-drug_n-EF-1
Wort	E-drug_n-EF-1
with	O
hormonal	B-group-EF-2
contraceptive	I-group-EF-2
agents	E-group-EF-2
may	O
reduce	O
the	O
effectiveness	O
of	O
the	O
contraception	O
and	O
up	O
to	O
one	O
month	O
after	O
discontinuation	O
of	O
these	O
concomitant	O
therapies	O
.	O

Therefore	O
,	O
women	O
requiring	O
treatment	O
with	O
one	O
or	O
more	O
of	O
these	O
drugs	O
must	O
use	O
two	O
OTHER	O
effective	O
or	O
highly	O
effective	O
methods	O
of	O
contraception	O
or	O
abstain	O
from	O
heterosexual	O
sexual	O
contact	O
while	O
taking	O
thalidomide	S-drug
.	O

Thiabendazole	S-drug-ME-1
may	O
compete	O
with	O
other	O
drugs	O
,	O
such	O
as	O
theophylline	S-drug-ME-2
,	O
for	O
sites	O
of	O
metabolism	O
in	O
the	O
liver	O
,	O
thus	O
elevating	O
the	O
serum	O
levels	O
of	O
such	O
compounds	O
to	O
potentially	O
toxic	O
levels	O
.	O

Therefore	O
,	O
when	O
concomitant	O
use	O
of	O
thiabendazole	S-drug-AD-1
and	O
xanthine	B-group-AD-2
derivatives	E-group-AD-2
is	O
anticipated	O
,	O
it	O
may	O
be	O
necessary	O
to	O
monitor	O
blood	O
levels	O
and	O
/	O
or	O
reduce	O
the	O
dosage	O
of	O
such	O
compounds	O
.	O

Such	O
concomitant	O
use	O
should	O
be	O
administered	O
under	O
careful	O
medical	O
supervision	O
.	O

Interactions	O
for	O
Vitamin	B-drug-IN-1
B1	E-drug-IN-1
(	O
Thiamine	S-drug-IN-1
)	O
:	O
Loop	B-group-IN-2
Diuretics	E-group-IN-2
,	O
Oral	O
Contraceptives	S-group-IN-2
,	O
Stavudine	S-drug-IN-2
,	O
Tricyclic	B-group-IN-2
Antidepressants	E-group-IN-2

Phenothiazines	S-group-EF-1
are	O
capable	O
of	O
potentiating	O
CNS	B-group-EF-2
depressants	E-group-EF-2
(	O
e.g	O
.	O
,	O
barbiturates	S-group-EF-2
,	O
anesthetics	S-group-EF-2
,	O
opiates	S-group-EF-2
,	O
alcohol	S-drug-EF-2
,	O
etc	O
.	O
)	O

as	O
well	O
as	O
atropine	S-drug
and	O
phosphorous	B-drug_n
insecticides	E-drug_n
.	O

There	O
is	O
usually	O
complete	O
cross	O
-	O
resistance	O
between	O
PURINETHOL	S-brand-EF-1
(	O
mercaptopurine	S-drug-EF-1
)	O
and	O
TABLOID	S-brand-EF-2
brand	O
Thioguanine	S-drug-EF-2
.	O

As	O
there	O
is	O
in	O
vitro	O
evidence	O
that	O
aminosalicylate	B-group-ME-1
derivatives	E-group-ME-1
(	O
e.g	O
.	O
,	O
olsalazine	S-drug-ME-1
,	O
mesalazine	S-drug-ME-1
,	O
or	O
sulphasalazine	S-drug-ME-1
)	O
inhibit	O
the	O
TPMT	O
enzyme	O
,	O
they	O
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
receiving	O
concurrent	O
thioguanine	S-drug-ME-2
therapy	O
.	O

Interactions	O
between	O
ZADAXIN	S-brand
and	O
other	O
drugs	O
have	O
not	O
been	O
fully	O
evaluated	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
administering	O
ZADAXIN	S-brand-AD-1
therapy	O
in	O
combination	O
with	O
other	O
immunomodulating	B-group-AD-2
drugs	E-group-AD-2
.	O

ZADAXIN	S-brand
should	O
not	O
be	O
mixed	O
with	O
any	O
other	O
drug	O
.	O

Prothrombin	O
time	O
or	O
other	O
suitable	O
anticoagulation	O
test	O
should	O
be	O
monitored	O
if	O
tigecycline	S-drug-AD-1
is	O
administered	O
with	O
warfarin	S-drug-AD-2
.	O

Concurrent	O
use	O
of	O
antibacterial	B-group-EF-1
drugs	E-group-EF-1
with	O
oral	O
contraceptives	S-group-EF-2
may	O
render	O
oral	O
contraceptives	S-group
less	O
effective	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
drug	O
-	O
laboratory	O
test	O
interactions	O
.	O

The	O
bioavailability	O
of	O
SKELID	S-brand-ME-1
is	O
decreased	O
80	O
%	O
by	O
calcium	S-drug-ME-2
,	O
when	O
calcium	S-drug
and	O
SKELID	S-brand
are	O
administered	O
at	O
the	O
same	O
time	O
,	O
and	O
60	O
%	O
by	O
some	O
aluminum	S-drug-ME-1
-	O
or	O
magnesium	S-drug-ME-1
-	O
containing	O
antacids	S-drug
,	O
when	O
administered	O
1	O
hour	O
before	O
SKELID	S-brand-ME-2
.	O

Aspirin	S-brand-ME-1
may	O
decrease	O
bioavailability	O
of	O
SKELID	S-brand-ME-2
by	O
up	O
to	O
50	O
%	O
when	O
taken	O
2	O
hours	O
after	O
SKELID	S-brand
.	O

The	O
bioavailability	O
of	O
SKELID	S-brand-ME-1
is	O
increased	O
2	O
-	O
4	O
fold	O
by	O
indomethacin	S-drug-ME-2
but	O
is	O
not	O
significantly	O
altered	O
by	O
coadministration	O
of	O
diclofenac	S-drug
.	O

The	O
pharmacokinetic	O
parameters	O
of	O
digoxin	S-drug
are	O
not	O
significantly	O
modified	O
by	O
SKELID	S-brand
coadministration	O
.	O

In	O
vitro	O
studies	O
show	O
that	O
tiludronate	S-drug
does	O
not	O
displace	O
warfarin	S-drug
from	O
its	O
binding	O
site	O
on	O
protein	O
.	O

SPIRIVA	S-brand
has	O
been	O
used	O
concomitantly	O
with	O
other	O
drugs	O
commonly	O
used	O
in	O
COPD	O
without	O
increases	O
in	O
adverse	O
drug	O
reactions	O
.	O

These	O
include	O
sympathomimetic	B-group
bronchodilators	E-group
,	O
methylxanthines	S-group
,	O
and	O
oral	O
and	O
inhaled	O
steroids	S-group
.	O

However	O
,	O
the	O
co	O
administration	O
of	O
SPIRIVA	S-brand-AD-1
with	O
other	O
anticholinergic	S-group-AD-2
containing	O
drugs	O
(	O
e.g	O
.	O
,	O
ipratropium	S-drug-AD-2
)	O
has	O
not	O
been	O
studied	O
and	O
is	O
therefore	O
not	O
recommended	O
.	O

AGGRASTAT	S-brand
has	O
been	O
studied	O
on	O
a	O
background	O
of	O
aspirin	S-brand
and	O
heparin	S-drug
.	O

The	O
use	O
of	O
AGGRASTAT	S-brand-EF-1
,	O
in	O
combination	O
with	O
heparin	S-drug-EF-2
and	O
aspirin	S-brand-EF-2
,	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
bleeding	O
compared	O
to	O
heparin	S-drug
and	O
aspirin	S-drug
alone	O
(	O
see	O

In	O
clinical	O
studies	O
of	O
TOBI	S-brand
,	O
patients	O
taking	O
TOBI	S-brand-EF-1
concomitantly	O
with	O
dornase	B-drug-EF-2
alfa	E-drug-EF-2
(	O
PULMOZYME	S-brand-EF-2
,	O
Genentech	O
)	O
,	O
(	B-group-EF-2
beta	I-group-EF-2
)	I-group-EF-2
-	I-group-EF-2
agonists	E-group-EF-2
,	O
inhaled	O
corticosteroids	S-group-EF-2
,	O
other	O
anti	B-group-EF-2
-	I-group-EF-2
pseudomonal	I-group-EF-2
antibiotics	E-group-EF-2
,	O
or	O
parenteral	O
aminoglycosides	S-group-EF-2
demonstrated	O
adverse	O
experience	O
profiles	O
similar	O
to	O
the	O
study	O
population	O
as	O
a	O
whole	O
.	O

Concurrent	O
and	O
/	O
or	O
sequential	O
use	O
of	O
TOBI	S-brand
with	O
other	O
drugs	O
with	O
neurotoxic	O
or	O
ototoxic	O
potential	O
should	O
be	O
avoided	O
.	O

Some	O
diuretics	S-group-EF-1
can	O
enhance	O
aminoglycoside	S-group-EF-2
toxicity	O
by	O
altering	O
antibiotic	S-group
concentrations	O
in	O
serum	O
and	O
tissue	O
.	O

TOBI	S-brand-AD-1
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
ethacrynic	B-drug-AD-2
acid	E-drug-AD-2
,	O
furosemide	S-drug-AD-2
,	O
urea	S-drug-AD-2
,	O
or	O
mannitol	S-drug-AD-2
.	O

The	O
in	O
vitro	O
binding	O
of	O
warfarin	S-drug
to	O
human	O
plasma	O
proteins	O
is	O
unaffected	O
by	O
tolmetin	S-drug
,	O
and	O
tolmetin	S-drug
does	O
not	O
alter	O
the	O
prothrombin	O
time	O
of	O
normal	O
volunteers	O
.	O

However	O
,	O
increased	O
prothrombin	O
time	O
and	O
bleeding	O
have	O
been	O
reported	O
in	O
patients	O
on	O
concomitant	O
TOLECTIN	S-brand-EF-1
and	O
warfarin	S-drug-EF-2
therapy	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TOLECTIN	S-brand-AD-1
to	O
patients	O
on	O
anticoagulants	S-group-AD-2
.	O

In	O
adult	O
diabetic	O
patients	O
under	O
treatment	O
with	O
either	O
sulfonylureas	S-group
or	O
insulin	S-drug
there	O
is	O
no	O
change	O
in	O
the	O
clinical	O
effects	O
of	O
either	O
TOLECTIN	S-brand
or	O
the	O
hypoglycemic	B-group
agents	E-group
.	O

Caution	O
should	O
be	O
used	O
if	O
TOLECTIN	S-brand-AD-1
is	O
administered	O
concomitantly	O
with	O
methotrexate	S-drug-AD-2
.	O

TOLECTIN	S-brand-ME-1
and	O
other	O
nonsteroidal	B-group-ME-1
anti	I-group-ME-1
-	I-group-ME-1
inflammatory	I-group-ME-1
drugs	E-group-ME-1
have	O
been	O
reported	O
to	O
reduce	O
the	O
tubular	O
secretion	O
of	O
methotrexate	S-drug-ME-2
in	O
an	O
animal	O
model	O
,	O
possibly	O
enhancing	O
the	O
toxicity	O
of	O
methotrexate	S-drug
.	O

Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulceration	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
,	O
physicians	O
should	O
follow	O
chronically	O
treated	O
patients	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
ulceration	O
and	O
bleeding	O
and	O
should	O
inform	O
them	O
of	O
the	O
importance	O
of	O
this	O
follow	O
-	O
up	O
.	O

CYP3A4	O
Inhibitors	O
:	O
Ketoconazole	S-drug-ME-1
,	O
an	O
inhibitor	O
of	O
the	O
drug	O
metabolizing	O
enzyme	O
CYP3A4	O
,	O
significantly	O
increased	O
plasma	O
concentrations	O
of	O
tolterodine	S-drug-ME-2
when	O
coadministered	O
to	O
subjects	O
who	O
were	O
poor	O
metabolizers	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Variability	O
in	O
Metabolism	O
and	O
Drug	O
-	O
Drug	O
Interactions	O
)	O
.	O

For	O
patients	O
receiving	O
ketoconazole	S-drug-AD-1
or	O
other	O
potent	O
CYP3A4	O
inhibitors	O
such	O
as	O
other	O
azole	B-group-AD-1
antifungals	E-group-AD-1
(	O
eg	O
,	O
itraconazole	S-drug-AD-1
,	O
miconazole	S-drug-AD-1
)	O
or	O
macrolide	B-group-AD-1
antibiotics	E-group-AD-1
(	O
eg	O
,	O
erythromycin	S-drug-AD-1
,	O
clarithromycin	S-drug-AD-1
)	O
or	O
cyclosporine	S-drug-AD-1
or	O
vinblastine	S-drug-AD-1
,	O
the	O
recommended	O
dose	O
of	O
DETROL	B-brand-AD-2
LA	E-brand-AD-2
is	O
2	O
mg	O
daily	O
.	O

Drug	O
-	O
Laboratory	O
-	O
Test	O
Interactions	O
Interactions	O
between	O
tolterodine	S-drug
and	O
laboratory	O
tests	O
have	O
not	O
been	O
studied	O
.	O

There	O
have	O
been	O
no	O
formal	O
drug	O
interaction	O
studies	O
performed	O
with	O
HERCEPTIN	S-brand
in	O
humans	O
.	O

Administration	O
of	O
paclitaxel	S-drug-ME-1
in	O
combination	O
with	O
HERCEPTIN	S-brand-ME-2
resulted	O
in	O
a	O
two	O
-	O
fold	O
decrease	O
in	O
HERCEPTIN	S-brand
clearance	O
in	O
a	O
non	O
-	O
human	O
primate	O
study	O
and	O
in	O
a	O
1.5	O
-	O
fold	O
increase	O
in	O
HERCEPTIN	S-brand
serum	O
levels	O
in	O
clinical	O
studies	O
.	O

Trilostane	S-drug-IN-1
may	O
interact	O
with	O
aminoglutethimide	S-drug-IN-2
or	O
mitotane	S-drug-IN-2
(	O
causing	O
too	O
great	O
a	O
decrease	O
in	O
adrenal	O
function	O
)	O
.	O

Trimethoprim	S-drug-ME-1
may	O
inhibit	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	S-drug-ME-2
.	O

Trimethoprim	S-drug-ME-1
,	O
given	O
at	O
a	O
common	O
clinical	O
dosage	O
,	O
increased	O
the	O
phenytoin	S-drug-ME-2
half	O
-	O
life	O
by	O
51	O
%	O
and	O
decreased	O
the	O
phenytoin	S-drug-ME-2
metabolic	O
clearance	O
rate	O
by	O
30	O
%	O
.	O

When	O
administering	O
these	O
drugs	O
concurrently	O
,	O
one	O
should	O
be	O
alert	O
for	O
possible	O
excessive	O
phenytoin	S-drug
effect	O
.	O

Since	O
trimetrexate	S-drug
is	O
metabolized	O
by	O
a	O
P450	O
enzyme	O
system	O
,	O
drugs	O
that	O
induce	O
or	O
inhibit	O
this	O
drug	O
metabolizing	O
enzyme	O
system	O
may	O
elicit	O
important	O
drug	O
-	O
drug	O
interactions	O
that	O
may	O
alter	O
trimetrexate	S-drug
plasma	O
concentrations	O
.	O

Agents	O
that	O
might	O
be	O
coadministered	O
with	O
trimetrexate	S-drug-EF-1
in	O
AIDS	O
patients	O
for	O
other	O
indications	O
that	O
could	O
elicit	O
this	O
activity	O
include	O
erythromycin	S-drug-EF-2
,	O
rifampin	S-drug-EF-2
,	O
rifabutin	S-drug-EF-2
,	O
ketoconazole	S-drug-EF-2
,	O
and	O
fluconazole	S-drug-EF-2
.	O

In	O
vitro	O
perfusion	O
of	O
isolated	O
rat	O
liver	O
has	O
shown	O
that	O
cimetidine	S-drug-ME-1
caused	O
a	O
significant	O
reduction	O
in	O
trimetrexate	S-drug-ME-2
metabolism	O
and	O
that	O
acetaminophen	S-drug
altered	O
the	O
relative	O
concentration	O
of	O
trimetrexate	O
metabolites	O
possibly	O
by	O
competing	O
for	O
sulfate	O
metabolites	O
.	O

Based	O
on	O
an	O
in	O
vitro	O
rat	O
liver	O
model	O
,	O
nitrogen	O
substituted	O
imidazole	B-group-ME-1
drugs	E-group-ME-1
(	O
clotrimazole	S-drug-ME-1
,	O
ketoconazole	S-drug-ME-1
,	O
miconazole	S-drug-ME-1
)	O
were	O
potent	O
,	O
non	O
-	O
competitive	O
inhibitors	O
of	O
trimetrexate	S-drug-ME-2
metabolism	O
.	O

Patients	O
medicated	O
with	O
these	O
drugs	O
and	O
trimetrexate	S-drug
should	O
be	O
carefully	O
monitored	O
.	O

Triprolidine	S-drug-EF-1
may	O
enhance	O
the	O
sedative	O
effects	O
of	O
central	B-group-EF-2
nervous	I-group-EF-2
system	I-group-EF-2
depressants	E-group-EF-2
including	O
alcohol	S-drug-EF-2
,	O
barbiturates	S-group-EF-2
,	O
hypnotics	S-group-EF-2
,	O
narcotic	B-group-EF-2
analgesics	E-group-EF-2
,	O
sedatives	S-group-EF-2
,	O
and	O
tranquillisers	S-group-EF-2
.	O

The	O
effects	O
of	O
anticholinergic	B-group-EF-1
drugs	E-group-EF-1
,	O
such	O
as	O
atropine	S-drug-EF-1
and	O
tricyclic	B-group-EF-1
antidepressants	E-group-EF-1
may	O
be	O
enhanced	O
by	O
the	O
concomitant	O
administration	O
of	O
triprolidine	S-drug-EF-2
.	O

Triprolidine	S-drug
may	O
effect	O
the	O
metabolism	O
of	O
drugs	O
in	O
the	O
liver	O
.	O

The	O
concomitant	O
use	O
of	O
Sanctura	S-brand-EF-1
with	O
other	O
anticholinergic	B-group-EF-2
agents	E-group-EF-2
that	O
produce	O
dry	O
mouth	O
,	O
constipation	O
,	O
and	O
other	O
anticholinergic	O
pharmacological	O
effects	O
may	O
increase	O
the	O
frequency	O
and	O
/	O
or	O
severity	O
of	O
such	O
effects	O
.	O

Anticholinergic	B-group
agents	E-group
may	O
potentially	O
alter	O
the	O
absorption	O
of	O
some	O
concomitantly	O
administered	O
drugs	O
due	O
to	O
anticholinergic	O
effects	O
on	O
gastrointestinal	O
motility	O
.	O

Drugs	O
Eliminated	O
by	O
Active	O
Tubular	O
Secretion	O
:	O
Although	O
studies	O
to	O
assess	O
drug	O
-	O
drug	O
interactions	O
with	O
Sanctura	S-brand
have	O
not	O
been	O
conducted	O
,	O
Sanctura	S-brand-ME-1
has	O
the	O
potential	O
for	O
pharmacokinetic	O
interactions	O
with	O
other	O
drugs	O
that	O
are	O
eliminated	O
by	O
active	O
tubular	O
secretion	O
(	O
e.g	O
.	O
digoxin	S-drug-ME-2
,	O
procainamide	S-drug-ME-2
,	O
pancuronium	S-drug-ME-2
,	O
morphine	S-drug-ME-2
,	O
vancomycin	S-drug-ME-2
,	O
metformin	S-drug-ME-2
and	O
tenofovir	S-drug-ME-2
)	O
.	O

Coadministration	O
of	O
Sanctura	S-brand
with	O
drugs	O
that	O
are	O
eliminated	O
by	O
active	O
renal	O
tubular	O
secretion	O
may	O
increase	O
the	O
serum	O
concentration	O
of	O
Sanctura	S-brand
and	O
/	O
or	O
the	O
coadministered	O
drug	O
due	O
to	O
competition	O
for	O
this	O
elimination	O
pathway	O
.	O

Careful	O
patient	O
monitoring	O
is	O
recommended	O
in	O
patients	O
receiving	O
such	O
drugs	O
.	O

Drug	O
-	O
Laboratory	O
-	O
Test	O
Interactions	O
Interactions	O
between	O
Sanctura	S-brand
and	O
laboratory	O
tests	O
have	O
not	O
been	O
studied	O
.	O

Concomitant	O
administration	O
of	O
vancomycin	S-drug-EF-1
and	O
anesthetic	B-group-EF-2
agents	E-group-EF-2
has	O
been	O
associated	O
with	O
erythema	O
and	O
histamine	O
-	O
like	O
flushing	O
and	O
anaphylactoid	O
reactions	O
.	O

Concurrent	O
and	O
/	O
or	O
sequential	O
systemic	O
or	O
topical	O
use	O
of	O
other	O
potentially	O
neurotoxic	O
and	O
/	O
or	O
nephrotoxic	O
drugs	O
,	O
such	O
as	O
amphotericin	B-drug
B	E-drug
,	O
aminoglycosides	S-group
,	O
bacitracin	S-drug
,	O
polymyxin	B-drug
B	E-drug
,	O
colistin	S-drug
,	O
viomycin	S-drug
,	O
or	O
cisplatin	S-drug
,	O
when	O
indicated	O
,	O
requires	O
careful	O
monitoring	O
.	O

A	O
study	O
published	O
in	O
2002	O
found	O
that	O
vigabatrin	S-drug-ME-1
causes	O
a	O
statistically	O
significant	O
increase	O
in	O
plasma	O
clearance	O
of	O
carbamazepine	S-drug-ME-2
.	O

In	O
1984	O
,	O
Drs	O
Rimmer	O
and	O
Richens	O
at	O
the	O
University	O
of	O
Wales	O
reported	O
that	O
administering	O
vigabatrin	S-drug-ME-1
with	O
phenytoin	S-drug-ME-2
lowered	O
the	O
serum	O
phenytoin	S-drug
concentration	O
in	O
patients	O
with	O
treatment	O
-	O
resistant	O
epilepsy	O
.	O

The	O
concentration	O
of	O
phenytoin	S-drug
falls	O
to	O
23	O
%	O
within	O
five	O
weeks	O
,	O
according	O
to	O
an	O
experiment	O
published	O
in	O
1989	O
by	O
the	O
same	O
two	O
scientists	O
that	O
tried	O
and	O
failed	O
to	O
elucidate	O
the	O
mechanism	O
behind	O
this	O
interaction	O
.	O

Vindesine	S-drug-IN-1
can	O
interact	O
with	O
the	O
drugs	O
of	O
the	O
following	O
categories	O
:	O
-	O
Blood	O
dyscrasia	O
:	O
can	O
cause	O
unpredictable	O
myelotoxicity	O
-	O
Bone	O
marrow	O
depressants	O
:	O
can	O
cause	O
a	O
predictable	O
dose	O
-	O
related	O
myelotoxicity	O
-	O
Radiation	O
therapy	O
:	O
may	O
cause	O
marrow	O
depression	O
-	O
Neurotoxic	O
medications	O
:	O
can	O
cause	O
neurologic	O
toxicity	O
-	O
Phenytoin	S-drug-IN-2
:	O
can	O
increase	O
seizure	O
activity	O
-	O
Live	B-group-IN-2
virus	I-group-IN-2
vaccines	E-group-IN-2
:	O
may	O
potentiate	O
the	O
replication	O
of	O
the	O
vaccine	S-drug
virus	O
,	O
may	O
increase	O
the	O
side	O
effects	O
of	O
the	O
vaccination	O
,	O
and	O
decrease	O
patient	O
's	O
response	O
to	O
the	O
vaccine	O
-	O
Mitomycin	B-drug-IN-2
-	I-drug-IN-2
C	E-drug-IN-2
:	O
may	O
cause	O
shortness	O
of	O
breath	O
and	O
bronchospasm	O
-	O
Killed	B-group-IN-2
virus	I-group-IN-2
vaccines	E-group-IN-2
:	O
may	O
decrease	O
patient	O
's	O
response	O
to	O
the	O
vaccine	S-group

Drug	O
Interactions	O
:	O
Women	O
on	O
oral	O
contraceptives	S-group-ME-1
have	O
shown	O
a	O
significant	O
increase	O
in	O
plasma	O
vitamin	B-group-ME-2
A	E-group-ME-2
levels	O
.	O

Limited	O
evidence	O
suggests	O
that	O
ascorbic	B-drug-ME-1
acid	E-drug-ME-1
may	O
influence	O
the	O
intensity	O
and	O
duration	O
of	O
action	O
of	O
bishydroxycoumarin	S-drug-ME-2
.	O

Coumarin	B-group
-	I-group
Derivative	I-group
Anticoagulants	E-group
:	O
Prolongation	O
of	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
were	O
observed	O
in	O
patients	O
receiving	O
ZOLINZA	S-brand-EF-1
concomitantly	O
with	O
coumarin	B-group-EF-2
-	I-group-EF-2
derivative	I-group-EF-2
anticoagulants	E-group-EF-2
.	O

Physicians	O
should	O
carefully	O
monitor	O
PT	O
and	O
INR	O
in	O
patients	O
concurrently	O
administered	O
ZOLINZA	S-brand-AD-1
and	O
coumarin	B-group-AD-2
derivatives	E-group-AD-2
.	O

Other	O
HDAC	B-group
Inhibitors	E-group
Severe	O
thrombocytopenia	O
and	O
gastrointestinal	O
bleeding	O
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
ZOLINZA	S-brand-EF-1
and	O
other	O
HDAC	B-group-EF-2
inhibitors	E-group-EF-2
(	O
e.g	O
.	O
,	O
valproic	B-drug-EF-2
acid	E-drug-EF-2
)	O
.	O

Monitor	O
platelet	O
count	O
every	O
2	O
weeks	O
for	O
the	O
first	O
2	O
months	O
.	O

Metabotropic	O
glutamate	O
receptor	O
5	O
antagonist	O
protects	O
dopaminergic	O
and	O
noradrenergic	O
neurons	O
from	O
degeneration	O
in	O
MPTP	S-drug_n
-	O
treated	O
monkeys	O
.	O

Degeneration	O
of	O
the	O
dopaminergic	O
nigrostriatal	O
system	O
and	O
of	O
noradrenergic	O
neurons	O
in	O
the	O
locus	O
coeruleus	O
are	O
important	O
pathological	O
features	O
of	O
Parkinson	O
's	O
disease	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
therapies	O
that	O
slow	O
down	O
the	O
progression	O
of	O
neurodegeneration	O
in	O
Parkinson	O
's	O
disease	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
tested	O
whether	O
the	O
highly	O
specific	O
metabotropic	O
glutamate	O
receptor	O
5	O
antagonist	O
,	O
3	B-drug_n
-	I-drug_n
[	I-drug_n
(	I-drug_n
2	I-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
1,3	I-drug_n
-	I-drug_n
thiazol	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
yl	I-drug_n
)	I-drug_n
ethynyl	I-drug_n
]	I-drug_n
pyridine	E-drug_n
,	O
reduces	O
dopaminergic	O
and	O
noradrenergic	O
neuronal	O
loss	O
in	O
monkeys	O
rendered	O
parkinsonian	O
by	O
chronic	O
treatment	O
with	O
low	O
doses	O
of	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
.	O

Weekly	O
intramuscular	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
injections	O
(	O
0.2	O
-	O
0.5	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
,	O
in	O
combination	O
with	O
daily	O
administration	O
of	O
3	B-drug_n
-	I-drug_n
[	I-drug_n
(	I-drug_n
2	I-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
1,3	I-drug_n
-	I-drug_n
thiazol	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
yl	I-drug_n
)	I-drug_n
ethynyl	I-drug_n
]	I-drug_n
pyridine	E-drug_n
or	O
vehicle	O
,	O
were	O
performed	O
until	O
the	O
development	O
of	O
parkinsonian	O
motor	O
symptoms	O
in	O
either	O
of	O
the	O
two	O
experimental	O
groups	O
(	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
/	O
3	B-drug_n
-	I-drug_n
[	I-drug_n
(	I-drug_n
2	I-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
1,3	I-drug_n
-	I-drug_n
thiazol	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
yl	I-drug_n
)	I-drug_n
ethynyl	I-drug_n
]	I-drug_n
pyridine	E-drug_n
versus	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
/	O
vehicle	O
)	O
.	O

After	O
21	O
weeks	O
of	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
treatment	O
,	O
all	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
/	O
vehicle	O
-	O
treated	O
animals	O
displayed	O
parkinsonian	O
symptoms	O
,	O
whereas	O
none	O
of	O
the	O
1	B-drug_n-EF-1
-	I-drug_n-EF-1
methyl	I-drug_n-EF-1
-	I-drug_n-EF-1
4	I-drug_n-EF-1
-	I-drug_n-EF-1
phenyl	I-drug_n-EF-1
-	I-drug_n-EF-1
1,2,3,6	I-drug_n-EF-1
-	I-drug_n-EF-1
tetrahydropyridine	E-drug_n-EF-1
/	O
3	B-drug_n-EF-2
-	I-drug_n-EF-2
[	I-drug_n-EF-2
(	I-drug_n-EF-2
2	I-drug_n-EF-2
-	I-drug_n-EF-2
methyl	I-drug_n-EF-2
-	I-drug_n-EF-2
1,3	I-drug_n-EF-2
-	I-drug_n-EF-2
thiazol	I-drug_n-EF-2
-	I-drug_n-EF-2
4	I-drug_n-EF-2
-	I-drug_n-EF-2
yl	I-drug_n-EF-2
)	I-drug_n-EF-2
ethynyl	I-drug_n-EF-2
]	I-drug_n-EF-2
pyridine	E-drug_n-EF-2
-	O
treated	O
monkeys	O
were	O
significantly	O
affected	O
.	O

These	O
behavioural	O
observations	O
were	O
consistent	O
with	O
in	O
vivo	O
positron	O
emission	O
tomography	O
dopamine	O
transporter	O
imaging	O
data	O
,	O
and	O
with	O
post	O
-	O
mortem	O
stereological	O
counts	O
of	O
midbrain	O
dopaminergic	O
neurons	O
,	O
as	O
well	O
as	O
striatal	O
intensity	O
measurements	O
of	O
dopamine	O
transporter	O
and	O
tyrosine	O
hydroxylase	O
immunoreactivity	O
,	O
which	O
were	O
all	O
significantly	O
higher	O
in	O
1	B-drug_n-EF-1
-	I-drug_n-EF-1
methyl	I-drug_n-EF-1
-	I-drug_n-EF-1
4	I-drug_n-EF-1
-	I-drug_n-EF-1
phenyl	I-drug_n-EF-1
-	I-drug_n-EF-1
1,2,3,6	I-drug_n-EF-1
-	I-drug_n-EF-1
tetrahydropyridine	E-drug_n-EF-1
/	O
3	B-drug_n-EF-2
-	I-drug_n-EF-2
[	I-drug_n-EF-2
(	I-drug_n-EF-2
2	I-drug_n-EF-2
-	I-drug_n-EF-2
methyl	I-drug_n-EF-2
-	I-drug_n-EF-2
1,3	I-drug_n-EF-2
-	I-drug_n-EF-2
thiazol	I-drug_n-EF-2
-	I-drug_n-EF-2
4	I-drug_n-EF-2
-	I-drug_n-EF-2
yl	I-drug_n-EF-2
)	I-drug_n-EF-2
ethynyl	I-drug_n-EF-2
]	I-drug_n-EF-2
pyridine	E-drug_n-EF-2
-	O
treated	O
animals	O
than	O
in	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
/	O
vehicle	O
-	O
treated	O
monkeys	O
.	O

The	O
3	B-drug_n-EF-1
-	I-drug_n-EF-1
[	I-drug_n-EF-1
(	I-drug_n-EF-1
2	I-drug_n-EF-1
-	I-drug_n-EF-1
methyl	I-drug_n-EF-1
-	I-drug_n-EF-1
1,3	I-drug_n-EF-1
-	I-drug_n-EF-1
thiazol	I-drug_n-EF-1
-	I-drug_n-EF-1
4	I-drug_n-EF-1
-	I-drug_n-EF-1
yl	I-drug_n-EF-1
)	I-drug_n-EF-1
ethynyl	I-drug_n-EF-1
]	I-drug_n-EF-1
pyridine	E-drug_n-EF-1
treatment	O
also	O
had	O
a	O
significant	O
effect	O
on	O
the	O
1	B-drug_n-EF-2
-	I-drug_n-EF-2
methyl	I-drug_n-EF-2
-	I-drug_n-EF-2
4	I-drug_n-EF-2
-	I-drug_n-EF-2
phenyl	I-drug_n-EF-2
-	I-drug_n-EF-2
1,2,3,6	I-drug_n-EF-2
-	I-drug_n-EF-2
tetrahydropyridine	E-drug_n-EF-2
-	O
induced	O
loss	O
of	O
norepinephrine	O
neurons	O
in	O
the	O
locus	O
coeruleus	O
and	O
adjoining	O
A5	O
and	O
A7	O
noradrenaline	O
cell	O
groups	O
.	O

In	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,6	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
/	O
vehicle	O
-	O
treated	O
animals	O
,	O
almost	O
40	O
%	O
loss	O
of	O
tyrosine	O
hydroxylase	O
-	O
positive	O
norepinephrine	O
neurons	O
was	O
found	O
in	O
locus	O
coeruleus	O
/	O
A5	O
/	O
A7	O
noradrenaline	O
cell	O
groups	O
,	O
whereas	O
the	O
extent	O
of	O
neuronal	O
loss	O
was	O
lower	O
than	O
15	O
%	O
of	O
control	O
values	O
in	O
1	B-drug_n-EF-1
-	I-drug_n-EF-1
methyl	I-drug_n-EF-1
-	I-drug_n-EF-1
4	I-drug_n-EF-1
-	I-drug_n-EF-1
phenyl	I-drug_n-EF-1
-	I-drug_n-EF-1
1,2,3,6	I-drug_n-EF-1
-	I-drug_n-EF-1
tetrahydropyridine	E-drug_n-EF-1
/	O
3	B-drug_n-EF-2
-	I-drug_n-EF-2
[	I-drug_n-EF-2
(	I-drug_n-EF-2
2	I-drug_n-EF-2
-	I-drug_n-EF-2
methyl	I-drug_n-EF-2
-	I-drug_n-EF-2
1,3	I-drug_n-EF-2
-	I-drug_n-EF-2
thiazol	I-drug_n-EF-2
-	I-drug_n-EF-2
4	I-drug_n-EF-2
-	I-drug_n-EF-2
yl	I-drug_n-EF-2
)	I-drug_n-EF-2
ethynyl	I-drug_n-EF-2
]	I-drug_n-EF-2
pyridine	E-drug_n-EF-2
-	O
treated	O
monkeys	O
.	O

Our	O
data	O
demonstrate	O
that	O
chronic	O
treatment	O
with	O
the	O
metabotropic	O
glutamate	O
receptor	O
5	O
antagonist	O
,	O
3	B-drug_n-EF-1
-	I-drug_n-EF-1
[	I-drug_n-EF-1
(	I-drug_n-EF-1
2	I-drug_n-EF-1
-	I-drug_n-EF-1
methyl	I-drug_n-EF-1
-	I-drug_n-EF-1
1,3	I-drug_n-EF-1
-	I-drug_n-EF-1
thiazol	I-drug_n-EF-1
-	I-drug_n-EF-1
4	I-drug_n-EF-1
-	I-drug_n-EF-1
yl	I-drug_n-EF-1
)	I-drug_n-EF-1
ethynyl	I-drug_n-EF-1
]	I-drug_n-EF-1
pyridine	E-drug_n-EF-1
,	O
significantly	O
reduces	O
1	B-drug_n-EF-2
-	I-drug_n-EF-2
methyl	I-drug_n-EF-2
-	I-drug_n-EF-2
4	I-drug_n-EF-2
-	I-drug_n-EF-2
phenyl	I-drug_n-EF-2
-	I-drug_n-EF-2
1,2,3,6	I-drug_n-EF-2
-	I-drug_n-EF-2
tetrahydropyridine	E-drug_n-EF-2
toxicity	O
towards	O
dopaminergic	O
and	O
noradrenergic	O
cell	O
groups	O
in	O
non	O
-	O
human	O
primates	O
.	O

This	O
suggests	O
that	O
the	O
use	O
of	O
metabotropic	O
glutamate	O
receptor	O
5	O
antagonists	O
may	O
be	O
a	O
useful	O
strategy	O
to	O
reduce	O
degeneration	O
of	O
catecholaminergic	O
neurons	O
in	O
Parkinson	O
's	O
disease	O
.	O

Effect	O
of	O
ketoconazole	S-drug
-	O
mediated	O
CYP3A4	O
inhibition	O
on	O
clinical	O
pharmacokinetics	O
of	O
panobinostat	S-drug
(	O
LBH589	S-drug
)	O
,	O
an	O
orally	O
active	O
histone	B-group
deacetylase	I-group
inhibitor	E-group
.	O

Panobinostat	S-drug
is	O
partly	O
metabolized	O
by	O
CYP3A4	O
in	O
vitro	O
.	O

This	O
study	O
evaluated	O
the	O
effect	O
of	O
a	O
potent	O
CYP3A	O
inhibitor	O
,	O
ketoconazole	S-drug
,	O
on	O
the	O
pharmacokinetics	O
and	O
safety	O
of	O
panobinostat	S-drug
.	O

Patients	O
received	O
a	O
single	O
panobinostat	S-drug
oral	O
dose	O
on	O
day	O
1	O
,	O
followed	O
by	O
4	O
days	O
wash	O
-	O
out	O
period	O
.	O

On	O
days	O
5	O
-	O
9	O
,	O
ketoconazole	S-drug
was	O
administered	O
.	O

On	O
day	O
8	O
,	O
a	O
single	O
panobinostat	S-drug
dose	O
was	O
co	O
-	O
administered	O
with	O
ketoconazole	S-drug
.	O

Panobinostat	S-drug
was	O
administered	O
as	O
single	O
agent	O
three	O
times	O
a	O
week	O
on	O
day	O
15	O
and	O
onward	O
.	O

In	O
the	O
presence	O
of	O
ketoconazole	S-drug-ME-1
,	O
there	O
was	O
1.6	O
-	O
and	O
1.8	O
-	O
fold	O
increase	O
in	O
C	O
(	O
max	O
)	O
and	O
AUC	O
of	O
panobinostat	S-drug-ME-2
,	O
respectively	O
.	O

No	O
substantial	O
change	O
in	O
T	O
(	O
max	O
)	O
or	O
half	O
-	O
life	O
was	O
observed	O
.	O

No	O
difference	O
in	O
panobinostat	S-drug
-	O
pharmacokinetics	O
between	O
patients	O
carrying	O
CYP3A5	O
*	O
1	O
/	O
*	O
3	O
and	O
CYP3A5	O
*	O
3	O
/	O
*	O
3	O
alleles	O
was	O
observed	O
.	O

Most	O
frequently	O
reported	O
adverse	O
events	O
were	O
gastrointestinal	O
related	O
.	O

Patients	O
had	O
asymptomatic	O
hypophosphatemia	O
(	O
64	O
%	O
)	O
,	O
and	O
urine	O
analysis	O
suggested	O
renal	O
phosphate	O
wasting	O
.	O

Co	O
-	O
administration	O
of	O
panobinostat	S-drug
with	O
CYP3A	O
inhibitors	O
is	O
feasible	O
as	O
the	O
observed	O
increase	O
in	O
panobinostat	S-drug
PK	O
parameters	O
was	O
not	O
considered	O
clinically	O
relevant	O
.	O

Considering	O
the	O
variability	O
in	O
exposure	O
following	O
enzyme	O
inhibition	O
and	O
the	O
fact	O
that	O
chronic	O
dosing	O
of	O
panobinostat	S-drug
was	O
not	O
studied	O
with	O
CYP3A	O
inhibitors	O
,	O
close	O
monitoring	O
of	O
panobinostat	S-drug
-	O
related	O
adverse	O
events	O
is	O
necessary	O
.	O

Interaction	O
study	O
of	O
moxifloxacin	S-drug
and	O
lomefloxacin	S-drug
with	O
co	O
-	O
administered	O
drugs	O
.	O

Moxifloxacin	S-drug
and	O
lomefloxacin	S-drug
are	O
fluoroquinolone	B-group
antibiotics	E-group
used	O
in	O
treating	O
urinary	O
and	O
respiratory	O
tract	O
infections	O
.	O

Fluoroquinolones	S-group
are	O
known	O
to	O
have	O
interactions	O
with	O
drugs	O
that	O
are	O
active	O
in	O
gastro	O
intestinal	O
tract	O
.	O

Being	O
moxifloxacin	S-drug
and	O
lomefloxacin	O
fluoroquinolones	S-group
the	O
interaction	O
study	O
of	O
was	O
carried	O
out	O
with	O
sucralfate	S-drug
,	O
gelusil	S-brand
,	O
erythromycin	S-drug
and	O
multi	B-group
minerals	E-group
.	O

The	O
interaction	O
was	O
studied	O
at	O
neutral	O
,	O
acidic	O
and	O
basic	O
conditions	O
both	O
at	O
room	O
temperature	O
and	O
37	O
C	O
.	O

The	O
effect	O
of	O
dissolution	O
medium	O
simulating	O
various	O
body	O
environments	O
with	O
response	O
to	O
pH	O
has	O
been	O
examined	O
in	O
order	O
to	O
elucidate	O
the	O
interactions	O
.	O

The	O
response	O
of	O
moxifloxacin	S-drug
and	O
lomefloxacin	S-drug
after	O
interaction	O
with	O
co	O
-	O
administered	O
drugs	O
at	O
different	O
conditions	O
and	O
temperature	O
were	O
noted	O
using	O
a	O
Shimadzu	O
HPLC	O
system	O
with	O
PDA	O
detector	O
.	O

It	O
was	O
seen	O
that	O
interaction	O
of	O
these	O
fluoroquinolones	S-group
was	O
more	O
at	O
37	O
C	O
than	O
at	O
room	O
temperature	O
.	O

Moxifloxacin	S-drug-ME-1
and	O
Lomefloxacin	S-drug-ME-1
reacts	O
faster	O
with	O
sucralfate	S-drug-ME-2
and	O
gelusil	S-brand-ME-2
in	O
acidic	O
media	O
whereas	O
with	O
erythromycin	S-drug-ME-2
in	O
basic	O
media	O
and	O
multi	B-group-ME-2
-	I-group-ME-2
minerals	E-group-ME-2
in	O
neutral	O
media	O
.	O

The	O
study	O
ensures	O
the	O
interaction	O
of	O
fluoroquinolones	S-group
with	O
selected	O
class	O
of	O
drugs	O
.	O

In	O
order	O
to	O
achieve	O
the	O
effective	O
therapeutic	O
effect	O
appropriate	O
time	O
intervals	O
between	O
administrations	O
of	O
drugs	O
is	O
essential	O
.	O

Exposure	O
to	O
oral	O
S	B-drug-EF-1
-	I-drug-EF-1
ketamine	E-drug-EF-1
is	O
unaffected	O
by	O
itraconazole	S-drug
but	O
greatly	O
increased	O
by	O
ticlopidine	S-drug-EF-2
.	O

This	O
study	O
examined	O
drug	O
-	O
drug	O
interactions	O
of	O
oral	O
S	B-drug
-	I-drug
ketamine	E-drug
with	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
2B6	O
inhibitor	O
ticlopidine	S-drug
and	O
the	O
CYP3A	O
inhibitor	O
itraconazole	S-drug
.	O

In	O
this	O
randomized	O
,	O
blinded	O
,	O
crossover	O
study	O
,	O
11	O
healthy	O
volunteers	O
ingested	O
0.2	O
mg	O
/	O
kg	O
S	B-drug
-	I-drug
ketamine	E-drug
after	O
pretreatments	O
with	O
oral	O
ticlopidine	S-drug
(	O
250	O
mg	O
twice	O
daily	O
)	O
,	O
itraconazole	S-drug
(	O
200	O
mg	O
once	O
daily	O
)	O
,	O
or	O
placebo	O
in	O
6	O
-	O
day	O
treatment	O
periods	O
at	O
intervals	O
of	O
4	O
weeks	O
.	O

Ticlopidine	S-drug-ME-1
treatment	O
increased	O
the	O
mean	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
extrapolated	O
to	O
infinity	O
(	O
AUC	O
(	O
0	O
-	O
)	O
)	O
of	O
oral	O
ketamine	S-drug-ME-2
by	O
2.4	O
-	O
fold	O
,	O
whereas	O
itraconazole	S-drug
treatment	O
did	O
not	O
increase	O
the	O
exposure	O
to	O
S	B-drug
-	I-drug
ketamine	E-drug
.	O

The	O
ratio	O
of	O
norketamine	S-drug_n
AUC	O
(	O
0	O
-	O
)	O
to	O
ketamine	S-drug
AUC	O
(	O
0	O
-	O
)	O
was	O
significantly	O
decreased	O
in	O
the	O
ticlopidine	S-drug
(	O
P	O
&	O
lt	O
;	O
0.001	O
)	O
and	O
itraconazole	S-drug
phases	O
(	O
P	O
=	O
0.006	O
)	O
as	O
compared	O
to	O
placebo	O
.	O

In	O
the	O
ticlopidine	S-drug
and	O
itraconazole	S-drug
phases	O
,	O
the	O
areas	O
under	O
the	O
effect	O
-	O
time	O
curves	O
(	O
self	O
-	O
reported	O
drowsiness	O
and	O
performance	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
placebo	O
phase	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
dosage	O
of	O
S	B-drug-AD-1
-	I-drug-AD-1
ketamine	E-drug-AD-1
should	O
be	O
reduced	O
in	O
patients	O
receiving	O
ticlopidine	S-drug-AD-2
.	O

Determinants	O
of	O
sensitivity	O
to	O
DZNep	S-drug_n
induced	O
apoptosis	O
in	O
multiple	O
myeloma	O
cells	O
.	O

The	O
3	B-drug_n
-	I-drug_n
Deazaneplanocin	I-drug_n
A	E-drug_n
(	O
DZNep	S-drug_n
)	O
,	O
one	O
of	O
S	O
-	O
adenosylhomocysteine	O
(	O
AdoHcy	O
)	O
hydrolase	O
inhibitors	O
,	O
has	O
shown	O
antitumor	O
activities	O
in	O
a	O
broad	O
range	O
of	O
solid	O
tumors	O
and	O
acute	O
myeloid	O
leukemia	O
.	O

Here	O
,	O
we	O
examined	O
its	O
effects	O
on	O
multiple	O
myeloma	O
(	O
MM	O
)	O
cells	O
and	O
found	O
that	O
,	O
at	O
500	O
nM	O
,	O
it	O
potently	O
inhibited	O
growth	O
and	O
induced	O
apoptosis	O
in	O
2	O
of	O
8	O
MM	O
cell	O
lines	O
.	O

RNA	O
from	O
un	O
-	O
treated	O
and	O
DZNep	S-drug_n
treated	O
cells	O
was	O
profiled	O
by	O
Affymetrix	O
HG	O
-	O
U133	O
Plus	O
2.0	O
microarray	O
and	O
genes	O
with	O
a	O
significant	O
change	O
in	O
gene	O
expression	O
were	O
determined	O
by	O
significance	O
analysis	O
of	O
microarray	O
(	O
SAM	O
)	O
testing	O
.	O

ALOX5	O
was	O
the	O
most	O
down	O
-	O
regulated	O
gene	O
(	O
5.8	O
-	O
fold	O
)	O
in	O
sensitive	O
cells	O
and	O
was	O
expressed	O
at	O
low	O
level	O
in	O
resistant	O
cells	O
.	O

The	O
results	O
were	O
corroborated	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Western	O
-	O
blot	O
analysis	O
indicated	O
ALOX5	O
was	O
highly	O
expressed	O
only	O
in	O
sensitive	O
cell	O
line	O
H929	O
and	O
greatly	O
decreased	O
upon	O
DZNep	S-drug_n
treatment	O
.	O

Ectopic	O
expression	O
of	O
ALOX5	O
reduced	O
sensitivity	O
to	O
DZNep	S-drug_n
in	O
H929	O
cells	O
.	O

Furthermore	O
,	O
down	O
-	O
regulation	O
of	O
ALOX5	O
by	O
RNA	O
interference	O
could	O
also	O
induce	O
apoptosis	O
in	O
H929	O
.	O

Gene	O
expression	O
analysis	O
on	O
MM	O
patient	O
dataset	O
indicated	O
ALOX5	O
expression	O
was	O
significantly	O
higher	O
in	O
MM	O
patients	O
compared	O
to	O
normal	O
plasma	O
cells	O
.	O

We	O
also	O
found	O
that	O
Bcl	O
-	O
2	O
was	O
overexpressed	O
in	O
DZNep	S-drug_n
insensitive	O
cells	O
,	O
and	O
cotreatment	O
with	O
DZNep	S-drug_n-EF-1
and	O
ABT	B-drug_n-EF-2
-	I-drug_n-EF-2
737	E-drug_n-EF-2
,	O
a	O
Bcl	O
-	O
2	O
family	O
inhibitor	O
,	O
synergistically	O
inhibited	O
growth	O
and	O
induced	O
apoptosis	O
of	O
DZNep	S-drug_n
insensitive	O
MM	O
cells	O
.	O

Taken	O
together	O
,	O
this	O
study	O
shows	O
one	O
of	O
mechanisms	O
of	O
the	O
DZNep	S-drug_n
efficacy	O
on	O
MM	O
correlates	O
with	O
its	O
ability	O
to	O
down	O
-	O
regulate	O
the	O
ALOX5	O
levels	O
.	O

In	O
addition	O
,	O
DZNep	S-drug_n
insensitivity	O
might	O
be	O
associated	O
with	O
overexpression	O
of	O
Bcl	O
-	O
2	O
,	O
and	O
the	O
combination	O
of	O
ABT	B-drug_n-EF-1
-	I-drug_n-EF-1
737	E-drug_n-EF-1
and	O
DZNep	S-drug_n-EF-2
could	O
synergistically	O
induced	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
DZNep	S-drug_n
may	O
be	O
exploited	O
therapeutically	O
for	O
a	O
subset	O
of	O
MM	O
.	O

Implanon	S-brand-EF-1
failure	O
in	O
an	O
HIV	O
-	O
positive	O
woman	O
on	O
antiretroviral	S-group-EF-2
therapy	O
resulting	O
in	O
two	O
ectopic	O
pregnancies	O
.	O

Since	O
its	O
introduction	O
in	O
1999	O
,	O
Implanon	S-brand
remains	O
one	O
of	O
the	O
preferred	O
contraceptive	O
choices	O
for	O
many	O
women	O
as	O
it	O
offers	O
a	O
highly	O
effective	O
means	O
of	O
long	O
-	O
term	O
contraception	O
for	O
three	O
years	O
that	O
does	O
not	O
rely	O
on	O
adherence	O
.	O

Like	O
all	O
hormonal	B-group
contraceptives	E-group
,	O
certain	O
hepatic	O
enzyme	O
-	O
inducing	O
drugs	O
may	O
reduce	O
its	O
efficacy	O
.	O

We	O
present	O
an	O
interesting	O
case	O
of	O
an	O
HIV	O
-	O
positive	O
woman	O
on	O
antiretroviral	S-group-EF-1
therapy	O
having	O
tubal	O
pregnancies	O
on	O
two	O
separate	O
occasions	O
with	O
Implanon	S-brand-EF-2
in	O
place	O
.	O

Antidepressant	S-group
-	O
warfarin	S-drug
interaction	O
and	O
associated	O
gastrointestinal	O
bleeding	O
risk	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

Bleeding	O
is	O
the	O
most	O
common	O
and	O
worrisome	O
adverse	O
effect	O
of	O
warfarin	S-drug
therapy	O
.	O

One	O
of	O
the	O
factors	O
that	O
might	O
increase	O
bleeding	O
risk	O
is	O
initiation	O
of	O
interacting	O
drugs	O
that	O
potentiate	O
warfarin	S-drug
.	O

We	O
sought	O
to	O
evaluate	O
whether	O
initiation	O
of	O
an	O
antidepressant	S-group
increases	O
the	O
risk	O
of	O
hospitalization	O
for	O
gastrointestinal	O
bleeding	O
in	O
warfarin	S-drug
users	O
.	O

Medicaid	O
claims	O
data	O
(	O
1999	O
-	O
2005	O
)	O
were	O
used	O
to	O
perform	O
an	O
observational	O
case	O
-	O
control	O
study	O
nested	O
within	O
person	O
-	O
time	O
exposed	O
to	O
warfarin	S-drug
in	O
those	O
18	O
years	O
.	O

In	O
total	O
,	O
430,455	O
warfarin	S-drug
users	O
contributed	O
407,370	O
person	O
-	O
years	O
of	O
warfarin	S-drug
use	O
.	O

The	O
incidence	O
rate	O
of	O
hospitalization	O
for	O
GI	O
bleeding	O
among	O
warfarin	S-drug
users	O
was	O
4.48	O
per	O
100	O
person	O
-	O
years	O
(	O
95	O
%	O
CI	O
,	O
4.42	O
-	O
4.55	O
)	O
.	O

Each	O
gastrointestinal	O
bleeding	O
cases	O
was	O
matched	O
to	O
50	O
controls	O
based	O
on	O
index	O
date	O
and	O
state	O
.	O

Warfarin	S-drug-EF-1
users	O
had	O
an	O
increased	O
odds	O
ratio	O
of	O
gastrointestinal	O
bleeding	O
upon	O
initiation	O
of	O
citalopram	S-drug-EF-2
(	O
OR	O
=	O
1.73	O
[	O
95	O
%	O
CI	O
,	O
1.25	O
-	O
2.38	O
]	O
)	O
,	O
fluoxetine	S-drug-EF-2
(	O
OR	O
=	O
1.63	O
[	O
95	O
%	O
CI	O
,	O
1.11	O
-	O
2.38	O
]	O
)	O
,	O
paroxetine	S-drug-EF-2
(	O
OR	O
=	O
1.64	O
[	O
95	O
%	O
CI	O
,	O
1.27	O
-	O
2.12	O
]	O
)	O
,	O
amitriptyline	S-drug-EF-2
(	O
OR	O
=	O
1.47	O
[	O
95	O
%	O
CI	O
,	O
1.02	O
-	O
2.11	O
]	O
)	O
.	O

Also	O
mirtazapine	S-drug-EF-1
,	O
which	O
is	O
not	O
believed	O
to	O
interact	O
with	O
warfarin	S-drug-EF-2
,	O
increased	O
the	O
risk	O
of	O
GI	O
bleeding	O
(	O
OR	O
=	O
1.75	O
[	O
95	O
%	O
CI	O
,	O
1.30	O
-	O
2.35	O
]	O
)	O
.	O

Warfarin	S-drug-EF-1
users	O
who	O
initiated	O
citalopram	S-drug-EF-2
,	O
fluoxetine	S-drug-EF-2
,	O
paroxetine	S-drug-EF-2
,	O
amitriptyline	S-drug-EF-2
,	O
or	O
mirtazapine	S-drug-EF-2
had	O
an	O
increased	O
risk	O
of	O
hospitalization	O
for	O
gastrointestinal	O
bleeding	O
.	O

However	O
,	O
the	O
elevated	O
risk	O
with	O
mirtazapine	S-drug
suggests	O
that	O
a	O
drug	O
-	O
drug	O
interaction	O
may	O
not	O
have	O
been	O
responsible	O
for	O
all	O
of	O
the	O
observed	O
increased	O
risk	O
.	O

Effects	O
of	O
CYP	O
inhibitors	O
on	O
precocene	B-drug_n
I	E-drug_n
metabolism	O
and	O
toxicity	O
in	O
rat	O
liver	O
slices	O
.	O

We	O
present	O
a	O
comprehensive	O
in	O
vitro	O
approach	O
to	O
assessing	O
metabolism	O
-	O
mediated	O
hepatotoxicity	O
using	O
male	O
Sprague	O
-	O
Dawley	O
rat	O
liver	O
slices	O
incubated	O
with	O
the	O
well	O
characterized	O
hepatotoxicant	O
,	O
precocene	B-drug_n
I	E-drug_n
,	O
and	O
inhibitors	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
enzymes	O
.	O

This	O
approach	O
combines	O
liquid	O
chromatography	O
mass	O
spectrometry	O
(	O
LC	O
MS	O
)	O
detection	O
methods	O
with	O
multiple	O
toxicity	O
endpoints	O
to	O
enable	O
identification	O
of	O
critical	O
metabolic	O
pathways	O
for	O
hepatotoxicity	O
.	O

The	O
incubations	O
were	O
performed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
the	O
non	O
-	O
specific	O
CYP	O
inhibitor	O
,	O
1	B-drug_n
-	I-drug_n
aminobenzotriazole	E-drug_n
(	O
ABT	S-drug_n
)	O
and	O
isoform	O
-	O
specific	O
inhibitors	O
.	O

The	O
metabolite	O
profile	O
of	O
precocene	B-drug_n
I	E-drug_n
in	O
rat	O
liver	O
slices	O
shares	O
some	O
features	O
of	O
the	O
in	O
vivo	O
profile	O
,	O
but	O
also	O
had	O
a	O
major	O
difference	O
in	O
that	O
epoxide	O
dihydrodiol	O
hydrolysis	O
products	O
were	O
not	O
observed	O
to	O
a	O
measurable	O
extent	O
.	O

As	O
examples	O
of	O
our	O
liver	O
slice	O
metabolite	O
identification	O
procedure	O
,	O
a	O
minor	O
glutathione	O
adduct	O
and	O
previously	O
unreported	O
7	O
-	O
O	O
-	O
desmethyl	O
and	O
glucuronidated	O
metabolites	O
of	O
precocene	B-drug_n
I	E-drug_n
are	O
reported	O
.	O

Precocene	B-drug_n
I	E-drug_n
induced	O
hepatocellular	O
necrosis	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

ABT	S-drug_n-EF-1
decreased	O
the	O
toxicity	O
of	O
precocene	B-drug_n-EF-2
I	E-drug_n-EF-2
,	O
increased	O
exposure	O
to	O
parent	O
compound	O
,	O
and	O
decreased	O
metabolite	O
levels	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Of	O
the	O
isoform	O
-	O
specific	O
CYP	O
inhibitors	O
tested	O
for	O
an	O
effect	O
on	O
the	O
precocene	B-drug_n
I	E-drug_n
metabolite	O
profile	O
,	O
only	O
tranylcypromine	S-drug
was	O
noticeably	O
effective	O
,	O
indicating	O
a	O
role	O
of	O
CYPs	O
2A6	O
,	O
2C9	O
,	O
2Cl9	O
,	O
and	O
2E1	O
.	O

With	O
respect	O
to	O
toxicity	O
,	O
the	O
order	O
of	O
CYP	O
inhibitor	O
effectiveness	O
was	O
ABT	S-drug_n
>	O
diethyldithiocarbamate	S-drug_n
~	O
tranylcypromine	S-drug
>	O
ketoconazole	S-drug
.	O

Furafylline	S-drug_n
and	O
sulfaphenazole	S-drug_n
had	O
no	O
effect	O
,	O
while	O
quinidine	S-drug-EF-1
appeared	O
to	O
augment	O
precocene	B-drug_n-EF-2
I	E-drug_n-EF-2
toxicity	O
.	O

These	O
results	O
suggest	O
that	O
rat	O
liver	O
slices	O
do	O
not	O
reproduce	O
the	O
reported	O
in	O
vivo	O
biotransformation	O
of	O
precocene	B-drug_n
I	E-drug_n
and	O
therefore	O
may	O
not	O
be	O
an	O
appropriate	O
model	O
for	O
precocene	B-drug_n
I	E-drug_n
metabolism	O
.	O

However	O
,	O
these	O
results	O
provide	O
an	O
example	O
of	O
how	O
small	O
molecule	O
manipulation	O
of	O
CYP	O
activity	O
in	O
an	O
in	O
vitro	O
model	O
can	O
be	O
used	O
to	O
confirm	O
metabolism	O
-	O
mediated	O
toxicity	O
.	O

Glycosidic	O
enzymes	O
enhance	O
retinal	O
transduction	O
following	O
intravitreal	O
delivery	O
of	O
AAV2	S-drug_n
.	O

To	O
determine	O
whether	O
the	O
co	O
-	O
injection	O
of	O
extracellular	O
matrix	O
degrading	O
enzymes	O
improves	O
retinal	O
transduction	O
following	O
intravitreal	O
delivery	O
of	O
adeno	B-drug_n
-	I-drug_n
associated	I-drug_n
virus	I-drug_n
-	I-drug_n
2	E-drug_n
(	O
AAV2	S-drug_n
)	O
.	O

AAV2	S-drug_n
containing	O
cDNA	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
,	O
under	O
the	O
control	O
of	O
a	O
chicken	O
-	O
actin	O
promoter	O
,	O
was	O
delivered	O
by	O
intravitreal	O
injection	O
to	O
adult	O
mice	O
in	O
conjunction	O
with	O
enzymes	O
including	O
collagenase	S-drug_n
,	O
hyaluronan	B-drug_n
lyase	E-drug_n
,	O
heparinase	B-drug_n
III	E-drug_n
,	O
or	O
chondroitin	B-drug_n
ABC	I-drug_n
lyase	E-drug_n
.	O

Two	O
weeks	O
later	O
,	O
retinal	O
flatmounts	O
were	O
examined	O
for	O
GFP	O
expression	O
using	O
confocal	O
microscopy	O
.	O

Without	O
the	O
addition	O
of	O
enzymes	O
,	O
transduction	O
was	O
limited	O
to	O
occasional	O
cells	O
in	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
.	O

The	O
addition	O
of	O
heparinase	B-drug_n
III	E-drug_n
or	O
chondroitin	B-drug_n
ABC	I-drug_n
lyase	E-drug_n
greatly	O
enhanced	O
transduction	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
and	O
increased	O
the	O
depth	O
of	O
transduction	O
into	O
the	O
outer	O
retina	O
.	O

Hyaluronan	B-drug_n
lyase	E-drug_n
had	O
a	O
limited	O
effect	O
and	O
collagenase	S-drug_n
was	O
ineffective	O
.	O

Electroretinograms	O
survived	O
with	O
higher	O
concentrations	O
of	O
heparinase	B-drug_n
III	E-drug_n
and	O
chondroitin	B-drug_n
ABC	I-drug_n
lyase	E-drug_n
than	O
were	O
required	O
for	O
optimal	O
retinal	O
transduction	O
.	O

AAV2	S-drug_n-EF-1
-	O
mediated	O
retinal	O
transduction	O
is	O
improved	O
by	O
co	O
-	O
injection	O
of	O
heparinase	B-drug_n-EF-2
III	E-drug_n-EF-2
or	O
chondroitin	B-drug_n-EF-2
ABC	I-drug_n-EF-2
lyase	E-drug_n-EF-2
.	O

Improved	O
transduction	O
efficiency	O
may	O
allow	O
intravitreal	O
injection	O
to	O
become	O
the	O
preferred	O
route	O
for	O
delivering	O
gene	O
therapy	O
to	O
both	O
the	O
inner	O
and	O
outer	O
retina	O
.	O

Prevention	O
of	O
emergence	O
agitation	O
in	O
seven	O
children	O
receiving	O
low	O
-	O
dose	O
ketamine	S-drug
and	O
propofol	S-drug
total	O
intravenous	O
anesthesia	O
.	O

Emergence	O
agitation	O
(	O
EA	O
)	O
can	O
be	O
a	O
distressing	O
side	O
effect	O
of	O
pediatric	O
anesthesia	O
.	O

We	O
retrospectively	O
reviewed	O
the	O
records	O
of	O
7	O
pediatric	O
oncology	O
patients	O
who	O
received	O
low	O
-	O
dose	O
ketamine	S-drug
in	O
conjunction	O
with	O
propofol	S-drug
for	O
total	O
intravenous	O
anesthesia	O
(	O
TIVA	O
)	O
repeatedly	O
for	O
radiation	O
therapy	O
.	O

EA	O
signs	O
were	O
observed	O
in	O
all	O
7	O
patients	O
in	O
association	O
with	O
propofol	S-drug
TIVA	O
but	O
did	O
not	O
recur	O
in	O
any	O
of	O
123	O
subsequent	O
anesthetics	O
sessions	O
during	O
which	O
low	O
-	O
dose	O
ketamine	S-drug
was	O
added	O
to	O
propofol	S-drug
.	O

Based	O
on	O
this	O
experience	O
,	O
we	O
suggest	O
that	O
low	O
-	O
dose	O
ketamine	S-drug-EF-1
added	O
to	O
propofol	S-drug-EF-2
may	O
be	O
associated	O
with	O
prevention	O
of	O
EA	O
in	O
children	O
with	O
a	O
history	O
of	O
EA	O
with	O
propofol	S-drug
TIVA	O
.	O

Tamoxifen	S-drug
and	O
CYP	O
2D6	O
inhibitors	O
:	O
caution	O
.	O

Tamoxifen	S-drug
,	O
an	O
estrogen	B-group
antagonist	E-group
,	O
is	O
the	O
standard	O
hormone	O
treatment	O
for	O
breast	O
cancer	O
.	O

It	O
is	O
extensively	O
transformed	O
into	O
its	O
active	O
metabolites	O
by	O
the	O
cytochrome	O
P450	O
enzyme	O
system	O
,	O
especially	O
into	O
endoxifen	S-drug_n
by	O
isoenzyme	O
CYP	O
2D6	O
.	O

Co	O
-	O
administration	O
of	O
tamoxifen	S-drug
with	O
isoenzyme	O
CYP	O
2D6	O
inhibitors	O
reduces	O
this	O
metabolism	O
.	O

Selective	B-group
serotonin	I-group
reuptake	I-group
inhibitor	I-group
(	I-group
SSRI	I-group
)	I-group
antidepressants	E-group
inhibit	O
isoenzyme	O
CYP	O
2D6	O
.	O

Paroxetine	S-drug-ME-1
and	O
fluoxetine	S-drug-ME-1
reduce	O
the	O
plasma	O
concentration	O
of	O
endoxifen	S-drug_n-ME-2
by	O
about	O
50	O
%	O
.	O

Two	O
epidemiological	O
studies	O
involving	O
about	O
3700	O
women	O
have	O
shown	O
a	O
link	O
between	O
the	O
use	O
of	O
SSRI	B-group
antidepressants	E-group
and	O
an	O
increased	O
frequency	O
of	O
breast	O
cancer	O
recurrence	O
.	O

Other	O
studies	O
,	O
with	O
a	O
lower	O
level	O
of	O
evidence	O
,	O
were	O
less	O
convincing	O
.	O

Studies	O
of	O
other	O
isoenzyme	O
CYP	O
2D6	O
inhibitors	O
showed	O
no	O
increase	O
in	O
the	O
risk	O
of	O
breast	O
cancer	O
recurrence	O
,	O
but	O
they	O
lacked	O
statistical	O
power	O
.	O

It	O
is	O
better	O
to	O
avoid	O
prescribing	O
isoenzyme	O
CYP	O
2D6	O
inhibitors	O
to	O
women	O
treated	O
with	O
tamoxifen	S-drug-AD-1
for	O
breast	O
cancer	O
,	O
especially	O
SSRI	B-group-AD-2
antidepressants	E-group-AD-2
such	O
as	O
paroxetine	S-drug-AD-2
and	O
fluoxetine	S-drug-AD-2
.	O

Depression	O
does	O
not	O
always	O
require	O
antidepressant	B-group
drug	E-group
therapy	O
,	O
and	O
antidepressants	S-group
have	O
no	O
proven	O
preventive	O
impact	O
on	O
hot	O
flushes	O
linked	O
to	O
the	O
menopause	O
.	O

If	O
in	O
certain	O
cases	O
,	O
an	O
antidepressant	S-group-AD-1
is	O
considered	O
necessary	O
,	O
it	O
may	O
be	O
advisable	O
to	O
replace	O
tamoxifen	S-drug-AD-2
with	O
anastrozole	S-drug
.	O

Amphetamine	S-drug
locomotor	O
sensitization	O
and	O
conditioned	O
place	O
preference	O
in	O
adolescent	O
male	O
and	O
female	O
rats	O
neonatally	O
treated	O
with	O
quinpirole	S-drug_n
.	O

Neonatal	O
quinpirole	S-drug_n
treatment	O
has	O
been	O
shown	O
to	O
produce	O
an	O
increase	O
in	O
dopamine	O
D2	O
-	O
like	O
receptor	O
sensitivity	O
that	O
persists	O
throughout	O
the	O
subject	O
's	O
lifetime	O
.	O

The	O
objective	O
was	O
to	O
analyze	O
the	O
effects	O
of	O
neonatal	O
quinpirole	S-drug_n
treatment	O
on	O
effects	O
of	O
amphetamine	S-drug
in	O
adolescent	O
rats	O
using	O
locomotor	O
sensitization	O
and	O
conditioned	O
place	O
preference	O
procedures	O
.	O

Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
quinpirole	S-drug_n
(	O
1	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
from	O
postnatal	O
days	O
(	O
P	O
)	O
1	O
to	O
P11	O
and	O
raised	O
to	O
adolescence	O
.	O

For	O
locomotor	O
sensitization	O
,	O
subjects	O
were	O
given	O
amphetamine	S-drug
(	O
1	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
every	O
second	O
day	O
from	O
P35	O
to	O
P47	O
and	O
were	O
placed	O
into	O
a	O
locomotor	O
arena	O
.	O

In	O
female	O
rats	O
,	O
neonatal	O
quinpirole	S-drug_n-EF-1
treatment	O
enhanced	O
amphetamine	S-drug-EF-2
locomotor	O
sensitization	O
compared	O
with	O
quinpirole	S-drug_n
-	O
free	O
controls	O
sensitized	O
to	O
amphetamine	S-drug
.	O

Male	O
rats	O
demonstrated	O
sensitization	O
to	O
amphetamine	S-drug
,	O
although	O
this	O
was	O
muted	O
compared	O
with	O
female	O
rats	O
,	O
and	O
were	O
unaffected	O
by	O
neonatal	O
quinpirole	S-drug_n
.	O

For	O
conditioned	O
place	O
preference	O
,	O
subjects	O
were	O
conditioned	O
for	O
8	O
consecutive	O
days	O
(	O
P32	O
-	O
39	O
)	O
with	O
amphetamine	S-drug
(	O
1	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
and	O
a	O
drug	O
-	O
free	O
preference	O
test	O
was	O
conducted	O
at	O
P40	O
.	O

Rats	O
treated	O
with	O
neonatal	O
quinpirole	S-drug_n
enhanced	O
time	O
spent	O
in	O
the	O
amphetamine	S-drug
-	O
paired	O
context	O
compared	O
with	O
quinpirole	S-drug_n
-	O
free	O
controls	O
conditioned	O
with	O
amphetamine	S-drug
,	O
but	O
only	O
female	O
controls	O
conditioned	O
with	O
amphetamine	S-drug
spent	O
more	O
time	O
in	O
the	O
drug	O
-	O
paired	O
context	O
compared	O
with	O
saline	O
-	O
treated	O
controls	O
.	O

Increased	O
D	O
-	O
like	O
receptor	O
sensitivity	O
appears	O
to	O
have	O
enhanced	O
the	O
behavioral	O
effects	O
of	O
amphetamine	S-drug
,	O
but	O
these	O
effects	O
were	O
more	O
prevalent	O
in	O
adolescent	O
female	O
rats	O
compared	O
with	O
male	O
rats	O
.	O

In	O
vivo	O
CYP3A	O
activity	O
is	O
significantly	O
lower	O
in	O
cyclosporine	S-drug
-	O
treated	O
as	O
compared	O
with	O
tacrolimus	S-drug
-	O
treated	O
renal	O
allograft	O
recipients	O
.	O

In	O
vitro	O
studies	O
have	O
identified	O
cyclosporine	S-drug
and	O
tacrolimus	S-drug
as	O
CYP3A	O
inhibitors	O
.	O

In	O
the	O
current	O
study	O
in	O
renal	O
allograft	O
recipients	O
,	O
we	O
used	O
intravenously	O
and	O
orally	O
administered	O
midazolam	S-drug
as	O
a	O
drug	O
probe	O
to	O
assess	O
whether	O
the	O
study	O
drugs	O
at	O
doses	O
that	O
are	O
generally	O
used	O
in	O
clinical	O
practice	O
have	O
differential	O
effects	O
on	O
in	O
vivo	O
hepatic	O
and	O
first	O
-	O
pass	O
CYP3A	O
activities	O
.	O

Systemic	O
and	O
apparent	O
oral	O
midazolam	S-drug-ME-1
clearance	O
were	O
24	O
%	O
(	O
269	O
73	O
vs.	O
354	O
102	O
ml	O
/	O
min	O
,	O
P	O
=	O
0.022	O
)	O
and	O
31	O
%	O
(	O
479	O
190	O
vs.	O
688	O
265	O
ml	O
/	O
min	O
,	O
P	O
=	O
0.013	O
)	O
,	O
respectively	O
,	O
lower	O
in	O
cyclosporine	S-drug-ME-2
-	O
treated	O
patients	O
(	O
n	O
=	O
20	O
)	O
than	O
in	O
matched	O
tacrolimus	S-drug
-	O
treated	O
patients	O
(	O
n	O
=	O
20	O
)	O
.	O

The	O
latter	O
displayed	O
midazolam	S-drug
clearances	O
similar	O
to	O
those	O
in	O
two	O
larger	O
cohorts	O
of	O
nonmatched	O
tacrolimus	S-drug
-	O
treated	O
patients	O
(	O
n	O
=	O
58	O
and	O
n	O
=	O
80	O
)	O
and	O
to	O
those	O
receiving	O
a	O
calcineurin	B-group
inhibitor	E-group
-	O
free	O
regimen	O
(	O
n	O
=	O
6	O
)	O
.	O

This	O
implies	O
that	O
in	O
vivo	O
hepatic	O
and	O
first	O
-	O
pass	O
CYP3A	O
activities	O
are	O
significantly	O
lower	O
in	O
patients	O
receiving	O
cyclosporine	S-drug
than	O
in	O
those	O
receiving	O
tacrolimus	S-drug
,	O
indicating	O
that	O
,	O
at	O
the	O
doses	O
generally	O
used	O
in	O
clinical	O
practice	O
,	O
cyclosporine	S-drug
is	O
the	O
stronger	O
of	O
the	O
two	O
with	O
respect	O
to	O
CYP3A	O
inhibition	O
.	O

This	O
observation	O
has	O
important	O
implications	O
in	O
the	O
context	O
of	O
drug	O
-	O
drug	O
interactions	O
in	O
transplant	O
recipients	O
.	O

Improved	O
parathyroid	O
hormone	O
control	O
by	O
cinacalcet	S-drug
is	O
associated	O
with	O
reduction	O
in	O
darbepoetin	S-drug
requirement	O
in	O
patients	O
with	O
end	O
-	O
stage	O
renal	O
disease	O
.	O

Uncontrolled	O
hy	O
-	O
per	O
-	O
parathyroidism	O
causes	O
bone	O
marrow	O
fibrosis	O
,	O
leading	O
to	O
erythropoietin	S-drug
(	O
EPO	S-drug
)	O
resistance	O
.	O

Medical	O
treatment	O
with	O
cinacalcet	S-drug
is	O
effective	O
in	O
reducing	O
plasma	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
levels	O
,	O
but	O
its	O
effect	O
on	O
darbepoetin	S-drug
dosing	O
is	O
unknown	O
.	O

METHODS	O
AND	O
AIMS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
of	O
40	O
end	O
-	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
patients	O
(	O
age	O
:	O
55	O
14	O
;	O
mean	O
SD	O
;	O
21	O
:	O
male	O
)	O
who	O
had	O
at	O
least	O
12	O
months	O
of	O
cinacalcet	S-drug
therapy	O
.	O

The	O
distribution	O
of	O
renal	O
replacement	O
therapies	O
were	O
:	O
14	O
peritoneal	O
dialysis	O
,	O
18	O
conventional	O
hemodialysis	O
and	O
8	O
nocturnal	O
hemodialysis	O
.	O

Standard	O
dialysis	O
related	O
biochemical	O
indices	O
and	O
medications	O
used	O
were	O
recorded	O
.	O

The	O
primary	O
objective	O
of	O
the	O
study	O
was	O
to	O
ascertain	O
the	O
difference	O
in	O
darbepoetin	S-drug
responsiveness	O
before	O
and	O
after	O
12	O
months	O
of	O
cinacalcet	S-drug
therapy	O
.	O

Our	O
secondary	O
objective	O
was	O
to	O
determine	O
if	O
there	O
was	O
a	O
relationship	O
between	O
the	O
changes	O
in	O
PTH	O
and	O
darbepoetin	S-drug
requirement	O
.	O

Overall	O
,	O
PTH	O
levels	O
decreased	O
from	O
197.5	O
(	O
151.8	O
;	O
249.2	O
)	O
to	O
66.1	O
(	O
41.2	O
;	O
136.5	O
)	O
(	O
median	O
(	O
25th	O
;	O
75th	O
percentile	O
)	O
)	O
pmol	O
/	O
l	O
;	O

p	O
&	O
lt	O
;	O

0.001	O
.	O

Cinacalcet	S-drug
dose	O
increased	O
from	O
30.0	O
6	O
to	O
63	O
25	O
mg	O
/	O
day	O
,	O
p	O
<	O

0.05	O
.	O

Hemoglobin	O
remained	O
unchanged	O
(	O
116	O
13	O
to	O
116	O
13	O
g	O
/	O
l	O
)	O
,	O
while	O
darbepoetin	S-drug
requirement	O
decreased	O
from	O
40	O
(	O
20	O
;	O
60	O
)	O
to	O
24	O
(	O
19	O
;	O
59	O
)	O
g	O
/	O
week	O
,	O
p	O
=	O
0.02	O
.	O

The	O
remainder	O
of	O
the	O
dialysis	O
-	O
related	O
biochemistry	O
(	O
electrolytes	O
,	O
calcium	O
,	O
phosphate	O
,	O
iron	O
status	O
)	O
and	O
vitamin	O
D	O
use	O
remained	O
unchanged	O
.	O

A	O
reduction	O
in	O
PTH	O
level	O
of	O
greater	O
than	O
30	O
%	O
was	O
experienced	O
by	O
82.5	O
%	O
(	O
33	O
/	O
40	O
)	O
of	O
our	O
cohort	O
.	O

Among	O
the	O
responders	O
,	O
the	O
fall	O
in	O
PTH	O
and	O
reduction	O
darbepoetin	S-drug
requirement	O
were	O
related	O
(	O
R	O
=	O
-	O
0.48	O
,	O
p	O
=	O
0.004	O
)	O
.	O

Reduction	O
of	O
PTH	O
by	O
cinacalcet	S-drug-EF-1
is	O
associated	O
with	O
a	O
decrease	O
in	O
darbepoetin	S-drug-EF-2
requirement	O
.	O

The	O
interface	O
between	O
bone	O
and	O
bone	O
marrow	O
in	O
uremia	O
represents	O
a	O
critical	O
step	O
in	O
red	O
blood	O
cell	O
production	O
which	O
merits	O
further	O
investigation	O
.	O

Interaction	O
of	O
celecoxib	S-drug-EF-1
with	O
different	O
anti	B-group-EF-2
-	I-group-EF-2
cancer	I-group-EF-2
drugs	E-group-EF-2
is	O
antagonistic	O
in	O
breast	O
but	O
not	O
in	O
other	O
cancer	O
cells	O
.	O

Celecoxib	S-drug
,	O
an	O
inhibitor	O
of	O
cyclooxygenase	O
-	O
2	O
,	O
is	O
being	O
investigated	O
for	O
enhancement	O
of	O
chemotherapy	O
efficacy	O
in	O
cancer	O
clinical	O
trials	O
.	O

This	O
study	O
investigates	O
the	O
ability	O
of	O
cyclooxygenase	B-group
-	I-group
2	I-group
inhibitors	E-group
to	O
sensitize	O
cells	O
from	O
different	O
origins	O
to	O
several	O
chemotherapeutic	B-group
agents	E-group
.	O

The	O
effect	O
of	O
the	O
drug	O
's	O
mechanism	O
of	O
action	O
and	O
sequence	O
of	O
administration	O
are	O
also	O
investigated	O
.	O

The	O
sensitivity	O
,	O
cell	O
cycle	O
,	O
apoptosis	O
and	O
DNA	O
damage	O
of	O
five	O
different	O
cancer	O
cell	O
lines	O
(	O
HeLa	O
,	O
HCT116	O
,	O
HepG2	O
,	O
MCF7	O
and	O
U251	O
)	O
to	O
5	B-drug
-	I-drug
FU	E-drug
,	O
cisplatin	S-drug
,	O
doxorubicin	S-drug
and	O
etoposide	S-drug
celecoxib	S-drug
following	O
different	O
incubation	O
schedules	O
were	O
analyzed	O
.	O

We	O
found	O
antagonism	O
between	O
celecoxib	S-drug
and	O
the	O
four	O
drugs	O
in	O
the	O
breast	O
cancer	O
cells	O
MCF7	O
following	O
all	O
incubation	O
schedules	O
and	O
between	O
celecoxib	S-drug-EF-1
and	O
doxorubicin	S-drug-EF-2
in	O
all	O
cell	O
lines	O
except	O
for	O
two	O
combinations	O
in	O
HCT116	O
cells	O
.	O

Celecoxib	S-drug
with	O
the	O
other	O
three	O
drugs	O
in	O
the	O
remaining	O
four	O
cell	O
lines	O
resulted	O
in	O
variable	O
interactions	O
.	O

Mechanistic	O
investigations	O
revealed	O
that	O
celecoxib	S-drug
exerts	O
different	O
molecular	O
effects	O
in	O
different	O
cells	O
.	O

In	O
some	O
lines	O
,	O
it	O
abrogates	O
the	O
drug	O
-	O
induced	O
G2	O
/	O
M	O
arrest	O
enhancing	O
pre	O
-	O
mature	O
entry	O
into	O
mitosis	O
with	O
damaged	O
DNA	O
thus	O
increasing	O
apoptosis	O
and	O
resulting	O
in	O
synergism	O
.	O

In	O
other	O
cells	O
,	O
it	O
enhances	O
drug	O
-	O
induced	O
G2	O
/	O
M	O
arrest	O
allowing	O
time	O
to	O
repair	O
drug	O
-	O
induced	O
DNA	O
damage	O
before	O
entry	O
into	O
mitosis	O
and	O
decreasing	O
cell	O
death	O
resulting	O
in	O
antagonism	O
.	O

In	O
some	O
synergistic	O
combinations	O
,	O
celecoxib	O
-	O
induced	O
abrogation	O
of	O
G2	O
/	O
M	O
arrest	O
was	O
not	O
associated	O
with	O
apoptosis	O
but	O
permanent	O
arrest	O
in	O
G1	O
phase	O
.	O

These	O
results	O
,	O
if	O
confirmed	O
in	O
-	O
vivo	O
,	O
indicate	O
that	O
celecoxib	S-drug
is	O
not	O
a	O
suitable	O
chemosensitizer	O
for	O
breast	O
cancer	O
or	O
with	O
doxorubicin	S-drug
for	O
other	O
cancers	O
.	O

Moreover	O
,	O
combination	O
of	O
celecoxib	S-drug
with	O
other	O
drugs	O
should	O
be	O
tailored	O
to	O
the	O
tumor	O
type	O
,	O
drug	O
and	O
administration	O
schedule	O
.	O

[	O
Interaction	O
between	O
clopidogrel	S-drug
and	O
proton	B-group
pump	I-group
inhibitors	E-group
]	O
.	O

The	O
drug	O
interaction	O
between	O
proton	B-group
pump	I-group
inhibitors	E-group
and	O
clopidogrel	S-drug
has	O
been	O
the	O
subject	O
of	O
much	O
study	O
in	O
recent	O
years	O
.	O

Contradictory	O
results	O
regarding	O
the	O
effect	O
of	O
proton	B-group
pump	I-group
inhibitors	E-group
on	O
platelet	O
reactivity	O
and	O
on	O
clinical	O
outcome	O
in	O
clopidogrel	S-drug
-	O
treated	O
patients	O
have	O
been	O
reported	O
in	O
literature	O
.	O

Concomitant	O
use	O
of	O
omeprazole	S-drug-ME-1
and	O
clopidogrel	S-drug-ME-2
was	O
found	O
to	O
decrease	O
the	O
exposure	O
(	O
AUC	O
)	O
to	O
clopidogrel	O
's	O
active	O
metabolite	O
by	O
50	O
%	O
and	O
to	O
sharply	O
increase	O
platelet	O
reactivity	O
,	O
as	O
a	O
result	O
of	O
inhibition	O
by	O
omeprazole	S-drug
of	O
CYP2C19	O
,	O
a	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
enzyme	O
.	O

Pantoprazole	S-drug-ME-1
has	O
a	O
much	O
weaker	O
effect	O
on	O
clopidogrel	S-drug-ME-2
's	O
pharmacokinetics	O
and	O
on	O
platelet	O
reactivity	O
during	O
concomitant	O
use	O
.	O

The	O
influence	O
of	O
the	O
other	O
proton	B-group
pump	I-group
inhibitors	E-group
when	O
used	O
simultaneously	O
with	O
clopidogrel	S-drug
has	O
not	O
yet	O
been	O
investigated	O
in	O
adequately	O
randomized	O
studies	O
.	O

Regulatory	O
agencies	O
state	O
that	O
the	O
combination	O
of	O
clopidogrel	S-drug-AD-1
and	O
the	O
CYP2C19	O
inhibitors	O
omeprazole	S-drug-AD-2
and	O
esomeprazole	S-drug-AD-2
should	O
be	O
avoided	O
.	O

To	O
date	O
,	O
there	O
is	O
no	O
conclusive	O
evidence	O
of	O
a	O
clinically	O
-	O
relevant	O
interaction	O
between	O
any	O
of	O
the	O
proton	B-group
pump	I-group
inhibitors	E-group
and	O
clopidogrel	S-drug
.	O

In	O
vitro	O
activity	O
of	O
minocycline	S-drug
combined	O
with	O
fosfomycin	S-drug
against	O
clinical	O
isolates	O
of	O
methicillin	S-drug
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
in	O
vitro	O
activity	O
of	O
minocycline	S-drug
combined	O
with	O
fosfomycin	S-drug
against	O
isolates	O
of	O
methicillin	S-drug
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
.	O

A	O
total	O
of	O
87	O
clinical	O
isolates	O
of	O
MRSA	O
collected	O
from	O
three	O
Chinese	O
hospitals	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
checkerboard	O
method	O
with	O
determination	O
of	O
the	O
fractional	O
IC	O
index	O
(	O
FICI	O
)	O
was	O
used	O
to	O
determine	O
whether	O
antibiotic	S-group
combinations	O
act	O
synergistically	O
against	O
these	O
isolates	O
.	O

The	O
susceptibility	O
results	O
for	O
minocycline	S-drug
and	O
fosfomycin	S-drug
were	O
interpreted	O
according	O
to	O
the	O
most	O
relevant	O
criteria	O
.	O

The	O
results	O
demonstrated	O
the	O
following	O
interactions	O
:	O
76	O
isolates	O
(	O
87.4	O
%	O
)	O
showed	O
synergistic	O
interactions	O
(	O
FICI	O
0.5	O
)	O
and	O
11	O
isolates	O
(	O
12.6	O
%	O
)	O
showed	O
indifferent	O
interactions	O
(	O
0.5	O
&	O
lt	O
;	O
FICI	O
&	O
lt	O
;	O
4	O
)	O
.	O

No	O
antagonistic	O
interactions	O
(	O
FICI	O
4	O
)	O
were	O
observed	O
.	O

The	O
combination	O
of	O
minocycline	S-drug-EF-1
and	O
fosfomycin	S-drug-EF-2
can	O
be	O
synergistic	O
against	O
MRSA	O
.	O

Further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
potential	O
clinical	O
role	O
of	O
this	O
combination	O
regimen	O
as	O
a	O
therapeutic	O
alternative	O
for	O
certain	O
types	O
of	O
MRSA	O
infections	O
.	O

Drug	O
interaction	O
of	O
levothyroxine	S-drug
with	O
infant	O
colic	O
drops	O
.	O

Infacol	S-brand
(	O
Forest	O
Laboratories	O
UK	O
,	O
Kent	O
,	O
UK	O
)	O
is	O
a	O
widely	O
available	O
over	O
-	O
the	O
-	O
counter	O
preparation	O
used	O
to	O
relieve	O
colic	O
symptoms	O
in	O
neonates	O
and	O
infants	O
.	O

The	O
active	O
ingredient	O
is	O
simeticone	S-drug
.	O

No	O
drug	O
interactions	O
with	O
simeticone	S-drug
are	O
documented	O
in	O
the	O
current	O
summary	O
of	O
product	O
characteristics	O
.	O

The	O
authors	O
report	O
the	O
case	O
of	O
an	O
infant	O
with	O
confirmed	O
congenital	O
hypothyroidism	O
on	O
levothyroxine	S-drug-IN-1
who	O
experienced	O
a	O
possible	O
drug	O
interaction	O
with	O
simeticone	S-drug-IN-2
.	O

Despite	O
adequate	O
levothyroxine	S-drug
dosage	O
,	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
was	O
high	O
,	O
suggesting	O
undertreatment	O
.	O

Questioning	O
revealed	O
the	O
child	O
was	O
taking	O
Infacol	S-brand
drops	O
before	O
feeds	O
while	O
on	O
levothyroxine	S-drug
.	O

The	O
colic	O
drops	O
were	O
immediately	O
discontinued	O
and	O
TSH	O
promptly	O
normalised	O
with	O
a	O
reduction	O
in	O
thyroxine	O
requirement	O
to	O
an	O
age	O
appropriate	O
dosage	O
.	O

Drug	O
interaction	O
of	O
thyroxine	S-drug
with	O
simeticone	S-drug
has	O
not	O
been	O
reported	O
previously	O
and	O
is	O
not	O
listed	O
in	O
the	O
British	O
National	O
Formulary	O
for	O
Children	O
.	O

Clinicians	O
and	O
parents	O
need	O
to	O
be	O
aware	O
of	O
this	O
interaction	O
to	O
avoid	O
unnecessary	O
undertreatment	O
and	O
prevent	O
potential	O
long	O
-	O
term	O
neurological	O
sequelae	O
.	O

Calcium	S-drug
does	O
not	O
inhibit	O
the	O
absorption	O
of	O
5	O
milligrams	O
of	O
nonheme	S-drug
or	O
heme	B-drug
iron	E-drug
at	O
doses	O
less	O
than	O
800	O
milligrams	O
in	O
nonpregnant	O
women	O
.	O

Calcium	S-drug-ME-1
is	O
the	O
only	O
known	O
component	O
in	O
the	O
diet	O
that	O
may	O
affect	O
absorption	O
of	O
both	O
nonheme	S-drug-ME-2
and	O
heme	B-drug-ME-2
iron	E-drug-ME-2
.	O

However	O
,	O
the	O
evidence	O
for	O
a	O
calcium	S-drug-ME-1
effect	O
on	O
iron	S-drug-ME-2
absorption	O
mainly	O
comes	O
from	O
studies	O
that	O
did	O
not	O
isolate	O
the	O
effect	O
of	O
calcium	S-drug
from	O
that	O
of	O
other	O
dietary	O
components	O
,	O
because	O
it	O
was	O
detected	O
in	O
single	O
-	O
meal	O
studies	O
.	O

Our	O
objective	O
was	O
to	O
establish	O
potential	O
effects	O
of	O
calcium	S-drug
on	O
absorption	O
of	O
nonheme	S-drug
and	O
heme	B-drug
iron	E-drug
and	O
the	O
dose	O
response	O
for	O
this	O
effect	O
in	O
the	O
absence	O
of	O
a	O
meal	O
.	O

Fifty	O
-	O
four	O
healthy	O
,	O
nonpregnant	O
women	O
were	O
selected	O
to	O
participate	O
in	O
4	O
iron	S-drug
absorption	O
studies	O
using	O
iron	O
radioactive	O
tracers	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
calcium	S-drug
doses	O
between	O
200	O
and	O
1500	O
mg	O
on	O
absorption	O
of	O
5	O
mg	O
nonheme	B-drug
iron	E-drug
(	O
as	O
ferrous	B-drug
sulfate	E-drug
)	O
.	O

We	O
also	O
evaluated	O
the	O
effects	O
of	O
calcium	S-drug
doses	O
between	O
200	O
and	O
800	O
mg	O
on	O
absorption	O
of	O
5	O
mg	O
heme	B-drug
iron	E-drug
[	O
as	O
concentrated	O
RBC	O
(	O
CRBC	O
)	O
]	O
.	O

Calcium	S-drug
was	O
administered	O
as	O
calcium	B-drug
chloride	E-drug
in	O
all	O
studies	O
and	O
minerals	S-group
were	O
ingested	O
on	O
an	O
empty	O
stomach	O
.	O

Calcium	S-drug-ME-1
doses	O
1000	O
mg	O
diminished	O
nonheme	B-drug-ME-2
iron	E-drug-ME-2
absorption	O
by	O
an	O
average	O
of	O
49.6	O
%	O
.	O

A	O
calcium	S-drug-ME-1
dose	O
of	O
800	O
mg	O
diminished	O
absorption	O
of	O
5	O
mg	O
heme	B-drug-ME-2
iron	E-drug-ME-2
by	O
37.7	O
%	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
an	O
isolated	O
effect	O
of	O
calcium	S-drug-ME-1
(	O
as	O
chloride	O
)	O
on	O
absorption	O
of	O
5	O
mg	O
of	O
iron	O
provided	O
as	O
nonheme	S-drug-ME-2
(	O
as	O
sulfate	O
)	O
and	O
heme	S-drug-ME-2
(	O
as	O
CRBC	O
)	O
iron	O
.	O

This	O
effect	O
was	O
observed	O
at	O
doses	O
higher	O
than	O
previously	O
reported	O
from	O
single	O
-	O
meal	O
studies	O
,	O
starting	O
at	O
~	O
800	O
mg	O
of	O
calcium	S-drug
.	O

Synergistic	O
interaction	O
between	O
sunitinib	S-drug-IN-1
and	O
docetaxel	S-drug-IN-2
is	O
sequence	O
dependent	O
in	O
human	O
non	O
-	O
small	O
lung	O
cancer	O
with	O
EGFR	O
TKIs	O
-	O
resistant	O
mutation	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
sunitinib	S-drug
has	O
the	O
anti	O
-	O
tumor	O
activity	O
in	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

This	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
efficacy	O
of	O
single	O
use	O
of	O
sunitinib	S-drug
and	O
that	O
of	O
concurrent	O
or	O
sequential	O
administration	O
of	O
sunitinib	S-drug
and	O
docetaxel	S-drug
in	O
NSCLC	O
cell	O
lines	O
that	O
are	O
resistant	O
to	O
EGFR	O
TKIs	O
.	O

NSCLC	O
cell	O
lines	O
with	O
EGFR	O
T790M	O
mutation	O
and	O
K	O
-	O
ras	O
mutation	O
were	O
exposed	O
to	O
either	O
sunitinib	S-drug
or	O
docetaxel	S-drug
or	O
both	O
based	O
on	O
various	O
sequential	O
administrations	O
.	O

After	O
exposure	O
,	O
the	O
cell	O
viability	O
was	O
measured	O
by	O
MTT	O
assay	O
,	O
cell	O
cycle	O
distribution	O
was	O
analyzed	O
by	O
flow	O
cytometry	O
,	O
and	O
alterations	O
in	O
signaling	O
pathway	O
were	O
determined	O
by	O
immunoblotting	O
.	O

Sunitinib	S-drug
exhibited	O
dose	O
-	O
dependent	O
growth	O
inhibition	O
in	O
NSCLC	O
cell	O
lines	O
and	O
arrested	O
cell	O
cycle	O
at	O
G1	O
phase	O
,	O
whereas	O
docetaxel	S-drug
arrested	O
at	O
S	O
phase	O
.	O

Although	O
single	O
or	O
concurrent	O
use	O
of	O
sunitinib	S-drug-EF-1
and	O
docetaxel	S-drug-EF-2
has	O
some	O
anti	O
-	O
proliferative	O
effects	O
,	O
the	O
sequential	O
administrations	O
of	O
both	O
drugs	O
remarkably	O
enhanced	O
anti	O
-	O
tumor	O
activity	O
.	O

When	O
cells	O
were	O
exposed	O
to	O
docetaxel	S-drug-EF-1
followed	O
by	O
sunitinib	S-drug-EF-2
,	O
synergism	O
was	O
observed	O
.	O

The	O
molecular	O
basis	O
of	O
this	O
synergism	O
is	O
that	O
the	O
signaling	O
pathways	O
that	O
were	O
initially	O
activated	O
by	O
docetaxel	S-drug-EF-1
exposure	O
were	O
efficiently	O
suppressed	O
by	O
the	O
subsequent	O
exposure	O
to	O
sunitinib	S-drug-EF-2
.	O

In	O
contrast	O
,	O
the	O
reverse	O
of	O
this	O
sequential	O
administration	O
resulted	O
in	O
antagonism	O
,	O
which	O
may	O
be	O
due	O
to	O
differential	O
effects	O
on	O
cell	O
cycle	O
arrest	O
.	O

Sunitinib	S-drug
as	O
a	O
single	O
agent	O
exhibits	O
anti	O
-	O
proliferative	O
effects	O
in	O
vitro	O
in	O
NSCLC	O
cell	O
lines	O
with	O
EGFR	O
T790M	O
and	O
K	O
-	O
ras	O
mutations	O
but	O
the	O
sequential	O
administration	O
of	O
docetaxel	S-drug-EF-1
followed	O
by	O
sunitinib	S-drug-EF-2
is	O
superior	O
to	O
sunitinib	S-drug
followed	O
by	O
docetaxel	S-drug
and	O
concurrent	O
administration	O
.	O

Distinct	O
synergistic	O
action	O
of	O
piperacillin	S-drug
and	O
methylglyoxal	S-drug_n
against	O
Pseudomonas	O
aeruginosa	O
.	O

The	O
dicarbonyl	O
compound	O
methylglyoxal	S-drug_n
is	O
a	O
natural	O
constituent	O
of	O
Manuka	O
honey	O
produced	O
from	O
Manuka	O
flowers	O
in	O
New	O
Zealand	O
.	O

It	O
is	O
known	O
to	O
possess	O
both	O
anticancer	O
and	O
antibacterial	O
activity	O
.	O

Such	O
observations	O
prompted	O
to	O
investigate	O
the	O
ability	O
of	O
methylglyoxal	S-drug_n
as	O
a	O
potent	O
drug	O
against	O
multidrug	O
resistant	O
Pseudomonas	O
aeruginosa	O
.	O

A	O
total	O
of	O
12	O
test	O
P	O
.	O

aeruginosa	O
strains	O
isolated	O
from	O
various	O
hospitals	O
were	O
tested	O
for	O
their	O
resistances	O
against	O
many	O
antibiotics	S-group
,	O
most	O
of	O
which	O
are	O
applied	O
in	O
the	O
treatment	O
of	O
P	O
.	O

aeruginosa	O
infections	O
.	O

Results	O
revealed	O
that	O
the	O
strains	O
were	O
resistant	O
to	O
many	O
drugs	O
at	O
high	O
levels	O
,	O
only	O
piperacillin	S-drug
,	O
carbenicillin	S-drug
,	O
amikacin	S-drug
and	O
ciprofloxacin	S-drug
showed	O
resistances	O
at	O
comparatively	O
lower	O
levels	O
.	O

Following	O
multiple	O
experimentations	O
it	O
was	O
observed	O
that	O
methylglyoxal	S-drug_n
was	O
also	O
antimicrobic	O
against	O
all	O
the	O
strains	O
at	O
comparable	O
levels	O
.	O

Distinct	O
and	O
statistically	O
significant	O
synergism	O
was	O
observed	O
between	O
methylglyoxal	S-drug_n-EF-1
and	O
piperacillin	S-drug-EF-2
by	O
disc	O
diffusion	O
tests	O
when	O
compared	O
with	O
their	O
individual	O
effects	O
.	O

The	O
fractional	O
inhibitory	O
concentration	O
index	O
of	O
this	O
combination	O
evaluated	O
by	O
checkerboard	O
analysis	O
,	O
was	O
0.5	O
,	O
which	O
confirmed	O
synergism	O
between	O
the	O
pair	O
.	O

Synergism	O
was	O
also	O
noted	O
when	O
methylglyoxal	S-drug_n-EF-1
was	O
combined	O
with	O
carbenicillin	S-drug-EF-2
and	O
amikacin	S-drug-EF-2
.	O

Protective	O
effect	O
of	O
acetyl	B-drug
-	I-drug
l	I-drug
-	I-drug
carnitine	E-drug
and	O
alpha	B-drug_n
lipoic	I-drug_n
acid	E-drug_n
against	O
the	O
acute	O
toxicity	O
of	O
diepoxybutane	O
to	O
human	O
lymphocytes	O
.	O

The	O
biotransformation	O
and	O
oxidative	O
stress	O
may	O
contribute	O
to	O
1,2	O
:	O
3,4	O
-	O
diepoxybutane	O
(	O
DEB	O
)	O
-	O
induced	O
toxicity	O
to	O
human	O
lymphocytes	O
of	O
Fanconi	O
Anemia	O
(	O
FA	O
)	O
patients	O
.	O

Thus	O
,	O
the	O
identification	O
of	O
putative	O
inhibitors	O
of	O
bioactivation	O
,	O
as	O
well	O
as	O
the	O
determination	O
of	O
the	O
protective	O
role	O
of	O
oxidant	O
defenses	O
,	O
on	O
DEB	O
-	O
induced	O
toxicity	O
,	O
can	O
help	O
to	O
understand	O
what	O
is	O
failing	O
in	O
FA	O
cells	O
.	O

In	O
the	O
present	O
work	O
we	O
studied	O
the	O
contribution	O
of	O
several	O
biochemical	O
pathways	O
for	O
DEB	O
-	O
induced	O
acute	O
toxicity	O
in	O
human	O
lymphocyte	O
suspensions	O
,	O
by	O
using	O
inhibitors	O
of	O
epoxide	O
hydrolases	O
,	O
inhibitors	O
of	O
protective	O
enzymes	O
as	O
glutathione	O
S	O
-	O
transferase	O
and	O
catalase	O
,	O
the	O
depletion	O
of	O
glutathione	O
(	O
GSH	O
)	O
,	O
and	O
the	O
inhibition	O
of	O
protein	O
synthesis	O
;	O

and	O
a	O
variety	O
of	O
putative	O
protective	O
compounds	O
,	O
including	O
antioxidants	O
,	O
and	O
mitochondrial	O
protective	O
agents	O
.	O

The	O
present	O
study	O
reports	O
two	O
novel	O
findings	O
:	O
(	O
i	O
)	O
it	O
was	O
clearly	O
evidenced	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
acute	O
exposure	O
of	O
freshly	O
isolated	O
human	O
lymphocytes	O
to	O
DEB	O
results	O
in	O
severe	O
GSH	O
depletion	O
and	O
loss	O
of	O
ATP	O
,	O
followed	O
by	O
cell	O
death	O
;	O

(	O
ii	O
)	O
acetyl	B-drug-EF-1
-	I-drug-EF-1
l	I-drug-EF-1
-	I-drug-EF-1
carnitine	E-drug-EF-1
elicits	O
a	O
significant	O
protective	O
effect	O
on	O
DEB	O
induced	O
toxicity	O
,	O
which	O
was	O
potentiated	O
by	O
alpha	B-drug-EF-2
-	I-drug-EF-2
lipoic	I-drug-EF-2
acid	E-drug-EF-2
.	O

Collectively	O
,	O
these	O
findings	O
contribute	O
to	O
increase	O
our	O
knowledge	O
of	O
DEB	O
-	O
induce	O
toxicity	O
and	O
will	O
be	O
very	O
useful	O
when	O
applied	O
in	O
studies	O
with	O
lymphocytes	O
from	O
FA	O
patients	O
,	O
in	O
order	O
to	O
find	O
out	O
a	O
protective	O
agent	O
against	O
spontaneous	O
and	O
DEB	O
-	O
induced	O
chromosome	O
instability	O
.	O

[	O
Influence	O
of	O
hemantane	S-drug_n
and	O
doxycycline	S-drug
on	O
MPTP	O
-	O
evoked	O
behavior	O
violations	O
in	O
C57BL	O
/	O
6	O
mice	O
]	O
.	O

The	O
effects	O
of	O
anti	B-group
-	I-group
parkinsonian	I-group
drug	E-group
hemantane	S-drug_n
[	O
(	B-drug_n
2	I-drug_n
-	I-drug_n
adamantyl	I-drug_n
)	I-drug_n
hexamethylenimine	E-drug_n
]	O
(	O
10	O
mg	O
/	O
kg	O
,	O
p.	O
o	O
.	O
)	O

and	O
/	O
or	O
antibiotic	B-group
drug	E-group
doxycycline	S-drug
(	O
100	O
mg	O
/	O
kg	O
,	O
p.	O
o	O
.	O
)	O
,	O
as	O
well	O
as	O
that	O
of	O
neurotoxin	O
1	B-drug_n
-	I-drug_n
methyl	I-drug_n
-	I-drug_n
4	I-drug_n
-	I-drug_n
phenyl	I-drug_n
-	I-drug_n
1,2,3,4	I-drug_n
-	I-drug_n
tetrahydropyridine	E-drug_n
(	O
MPTP	S-drug_n
)	O
(	O
4	O
x	O
20	O
mg	O
/	O
kg	O
,	O
i.	O
p	O
.	O
)	O

were	O
studied	O
in	O
elevated	O
plus	O
maze	O
test	O
on	O
C57BL	O
/	O
6	O
mice	O
.	O

On	O
second	O
day	O
after	O
injection	O
,	O
MPTP	S-drug_n
decreased	O
the	O
locomot	O
or	O
activity	O
in	O
comparison	O
to	O
saline	O
.	O

Acute	O
administration	O
of	O
hemantane	S-drug_n-EF-1
or	O
doxycycline	S-drug-EF-2
failed	O
to	O
influence	O
locomotion	O
in	O
mice	O
,	O
while	O
their	O
combination	O
normalized	O
motor	O
activity	O
.	O

The	O
results	O
obtained	O
confirm	O
the	O
role	O
of	O
inflammatory	O
processes	O
in	O
parkinsonism	O
and	O
suggest	O
expediency	O
of	O
combined	O
pharmacotherapy	O
of	O
neurodegenerative	O
diseases	O
.	O

The	O
role	O
of	O
p27	O
(	O
Kip1	O
)	O
in	O
dasatinib	S-drug-EF-1
-	O
enhanced	O
paclitaxel	S-drug-EF-2
cytotoxicity	O
in	O
human	O
ovarian	O
cancer	O
cells	O
.	O

Less	O
than	O
50	O
%	O
of	O
ovarian	O
cancers	O
respond	O
to	O
paclitaxel	S-drug
.	O

Effective	O
strategies	O
are	O
needed	O
to	O
enhance	O
paclitaxel	S-drug
sensitivity	O
.	O

A	O
library	O
of	O
silencing	O
RNAs	O
(	O
siRNAs	O
)	O
was	O
used	O
to	O
identify	O
kinases	O
that	O
regulate	O
paclitaxel	S-drug
sensitivity	O
in	O
human	O
ovarian	O
cancer	O
SKOv3	O
cells	O
.	O

The	O
effect	O
of	O
dasatinib	S-drug
,	O
an	O
inhibitor	O
of	O
Src	O
and	O
Abl	O
kinases	O
,	O
on	O
paclitaxel	S-drug
sensitivity	O
was	O
measured	O
in	O
ovarian	O
cancer	O
cells	O
and	O
HEY	O
xenografts	O
.	O

The	O
roles	O
of	O
p27	O
(	O
Kip1	O
)	O
,	O
Bcl	O
-	O
2	O
,	O
and	O
Cdk1	O
in	O
apoptosis	O
induced	O
by	O
dasatinib	S-drug
and	O
paclitaxel	S-drug
were	O
assessed	O
using	O
a	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
-	O
end	O
labeling	O
(	O
TUNEL	O
)	O
assay	O
,	O
siRNA	O
knockdown	O
of	O
gene	O
expression	O
,	O
transfection	O
with	O
Bcl	O
-	O
2	O
and	O
Cdk1	O
expression	O
vectors	O
,	O
and	O
flow	O
cytometry	O
.	O

All	O
statistical	O
tests	O
were	O
two	O
-	O
sided	O
.	O

Src	O
family	O
and	O
Abl	O
kinases	O
were	O
identified	O
as	O
modulators	O
of	O
paclitaxel	S-drug
sensitivity	O
in	O
SKOv3	O
cells	O
.	O

The	O
siRNA	O
knockdown	O
of	O
Src	O
,	O
Fyn	O
,	O
or	O
Abl1	O
enhanced	O
paclitaxel	S-drug
-	O
mediated	O
growth	O
inhibition	O
in	O
ovarian	O
cancer	O
cells	O
compared	O
with	O
a	O
control	O
siRNA	O
.	O

HEY	O
cells	O
treated	O
with	O
dasatinib	S-drug-EF-1
plus	O
paclitaxel	S-drug-EF-2
formed	O
fewer	O
colonies	O
than	O
did	O
cells	O
treated	O
with	O
either	O
agent	O
alone	O
.	O

Treatment	O
of	O
HEY	O
xenograft	O
-	O
bearing	O
mice	O
with	O
dasatinib	S-drug-EF-1
plus	O
paclitaxel	S-drug-EF-2
inhibited	O
tumor	O
growth	O
more	O
than	O
treatment	O
with	O
either	O
agent	O
alone	O
(	O
average	O
tumor	O
volume	O
per	O
mouse	O
,	O
dasatinib	S-drug
+	O
paclitaxel	S-drug
vs	O
paclitaxel	S-drug
:	O
0.28	O
vs.	O
0.81	O
cm3	O
,	O
difference	O
=	O
0.53	O
cm3	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0.44	O
to	O
0.62	O
cm3	O
,	O
P	O
=	O
.014	O
)	O
;	O

dasatinib	S-drug
+	O
paclitaxel	S-drug
vs	O
.	O

dasatinib	S-drug
:	O
0.28	O
vs	O
.	O

0.55	O
cm3	O
,	O
difference	O
=	O
0.27	O
cm3	O
,	O
95	O
%	O
CI	O
=	O
0.21	O
to	O
0.33	O
cm3	O
,	O
P	O
=	O
.035	O
)	O
.	O

Combined	O
treatment	O
induced	O
more	O
TUNEL	O
-	O
positive	O
apoptotic	O
cells	O
than	O
did	O
either	O
agent	O
alone	O
.	O

The	O
siRNA	O
knockdown	O
of	O
p27	O
(	O
Kip1	O
)	O
decreased	O
dasatinib	S-drug
-	O
and	O
paclitaxel	S-drug
-	O
induced	O
apoptosis	O
compared	O
with	O
a	O
negative	O
control	O
siRNA	O
(	O
sub	O
-	O
G1	O
fraction	O
,	O
control	O
siRNA	O
vs.	O
p27	O
(	O
Kip1	O
)	O
siRNA	O
:	O
42.5	O
%	O
vs.	O
20.1	O
%	O
,	O
difference	O
=	O
22.4	O
%	O
,	O
95	O
%	O
CI	O
=	O
20.1	O
%	O
to	O
24.7	O
%	O
,	O
P	O
=	O
.017	O
)	O
.	O

Studies	O
with	O
forced	O
expression	O
and	O
siRNA	O
knockdown	O
of	O
Bcl	O
-	O
2	O
and	O
Cdk1	O
suggest	O
that	O
dasatinib	S-drug-EF-1
-	O
mediated	O
induction	O
of	O
p27	O
(	O
Kip1	O
)	O
enhanced	O
paclitaxel	S-drug-EF-2
-	O
induced	O
apoptosis	O
by	O
negatively	O
regulating	O
Bcl	O
-	O
2	O
and	O
Cdk1	O
expression	O
.	O

Inhibition	O
of	O
Src	O
family	O
and	O
Abl	O
kinases	O
with	O
either	O
siRNAs	O
or	O
dasatinib	S-drug-EF-1
enhances	O
paclitaxel	S-drug-EF-2
sensitivity	O
of	O
ovarian	O
cancer	O
cells	O
through	O
p27	O
(	O
Kip1	O
)	O
-	O
mediated	O
suppression	O
of	O
Bcl	O
-	O
2	O
and	O
Cdk1	O
expression	O
.	O

Phase	O
I	O
trial	O
of	O
lenalidomide	S-drug
and	O
CCI	B-drug
-	I-drug
779	E-drug
in	O
patients	O
with	O
relapsed	O
multiple	O
myeloma	O
:	O
evidence	O
for	O
lenalidomide	S-drug
-	O
CCI	B-drug
-	I-drug
779	E-drug
interaction	O
via	O
P	O
-	O
glycoprotein	O
.	O

Multiple	O
myeloma	O
(	O
MM	O
)	O
is	O
an	O
incurable	O
plasma	O
-	O
cell	O
neoplasm	O
for	O
which	O
most	O
treatments	O
involve	O
a	O
therapeutic	O
agent	O
combined	O
with	O
dexamethasone	S-drug
.	O

The	O
preclinical	O
combination	O
of	O
lenalidomide	S-drug-EF-1
with	O
the	O
mTOR	O
inhibitor	O
CCI	B-drug-EF-2
-	I-drug-EF-2
779	E-drug-EF-2
has	O
displayed	O
synergy	O
in	O
vitro	O
and	O
represents	O
a	O
novel	O
combination	O
in	O
MM	O
.	O

Enhancement	O
of	O
humoral	O
immune	O
responses	O
to	O
inactivated	O
Newcastle	O
disease	O
and	O
avian	B-group
influenza	I-group
vaccines	E-group
by	O
oral	O
administration	O
of	O
ginseng	B-drug_n
stem	I-drug_n
-	I-drug_n
and	I-drug_n
-	I-drug_n
leaf	I-drug_n
saponins	E-drug_n
in	O
chickens	O
.	O

Newcastle	O
disease	O
(	O
ND	O
)	O
and	O
avian	O
influenza	O
(	O
AI	O
)	O
are	O
common	O
in	O
the	O
poultry	O
industry	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
oral	O
administration	O
of	O
ginseng	B-drug_n
stem	I-drug_n
-	I-drug_n
and	I-drug_n
-	I-drug_n
leaf	I-drug_n
saponins	E-drug_n
(	O
GSLS	S-drug_n
)	O
on	O
the	O
humoral	O
immune	O
responses	O
of	O
chickens	O
to	O
inactivated	B-drug
ND	E-drug
and	O
AI	O
vaccines	O
.	O

In	O
experiment	O
1	O
,	O
oral	O
administration	O
of	O
GSLS	S-drug_n
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
of	O
BW	O
for	O
7	O
d	O
on	O
the	O
immune	O
response	O
in	O
chickens	O
intramuscularly	O
injected	O
with	O
inactivated	B-drug
ND	I-drug
vaccine	E-drug
was	O
evaluated	O
.	O

Results	O
showed	O
that	O
GSLS	S-drug_n
significantly	O
increased	O
the	O
antibody	O
level	O
against	O
ND	O
in	O
the	O
serum	O
of	O
chickens	O
.	O

In	O
experiment	O
2	O
,	O
the	O
same	O
regimen	O
of	O
GSLS	S-drug_n-EF-1
was	O
administered	O
to	O
chickens	O
inoculated	O
with	O
inactivated	B-drug-EF-2
AI	I-drug-EF-2
vaccines	E-drug-EF-2
,	O
and	O
an	O
enhanced	O
serum	O
antibody	O
response	O
to	O
AI	O
vaccination	O
was	O
also	O
observed	O
.	O

Considering	O
the	O
safety	O
of	O
GSLS	S-drug_n
,	O
because	O
no	O
adverse	O
effect	O
was	O
found	O
throughout	O
the	O
experiments	O
,	O
GSLS	S-drug_n
may	O
be	O
a	O
promising	O
oral	O
adjuvant	O
to	O
improve	O
immunization	O
in	O
poultry	O
.	O

Interaction	O
of	O
dacarbazine	S-drug
and	O
imexon	S-drug_n
,	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
human	O
A375	O
melanoma	O
cells	O
.	O

We	O
evaluated	O
mechanisms	O
of	O
interaction	O
between	O
the	O
alkyating	O
agent	O
dacarbazine	S-drug
(	O
DTIC	S-drug
)	O
and	O
the	O
pro	O
-	O
oxidant	O
,	O
imexon	S-drug
,	O
in	O
the	O
human	O
A375	O
melanoma	O
cell	O
line	O
.	O

The	O
effect	O
of	O
DTIC	S-drug
and	O
imexon	S-drug
,	O
alone	O
and	O
in	O
combination	O
,	O
was	O
evaluated	O
for	O
growth	O
inhibition	O
(	O
MTT	O
)	O
,	O
radiolabeled	O
drug	O
uptake	O
,	O
cellular	O
thiol	O
content	O
(	O
HPLC	O
)	O
,	O
and	O
DNA	O
strand	O
breaks	O
(	O
Comet	O
assay	O
)	O
.	O

Pharmacokinetic	O
and	O
antitumor	O
effects	O
were	O
evaluated	O
in	O
mice	O
.	O

Growth	O
inhibition	O
in	O
vitro	O
was	O
additive	O
with	O
the	O
two	O
drugs	O
.	O

There	O
was	O
no	O
effect	O
on	O
drug	O
uptake	O
or	O
on	O
the	O
number	O
of	O
DNA	O
strand	O
breaks	O
.	O

There	O
was	O
a	O
>	O
75	O
%	O
reduction	O
in	O
cellular	O
glutathione	O
and	O
cysteine	O
with	O
imexon	S-drug
but	O
not	O
DTIC	S-drug
.	O

Co	O
-	O
administration	O
of	O
the	O
two	O
drugs	O
in	O
mice	O
caused	O
an	O
increase	O
in	O
the	O
area	O
under	O
the	O
curve	O
of	O
both	O
drugs	O
,	O
but	O
the	O
combination	O
was	O
not	O
effective	O
in	O
reducing	O
human	O
A375	O
melanoma	O
tumors	O
in	O
vivo	O
.	O

Imexon	S-drug-EF-1
and	O
dacarbazine	S-drug-EF-2
show	O
additive	O
effects	O
in	O
vitro	O
but	O
not	O
in	O
vivo	O
in	O
human	O
A375	O
melanoma	O
cells	O
.	O

Lapatinib	S-drug-EF-1
enhances	O
herceptin	S-brand-EF-2
-	O
mediated	O
antibody	O
-	O
dependent	O
cellular	O
cytotoxicity	O
by	O
up	O
-	O
regulation	O
of	O
cell	O
surface	O
HER2	O
expression	O
.	O

Although	O
it	O
was	O
previously	O
reported	O
that	O
lapatinib	S-drug-EF-1
combined	O
with	O
Herceptin	S-brand-EF-2
improved	O
the	O
progression	O
-	O
free	O
survival	O
rate	O
compared	O
with	O
lapatinib	S-drug
alone	O
for	O
patients	O
with	O
Herceptin	S-brand
-	O
refractory	O
HER2	O
-	O
positive	O
metastatic	O
breast	O
cancer	O
,	O
the	O
mechanism	O
is	O
purported	O
to	O
be	O
an	O
antiproliferative	O
effect	O
relating	O
to	O
the	O
synergism	O
of	O
these	O
two	O
agents	O
.	O

We	O
evaluated	O
how	O
lapatinib	S-drug
interacts	O
with	O
Herceptin	S-brand
in	O
HER2	O
-	O
positive	O
breast	O
cancer	O
,	O
with	O
a	O
particular	O
focus	O
on	O
Herceptin	S-brand
-	O
mediated	O
antibody	O
-	O
dependent	O
cellular	O
cytotoxicity	O
(	O
ADCC	O
)	O
.	O

In	O
an	O
in	O
vitro	O
assay	O
,	O
lapatinib	S-drug-EF-1
induced	O
HER2	O
expression	O
at	O
the	O
cell	O
surface	O
of	O
HER2	O
-	O
positive	O
breast	O
cancer	O
cell	O
lines	O
,	O
leading	O
to	O
the	O
enhancement	O
of	O
Herceptin	S-brand-EF-2
-	O
mediated	O
ADCC	O
.	O

Furthermore	O
,	O
we	O
present	O
a	O
case	O
report	O
in	O
which	O
a	O
second	O
Herceptin	S-brand-EF-1
treatment	O
following	O
lapatinib	S-drug-EF-2
resulted	O
in	O
the	O
marked	O
shrinkage	O
of	O
multiple	O
metastatic	O
tumors	O
in	O
HER2	O
-	O
positive	O
breast	O
cancer	O
.	O

Lapatinib	S-drug
may	O
have	O
the	O
potential	O
to	O
convert	O
Herceptin	S-brand
-	O
refractory	O
to	O
Herceptin	S-brand
-	O
sensitive	O
tumors	O
in	O
HER2	O
-	O
positive	O
breast	O
cancer	O
by	O
up	O
-	O
regulation	O
of	O
the	O
cell	O
surface	O
expression	O
of	O
HER2	O
.	O

Antitumor	O
effects	O
of	O
CRM197	S-drug_n
,	O
a	O
specific	O
inhibitor	O
of	O
HB	O
-	O
EGF	O
,	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
therapeutic	O
outcome	O
for	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
remains	O
poor	O
;	O

thus	O
,	O
novel	O
,	O
targeted	O
therapies	O
are	O
urgently	O
needed	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
heparin	O
-	O
binding	O
epidermal	O
growth	O
factor	O
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	O
)	O
,	O
a	O
member	O
of	O
the	O
EGF	O
family	O
,	O
is	O
a	O
promising	O
target	O
for	O
the	O
treatment	O
of	O
various	O
types	O
of	O
cancer	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
HB	O
-	O
EGF	O
is	O
a	O
therapeutic	O
target	O
for	O
T	O
-	O
ALL	O
,	O
and	O
to	O
further	O
elucidate	O
the	O
antitumor	O
effects	O
of	O
a	O
specific	O
inhibitor	O
of	O
HB	O
-	O
EGF	O
,	O
cross	B-drug_n
-	I-drug_n
reacting	I-drug_n
material	I-drug_n
197	E-drug_n
(	O
CRM197	S-drug_n
)	O
.	O

We	O
elucidated	O
the	O
expression	O
of	O
HB	O
-	O
EGF	O
in	O
T	O
-	O
ALL	O
cell	O
lines	O
,	O
and	O
evaluated	O
the	O
effect	O
of	O
CRM197	S-drug_n
on	O
these	O
cells	O
alone	O
or	O
in	O
combination	O
with	O
anticancer	B-group
agent	E-group
.	O

The	O
expression	O
of	O
EGFR	O
and	O
EGFR	O
ligands	O
was	O
determined	O
by	O
flow	O
cytometry	O
,	O
RT	O
-	O
PCR	O
and	O
real	O
-	O
time	O
quantitative	O
PCR	O
.	O

Induction	O
of	O
apoptosis	O
was	O
assessed	O
by	O
TUNEL	O
assay	O
.	O

HB	O
-	O
EGF	O
was	O
strongly	O
expressed	O
by	O
T	O
-	O
ALL	O
cell	O
lines	O
,	O
and	O
the	O
expression	O
of	O
both	O
HB	O
-	O
EGF	O
and	O
EGFR	O
was	O
enhanced	O
by	O
doxorubicin	S-drug
.	O

CRM197	S-drug_n
induced	O
apoptosis	O
,	O
and	O
furthermore	O
,	O
the	O
combination	O
of	O
CRM197	S-drug_n-EF-1
plus	O
doxorubicin	S-drug-EF-2
enhanced	O
cytotoxicity	O
in	O
a	O
T	O
-	O
ALL	O
cell	O
line	O
.	O

These	O
results	O
suggest	O
that	O
HB	O
-	O
EGF	O
is	O
a	O
promising	O
therapeutic	O
target	O
for	O
T	O
-	O
ALL	O
.	O

Ephedrine	S-drug-EF-1
enhances	O
the	O
antinociceptive	O
effect	O
of	O
dexmedetomidine	S-drug-EF-2
in	O
mice	O
.	O

Dexmedetomidine	S-drug
,	O
a	O
highly	O
selective	O
alpha	O
-	O
2	O
-	O
adrenoceptor	O
agonist	O
,	O
was	O
recently	O
introduced	O
into	O
clinical	O
practice	O
for	O
its	O
sedative	O
and	O
analgesic	O
properties	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
psychostimulant	O
drug	O
ephedrine	S-drug
has	O
any	O
effect	O
on	O
dexmedetomidine	S-drug
-	O
induced	O
antinociception	O
and	O
locomotor	O
inhibitor	O
activity	O
in	O
mice	O
in	O
acute	O
application	O
.	O

In	O
both	O
sexes	O
of	O
swiss	O
albino	O
mice	O
;	O

antinociception	O
was	O
assessed	O
with	O
hot	O
-	O
plate	O
test	O
and	O
the	O
locomotor	O
,	O
exploratory	O
activities	O
were	O
assessed	O
with	O
holed	O
open	O
field	O
test	O
.	O

The	O
animals	O
were	O
received	O
;	O

saline	O
+	O
saline	O
,	O
ephedrine	S-drug
(	O
10	O
mg	O
/	O
kg	O
)	O
+	O
saline	O
,	O
saline	O
+	O
dexmedetomidine	S-drug
(	O
15	O
g	O
/	O
kg	O
)	O
and	O
ephedrine	S-drug
(	O
10	O
mg	O
/	O
kg	O
)	O
+	O
dexmedetomidine	S-drug
(	O
15	O
g	O
/	O
kg	O
)	O
,	O
intraperitoneally	O
,	O
30	O
min	O
before	O
hot	O
plate	O
or	O
holed	O
open	O
field	O
tests	O
.	O

In	O
the	O
hot	O
plate	O
test	O
in	O
mice	O
,	O
co	O
-	O
administration	O
of	O
15	O
g	O
/	O
kg	O
dexmedetomidine	S-drug-EF-1
with	O
10	O
mg	O
/	O
kg	O
ephedrine	S-drug-EF-2
intraperitoneally	O
not	O
only	O
enhanced	O
,	O
but	O
also	O
prolonged	O
the	O
duration	O
of	O
antinociception	O
induced	O
by	O
dexmedetomidine	S-drug
.	O

At	O
the	O
same	O
time	O
,	O
the	O
locomotor	O
inhibitory	O
effect	O
of	O
dexmedetomidine	S-drug-EF-1
was	O
counteracted	O
by	O
ephedrine	S-drug-EF-2
.	O

We	O
concluded	O
that	O
the	O
combined	O
administration	O
of	O
dexmedetomidine	S-drug-EF-1
with	O
ephedrine	S-drug-EF-2
may	O
have	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
pain	O
without	O
causing	O
sedation	O
,	O
which	O
limits	O
the	O
use	O
of	O
dexmedetomidine	S-drug
as	O
an	O
analgesic	S-group
in	O
humans	O
.	O

[	O
Efficacy	O
of	O
fixed	O
combination	O
amlodipine	S-drug
/	O
valsartan	S-drug
in	O
hospitalized	O
patients	O
with	O
hypertensive	O
disease	O
]	O

Efficacy	O
and	O
tolerability	O
of	O
fixed	O
amlodipine	S-drug
/	O
valsartan	S-drug
combination	O
was	O
studied	O
in	O
86	O
patients	O
with	O
hypertensive	O
disease	O
hospitalized	O
in	O
departments	O
of	O
general	O
internal	O
medicine	O
or	O
cardiology	O
.	O

All	O
patients	O
had	O
indications	O
for	O
antihypertensive	O
therapy	O
and	O
were	O
randomized	O
either	O
to	O
fixed	O
combination	O
amlodipine	S-drug
/	O
valsartan	S-drug
(	O
n	O
=	O
43	O
)	O
or	O
to	O
therapy	O
which	O
corresponded	O
to	O
the	O
hospital	O
formulary	O
(	O
n	O
=	O
43	O
)	O
.	O

Correction	O
of	O
antihypertensive	S-group
therapy	O
was	O
performed	O
by	O
treating	O
physician	O
at	O
daily	O
rounds	O
.	O

Self	O
-	O
control	O
of	O
blood	O
pressure	O
(	O
BP	O
)	O
was	O
performed	O
by	O
patients	O
with	O
the	O
use	O
of	O
UA767PC	O
apparatus	O
.	O

Results	O
of	O
BP	O
self	O
-	O
control	O
were	O
compared	O
with	O
clinical	O
measurements	O
in	O
order	O
to	O
detect	O
concealed	O
inefficacy	O
of	O
treatment	O
.	O

Results	O
.	O

Rate	O
of	O
achievement	O
of	O
target	O
BP	O
with	O
fixed	O
combination	O
amlodipine	S-drug
/	O
valsartan	S-drug
(	O
93	O
%	O
)	O
was	O
comparable	O
with	O
that	O
on	O
traditional	O
therapy	O
(	O
90	O
%	O
)	O
.	O

But	O
the	O
use	O
of	O
fixed	O
combination	O
amlodipine	S-drug-EF-1
/	O
valsartan	S-drug-EF-2
compared	O
with	O
traditional	O
therapy	O
was	O
associated	O
with	O
lower	O
clinical	O
and	O
self	O
measured	O
BP	O
,	O
quicker	O
achievement	O
of	O
target	O
BP	O
(	O
5.8	O
+	O
/	O
-	O
2.3	O
and	O
9.2	O
+	O
/	O
-	O
1.8	O
days	O
,	O
respectively	O
,	O
0.05	O
)	O
,	O
lesser	O
number	O
of	O
antihypertensive	B-group
drugs	E-group
(	O
2.5	O
+	O
/	O
-	O
0.6	O
and	O
3.0	O
+	O
/	O
-	O
0.9	O
days	O
,	O
respectively	O
)	O
,	O
lower	O
rate	O
of	O
concealed	O
inefficacy	O
of	O
treatment	O
(	O
12	O
and	O
31	O
%	O
,	O
respectively	O
,	O
0.05	O
)	O
.	O

Conclusions	O
.	O

We	O
have	O
demonstrated	O
appropriateness	O
of	O
inhospital	O
administration	O
of	O
fixed	O
amlodipine	S-drug-EF-1
/	O
valsartan	S-drug-EF-2
combination	O
as	O
an	O
approach	O
allowing	O
to	O
achieve	O
target	O
BP	O
in	O
shorter	O
time	O
,	O
with	O
the	O
use	O
of	O
fewer	O
antihypertensive	B-group
drugs	E-group
,	O
and	O
diminishing	O
concealed	O
inefficacy	O
of	O
treatment	O
.	O

Ticagrelor	S-drug
(	O
Brilinta	S-brand
)	O
-	O
-	O
better	O
than	O
clopidogrel	S-drug
(	O
Plavix	S-brand
)	O

The	O
FDA	O
has	O
approved	O
ticagrelor	S-drug-EF-1
(	O
Brilinta	S-brand-EF-1
-	O
AstraZeneca	O
)	O
,	O
an	O
oral	O
antiplatelet	B-group
drug	E-group
,	O
for	O
use	O
with	O
low	O
-	O
dose	O
aspirin	S-brand-EF-2
to	O
reduce	O
the	O
rate	O
of	O
thrombotic	O
cardiovascular	O
events	O
in	O
patients	O
with	O
acute	O
coronary	O
syndrome	O
(	O
ACS	O
)	O
.	O

It	O
will	O
compete	O
with	O
clopidogrel	S-drug
(	O
Plavix	S-brand
)	O
and	O
prasugrel	S-drug
(	O
Effient	S-brand
)	O
for	O
such	O
use	O
.	O

Clopidogrel	S-drug
is	O
expected	O
to	O
become	O
available	O
generically	O
in	O
the	O
US	O
within	O
the	O
next	O
few	O
months	O
.	O

Influence	O
of	O
piperine	S-drug_n
on	O
ibuprofen	S-drug
induced	O
antinociception	O
and	O
its	O
pharmacokinetics	O
.	O

Piperine	S-drug_n
(	O
CAS	O
94	O
-	O
62	O
-	O
2	O
)	O
,	O
an	O
alkaloid	O
obtained	O
from	O
Piper	O
nigrum	O
and	O
P	O
.	O

longum	O
,	O
is	O
a	O
known	O
inhibitor	O
of	O
various	O
enzymes	O
(	O
CYP	O
isozymes	O
)	O
responsible	O
for	O
biotransformation	O
of	O
drugs	O
.	O

By	O
inhibiting	O
the	O
metabolism	O
of	O
drugs	O
,	O
piperine	S-drug_n
improves	O
the	O
bioavailability	O
of	O
drugs	O
.	O

In	O
the	O
present	O
study	O
piperine	S-drug_n-EF-1
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
dose	O
-	O
dependent	O
antinociceptive	O
activity	O
of	O
ibuprofen	S-drug-EF-2
evaluated	O
by	O
both	O
acetic	B-drug
acid	E-drug
writhing	O
and	O
formalin	O
test	O
,	O
when	O
it	O
was	O
administered	O
with	O
ibuprofen	S-drug
.	O

Ibuprofen	S-drug-ME-1
plasma	O
concentration	O
was	O
also	O
increased	O
when	O
it	O
was	O
administered	O
with	O
piperine	S-drug_n-ME-2
.	O

The	O
synergistic	O
antinociception	O
activity	O
of	O
ibuprofen	S-drug-ME-1
when	O
administered	O
with	O
piperine	S-drug_n-ME-2
can	O
be	O
attributed	O
to	O
increased	O
plasma	O
concentration	O
of	O
ibuprofen	S-drug
.	O

From	O
this	O
study	O
it	O
can	O
be	O
concluded	O
that	O
piperine	S-drug_n-EF-1
can	O
be	O
used	O
as	O
a	O
bioenhancer	O
along	O
with	O
ibuprofen	S-drug-EF-2
.	O

